5,018 Matching Annotations
  1. Mar 2021
    1. SciScore for 10.1101/2020.09.01.20186213: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">Consent: Ethics: The prospective observational study in Covid-19 patients was approved by CER-Sorbonne University IRB,CER-2020-14, with a signed informed consent.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      No key resources detected.


      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      These results have certain strengths and limitations. Decrease of apolipoprotein-A1 in 2020: The originality of these results was not the decrease in apolipoprotein-A1 during the peak of the pandemic in April, as very low levels of HDL-cholesterol in sera collected in Covid-19 were known in severe pneumonia since 1920 (supplementaryTable1).2 More intriguing was the very early decrease observed since January 2020 in the USA when the number of Covid-19 cases was unknown. The first known Covid-19 patient was detected on 27/12/2019 and 19/01/2020 in France and the USA, respectively(supplementaryFile3). The larger sample size of the US surveillance population, compared to the French, allowed detection of a significant 1% increase in the proportion of subjects possibly infected using the 1.25 g/L cutoff in January (fig1C), without any inflammatory signal using haptoglobin. We hypothesized that the SARS-CoV2 virus influenced the liver or intestinal synthesis of apolipoprotein-A1, in asymptomatic patients or in those with unusual mild symptoms. Confounding factors: The decrease of apolipoprotein-A1 in 2020 vs. previous years, as well as the time-related association of apolipoprotein-A1 in 2020 and Covid-19 might be due to numerous confounding factors. In the context of the pandemic we used cohorts of subjects requiring surveillance of liver fibrosis biomarkers which represent at least 30% of the general adult population in the USA and in France. In these cohorts 70% of the subjects h...

      Results from TrialIdentifier: We found the following clinical trial numbers in your paper:<br><table><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Identifier</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Status</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Title</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT01927133</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Unknown status</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">LIVER FIBROSIS PREVALENCE IN FRANCE</td></tr></table>


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a protocol registration statement.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.06.12.148726: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">1 μg/ml anti-p30 MLV gag antibody (Abcam, ab130757) and 1:10,000 dilution of goat-anti-mouse IgG-HRP polyclonal antibody (Jackson ImmunoResearch, 115-036-062) were used to detect MLV gag protein as an internal control.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>1 μg/ml anti-p30 MLV gag antibody ( Abcam , ab130757 )</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-p30 MLV gag antibody ( Abcam , ab130757 )</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>IgG-HRP</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">As with MLV PV, the S-protein bands were visualized using the anti-Flag M2 antibody, and the N-protein band was detected using pooled convalescent plasma at a 1:500 dilution and 10 ng/ml goat-anti-human IgG antibody conjugated with polymerized HRP (Fitzgerald, 61R-I166AHRP40).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-Flag</div><div>suggested: (Advanced Targeting Systems Cat# AB-450-500, RRID:AB_10585851)</div></div><div style="margin-bottom:8px"><div>IgG</div><div>suggested: (Fitzgerald Industries International Cat# 61R-I166AHRP40, RRID:AB_10815602)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To measure ACE2-binding ability or the level of the S1 domain present on the cell surface, cells were detached two days post transfection with Accutase (Stemcell Technologies Inc.) and incubated with either 1 μg/ml purified hACE2-NN-Ig or anti-Myc antibody (clone 9E10, National Cell Culture Center, Minneapolis, MN), respectively, on ice. hACE2-NN-Ig was previous described and was purified using Protein A-Sepharose CL-4B (GE Healthcare)31.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-Myc</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Infection assays were performed by spinoculating (at 2,100 x g for 30 min at 10°C) PVs onto the Mock- and hACE2-293T cells seeded on multiwell plates.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>hACE2-293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell-surface expression and analysis of the S protein: HEK293T cells, approximately 80% confluent in 6-well plates were transfected with 8 μl PEI 40,000</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Mock- and hACE2-HEK293T cells on 96-well plates were infected with the preincubation mixes and infection levels were assessed 24 h later by measuring luciferase activity using the Luc-Pair Firefly Luciferase HS Assay Kit (GeneCopoeia)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>hACE2-HEK293T</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Genotype frequency at residue 614 was calculated using R (R Foundation for Statistical Computing) with the Biostrings package.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Biostrings</div><div>suggested: (Biostrings, RRID:SCR_016949)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Logo plots of D614G variation were generated by WebLogo after sequence alignment.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>WebLogo</div><div>suggested: (WEBLOGO, RRID:SCR_010236)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analysis: All appropriate data were analyzed with GraphPad Prism 7 (GraphPad Software Inc.).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.06.17.157982: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      NIH rigor criteria are not applicable to paper type.

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Following overnight equilibration of ACE2 binding at room temperature, cells were washed in ice-cold PBS-BSA, and resuspended in PBS-BSA containing 1:200 diluted FITC-conjugated anti c-Myc antibody (Immunology Consultants Lab, CMYC-45F) to label for RBD surface expression via a C-terminal c-Myc epitope tag, and 1:200 diluted PE-conjugated streptavidin (Thermo Fisher S866) to detect bound biotinylated ACE2 ligand.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti c-Myc</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>c-Myc epitope tag ,</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For library expression experiments, 45 OD units yeast were washed twice with PBS-BSA and labeled in 3mL 1:100 diluted anti-Myc-FITC antibody for 1hr at 4°C with gentle mixing.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-Myc-FITC</div><div>suggested: (Sigma-Aldrich Cat# SAB4700448, RRID:AB_10896411)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Antibody epitopes were mapped from crystal structures 6W41 (Yuan et al., 2020b), 6WAQ (Wrapp et al., 2020b), 2DD8 (Prabakaran et al., 2006), 3BGF (Pak et al., 2009), 2GHW (Hwang et al., 2006), 7BZ5 (Wu et al., 2020), and cryo-EM structures 6NB6 and 6NB7 (Walls et al., 2019), and 6WPS (Pinto et al., 2020).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>6NB7</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, 2.5e5 293T cells per well were seeded in 12-well plates in 1 mL D10 growth media (DMEM with 10% heat-inactivated FBS, 2 mM l-glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Media was removed from the 293T-ACE2 cells and replaced with fresh D10 containing 50 μL of pseudovirus supernatant in a final volume of 150 μL.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T-ACE2</div><div>suggested: RRID:CVCL_YZ65)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plasmids were transfected into 150mL suspension expi293F or HEK293F cells at 37°C in a humidified 8% CO2 incubator rotating at 130 rpm and harvested 3 days later.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293F</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Alignment and phylogeny: We used the curated RBD sequence set from Letko et al. (Letko et al., 2020), adding newly described RBD sequences from sarbecovirus strains RaTG13 (Zhou et al., 2020b), RmYN02 (Zhou et al., 2020a), GD-Pangolin and GX-Pangolin (Lam et al., 2020), and the additional non-Asian bat sarbecovirus isolate BtKY72 (Tong et al., 2009).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>RaTG13</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For one bin in which the number of HiSeq reads was less than the number of cells sorted into a bin, we re-amplified PCR product from a newly purified plasmid aliquot, and obtained reads via a single lane of MiSeq 50bp single end sequencing.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MiSeq</div><div>suggested: (A5-miseq, RRID:SCR_012148)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data visualization: The interactive heatmap of mutational effects shown at https://jbloomlab.github.io/SARS-CoV-2-RBD_DMS/ was made using the altair (VanderPlas et al., 2018) Python package.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Python</div><div>suggested: (IPython, RRID:SCR_001658)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Structural images were rendered in PyMol.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>PyMol</div><div>suggested: (PyMOL, RRID:SCR_000305)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">RBD nucleotide sequences were aligned via mafft with a gap opening penalty of 4.5, and the maximum likelihood phylogeny was inferred in RAxML (Stamatakis, 2014) under the GTR model with 4 gamma-distributed discrete categories of among-site rate variation.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>RAxML</div><div>suggested: (RAxML, RRID:SCR_006086)</div></div></td></tr></table>

      Results from OddPub: Thank you for sharing your code and data.


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      To some degree, these caveats are universal of experimental studies, as even sophisticated animal models are imperfect proxies for true fitness (Louz et al., 2013)—but they are especially true for basic biochemical phenotypes like the ones we measure. However, on a hopeful note, our measurements correlate well with cellular entry by spike-pseudotyped viral particles expressing sarbecovirus RBD homologs (Figures 1D) and single mutants of the SARS-CoV-2 RBD (Figure 4E). Furthermore, fitness ultimately arises from the concerted action of biochemical phenotypes, which are in turn determined by genotype (Dean and Thornton, 2007; Harms and Thornton, 2013; Russell et al., 2014). By making the first link from mutations to biochemical phenotypes, we have taken a step towards enabling better interpretation of viral genetic variation. One important area where our maps do have clear relevance is assessing the potential for SARS-CoV-2 to undergo antigenic drift by fixing mutations at sites targeted by antibodies, as occurs for some other viruses such as influenza (Smith et al., 2004). The RBD is the dominant target of neutralizing antibodies (Cao et al., 2020; Ju et al., 2020; Pinto et al., 2020; Rogers et al., 2020; Seydoux et al., 2020; Shi et al., 2020; Wu et al., 2020; Zost et al., 2020), and so any antigenic drift will be constrained by its mutational tolerance. Our results show that many mutations to the RBD are well-tolerated with respect to both protein folding and ACE2 binding. H...

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.07.27.222836: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">Data analysis: A priori power analysis (G*Power 3.1 37) was used to estimate the required sample sizes.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Late endosomal/lysosomal compartments were identified by staining the endolysosomal marker protein CD63 with the mouse monoclonal anti-CD63 antibody H5C6 (1:300 in 2% BSA in PBS) for 90 min.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-CD63</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The secondary AlexaFluor594-coupled anti-mouse antibody was from Thermo Fisher Limited.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-mouse</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells and treatment: The human bronchioepithelial cell line Calu-3, the Madin-Darby canine kidney (MDCK) II cells, and the Vero E6 cell line were cultivated in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% standardized fetal bovine serum (FBS Advance; Capricorne), 2 mM L-glutamine, 100 U/mL penicillin, and 0.1 mg/mL streptomycin.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MDCK</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cytotoxicity assay: Calu-3 and Vero cells were treated at the indicated concentrations with the solvent DMSO, U18666A, fluoxetine, amiodarone and imipramine.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In brief, MDCK cells (for IAV infection) or Vero E6 cells (for SARS-CoV-2 infection) grown to a monolayer in six-well dishes were washed with PBS and infected with serial dilutions of the respective supernatants in infection-PBS for 1 hour at 37°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Single-cycle infection assay: Calu-3 cells were infected with SARS-CoV2 and fixed with 4% paraformaldehyde (PFA) in PBS for 15 min at room temperature at the indicated times p.i.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Calu-3</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The secondary AlexaFluor594-coupled anti-mouse antibody was from Thermo Fisher Limited.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Thermo Fisher Limited</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The colocalization of filipin and CD63 signals was analyzed using the JACoP plugin 35 for Fiji 36.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Fiji</div><div>suggested: (Fiji, RRID:SCR_002285)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data analysis: A priori power analysis (G*Power 3.1 37) was used to estimate the required sample sizes.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>G*Power</div><div>suggested: (G*Power, RRID:SCR_013726)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data were analyzed with Prism 8.00 (Graph-Pad).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Prism</div><div>suggested: (PRISM, RRID:SCR_005375)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.07.30.229377: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Transfected cells were incubated for 3 hours at RT with the following anti-SARS-CoV structural protein monoclonal or polyclonal antibodies at a 1:250 dilution:</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-CoV structural protein</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, mouse anti-SARS-CoV N monoclonal IgN 42c, rabbit anti-SARS-CoV S polyclonal sera (BEI Resources) and mouse anti-2xStrep-tag antibody (Sigma-Aldrich)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-CoV N</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-2xStrep-tag</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">. Anti-mouse IgG AF555, anti-rabbit IgG AF555, or anti-mouse IgM AF488 conjugated secondary antibodies were added at 1:500 dilution for 1 hour at RT (Invitrogen).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Anti-mouse IgG</div><div>suggested: (R and D Systems Cat# AF555, RRID:AB_355438)</div></div><div style="margin-bottom:8px"><div>anti-rabbit IgG</div><div>suggested: (SouthernBiotech Cat# 4030-32, RRID:AB_2795940)</div></div><div style="margin-bottom:8px"><div>anti-mouse IgM</div><div>suggested: (SouthernBiotech Cat# 1021-30, RRID:AB_2794251)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">LzGreen SARS-COV-2 S pseudotyped lentivirus were mixed with 2-fold dilutions of the following monoclonal or polyclonal anti-SARS-CoV-2 S antibodies: mouse anti-SARS-CoV S monoclonal IgM 154c</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-CoV-2 S</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The following anti SARS-CoV-2 S monoclonal and polyclonal antibodies were serially diluted by 2-fold dilutions in blocking buffer: mouse anti-SARS-CoV S monoclonal IgM 154c</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti SARS-CoV-2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-SARS-CoV S</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Anti-mouse HRP, and anti-human-HRP secondary antibodies were used at 1:4000 concentration in blocking buffer, and were incubated 1 hour at RT. 50 μL of TMB HRP substrate (ThermoFisher Scientific) was added, and following incubation for 10 minutes at RT, 50μL of 2N H2SO4 was added as a stopping solution.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Anti-mouse HRP</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-human-HRP secondary antibodies</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-human-HRP</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Resolved proteins were then transferred to a PVDF membrane, blocked in TBS with 2% BSA 0.1% Tween-20, then incubated with the following antibodies diluted to 1:500 in blocking buffer: mouse anti-SARS-CoV N monoclonal IgM 19c, mouse anti-SARS-CoV M monoclonal IgG1 283c, mouse anti-SARS-CoV E monoclonal IgM 472c, and mouse anti-2xStrep-tag antibody, and anti-His-HRP.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-CoV</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-His-HRP</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Virus transduction capability was then tittered on 293T-Ace2 cells treated with 50μl of 5μg/ml polybrene (Sigma-Aldritch LLC).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T-Ace2</div><div>suggested: RRID:CVCL_YZ65)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">His-tagged RBD bearing lentivirus was produced in HEK 293T cells and used to infect HEK 293-F suspension cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK 293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Western blot: 293T cells were seeded in 10 cm dishes at a density of 3.5 million cells per dish.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Maximum intensity z-projections were prepared in Fiji.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Fiji</div><div>suggested: (Fiji, RRID:SCR_002285)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.04.17.047480: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: Mice: Animal studies were approved by the University of Kansas Institutional Animal Care and Use Committee (IACUC) as directed by the Guide for the Care and Use of Laboratory Animals (Protocol #252-01).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Briefly, samples were obtained from nasopharyngeal swabs of from 430 male and female individuals with SARS-CoV-2 infection and 54 controls (32).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Blots were blocked with 5% Milk-PBST for 30 min, incubated O/N in primary antibody (Rabbit Pan-ADPr 1:1000, Cell Signaling E6F6A; Rabbit GFP 1:1000, Chromotek PABG1-100; Mouse Tubulin 1:1000; Cell Signaling DM1A).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GFP</div><div>suggested: (ChromoTek Cat# PABG1-20, RRID:AB_2749857)</div></div><div style="margin-bottom:8px"><div>Tubulin</div><div>suggested: (LSBio (LifeSpan Cat# LS-C89856-1000, RRID:AB_1940111)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Primary incubation was followed with HRP-conjugated secondary antibodies (Rabbit-HRP 1:10000, Jackson Laboratories 111-035-144; Mouse-HRP 1:5000, Invitrogen 62-6520).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Rabbit-HRP</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>Mouse-HRP</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">NHBE (Fig. 1B) and A549 (low MOI) (Fig.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>A549</div><div>suggested: NCI-DTP Cat# A549, RRID:CVCL_0023)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell culture: DBT, 17Cl-1, HEK293T, and HeLa cells expressing the MHV receptor carcinoembryonic antigen-related cell adhesion molecule 1 (a gift from Dr. Thomas Gallagher, Loyola University, Chicago, IL) were grown in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS), HEPES, sodium pyruvate, non-essential amino acids, L-glutamine, penicillin and streptomycin.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HeLa</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For analysis of the NAD metabolome HEK293T cells were transfected with 1µg of pEGFP-C1 Empty Vector or pEGFP-C1-CMV-PARP10 using CalPhos Mammalian Transfection Kit (Takara Bio).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pathogen-free C57BL/6 mice were purchased from Jackson Laboratories and maintained in the animal care facility at the University of Kansas.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>C57BL/6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">RNA was collected, and differential gene expression analysis was performed using the DESeq2 package.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>DESeq2</div><div>suggested: (DESeq, RRID:SCR_000154)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Graphs were generated using GraphPad Prism v8.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      However, there are a few caveats. First, that at pharmacological doses, NAM has the potential to function as a PARP inhibitor (41). Second, NAMPT is considered a driver of pulmonary vascular remodeling and potentially a target to be inhibited to maintain lung health of some people at risk for COVID-19 (42). Thus, in order to maximize the likelihood of success in human CoV prevention and treatment trials, care should be taken to carefully compare efficacy and dose-dependence of NR, SBI and NAM with respect to control of cytokine storm and antiviral activities in vivo. The cellular results presented herein warrant the testing of NAD boosting agents in the context of in vivo CoV infections. In addition to animal trials, the safety of various forms of vitamin B3 should allow rapid clinical assessments of NAD boosters to be evaluated in two placebo-controlled contexts. First, we suggest that improved NAD status could help blunt the severity of infection by sustaining PARP-dependent IFN signaling in the face of the self-limiting nature of cellular NAD during infection and by limiting the storm of inflammatory cytokines that is typically associated with serious disease (43). In a small placebo-controlled clinical trial designed to address the oral safety and activity of Niagen NR in older men, it was discovered that 1 gram of NR per day depresses levels of IL-6, IL-5, and IL-2 (22). Based on these findings, we suggest that NAD boosters be tested on hospitalized and nonhospitalized C...

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.07.25.221291: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: Experiment were approved by the Animal Care Committee located at the Canadian Science Center for Human and Animal Health in accordance with the guidelines provided by the Canadian Council on Animal Care.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">Deer mice were randomly assigned to their respective groups and were housed in a temperature-controlled, light-cycled facility.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Thirteen to thirty two-week old male or female deer mice were infected with 105 or 106 TCID50 of SARS-CoV-2 by an intranasal route (i.n.) of administration in a 50 μl volume.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">Contamination: The P1 virus was subsequently passaged at a 1:1000 dilution on mycoplasma-free VeroE6 cells (ATCC) in Dulbecco’s Modified Eagle’s Medium (Hyclone) containing 1% L-glutamine and 0.5 μg/ml of TPCK-trypsin and harvested when 80% cytopathic effect (CPE) became evident.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2-S-specific enzyme-linked immunosorbent assay (ELISA): SARS-CoV-2 spike/nucleoprotein (S/N)-specific IgG antibody responses were assessed using an in-house assay.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>S/N)-specific IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Deer mouse IgG was detected with a KPL peroxidase-labeled polyclonal goat antibodies against Peromyscus leucopus IgG (H+L) (Sera Care)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>antibodies against Peromyscus leucopus IgG</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The virus stock was titrated on Vero cells by conventional TCID50 assay, as described previously53.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The sera-virus mixtures were added to 24-well plates containing Vero E6 cells at 100% confluence, followed by incubation at 37 °C and 5% CO2 for 1 hour.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">GraphPad Prism’s multiple t test was used to perform the second subtraction so as not to lose the variation of the mock animals.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For the phylogenetic analysis, mitochondrial genome sequences (see Accession codes) were aligned with MAFFT v7.46759, with regions of poor alignment trimmed with Gblocks v0.91b60 resulting in a final alignment of 15,393bp in 115 blocks of minimum 5bp lengths.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MAFFT</div><div>suggested: (MAFFT, RRID:SCR_011811)</div></div><div style="margin-bottom:8px"><div>Gblocks</div><div>suggested: (Gblocks, RRID:SCR_015945)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">A maximum likelihood phylogeny was constructed with RAxML v8.2.1261 using the GTR+I+G4 substitution model as selected by modeltest-ng62.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>RAxML</div><div>suggested: (RAxML, RRID:SCR_006086)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.08.18.255810: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: Alveolar macrophages were prepared from broncheo-alveolar lavage (BAL) fluid that was obtained as spare material from the ongoing DIVA study (Netherlands Trial Register: NL6318; AMC Medical Ethical Committee approval number: 2014_294).<br>Consent: All subjects in the DIVA study have signed an informed consent form.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">The DIVA study includes healthy male volunteers aged 18-35.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Reagents and antibodies: The following antibodies were used (all anti-human): ACE-2 (R&D),</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human): ACE-2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Negative control included isotype-matched HIV-1 antibody VRC01 (59)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HIV-1</div><div>suggested: (bNAber Cat# bNAberID_1, RRID:AB_2491019)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Purity of LCs was routinely verified by flow cytometry using antibodies directed against CD207 (langerin) and CD1a.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CD207</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>CD1a</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell lines: The human B cell line Namalwa (ATCC, CRL-1432) and Namalwa cells stably expressing human Syndecan 1 and Syndecan 4 (57) were a gift from Dr. Guido David and Dr. Philippe A Gallay.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Namalwa</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The human epithelial Caco2 cells (ATCC, HTB-37™) were maintained in Dulbecco modified Eagle medium (Gibco Life Technologies, Gaithersburg, Md.) containing 10% fetal calf serum (FCS), L-glutamine and penicillin/streptomycin (10 μg/ml) and supplemented with MEM Non-Essential Amino Acids Solution (NEAA) (Gibco Life Technologies, Gaithersburg, Md.).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Caco2</div><div>suggested: ATCC Cat# HTB-37, RRID:CVCL_0025)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Biosynthesis inhibition and enzymatic treatment: HuH7.5 cells were treated in D-PBS/0.25% BSA with 46 miliunits heparinase III (Amsbio) for 1 hour at 37°C, washed and used in subsequent experiments.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HuH7.5</div><div>suggested: RRID:CVCL_7927)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data was analyzed using FlowJo vX.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analyses were performed using GraphPad Prism 8 software and significance was set at *P< 0.05, **P<0.01***P<0.001****P<0.0001.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.08.20.259531: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      NIH rigor criteria are not applicable to paper type.

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Virus isolates: The following virus isolates were used: Cell culture: Vero E6 cells (African green monkey kidney epithelial cell, ECACC, ID: 85020206) were cultivated in cell culture flasks with D-MEM, including 1% L-glutamine and 10% fetal bovine serum, for 1 d at 37°C and 5% CO2 to reach approximately 70% confluence.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Alignment of the tilt series (using 10 nm colloidal gold fiducials) and reconstruction of the tomograms were performed with the IMOD software package21 (version 4.9.12) using SIRT with 25 iterations after low pass filtering (cut off = 0.35, low pass radius sigma = 0.05) of the aligned image stack.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>IMOD</div><div>suggested: (IMOD, RRID:SCR_003297)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The volume containing the selected particle was extracted, filtered to increase contrast (Normalize local contrast; maximum pixel size, SD = 5, stretched and centered histogram) and resliced in z to a resolution of 1.5 nm using Fiji.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Fiji</div><div>suggested: (Fiji, RRID:SCR_002285)</div></div></td></tr></table>

      Results from OddPub: Thank you for sharing your data.


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • No funding statement was detected.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.10.30.20223198: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">All Ag-RDT determinations were performed by two blinded technicians, who used 100 μL of 1:3 mix of the Kit buffer and the sample previously thawed and homogenized.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">Statistical Analysis: We determined the sample size needed to estimate sensitivity with 80% power and precision 2·25% was 944 if the actual sensitivity of the index test was 93·5% (reported by the manufacturer) and specificity with 80% power and 2·25% precision was 450 if the actual specificity was 99·6% (reported by the manufacturer).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For a positive result, a gold conjugate human IgG specific to SARS-CoV-2 Ag and anti-SARS-CoV-2 antibody form a test line in the result window.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-CoV-2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Analytical performance of antigen rapid tests: The analytical performance of the Ag-RDT test was assessed using a SARS-CoV-2 isolate (ID EPI_ISL_510689) propagated in Vero E6 cells (ATCC CRL-1586).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, Standard F COVID-19 Ag FIA (SD Biosensor, Suwon, South Korea), and Panbio™ COVID-19 Ag Test (Abbott Laboratories, Illinois, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Abbott Laboratories</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Rapid antigen tests were performed according to the manufacturer’s IFU (Abbott, Illinois, USA) except for the use of a viral transport media (DeltaSwab Virus) and swab storage as a frozen specimen.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Abbott</div><div>suggested: (Abbott, RRID:SCR_010477)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      On the other hand, it has the limitation of not using the test under the conditions specified by the manufacturer. Our results indicate that the test can be used on frozen samples stored in transport media, thus allowing parallel sampling for Ag-RDT and PCR. However, caution should be taken when using coloured media that may affect the background of the test thin layer. In our experience, a 1:3 dilution with the Kit buffer prevented unspecific signal of yellow-coloured transport media and provided adequate results; nevertheless, we encourage validating this type of approaches before using the test. Likewise, our study was performed on stored samples rather than in a real-life setting. Owing to this last limitation, common in other assessments of the clinical performance of RDT in general,26 we simulated the PPV and NPV assuming a prevalence of disease based on surveillance estimates. According to our simulation, in a low prevalence setting (i.e., 5% prevalence or below), the NPV would be very high (99·6%), and screening will result in 4 (95% CI 3 – 5) false-negative results per thousand tests; the corresponding PPV would be relatively low (81·5%), stressing the need for confirmatory testing with nucleic acid amplification techniques. Irrespective of the predictive values, one must not lose sight of the relationship between the viral load and test sensitivity, a double-edged sword that better suits this test for ensuring lack of infectivity of a subject along a limited time pe...

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.06.07.137802: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: Human immunohistochemistry: All experiments with human materials were approved by the ethics committee of the University Medical Center Göttingen and were performed in accordance with the respective national, federal and institutional regulations.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">To measure the infectivity of cultured cells, three randomly selected areas per coverslip were imaged.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Adult male and female C57BL/6N mice (8 to 10 weeks of age) were taken for all experiments.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Generation of monoclonal antibodies against NRP1 b1b2: Female BALB/c and C57BL/6 mice, 8–9 weeks old, were immunized intraperitoneally with 17 μg of recombinant NRP1 b1b2 mixed with an equal volume of complete Freund’s adjuvant (Sigma–Aldrich Chemie, Steinheim, Germany), followed by a booster immunization four weeks later of the same dose mixed with incomplete Freund’s adjuvant (Sigma–Aldrich).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>NRP1</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Primary antibodies were diluted in 10% blocking solution: 1:250 NRP1 (monoclonal rabbit, ab81321, Abcam); 1:1000 TuJ1 (monoclonal mouse, G712A, Promega); 1:250 NeuN (polyclonal chicken, ABN91, Milipore); 1:2000 GFP (polyclonal rabbit, A-6455, Thermo Fisher Scientific), 1:250 ColIV (polyclonal goat, 1340-01, Southern Biotech)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>TuJ1</div><div>suggested: (Covance Cat# MMS-435P, RRID:AB_2313773)</div></div><div style="margin-bottom:8px"><div>NeuN</div><div>suggested: (Millipore Cat# ABN91, RRID:AB_11205760)</div></div><div style="margin-bottom:8px"><div>GFP</div><div>suggested: (Thermo Fisher Scientific Cat# PA1-86341, RRID:AB_931091)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After three washes in PBS, the sections were incubated in secondary antibody: Alexa Fluor 488 donkey anti-mouse (R37114, Thermo Fischer Scientific);</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-mouse ( R37114</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Primary antibodies were applied over night at a dilution of 1:100 for SARS-CoV S protein (monoclonal mouse, ab272420, Abcam; microwave, citric acid buffer, 10 mM, pH 6.0), 1:250 for NRP1 (monoclonal rabbit, ab81321, Abcam; microwave, Tris-EDTA, pH 8.0) and 1:150 for OLIG2 (polyclonal rabbit, 18953, IBL; microwave, Tris-EDTA, pH 8.0).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>OLIG2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Secondary antibodies were added as follows: biotinylated anti-mouse 1:200 (GE Healthcare RPN 1001) followed by Tyramide Super Boost with Alexa Fluor 488 1:500 (Thermo Fisher Scientific) and Alexa Fluor 555 anti rabbit 1:500 for 2 h, at room temperature.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Either the Envision+ System for mice (Dako) and alkaline phosphatase conjugated anti-rabbit antibodies with FastBlue (Sigma Aldrich) or alkaline phosphatase coupled anti-mouse antibodies with FastBlue (Sigma Aldrich) were used for immunohistochemistry.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-rabbit</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-mouse</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell culture: HEK 293T and Caco-2 (ATCC) cells were grown in complete growth media supplemented with 10% fetal calf serum (FCS), (pen/strep, L-Glutamine in DMEM) and passaged 1:8 (HEK-293 T) or 1:5 (Caco-2) every three</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK 293T</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>Caco-2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>HEK-293</div><div>suggested: CLS Cat# 300192/p777_HEK293, RRID:CVCL_0045)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">PPC-1 human primary prostate cells were obtained from Erkki Ruoslahti’s laboratory at the Cancer Research Center,</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>PPC-1</div><div>suggested: ATCC Cat# HTB-190, RRID:CVCL_4778)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Production of SARS-CoV-2 S-pseudotyped lentiviral particles: HEK-293T cells were grown in complete growth media (10% FCS, Pen/strep, L-Glutamine in DMEM) until 60 to 70% confluent in a 10 cm dish.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK-293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Isolation of WT SARS-CoV-2 from COVID-19 patient and virus propagation: Samples were obtained under the Helsinki University Hospital laboratory research permit HUS/32/2018 § 16. 500 µl of nasopharyngeal swab in Copan UTM® Universal Transport Medium was inoculated on Calu-3 cells and incubated for 1 h in +37°C, after which the inoculum was removed and replaced with Minimum Essential Medium supplemented with 2% FBS, L-glutamine, penicillin and streptomycin.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Calu-3</div><div>suggested: KCLB Cat# 30055, RRID:CVCL_0609)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">2 were propagated in VeroE6 cells (SARSmutFC) or Caco-2 cells up to passage 7 or passage 1, respectively.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VeroE6</div><div>suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Adult male and female C57BL/6N mice (8 to 10 weeks of age) were taken for all experiments.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>C57BL/6N</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">BALB/c mice were purchased from Jackson Laboratories.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BALB/c</div><div>suggested: RRID:IMSR_ORNL:BALB/cRl)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Generation of monoclonal antibodies against NRP1 b1b2: Female BALB/c and C57BL/6 mice, 8–9 weeks old, were immunized intraperitoneally with 17 μg of recombinant NRP1 b1b2 mixed with an equal volume of complete Freund’s adjuvant (Sigma–Aldrich Chemie, Steinheim, Germany), followed by a booster immunization four weeks later of the same dose mixed with incomplete Freund’s adjuvant (Sigma–Aldrich).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>C57BL/6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Image visualization was performed using Omero Server software 5.6</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Omero Server</div><div>suggested: (OME - Open Microscopy Environment, RRID:SCR_008849)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, Omero figure 4.0.2 (https://github.com/ome/omero-figure) and InkScape 0.9234.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Omero</div><div>suggested: (OMERO, RRID:SCR_002629)</div></div><div style="margin-bottom:8px"><div>InkScape</div><div>suggested: (Inkscape, RRID:SCR_014479)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Image analysis: Images were analysed with CellProfiler 3.1.8 (https://cellprofiler.org/).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CellProfiler</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>https://cellprofiler.org/</div><div>suggested: (CellProfiler Image Analysis Software, RRID:SCR_007358)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All other measurements were performed semiquantitatively using Fiji software 36.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Fiji</div><div>suggested: (Fiji, RRID:SCR_002285)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Primer pools targeting SARS-CoV-2 were designed using PrimalScheme tool http://primal.zibraproject.org38 and PCR was conducted using PhusionFlash PCR master mix (ThemoFisher)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ThemoFisher</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The trimmed sequence reads were assembled to the reference sequence (NC_045512.2) using BWA-MEM algorithm implemented in SAMTools version 1.840.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BWA-MEM</div><div>suggested: (Sniffles, RRID:SCR_017619)</div></div><div style="margin-bottom:8px"><div>SAMTools</div><div>suggested: (SAMTOOLS, RRID:SCR_002105)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The minority variants and insertion/deletion sites were called using LoFreq* version 2.1.441. scRNA-seq analysis: Analyses of the scRNA-seq datasets including filtering, normalization and clustering were conducted using Seurat 3.142</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>LoFreq*</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>Seurat</div><div>suggested: (SEURAT, RRID:SCR_007322)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Human olfactory neuroepithelium raw data from Durante et al.22, was downloaded from Gene Expression Omnibus under accession code GSE139522.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Gene Expression Omnibus</div><div>suggested: (Gene Expression Omnibus (GEO, RRID:SCR_005012)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistics were performed in GraphPad Prism.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.07.22.216150: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">hACE2 expression was confirmed by immunofluorescence staining using mouse monoclonal antibody against c-Myc antibody 9E10 (Thermo Fisher) and Goat-anti-mouse FITC (Jackson ImmunoResearch Laboratories, Inc).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>c-Myc</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>Goat-anti-mouse FITC</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To measure surface TMPRSS2 expression, cells were detached by 1mM EDTA in PBS and then stained by 4 ug/ml of anti-Flag M2 antibody (Sigma, F1804) and 2 ug/ml of Goat anti-mouse IgG (H+L) conjugated with Alexa 647 (Jackson ImmunoResearch Laboratories, Inc, Cat#</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-Flag</div><div>suggested: (Sigma-Aldrich Cat# F1804, RRID:AB_262044)</div></div><div style="margin-bottom:8px"><div>anti-mouse IgG</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, HEK293T cells were co-transfected with three plasmids, pMLV-gag-pol, pCAGGS-VSV-G and pQCXIP-myc-hACE2-c9, and the medium was refreshed after overnight incubation of transfection mix.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The parental 293T cells were transduced with generated MLV virus, and the 293T-hACE2 cell lines were selected and maintained with medium containing puromycin (Sigma).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T-hACE2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HEK293T/ACE2/TMPRSS2 stable cell line was also constructed by transducing 293T-hACE2 cell line with MLV pseudovirus made by cotransfection of pMLV-gag-pol, pQCXIB-TMPRSS2-Flag and pCAGGS-VSV-G at 3:2:1 ratio into 293T cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T/ACE2/TMPRSS2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>293T</div><div>suggested: NCBI_Iran Cat# C498, RRID:CVCL_0063)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For the 293T-ACE2 stable cell line, 3 μg/mL of puromycin was added to the growth medium to maintain expression of ACE2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T-ACE2</div><div>suggested: RRID:CVCL_YZ65)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pseudovirus infection: HEK293T-ACE2 cells were seeded at 30% density in poly-lysine pre-coated 96-well plates 12-15 hours prior to transfection.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T-ACE2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analysis: Data expressed as mean values ± S.D. or S.E.M, and all statistical analysis was performed in GraphPad Prism 7.0 software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: We found the following clinical trial numbers in your paper:<br><table><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Identifier</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Status</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Title</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04338906</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Withdrawn</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Combination Therapy With Camostat Mesilate + Hydroxychloroqu…</td></tr></table>


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • No funding statement was detected.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.08.24.265090: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: The animals were housed and handled in accordance with the standards of the Association for the Assessment and Accreditation of Laboratory Animal Care International under University of Miami Institutional Animal Care & Use Committee-approved protocol.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Both female and male mice were used at 6–10 weeks of age.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">Contamination: mouse parvovirus (MPV), minute virus of mice (MVM), mycoplasma pulmonis, Mycoplasma sp., Polyoma, pneumonia virus of mice (PVM), Reovirus 3 (REO3), Sendai, Theiler’s murine encephalomyelitis virus (TMEV), and all test results were negative.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">ELISA): Protein expression was verified by SDS-page and Western blotting using rabbit anti-SARS-CoV-2 spike glycoprotein antibody (MBS 150780) at 1/1000 dilution and secondary antibody: Peroxidase AffiniPure F(ab’)2 Fragment Donkey Anti-Rabbit IgG (H+L) (Jackson ImmunoResearch Laboratories)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Anti-Rabbit IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">One million cells were plated in 1 mL for 24 hours and secreted gp96-Ig production was determined by ELISA using antihuman IgG antibody for detection and human IgG1 as a standard (Figure 1b).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>antihuman IgG</div><div>suggested: (GeneTex Cat# GTX28798, RRID:AB_374523)</div></div><div style="margin-bottom:8px"><div>human IgG1</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Rabbit anti-SARS-CoV-2 spike glycoprotein antibody (Abcam ab272504) and Donkey antirabbit IgG FITC, (BioLegend Cat# 406403) fluorescent antibody— were added in 1/50 and 1/100 dilutions of the antibodies combined in 5% BSA in PBS and/or rabbit isotype control (Abcam Ab172730 diluted 1/50), and incubated overnight at 4° C in a dark moisture chamber.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-CoV-2 spike glycoprotein</div><div>suggested: (Abcam Cat# ab272504, RRID:AB_2847845)</div></div><div style="margin-bottom:8px"><div>antirabbit IgG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>rabbit isotype control</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Generation of Vaccine Cell Lines: Human embryonic kidney (HEK)-293 cells, obtained from the American Tissue Culture Collection (ATCC, #CRL-1573) and human lung adenocarcinoma cell lines (AD100)40,41 (source: University of Miami, FL, USA) were transfected with 2 plasmids: B45 encoding gp96-Ig (source: University of Miami) and pcDNA™ 3.1(-) (Invitrogen), encoding full-length SARS-CoV-2 protein S gene (Genomic Sequence: NC_045512.2; NCBI Reference Sequence: YP_009724390.1 GenBank Reference Sequence: QHD43416).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK)-293</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HEK-293 and AD100 cells were simultaneously transfected with B45 and pcDNA 3.1 plasmid by lipofectamine (Invitrogen) following the manufacturers’ protocols.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK-293</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Equivalent number of 293-gp96-Ig-protein S and AD100-gp96-Ig-protein S cells that produce 200-ng gp96-Ig or PBS were injected via the subcutaneous (s.c.) route in C57Bl/6 and HLA-A2 transgenic mice.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>AD100-gp96-Ig-protein S</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Animals and Vaccination: Mice used in this study were colony-bred mice (C57Bl/6) and human leukocyte antigen (HLA)-A02-01 transgenic mice (C57BL/6-Mcph1Tg (HLA-A2.1)1Enge/J, Stock No: 003475) purchased from JAX Mice (the Jackson Laboratory for Genomic Medicine, Farmington, CT, USA)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>C57Bl/6</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>HLA)-A02-01</div><div>suggested: RRID:IMSR_TAC:9659)</div></div><div style="margin-bottom:8px"><div>C57BL/6-Mcph1Tg ( HLA-A2.1)1Enge/J</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Peptide stimulated and non-stimulated cells were first labeled with live/dead detection kit (Thermo Fisher Scientific, Waltham, MA, USA) and then resuspended in BD Fc Block (clone 2.4G2) for 5 minutes at room temperature prior to staining with a surface-stain cocktail containing the following antibodies purchased from BioLegend® (San Diego, CA, USA): antigen presenting cell (APC)Cy7 CD45; Clone; AF700 CD3: Clone: 17A2; APC CD4:</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BioLegend®</div><div>suggested: (BioLegend, RRID:SCR_001134)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Analysis was performed using FlowJo™ software version 10.8</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo™</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were acquired on SP6800 Sony instrument and data analyzed using FlowJo software version 10.8.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Comparisons of flow cytometry cell frequencies were measured by the 2-way analysis of variance (ANOVA) test with Holm-Sidak multiple-comparison test, *p<0.05, **p<0.01, and ***p<0.001, or unpaired T-tests (2-tailed) were carried out to compare the control group with each of the experimental groups (alpha level of 0.05) using the Prism software (GraphPad Software, San Diego, CA, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Prism</div><div>suggested: (PRISM, RRID:SCR_005375)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All statistical analysis was conducted using GraphPad Prism 8 software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: We found the following clinical trial numbers in your paper:<br><table><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Identifier</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Status</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Title</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT02117024</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Terminated</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients Wi…</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT02439450</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Active, not recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">A Study of Combination Therapies With Viagenpumatucel-L (HS-…</td></tr></table>


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.08.23.263327: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In the present study, three types of plasmids pEGFP-C1 (maintained in the lab of Hao Zhou), pSARS and pCoV-ba, and three types (Hela, HEK293 and HEK293T) of cell maintained in our lab were used for transfection.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: NCBI_Iran Cat# C498, RRID:CVCL_0063)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The results were confirmed using Illumina RNA-seq data from the NCBI SRA database under the accession number SRP251618.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>NCBI SRA</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistics and plotting were conducted using the software R v2.15.3 with the package ggplot2 [10].</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ggplot2</div><div>suggested: (ggplot2, RRID:SCR_014601)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After 12 hours (0 hour in figure 2B), transfection of 1 μg of plasmid into one well was performed using 3 μL PolyJet (SignaGen Laboratories, USA), following the manufacturer’s instructions.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>PolyJet</div><div>suggested: None</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.08.24.264333: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      NIH rigor criteria are not applicable to paper type.

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HRP-conjugated secondary antibodies against T7-tag (Thermo) were diluted 1:7500 and incubated with the well for 1 hr at room temperature.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>T7-tag</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">A validated SARS-CoV-2 antibody-negative human serum control, a validated NIBSC SARS-CoV-2 plasma control, was obtained from the National Institute for Biological Standards and Control, UK) and an uninfected cells control were also performed to ensure that virus neutralization by antibodies was specific.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Control , UK </div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The RBD (residues 319-541) of the SARS-Cov-2 S protein was expressed as a secreted protein in Spodoptera frugiperda Sf9 cells (Expression Systems) using the Bac-to-bac baculovirus method (Invitrogen).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Sf9</div><div>suggested: CLS Cat# 604328/p700_Sf9, RRID:CVCL_0549)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pseudotyped SARS-CoV-2 neutralization assay: The 293T-hsACE2 stable cell line (Cat# C-HA101) and the pseudotyped SARS-CoV-2 (Wuhan-Hu-1 strain) particles with GFP (Cat# RVP-701G, Lot#CG-113A) or firefly luciferase (Cat# RVP-701L, Lot# CL109A, and CL-114A) reporters were purchased from the Integral Molecular.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T-hsACE2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The serum–virus mixes (220 μl total) were incubated at 37 °C for 1 h, after which they were added dropwise onto confluent Vero E6 cell monolayers in the six-well plates.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: RRID:CVCL_XD71)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The raw data was processed by Prism 7 (GraphPad) to fit into a 4PL curve and to calculate logIC50.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Prism</div><div>suggested: (PRISM, RRID:SCR_005375)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After the MS analysis, the data was searched by pLink for the identification of cross-linked peptides.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pLink</div><div>suggested: (PLINK, RRID:SCR_001757)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Each Nb model was then docked to the RBD structure (PDB 6LZG) by an antibody-antigen docking protocol of PatchDock software that focuses the search to the CDRs and optimizes CXMS-based distance restraints satisfaction (Schneidman-Duhovny, 2012 #52; Schneidman-Duhovny, 2020 #53).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>PatchDock</div><div>suggested: (PatchDock, RRID:SCR_017589)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The antigen interface residues (distance <6Å from Nb atoms) among the top 10 scoring models, according to the SOAP score, were used to determine the epitopes.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SOAP</div><div>suggested: (SOAP, RRID:SCR_000689)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The initial model was refined in Phenix (Adams, 2010 #61)and adjusted in COOT (Emsley, 2004 #62).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Phenix</div><div>suggested: (Phenix, RRID:SCR_014224)</div></div><div style="margin-bottom:8px"><div>COOT</div><div>suggested: (Coot, RRID:SCR_014222)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The model quality was checked by MolProbity (Williams, 2018 #63).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MolProbity</div><div>suggested: (MolProbity, RRID:SCR_014226)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Nb21 comparative modeling was done using the Nb20 structure as a template in MODELLER.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MODELLER</div><div>suggested: (MODELLER, RRID:SCR_008395)</div></div></td></tr></table>

      Results from OddPub: Thank you for sharing your data.


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.08.23.258574: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">Mice were randomized and received either vehicle 30% (m/v) Kolliphor 15 HS (Sigma) in PBS or 2 mg per 30 g mouse body weight of INCB054329 at 20 mg/ml in the Kolliphor solution (66.7 mg/kg).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">For some experiments apabetalone and RVX-2157 were sent blinded by Resverogix.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Single cells were separated using a 100 μm strainer and labelled with CD31 antibody (1:200, M082329-2, DAKO) at 4°C for 45 min followed by 30 min staining with a goat anti-mouse secondary antibody conjugated to AlexaFluor 488 or 555 (1:400, A-11001 and A-21422, ThermoFisher Scientific).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CD31</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-mouse</div><div>suggested: (Thermo Fisher Scientific Cat# A-11001, RRID:AB_2534069)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were stained with primary antibodies CD31 (1:200, M082329-2, DAKO), NG2 (1:200, 14-6504-82, ThermoFisher Scientific) and cardiac troponin T (1:400, ab45932, Abcam) in 5% FBS and 0.25% TritonX-100 Blocking Buffer at 4°C overnight on a rocker.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>NG2</div><div>suggested: (Thermo Fisher Scientific Cat# 14-6504-82, RRID:AB_10870987)</div></div><div style="margin-bottom:8px"><div>cardiac troponin T</div><div>suggested: (Abcam Cat# ab45932, RRID:AB_956386)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were washed twice for 1 h with Blocking Buffer and labelled with secondary antibodies goat anti-mouse IgG1 AlexaFluor 488 (1:400, A-21121),</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-mouse IgG1</div><div>suggested: (Molecular Probes Cat# A-21121, RRID:AB_2535764)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After 1 h blocking using a 1:1 mix of LI-COR Odyssey Blocking Buffer (LI-COR Biotechnology) and PBS, membranes were incubated overnight on a platform shaker with primary antibodies for ACE2 (1:200, R&D Systems, AF933) and GAPDH (1:1000, Cell Signaling Technologies, 97166S).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ACE2</div><div>suggested: (LSBio (LifeSpan Cat# LS-C347-1000, RRID:AB_1271963)</div></div><div style="margin-bottom:8px"><div>GAPDH</div><div>suggested: (Cell Signaling Technology Cat# 97166, RRID:AB_2756824)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Membranes were washed 5 times 3 minutes in PBS with 0.5% Tween, prior to incubation with IRDye® secondary antibodies (1:10000 for IRDye® 800CW Goat anti-Mouse IgG Secondary Antibody, 926-32210, and 680RD Donkey anti-Goat IgG Secondary Antibody, LI-COR Biotechnology, 925-68074) for 1 h at room temperature.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-Goat IgG</div><div>suggested: (LI-COR Biosciences Cat# 925-68074, RRID:AB_2650427)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For ACE2 assays the following was used for control, 1:200 Goat IgG Alexa Fluor 647-conjugated antibody, and assay 1:200 anti-human ACE2 AlexFluor 647 conjugated antibody and 1:200 anti-human CD90 (all RnD Systems) and were incubated for 60 min at 4°C in Binding Buffer.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human ACE2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-human CD90</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Both conditions were then incubated with 1:400 goat anti-mouse IgG secondary antibody conjugated to Alexa Fluor 555 (ThermoFisher Scientific) in Binding Buffer for 45 min at 4°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-mouse IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Both conditions were then incubated with 1:400 F(ab’)2-goat anti-human IgG Fc secondary antibody conjugated to Alexa Fluor 488 and 1:400 goat anti-mouse IgG secondary antibody conjugated to Alexa Fluor 555 (both ThermoFisher Scientific) in Binding Buffer for 45 min at 4°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG</div><div>suggested: (GenWay Biotech Inc. Cat# GWB-73F555, RRID:AB_10273468)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2 K18-hACE2 mouse infection model: Female K18-hACE2 mice were lightly anesthetized using isoflurane and 50 μl of SARS-CoV-2 at 5 × 104 TCID50 per mouse was administered via intranasal inoculation (i.n.).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>K18-hACE2</div><div>suggested: RRID:IMSR_GPT:T037657)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Videos were then analysed with a custom written Matlab program (Mills et al., 2017).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Matlab</div><div>suggested: (MATLAB, RRID:SCR_001622)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">MS data processing: RAW MS data was processed in the MaxQuant software environment (Cox and Mann, 2008)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MaxQuant</div><div>suggested: (MaxQuant, RRID:SCR_014485)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data analysis was performed using the Perseus software package (Tyanova and Cox, 2018).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Perseus</div><div>suggested: (Perseus, RRID:SCR_015753)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Default options were used with CellRanger and a custom made pre mRNA reference using GRCh38 v3.0.0 was used to map the reads and for count quantification with the CellRanger counts tool.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CellRanger</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All pre-processing and filtering steps of the datasets were subsequently carried out via the Python package Scanpy (https://scanpy.readthedocs.io/en/stable/) (Wolf et al., 2018).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Python</div><div>suggested: (IPython, RRID:SCR_001658)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">hCO comparison to bulk nuclei RNA sequencing data for PCA: Nuclear RNA-seq dataset generated from sorted cardiomyocyte nuclei at two stages (fetal and adult) was obtained from BioProject ID: PRJNA353755 (Gilsbach et al., 2018).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BioProject</div><div>suggested: (NCBI BioProject, RRID:SCR_004801)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Annotations and genome files (hg38) were obtained from Ensembl (release 102).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Ensembl</div><div>suggested: (Ensembl, RRID:SCR_002344)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Subsequent analyses of the count data were performed in the R statistical programming language with the Bioconductor packages edgeR (Robinson et al., 2010) and the annotation package org.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Bioconductor</div><div>suggested: (Bioconductor, RRID:SCR_006442)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Additionally, ribosomal and mitochondrial genes as well as pseudogenes, and genes with no annotation (Entrez Gene identification) were removed before normalization and statistical analysis.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Entrez Gene</div><div>suggested: (Entrez Gene, RRID:SCR_002473)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Sequence reads were trimmed for adapter sequences using Cutadapt version1.9 (Martin, 2011) and aligned using STAR version 2.5.2a (Dobin et al., 2013) to the Mus Musculus GRCm38 assembly with the gene, transcript, and exon features of Ensembl (release 102) gene model, and the SARS-CoV-2 Ensembl genome assembly ASM985889v3.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Cutadapt</div><div>suggested: (cutadapt, RRID:SCR_011841)</div></div><div style="margin-bottom:8px"><div>STAR</div><div>suggested: (STAR, RRID:SCR_015899)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Quality control metrics were computed using RNA-SeQC version 1.1.8 (DeLuca et al., 2012) and expression was estimated using RSEM version 1.2.30 (Li and Dewey, 2011).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>RNA-SeQC</div><div>suggested: (RNA-SeQC, RRID:SCR_005120)</div></div><div style="margin-bottom:8px"><div>RSEM</div><div>suggested: (RSEM, RRID:SCR_013027)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Trimmed mean of M-values (TMM) normalization and differential expression analysis were performed using the R package edgeR (Robinson et al., 2010).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>edgeR</div><div>suggested: (edgeR, RRID:SCR_012802)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To estimate SARS-CoV-2 replication levels, sequence reads were aligned to SARS-CoV-2 only, and samtools (Li et al., 2009) version 1.9 was used to estimate the mapping rate of the reads to the viral genes.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>samtools</div><div>suggested: (SAMTOOLS, RRID:SCR_002105)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Comparison of different RNA-seq data: KEGG and Encode TF analyses was performed using Enrichr (Kuleshov et al., 2016).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>KEGG</div><div>suggested: (KEGG, RRID:SCR_012773)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Networks were generated through the use of Ingenuity Pathway Analysis (IPA) on DEGs (QIAGEN Inc., https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Ingenuity Pathway Analysis</div><div>suggested: (Ingenuity Pathway Analysis, RRID:SCR_008653)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistics were performed using GraphPad Prism v8 unless noted.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: We found the following clinical trial numbers in your paper:<br><table><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Identifier</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Status</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Title</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT01067820</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Completed</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">ApoA-I Synthesis Stimulation and Intravascular Ultrasound fo…</td></tr></table>


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.02.16.21251850: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: Because only fit factors were measured and no identifiable private information was collected, the West Virginia University Office of Human Research Protections determined that Institutional Review Board approval was not required.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">For breathing tests, the system used a ventilation rate of 15 L/min with a breathing rate of 12 breathes/min and a tidal volume of 1.25 liters, which corresponds to the ISO standard for a female performing light work (ISO 2015).</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">A fit factor was calculated by the PortaCount® software for all measurements (Janssen and McKay 2017; TSI 2015).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>PortaCount®</div><div>suggested: None</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      Fit tests are designed to measure the effects of face seal leaks but have their own limitations when applied to cloth masks. As noted above, fit factor measurements for cloth masks reflect some combination of particle penetration through the media and face seal leakage which will likely vary from mask to mask. Thus, it is neither clear how to interpret fit factor measurements for cloth masks nor is it clear how this relates to the effectiveness of the mask as a source control device. In addition, fit test results can vary greatly from person to person and even somewhat for the same person during repeated tests (Lawrence et al. 2006). Similarly, a comparison of fit tests between humans and a pliable skin manikin headform found significant differences (Bergman et al. 2015). Much of this discrepancy is likely due to facial variations and differences in how the mask is placed on the person or manikin headform. It is possible to shift, stretch, tighten, loosen, or adjust the masks in many ways, and small differences in how the mask is worn may have substantial effects on the fit test results. For example, in tests with three subjects using the Artisan procedure mask, we found that tightening the mask against the face by using silicone ear loop adjusters increased the mean fit factor from 1.7 to 4.0 (Figure 8). In our tests of cloth masks, the r2 value for the manikin headform fit tests done before coughing experiments and before exhalation experiments was only 13%, suggesting that...

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.02.17.431704: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: Experiments using SARS-CoV-2 were performed at the University of Michigan under Biosafety Level 3 (BSL3) protocols in compliance with containment procedures in laboratories approved for use by the University of Michigan Institutional Biosafety Committee (IBC) and Environment, Health & Safety (EHS).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS coronavirus 2 (SARS-CoV-2), isolate USA-WA1/2020 (NR-52281) was obtained from Bei resources and was propagated in Vero E6 cells in DMEM supplemented with 2% FBS, 4.5 g/L D-glucose, 4 mM L-glutamine, 10 mM Non-Essential Amino Acids, 1 mM Sodium Pyruvate and 10 mM HEPES.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: RRID:CVCL_XD71)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Fifty thousand Calu-3 were seeded in 48 well plate and allowed to form 80% confluent monolayer.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Calu-3</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Host-virus chimeric read analysis: The raw sequencing files were download from the Sequence Read Archive (SRA) as shown in the Table S1.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Sequence Read Archive</div><div>suggested: (DDBJ Sequence Read Archive, RRID:SCR_001370)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Sequencing reads were aligned as single end to the chimeric genome of human (hg38) and SARS-CoV2 (NC_045512.2) using STAR aligner (v2.7.7a).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>STAR</div><div>suggested: (STAR, RRID:SCR_015899)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To examine the genomic features of the HVC reads, HOMER (v4.11) annotatePeaks.pl was used to annotate the HVC junctions and the corresponding RNA-seq library.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HOMER</div><div>suggested: (HOMER, RRID:SCR_010881)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In brief, reads in each RNA-seq library were converted to genomic regions by bamTobed (bedtools, v2.30.0) and the unique regions were kept using the following command”sort -k1,1 -k2,2n | uniq”.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>bedtools</div><div>suggested: (BEDTools, RRID:SCR_006646)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.02.17.431579: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      NIH rigor criteria are not applicable to paper type.

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Connectivity map analysis for identifying similarities with known perturbations: The connectivity map dataset currently contains 1,319,138 gene expression profiles, resulting in 473,647 signatures, generated against approximately 27,000 perturbations in 9 cell lines including MCF7, HEPG2, A549, A375, PC3, HCC515, HT29, HA1E and VCAP.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEPG2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>A549</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>A375</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>HCC515</div><div>suggested: RRID:CVCL_5136)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cipa treatment in DENV infection: MCF-7 were seeded at 100,000 cells per well in 24 well plate and were maintained for 24 hours (37 degrees; 5% CO2).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MCF-7</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">50,000 BHK-21 cells were plated per well in 24-well plate.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BHK-21</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">siRNA-mediated knockdown of ESR1 in MCF7 cells: 1 μM concentration of siRNA targeting ESR1 gene and non-targeting control (NTC) were mixed with Opti-MEM (Life Technologies) and 1 μl of Lipofectamine RNAiMax to a total volume of 100 μl in a 24-well plate.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MCF7</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Batch effects were removed and differential gene expression analysis was done using the limma package in R.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>limma</div><div>suggested: (LIMMA, RRID:SCR_010943)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After correcting for FDR<5%, enrichments were analyzed for GO: Molecular Function, Cellular Compartment, Biological Processes, KEGG and Reactome.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>KEGG</div><div>suggested: (KEGG, RRID:SCR_012773)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In order to identify the specific sets of genes modulated by Cipa, we used Gene set enrichment analysis.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Gene set enrichment analysis</div><div>suggested: (Gene Set Enrichment Analysis, RRID:SCR_003199)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">ERE analysis: Sequence of 5KB upstream region of genes were downloaded from UCSC genome browser for Human genome GRCh38 build.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>UCSC genome browser</div><div>suggested: (UCSC Genome Browser, RRID:SCR_005780)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The CIPA ligands available in the PubChem database were downloaded from there, the 3D structures of the rest of the ligands were drawn using Marvin Sketch, a computational tool for drawing 3 and 2 dimensional chemical structures.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>PubChem</div><div>suggested: (PubChem, RRID:SCR_004284)</div></div></td></tr></table>

      Results from OddPub: Thank you for sharing your data.


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.02.17.431630: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells and viruses: Human embryonic kidney cells (HEK) 293T (ATCC CRL-3216)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, HEK293T7-NP helper cells (stably expressing MV-N and MV-P genes), African green monkey kidney cells (Vero) and Vero C1008 clone E6 (ATCC CRL-1586) were maintained at 37°C, 5% CO2 in Dulbecco’s modified Eagle medium (DMEM) (Thermo Fisher) supplemented with 5% (for Vero cells) or 10% (for HEK293T cells) heat-inactivated fetal bovine serum (FBS) (Corning), 100 units/ml of penicillin-streptomycin and 100 ug/ml of streptomycin.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero C1008</div><div>suggested: ATCC Cat# CRL-1586, RRID:CVCL_0574)</div></div><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, helper HEK293T7-NP cells were individually transfected with 5 µg of pTM-MVSchwartz-based SARS-CoV-2 S plasmids and 0.02 µg of pEMC-La, plasmid expressing the MV polymerase (L) gene 60.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T7-NP</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Virus growth kinetics of rMVs was studied on monolayers of Vero cells in 6-well plates.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: None</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: We found the following clinical trial numbers in your paper:<br><table><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Identifier</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Status</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Title</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04357028</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Suspended</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Measles Vaccine in HCW</td></tr></table>


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on page 35. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.02.14.21251704: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were then washed with 1 mL PBS+, spun at 900 x g, and stained with 2 µg/mL of anti-human IgG-AF647 polyclonal antibody (Invitrogen) for 30 minutes at room temperature.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG-AF647</div><div>suggested: (SouthernBiotech Cat# 2040-31, RRID:AB_2795651)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2 receptor binding domain and spike IgG, IgM, and IgA ELISA: Quantitative detection of total antibodies to SARS-CoV-2 receptor binding domain (RBD) was performed as previously described (Garcia-Beltran et al. 2021).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SARS-CoV-2 receptor binding domain and spike IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, we used an indirect ELISA with a standard consisting of anti-SARS-CoV and -CoV-2 monoclonal antibody (CR3022) (IgG1 isotype).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-CoV</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>-CoV-2</div><div>suggested: (Imported from the IEDB Cat# CR3022, RRID:AB_2848080)</div></div><div style="margin-bottom:8px"><div>CR3022</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>(IgG1</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Total antibodies were detected with anti-human IgG/A/M(H+L)-HRP (Bethyl) diluted 1:25,000 for a 30 min incubation at room temperature.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG/A/M(H+L)-HRP</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Anti-RBD antibody levels were calculated by interpolating onto the standard curve and correcting for sample dilution; one unit per mL (U/mL) was defined as the equivalent reactivity seen by 1 µg/mL of CR3022.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Anti-RBD</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Following collection and filtering, production was quantified by titering via flow cytometry on 293T-ACE2 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T-ACE2</div><div>suggested: RRID:CVCL_YZ65)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Spike Expression: To compare the relative surface expression of pseudovirus spike variant proteins, we plated 400,000 293T cells per well of a 12-well plate.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data was analyzed using Graphpad Prism and NT50 values were calculated by taking the inverse of the 50% inhibitory concentration value for all samples with a neutralization value of 80% or higher at the highest concentration of serum.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Graphpad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.02.14.431177: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: Autopsy and biopsy materials were obtained from the Pontificia Universidade Catolica do Parana PUCPR the National Commission for Research Ethics (CONEP) under ethics approval numbers 2020001792/30188020.7.1001.0020 and 2020001934/30822820.8.000.0020.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Antibodies: The following antibodies were used: mouse anti-ACE2 (Santa Cruz, sc-390851, IF1:200) goat anti-ACE2 (R&D systems, AF933, WB 1:1000), mouse anti-dsRNA (Millipore, MABE1134, IF1:100)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-ACE2</div><div>suggested: (Santa Cruz Biotechnology Cat# sc-390851, RRID:AB_2861379)</div></div><div style="margin-bottom:8px"><div>anti-dsRNA</div><div>suggested: (Millipore Cat# MABE1134, RRID:AB_2819101)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell culture: Human umbilical vein endothelial cells (HUVECs), and human microvascular endothelial cells from lungs (HMVEC-L) purchased from Lonza (Cat# CC-2935, and CC-2527 respectively) were cultured until passage 8 in EGM-Plus or EGM-2MV medium, supplemented with singlequots (Lonza Cat# CC-5035, CC-3102)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HUVECs</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Calu-3 cells purchased from ATCC (Cat# HTB-55) were maintained in MEM (Invitrogen), containing 10% (v/v) heat-inactivated foetal bovine serum (Cytiva), 100 U/ml penicillin and streptomycin (Life Technologies Australia), and grown in EGM-2MV for endothelial co-culture experiments.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Calu-3</div><div>suggested: ATCC Cat# HTB-55, RRID:CVCL_0609)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Monocultures of HUVEC, HMVEC or Calu-3 cells were performed on 24 well cell culture inserts (Corning 6.5 mm Transwell, 0.4 µm polycarbonate membrane Cat#3413) coated with 5 µg/ml FN (Sigma).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HUVEC</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Virus was grown on Vero cells and titred [38].</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: CLS Cat# 605372/p622_VERO, RRID:CVCL_0059)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Image analysis: Analysis of immunofluorescent images was performed using ImageJ version 2.0.0-rc-69/1.52n.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ImageJ</div><div>suggested: (ImageJ, RRID:SCR_003070)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Imaris (Bitplane) version 8 was used to create the XZ projection in Figure 4B’’.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Imaris</div><div>suggested: (Imaris, RRID:SCR_007370)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analysis: All statistical analysis was performed using Graphpad Prism version 9.0.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Graphpad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      The present study was subject to several limitations. Firstly, coagulation, thrombosis and induction of angiogenesis in the lungs of deceased COVID-19 patients has been described in addition to endothelial dysfunction [3]. This angiogenic response is thought to be predominantly mediated through intussusceptive angiogenesis, where a new blood vessel is formed by splitting of an existing vessel. This effect appears to be specific to COVID-19 patients, as lungs from decreased influenza patients do not display increased angiogenic features. Whether this is due to relative hypoxia in the lungs remains unclear, although elevated angiogenic growth factors such as VEGF-A and VEGF-C have been associated with COVID-19 [3, 39]. In this study we have not addressed the effect of SARS-CoV-2 exposure on the angiogenic capacity of endothelial cells in culture. Given the intimate association between inflammation, endothelial dysfunction and angiogenesis [40, 55], these are critical aspects of COVID-19 pathology that remain to be addressed in subsequent studies. An additional limitation of the present study is that, due to the reductionist nature of the in vitro systems used herein, we were unable to address the contribution of immune cells to endothelial cell dysfunction during SARS-CoV-2 infection. Multiple studies attribute the sustained inflammatory response directly to immune cells, wherein macrophage activation, monocyte NLRP3 inflammasome signalling, complement activation and extrusion ...

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.02.15.431215: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: Ethics statement: The protocols for the human study were approved by the local Research Ethics Committee (REC) – Berkshire (REC 16/SC/0265).<br>Consent: The study conformed to the Helsinki declaration principles and Good Clinical Practice (GCP) guidelines and all subjects enrolled into the study provided written informed consent.<br>IACUC: All participants were recruited at the Mortimer Market Centre for Sexual Health and HIV Research and the Royal Free Hospital (London, UK) following written informed consent as part of a study approved by the local ethics board committee.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, ELISPOT plates (S5EJ044I10; Merck Millipore, Darmstadt, Germany) pre-wetted with 30 µl of 70% ethanol for a maximum of 2 minutes, washed with sterile PBS and coated overnight at 4 °C with anti–IFN-γ antibody (10 µg/ml in PBS; clone 1-D1K; Mabtech, Nacka Strand, Sweden).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti–IFN-γ</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After overnight rest, PBMCs were stimulated for 6 h with 2 μg/mL of SARS-CoV-2 peptide pools, Influenza, HIV-1 Gag or cytomegalovirus (CMV)-pp65 peptide pools, or with 0.005% dimethyl sulphoxide (DMSO) as a negative control in the presence of αCD28/αCD49d co-Stim antibodies (1 μg ml−1) GolgiStop</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Influenza</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>HIV-1 Gag</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>cytomegalovirus ( CMV)-pp65</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">(containing Monensin, 2 μmol/L), GolgiPlug (containing brefeldin A, 10 μg ml−1) (BD Biosciences) and anti-CD107α BV421 antibody (BD Biosciences).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Monensin , 2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-CD107α BV421</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After stimulation, cells were washed and stained with anti-CCR7 (BioLegend) for 30 min at 37 °C and then surface stained at 4°C for 20 min with different combinations of surface antibodies in the presence of fixable live/dead stain (Invitrogen).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-CCR7</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pseudovirus production and neutralization assays: HIV-1 particles pseudotyped with SARS-Cov-2 spike were produced by seeding 3×106 HEK- 293T cells in 10ml complete DMEM (DMEM supplemented with 10% FBS, L-Glutamine, 100 IU/ml penicillin and 100 µg/ml streptomycin) in a T-75 culture flask.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HeLa ACE-2 cells (gift from James E Voss, Scripps Institute) were then added to the assay (10,000 cells per 100 μL per well).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HeLa ACE-2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">ODs were measured using a MultiskanFC (Thermofisher) plate reader at 405nm and S1 & N-specific IgG titers interpolated from the IgG standard curve using 4PL regression curve-fitting on GraphPad Prism 8.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">(BD Bioscience) and data analysed using FlowJo 10 (TreeStar).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">: Prism 8 (GraphPad Software) was used for statistical analysis as follows: the Mann–Whitney U-test was used for single comparisons of independent groups, the Wilcoxon-test paired t-test was used to compare two paired groups.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Polyfunctionality tests were performed in SPICE version 6.0.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SPICE</div><div>suggested: (SPICE, RRID:SCR_016603)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      There are limitations to this study. The observed heterogeneity in the magnitude of cellular and humoral responses that are not always fully coordinated highlights the need to consider additional putative factors as they relate to adaptive immunity. This cross-sectional study was not powered to study age and demographic differences according to the full spectrum of COVID-19 disease by HIV serostatus. Larger studies are required to determine the role of gender, racial and ethnicity effects, especially in areas of high HIV burden and additional comorbidities, to help identify individuals who are particularly vulnerable to the impact of SARS-CoV-2 infection and need targeted vaccination interventions. Nonetheless, the prospective, longitudinal design of this current study, integrating clinical parameters, antibody and T cell responses, will help address longer term protective immunity and emerging questions, such as immune responses to new SARS-CoV-2 variants (C Rees-Spear 2021; Houriiyah Tegally 2020; SA Kemp 2020; Sandile Cele 2021; Wibmer et al. 2021), and during the subsequent vaccination roll-out. Collectively, our results provide benchmark data into the facets of adaptive immunity against SARS-CoV-2 in the setting of treated HIV infection, providing evidence for medium-term durable antibody and cellular responses. Although reassuring, our data also have implications for PLWH with inadequate immune reconstitution, reflected in the low/inverted CD4:CD8 ratio, and potentially...

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on page 55. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.02.16.430255: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The second antibody was prepared by diluting HRP-labeled goat anti-chicken(Provided by ZSGB-Bio) with a ratio of 1:10000, and incubated for 1.5 h at room temperature, TBST washed the membrane for 5 times, The mixed immunoblotting chemiluminescence solution was dripped on NC membrane, incubated at room temperature for 2-3 minutes, then placed in a cassette, and the X-ray film was developed (See Fig.4). 6.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-chicken(Provided by ZSGB-Bio</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The cells were further incubated with the primary antibody (a monoclonal antibody against viral S protein) for 2 h, followed by incubation with the secondary antibody (Alexa 488-labeled goat anti-mouse[1:500; Abcam]).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-mouse[1:500</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Forty-eight hours posttransfection, 150 μl pseudotyped VSV-ΔG bearing VSV-G protein were used to infect Vero E6 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: RRID:CVCL_XD71)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2 -IgY (dilution ratio: 1:10000) was incubated overnight by inversion method.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SARS-CoV-2 -IgY</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Western blot: SARS-CoV-2 S-RBD (provided by Sina Biological Company) was separated by polyacrylamide amine gel (10% separation gel+5% concentration gel) under the electrophoresis condition of 50 mA for 60 min.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Sina</div><div>suggested: (SINA, RRID:SCR_005067)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.01.29.21250790: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">Consent: Human samples: Samples were collected from healthy volunteers and subjects who provided informed consent to National Institutes of Health (NIH) Institutional Review Board (IRB)-approved protocols (20-D-0094, NCT04348240; 20-CC-0128, NCT04424446) at the NIH Clinical Center.<br>IRB: Human samples: Samples were collected from healthy volunteers and subjects who provided informed consent to National Institutes of Health (NIH) Institutional Review Board (IRB)-approved protocols (20-D-0094, NCT04348240; 20-CC-0128, NCT04424446) at the NIH Clinical Center.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, heat-inactivated FBS, 293FT cells were procured from Thermo Fisher Scientific</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293FT</div><div>suggested: ATCC Cat# PTA-5077, RRID:CVCL_6911)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Clinical laboratory CDC SARS-CoV-2 Assay: The conventional RNA-extraction RT-qPCR method following CDC guideline has been reported, and herein referred as easyMAG-CL (clinical laboratory) assay.21 Briefly, nucleic acid from individual specimens was extracted from 200 μL of Saliva/NPspecimens using the NucliSENS® easyMAG® platform (bioMérieux, Marcy l’Etoile, France) with an elution volume of 50 μL.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>NucliSENS®</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Molecular biology grade water (cat# 351-029-101), TE pH 8.0 (cat# 351-011-131), 1M Tris-HCl pH7.5 (cat# 351-006-101), HBSS with Ca2+/Mg2+ (cat# 114-061-101) were from Quality Biological (Gaithersburg, MD).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Quality Biological</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The Luna Universal Probe One-Step RT-qPCR Kit (#E3006X, NEB) was used for RT-qPCR with the following cycling conditions using a QuantStudio 3 real-time PCR system (ThermoFisher Scientific): NEB-Luna-Program I: 55°C for 10 min, 95°C for 1 min, and 45 cycles of 95 °C for 10 sec and 60 °C for 40 sec or NEB-Luna-Program II: 55°C for 10 min, 95°C for 1 min, and 45 cycles of 95 °C for 5 sec and 60 °C for 20 sec.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ThermoFisher Scientific)</div><div>suggested: None</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      One limitation of the current study was the low-level contamination observed in the RT-ddPCR assay, where one or two positive droplets were observed in the no-template control reactions. The contamination could result from either viral RNA or PCR amplicon present in the research laboratory. Due to the background contamination, we used 1.8 copies/µl as the low limit of detection for the SARS-CoV-2 N1/N2 RT-ddPCR assay. According to the FDA Emergency Use Authorization (EUA) by the manufacturer Bio-Rad, the low limit of detection in the 1-well RT-ddPCR assay system is 2 positive droplets and no positive droplets observed in no-template controls. Thus the low limit of detection in a RT-ddPCR assay could reach 0.1 copy/µl if performing in a clean room. In summary, we robustly demonstrate improvements in COVID-19 viral testing workflow using synthetic and real-world samples employing the Chelex-based extraction-free workflow. This methodology has the clear benefit of dramatic improvements in sensitivity, cost, and time savings for clinical laboratory testing. Additionally, this method exhibits improved safety characteristics including obviating the need for the use of a biological safety cabinet and harsh disinfection chemicals prior to testing. Finally, this method is easily adapted to both clinical and research laboratories and could be standard of care for nucleic acid testing and transport in the near future.

      Results from TrialIdentifier: We found the following clinical trial numbers in your paper:<br><table><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Identifier</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Status</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Title</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04348240</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Transmissibility and Viral Load of SARS-CoV-2 in Oral Secret…</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04424446</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Saliva as Source of Detection for SARS-CoV-2</td></tr></table>


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.02.01.429176: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells: A549 cells stably expressing ACE2 (A549-ACE2, kindly provided by Dr. Olivier Schwartz), were propagated at 37°C, 5% CO2 in DMEM with L-glutamine (Gibco) supplemented with 10% FBS, penicillin-streptomycin and 20 μg/mL blasticidin S.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>A549</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">It was propagated once in Vero-E6 cells. siRNA: Virus infections: For infections, the cell culture medium was replaced with virus inoculum (MOI 0.1 PFU/cell) and incubated for one hour at 37°C, 5% CO2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero-E6</div><div>suggested: None</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.02.01.429219: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: All animal experiments were conducted in accordance with the guidelines and approval of the Institutional Animal Care and Use Committee (IACUC) at KFMRC and the ethical approval from the bioethical committee at KAU (approval number 04-CEGMR-Bioeth-2020).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Animal Studies: Six to 8-week-old female BALB/c or C57BL/6J mice were obtained from and housed in the animal facility in King Fahd Medical Research Center (KFMRC), King Abdulaziz University (KAU), Jeddah, Saudi Arabia.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The harvested cell lysates were subjected to western blot analysis to verify the expression of S protein using in house mouse anti-S (SARS-CoV-2) polyclonal antibodies at a 1:2000 dilution.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-S</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>SARS-CoV-2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After three washes with PBS-T, cells were incubated with Alexa Fluor-488 labeled goat anti-mouse IgG H&L secondary antibody (Abcam, UK) at 1:500 dilution in blocking buffer in the dark at room temperature for 1 h.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-mouse IgG</div><div>suggested: (Abcam Cat# ab19639, RRID:AB_2040847)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">peroxidase-conjugated rabbit anti-mouse IgG secondary antibodies as well as anti-IgG1, IgG2a or IgG2b antibodies (Jackson Immunoresearch Laboratories, West Grove, PA) were added at dilutions recommended by the manufacturer and incubated for 1 h at 37°C as 100 μl/well.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>peroxidase-conjugated rabbit anti-mouse IgG secondary antibodies</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-IgG1 , IgG2a</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>IgG2b</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After washing with PBS, PB-conjugated anti-mouse CD8, PB-conjugated anti-mouse CD4, APC-conjugated anti-mouse CD44 antibody and Pe-Cy7-conjugated anti-mouse CD62L antibodies (BioLegend, UK) were used for surface markers staining.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-mouse CD8</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-mouse CD4</div><div>suggested: (Gen-Probe Cat# 873.045.050, RRID:AB_10408047)</div></div><div style="margin-bottom:8px"><div>anti-mouse CD44</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-mouse CD62L</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">PE-conjugated anti-mouse TNF-α (clone MP6-XT22) and Pe-Cy7–conjugated anti-mouse IL-2 (clone JES6-5H4) antibodies (BioLegend, UK) for 20 min at 4°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-mouse TNF-α</div><div>suggested: (Leinco Technologies Cat# T798, RRID:AB_2832121)</div></div><div style="margin-bottom:8px"><div>anti-mouse IL-2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells: Baby Hamster kidney BHK-21/WI-2 cell line (Kerafast, EH1011), African Green monkey kidney-derived Vero E6 cell line (ATCC, CRL-1586) and Human embryonic kidney 293 cells (ATCC, CRL-1573) were cultured in Dulbecco’s modified essential medium (DMEM) containing penicillin (100 U/ml) and streptomycin (100 μg/ml) and supplemented with 5 or 10% fetal bovine serum (FBS) in a 5% CO2 environment at 37°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BHK-21/WI-2</div><div>suggested: RRID:CVCL_HB78)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Immunofluorescence analysis: HEK-293 cells (70% confluent) on a 8-well cell culture slide [growth area/well (cm²): 0.98 and working volume/well (ml): 0.20 - 0.60] were transfected with 0.2 μg of VIU-1005 or control plasmid using JetPRIME® Transient Transfection Protocol and Reagents (Polyplus, New York, NY) according to manufacturer’s instructions, and followed incubated at 37°C in a 5% CO2 incubator for 24 h.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK-293</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pseudovirus–serum mixtures were transferred onto confluent Vero E6 cell monolayers in white 96-well plates and incubated for 24 h at 37°C in a 5% CO2 incubator.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In one experiment, two groups of BALB/c or C57BL/6J mice (10 per group) were intramuscularly immunized via needle injection with 3 doses of 100 μg of either VIU-1005 or control plasmid at 2-week interval and blood samples were collected for serological testing every 2 weeks starting from day 0 (pre-bleed) until week 8.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BALB/c</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>C57BL/6J</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In silico design of codon-optimized synthetic consensus S protein: All</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>All</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The final dataset was multiply aligned using CLUSTALW and the Shannon entropy for each amino acid position were determined and the consensus protein sequence was then obtained for the full-length S glycoprotein.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CLUSTALW</div><div>suggested: (ClustalW, RRID:SCR_017277)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Images were captured using Olympus BX51 Fluorescence Microscope and were analyzed using Image-Pro Plus software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Image-Pro Plus</div><div>suggested: (Image-Pro Plus, RRID:SCR_007369)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The median inhibitory concentration (IC50) of neutralizing antibodies (nAbs) was determined using four-parameter logistic (4PL) curve in GraphPad Prism V8 software (GraphPad Co.) and calculated as the reciprocal of the serum dilution at which RLU was reduced by 50% compared with the virus control wells after subtraction of the background RLUs in the control groups with cells only.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All data were collected using a 15 laser Aria flow cytometer (BD Biosciences, San Jose, CA) and analyzed using FlowJo v10 software (Tree Star).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.02.02.428995: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: Work was undertaken in accordance with UK Research Ethics Committee (REC) approval for laboratory research projects investigating the immune response to COVID-19 infection with academic collaborators (REC reference 20/SC/0310).<br>IACUC: Animal experiments: Treatment of animals was in accordance with regulations outlined in the U.S. Department of Agriculture (USDA) Animal Welfare Act and the conditions specified in the Guide for Care and Use of Laboratory Animals (National Institute of Health, 2011).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">Single colonies were randomly picked from the third cycle output and screen of specific binders was performed, using phage ELISA against NTD Vs RBD.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Female K18-hACE2 transgenic (B6.Cg-Tg (K18-hACE2)2Prlmn/J HEMI; Jackson Laboratories, USA) were maintained at 20−22 °C and a relative humidity of 50 ± 10% on a 12 hours light/dark cycle, fed with commercial rodent chow (Koffolk Inc.) and provided with tap water ad libitum.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Production of Antibodies: Phagemid DNA of the desired clones were isolated using QIAprep spin Miniprep kit (Qiagen, GmbH, Hilden, Germany), and the entire scFv was cloned into a pcDNA3.1+ based expression vector that was modified, providing the scFv with the human (IgG1) CH2-CH3 Fc fragments, resulting in scFv-Fc antibody format.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>IgG1</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For phage ELISA, HRP-conjugated anti-M13 antibody (Sino Biological, USA, Cat# 11973-MM05T-H lot HO13AU601; used at 1:8000 working dilution) was used following detection with TMB substrate (Millipore, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-M13</div><div>suggested: (Sino Biological Cat# 11973-MM05T-H, RRID:AB_2857928)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">ELISA of both sera and recombinant human antibodies was applied with AP-conjugated Donkey anti-human IgG (Jackson ImmunoResearch, USA, Cat# 709-055-149 lot 130049; used at 1:2000 working dilution) following detection using p-nitrophenyl phosphate (pNPP) substrate (Sigma, Israel).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG</div><div>suggested: (Jackson ImmunoResearch Labs Cat# 709-055-149, RRID:AB_2340501)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For L-SIGN binding inhibition assay, NTD-His (10 µg/ml) was immobilized on Ni-NTA sensors, incubated with anti-NTD antibodies washed and incubated with L-SIGN (20 µg/ml).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-NTD</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plated peptides were incubated with the individual monoclonal antibodies (5 µg/ml diluted in blocking buffer) and further incubated with donkey anti-human alkaline phosphatase-conjugated secondary antibody (Jackson ImmunoResearch, USA)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human alkaline phosphatase-conjugated secondary</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The original viral isolate was amplified by 5 passages and quantified by plaque titration assay in Vero E6 cells, and stored at −80°C until use.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: RRID:CVCL_XD71)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For ELISA inhibition assay, primary antibodies (1.5 µg/ml in blocking solution) were pre-incubated for two hours on ice in the presence or absence of inhibitors [blocking buffer for no-inhibition control, 8 mM 2-O-methyl-α-Neu5Ac (Ac2Me), 8 mM D-Glucuronic acid (GlcA; Sigma-Aldrich), or with 0.06 mM sialoglycopeptides (GP) produced from Neu5Gc-deficient Cmah−/− mice sera33 containing 3.4 mM Neu5Ac-GP (validated by DMB-HPLC)].</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Cmah−/−</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Glycan binding analyses: Cells and virus strains: Vero E6 (ATCC® CRL-1586™) were obtained from the American Type Culture Collection.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Female K18-hACE2 transgenic (B6.Cg-Tg (K18-hACE2)2Prlmn/J HEMI; Jackson Laboratories, USA) were maintained at 20−22 °C and a relative humidity of 50 ± 10% on a 12 hours light/dark cycle, fed with commercial rodent chow (Koffolk Inc.) and provided with tap water ad libitum.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>K18-hACE2</div><div>suggested: RRID:IMSR_GPT:T037657)</div></div><div style="margin-bottom:8px"><div>B6.Cg-Tg</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For the modeling of mAbs recognition sites on SARS-CoV-2 S protein, spike structure with PDB ID 7C2L24 was used and analyzed by The PyMOL Molecular Graphics System (Version 1.7 Schrödinger, LLC).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>PyMOL</div><div>suggested: (PyMOL, RRID:SCR_000305)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • No funding statement was detected.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.08.25.265223: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell monolayers were washed again (3x) and incubated with rabbit anti-CoV antibody (1:200; BEI Resources, NIAID, NIH) for 1h at RT, followed by incubation with goat anti-rabbit Alexa Fluor 488 (1:5000; Molecular Probe, Carlsbad, CA), secondary antibody for 1h at RT in the dark.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-CoV</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-rabbit</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">2.1. Cells: Vero E6 and HEK293L cells were maintained in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS, Atlanta Biologicals), 2 mM L-glutamine, 25 U/mL penicillin, and 25 μg/mL streptomycin.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: RRID:CVCL_XD71)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HCoV-NL63 was obtained from BEI Resources (1.6×106 TCID50/ml; lot 70033870, NIAID, NIH) and propagated in Vero cells by infecting the Vero cell monolayer with HCoV-NL63 for 2 h.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HCoV-NL63</div><div>suggested: RRID:CVCL_RW88)</div></div><div style="margin-bottom:8px"><div>Vero</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Virus from the TNP coated surfaces were recovered and used for total RNA extraction or applied onto a permissive, human embryonic kidney (HEK293L) cell monolayer for the detection of infectious virus.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293L</div><div>suggested: NIH-ARP Cat# 3553-138, RRID:CVCL_M775)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analyses were performed using Prism 8.0 software (Graphpad Inc.) and the p-values were calculated using 2-way ANOVA and the p-values are *, <0.1; and ** <0.01.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Prism</div><div>suggested: (PRISM, RRID:SCR_005375)</div></div><div style="margin-bottom:8px"><div>Graphpad</div><div>suggested: (GraphPad, RRID:SCR_000306)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • No funding statement was detected.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.08.25.20181404: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, 50 μl EDTA blood and 20 μl of antibody mix (6-color TBNK Reagent and CD123 BUV395 from BD, CD15 PB, CD193 BV605 and HLA-DR BV785 from Biolegend and CD14 PE-Cy5 from eBioscience) were added in BD trucount tubes and incubated for 15 min at room temperature in the dark.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CD123</div><div>suggested: (BioLegend Cat# 306032, RRID:AB_2566448)</div></div><div style="margin-bottom:8px"><div>CD193</div><div>suggested: (BD Biosciences Cat# 564188, RRID:AB_2738655)</div></div><div style="margin-bottom:8px"><div>HLA-DR BV785</div><div>suggested: (BioLegend Cat# 307641, RRID:AB_2561360)</div></div><div style="margin-bottom:8px"><div>CD14</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Flow cytometry analysis: Acquired data was analyzed using DIVA (BD Biosciences), FlowJo v.10.5.3 (BD Biosciences) and Prism v.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">8.0.2 (GraphPad Software Inc.)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Algorithms used for dimensionality reduction were UMAP (Becht et al., Nature Biotechnology, 2018; https://github.com/lmcinnes/umap) and Phenograph (Levine et al., Cell, 2015;</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Phenograph</div><div>suggested: (Phenograph, RRID:SCR_016919)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Single cell analysis: Seurat version 3 was used to re-analyze single cell data.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Seurat</div><div>suggested: (SEURAT, RRID:SCR_007322)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In brief, scRNA-seq from previously published report22 was used and 10X Genomics filtered_feature_bc_matrix files were acquired from Gene Expression Omnibus (GEO; accession number GSE145926).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Gene Expression Omnibus</div><div>suggested: (Gene Expression Omnibus (GEO, RRID:SCR_005012)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Ingenuity Pathway Analysis (IPA) was performed to study pathways (Content version: 51963813; Release Date: 2020-03-11; Ingenuity Systems)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Ingenuity Pathway Analysis</div><div>suggested: (Ingenuity Pathway Analysis, RRID:SCR_008653)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.04.27.062315: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To detect SARS-CoV and SARS-CoV-2, hAEC cultures were immunostained with a rabbit polyclonal antibody against SARS-CoV Nucleocapsid protein (Rockland, 200-401-A50), which also cross-react with SARS-CoV-2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SARS-CoV-2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>antibody against SARS-CoV Nucleocapsid protein ( Rockland , 200-401-A50)</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell distribution of ACE2 were detected with a rabbit polyclonal antibody against ACE2 (ab15348, Abcam).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ACE2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">488-labeled donkey anti-rabbit IgG (H + L) (Jackson Immunoresearch) was used as secondary antibody.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>488-labeled donkey anti-rabbit IgG</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells and human airway epithelial cell (hAEC) cultures: Vero-E6 cells (kindly provided by Doreen Muth, Marcel Müller, and Christian Drosten, Charité, Berlin, Germany) were propagated in Dulbecco’s Modified Eagle Medium-GlutaMAX supplemented with 1 mM sodium pyruvate, 10% (v/v) heat-inactivated fetal bovine serum (FBS), 100 μg/ml streptomycin, 100 IU/ml penicillin, 1% (w/v) non-essential amino acids and 15 mM HEPES (Gibco).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero-E6</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Viruses: SARS-CoV strain Frankfurt-1 (GenBank FJ429166) 35,54 and SARS-CoV-2 (SARS-CoV-2/München-1.1/2020/929) 55 were kindly provided by Daniela Niemeyer, Marcel Müller, and Christian Drosten, and propagated and titrated on Vero E6 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: RRID:CVCL_XD71)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All images were processed using FIJI software packages 57</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FIJI</div><div>suggested: (Fiji, RRID:SCR_002285)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The sequencing reads were demultiplexed using the BRB-seqTools suite and were aligned against a concatenation of the human gene annotation of the human genome (hg38), SARS coronavirus Frankfurt 1 (AY291315) and SARS-CoV-2/Wuhan-Hu1/2020 (NC_045512) viral genomes using STAR and HTSeq for producing the count matrices.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>STAR</div><div>suggested: (STAR, RRID:SCR_015899)</div></div><div style="margin-bottom:8px"><div>HTSeq</div><div>suggested: (HTSeq, RRID:SCR_005514)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">ComBat-seq was used with default settings to adjust for batch effects in the raw data and generate an adjusted count matrix used for downstream analyses 60 Library normalization and expression differences between uninfected and virus-infected samples were then quantified using the DESeq2 package in R (version 1.28) with a fold change (FC) cut-off of ≥ 1.5 and a False Discovery Rate (FDR) of ≤ 0.1 61.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>DESeq2</div><div>suggested: (DESeq, RRID:SCR_000154)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Venn diagrams were generated using the VennDiagram package in R for DEGs identified in approach 2 (Fig. 3a) and approach 1 (Supplementary Figure 3) 62</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VennDiagram</div><div>suggested: (VennDiagram, RRID:SCR_002414)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pathway enrichment analysis was performed using the clusterProfiler and ReactomePA packages in R 63,64.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>clusterProfiler</div><div>suggested: (clusterProfiler, RRID:SCR_016884)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Additional data analysis and visualization was performed using a variety of packages in R, including ComplexHeatmap and ggplot2.65.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ComplexHeatmap</div><div>suggested: (ComplexHeatmap, RRID:SCR_017270)</div></div></td></tr></table>

      Results from OddPub: Thank you for sharing your code and data.


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.06.14.151357: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">Contamination: Cells were regularly passaged and tested for presence of mycoplasma contamination (MycoAlert Plus Mycoplasma Detection Kit, Lonza)</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Primary antibody incubations were performed overnight at 4°C using the following antibodies: rabbit anti-GAPDH 14C10 (0.1 μg/mL, Cell Signaling 2118S), mouse anti-rhodopsin antibody clone 1D4 (1 μg/mL, Novus NBP1-47602) which recognizes the C9-tag added to the Spike proteins.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-GAPDH</div><div>suggested: (Cell Signaling Technology Cat# 2118, RRID:AB_561053)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Following the primary antibody, the blots were incubated with IRDye 680RD donkey anti-rabbit (0.2 μg/mL, LI-COR 926-68073) or with IRDye 800CW donkey anti-mouse (0.2 μg/mL, LI-COR 926-32212) for 1 hour at room temperature.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-rabbit</div><div>suggested: (LI-COR Biosciences Cat# 926-68073, RRID:AB_10954442)</div></div><div style="margin-bottom:8px"><div>anti-mouse</div><div>suggested: (LI-COR Biosciences Cat# 926-32212, RRID:AB_621847)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Spike was immunoprecipitated using 2 μg C9 antibodies (Novus NBP1-47602) per sample and incubated on a rotator at 4°C for at least 4 hours.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>C9</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Western blotting was performed as described above using mouse anti-rhodopsin antibody clone 1D4 (1 μg/mL, Novus NBP1-47602) which recognizes the C9-tag added to the Spike proteins.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-rhodopsin</div><div>suggested: (Novus Cat# NBP1-47602, RRID:AB_10010560)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell culture: A549 cells were obtained from ATCC, HEK293FT cells were obtained from Thermo Scientific, and Huh-7.5 and Caco-2 were a kind gift of B. tenOever (Mt. Sinai).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>A549</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>HEK293FT</div><div>suggested: ATCC Cat# PTA-5077, RRID:CVCL_6911)</div></div><div style="margin-bottom:8px"><div>Huh-7.5</div><div>suggested: RRID:CVCL_7927)</div></div><div style="margin-bottom:8px"><div>Caco-2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, for each virus, a T-225 flask of 80% confluent HEK293T cells (Thermo) was transfected in OptiMEM (Thermo) using 25 μg of the transfer plasmid, 20 μg psPAX2, 22 μg spike plasmid, and 175 μl of linear Polyethylenimine (1 mg/ml) (Polysciences).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">ACE2 lentiviral cloning and ACE2 stable cell line overexpression: To generate pLenti-ACE2-Hygro, we amplified human ACE2 (hACE2) from pcDNA3.1-ACE2 (Addgene 1786) and cloned it into a lentiviral transfer pLEX vector carrying the hygromycin resistance gene using Gibson Assembly Master Mix (NEB E2611L).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ACE2</div><div>suggested: RRID:CVCL_DR94)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Huh7.5-ACE2 and A549-ACE2 cell lines were generated by lentiviral transduction of ACE2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Huh7.5-ACE2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>A549-ACE2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2 was propagated in Vero E6 cells in DMEM supplemented with 2% FBS, 4.5 g/L D-glucose, 4 mM L-glutamine, 10 mM</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: RRID:CVCL_XD71)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Band intensity quantification was performed by first converting Odyssey multichannel TIFFs into 16-bit grayscale image (Fiji) and the then selecting lanes and bands in ImageLab 6.1 (BioRad).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Fiji</div><div>suggested: (Fiji, RRID:SCR_002285)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For each peptide, we computed the difference in predicted affinity between the D614 and G614 variant using R/RStudio and visualized them using the pheatmap R package.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>pheatmap</div><div>suggested: (pheatmap, RRID:SCR_016418)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analysis: Data analysis was performed using R/Rstudio 3.6.1 and GraphPad Prism 8 (GraphPad Software Inc.)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.02.08.429275: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: All animal experimental procedures without infection were approved by the Committee on the Use of Live Animals by the Ethics Committee of Nanjing University.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Evaluating the efficacy of Nbs in SARS-CoV-2 infected hACE2 mice: A total of 31 8-week-old male transgenic hACE2 mice (C57BL/6J) (cat.# T037630, GemPharmatech Co., Ltd., Nanjing, China) were challenged with SARS-CoV-2 as previously reported35 with following modifications.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The membrane was first blocked and then incubated overnight at 4 °C or 37 °C for one hour with diluted plasma or antibody, followed by incubation with the secondary antibody of either anti-human IgG or anti-rabbit IgG conjugated with an IRDye 800CW (cat.# 926-32232,</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG</div><div>suggested: (LI-COR Biosciences Cat# 926-32232, RRID:AB_10806644)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">ELISA analysis: Anti-sera titer and antibody characterization or antibody quantification in vivo were examined by ELISA as reported in our previously published method33 with modifications.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Anti-sera</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Following washing, goat anti-llama IgG (H+L) secondary antibody with HRP (Novus, cat.#</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>goat</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>IgG ( H+L ) secondary antibody with HRP ( Novus</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After washing, an anti-M13 bacteriophage antibody with HRP (1:10000 dilution, cat.# 11973-MM05T-H, Sino Biological) was added and incubated at 37 °C for 1 h.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-M13</div><div>suggested: (Sino Biological Cat# 11973-MM05T-H, RRID:AB_2857928)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were permeabilized with 0.2% Triton X-100 and incubated with cross-reactive rabbit anti-SARS-CoV-N IgG (Sino Biological, Inc) for 1 h at room temperature before the addition of HRP-conjugated goat anti-rabbit IgG (H+L) antibody (Jackson ImmunoResearch) and further incubated at room temperature.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-CoV-N IgG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-rabbit IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">250 μg SNB02 (Y-Clone, China), an anti-SFTSV antibody constructed by Nb fused with human Fc1 (Nb-Fc)13, was intranasally injected 1 h after infection and served as an isotype treated control (Isotype).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Y-Clone , China</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-SFTSV</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The neutralization potency of Nb15-Fc (A), Nb22-Fc (B), Nb31-Fc (C), SNB02 (isotype control antibody) (D) was detected based on authentic SARS-CoV-2 plaque reduction neutralization test.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SNB02</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Luc.R-E-, an HIV-1 NL4-3 luciferase reporter vector that contains defective Nef, Env and Vpr (HIV AIDS Reagent Program), and pCDNA3.1 (Invitrogen) expression vectors encoding the respective spike proteins (MN988668.1 for SARS-CoV-2, AAP13567.1 for SARS-CoV, AFS88936.1 for MERS-CoV) into 293T cells (ATCC)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: NCBI_Iran Cat# C498, RRID:CVCL_0063)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HEK293T-ACE2 cells (cat.# 41107ES03, Yeasen Biotech Co., Ltd. China) for SARS-CoV-2 and SARS-CoV, Huh7 cells (ATCC) for MERS-CoV (approximately 1.5×10 4 per well) were then added in duplicate to the virus-antibody mixture.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T-ACE2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>Huh7</div><div>suggested: CLS Cat# 300156/p7178_HuH7, RRID:CVCL_0336)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The mixtures were then transferred to 96-well plates seeded with Vero E6 cells and incubated at 37 °C for 1 h.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Evaluating the efficacy of Nbs in SARS-CoV-2 infected hACE2 mice: A total of 31 8-week-old male transgenic hACE2 mice (C57BL/6J) (cat.# T037630, GemPharmatech Co., Ltd., Nanjing, China) were challenged with SARS-CoV-2 as previously reported35 with following modifications.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>C57BL/6J</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Transgenic hACE2 mice typically clear virus within five days after SARS-CoV-235.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Transgenic hACE2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Images were obtained by OLYMPUS IX73 using HCImage Live (×64) software and analyzed by ImageJ (NIH). 15. Pharmacokinetics of Nbs in vivo: Purified Nbs were injected intranasally (i.n.), intraperitoneally (i.p.) or intravascularly into BALB/c (Qing Long Shan Animal Center, Nanjing, China) at a dose of 10-20 mg/kg.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BALB/c</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Luc.R-E-, an HIV-1 NL4-3 luciferase reporter vector that contains defective Nef, Env and Vpr (HIV AIDS Reagent Program), and pCDNA3.1 (Invitrogen) expression vectors encoding the respective spike proteins (MN988668.1 for SARS-CoV-2, AAP13567.1 for SARS-CoV, AFS88936.1 for MERS-CoV) into 293T cells (ATCC)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HIV AIDS Reagent Program</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Half-maximal inhibitory dilution (ND50) of the evaluated sera or half-maximal inhibitory concentrations (IC50) of the evaluated Nbs were determined by luciferase activity 48 h after exposure to virus-antibody mixture, and analyzed by GraphPad Prism 8.01 (GraphPad Software Inc.). 9.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Evaluating the efficacy of Nbs in SARS-CoV-2 infected hACE2 mice: A total of 31 8-week-old male transgenic hACE2 mice (C57BL/6J) (cat.# T037630, GemPharmatech Co., Ltd., Nanjing, China) were challenged with SARS-CoV-2 as previously reported35 with following modifications.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GemPharmatech</div><div>suggested: (GemPharmatech, RRID:SCR_017239)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Images were obtained by OLYMPUS IX73 using HCImage Live (×64) software and analyzed by ImageJ (NIH). 15. Pharmacokinetics of Nbs in vivo: Purified Nbs were injected intranasally (i.n.), intraperitoneally (i.p.) or intravascularly into BALB/c (Qing Long Shan Animal Center, Nanjing, China) at a dose of 10-20 mg/kg.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ImageJ</div><div>suggested: (ImageJ, RRID:SCR_003070)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistics: All statistical analyses were performed using GraphPad Prism 8.01 software (GraphPad) or OriginPro 8.5 software (OriginLab).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div><div style="margin-bottom:8px"><div>OriginPro</div><div>suggested: None</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.09.01.20184101: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">Consent: All samples were collected after subjects provided signed informed consent.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The concentration of protein conjugate, Cab (M) was determined using equation 2:

      where ε is the antibody extinction coefficient at A280, equal to 210,000 M-1cm-1 for IgG class anti IgG/IgM/IgA Ab, 240,000 M-1cm-1 for S protein, 80,200 M-1cm-1 for RBD and b is path length in cm (0.1 cm).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti IgG/IgM/IgA</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The degree of labeling (DOL) was calculated using equation 4: TR-FRET assay for RBD: Titration of CR3022 IgG/IgM/IgA1 antibody or dilution of tested human serum samples was added to assay mix with final concentrations of 15 nM Tb-labeled RBD, 250 nM BODIPY-labeled αIgG/αIgM/αIgA in a buffer containing PBS, 0.05% Tween-20</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CR3022 IgG/IgM/IgA1</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">50 μl/well of diluted detection antibody solution (HRP-anti human IgG Bethyl Laboratory #A80-104P) was added to the wells and incubated for 30 minutes at room temperature.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HRP-anti human IgG</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Antibodies were expressed in Expi293T cells following manufacturer protocol (Thermo Fischer Scientific, A14525) with transfection ratios of 1:1 or 2:1 of heavy to light chain.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Expi293T</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All samples were tested on an in house validated RBD-specific ELISA as well as on FDA approved Roche and Abbott assays that test for antibodies to N protein.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Abbott</div><div>suggested: (Abbott, RRID:SCR_010477)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">50μl/well of diluted detection antibody solution (HRP-anti human IgG, IgA or IgM; Bethyl Laboratory #A80-104P, A80-100P, A80-102P) was added to the wells and incubated for 30 minutes at room temperature.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Bethyl Laboratory</div><div>suggested: (Bethyl, RRID:SCR_013554)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistics: Statistical calculations were performed using Prism 8.0.2 and R v3.6.1; packages ggplot2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Prism</div><div>suggested: (PRISM, RRID:SCR_005375)</div></div><div style="margin-bottom:8px"><div>ggplot2</div><div>suggested: (ggplot2, RRID:SCR_014601)</div></div></td></tr></table>


      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.09.23.20197756: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">Consent: For child <18 yrs, consent had been obtained from his/her legal guardian.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">Five communities in each district and certain households in each community were randomly selected based on Probability Proportionate to Size (PPS) at two stages respectively.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The diluted serums were mixed with a virus suspension of 100 TCID50 (50 tissue culture infective dose) in 96-well plates at a ratio of 1:1, followed by 2 hours incubation at 36.5°C in a 5% CO2 incubator. 1-2×104 Vero cells were then added to the serum-virus mixture, and the plates were incubated for 5 days at 36.5°C in a 5% CO2 incubator.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: None</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      Our study has several limitations. One of the main limitations is the performance of test kits. According to the manufacturer, the two test kits were both used for the additional testing for suspected case with negative PCR, which indicated that they are unsuitable for general population screening. Although none was positive in neutralization assay among these 13 seropositive samples and 20 randomly selected seronegative samples, we could not preclude the possibility of false negativity since the neutralization assay was conducted only in targeted part of residents. Despite the acceptable sensitivity of the two colloidal gold methods provided by the manufacturers, Döhla et al. found that antibo dy-based rapid test showed low sensitivity (36.4%) in high-prevalence community setting. They recommended not to rely on an antibody-based rapid test for public health measures such as community screenings [15]. Considering that the sample sizes of patients and controls in our validation were limited, we used test performance data in manufacturer instructions to establish the test’s sensitivity and specificity [2]. Additional validation of the assays especially in general populations used could improve further our estimates. The availability of other high-quality serological testing kits suitable for general population screening was expected. Inadequate sample size and one-time cross-sectional study performed were also needed to be considered. Given the low seroprevalence in Beijing, l...

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a protocol registration statement.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.03.02.972927: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After three washes, 100 μl of horseradish peroxidase (HRP)-conjugated goat anti-human IgG antibody solution (Sangon Biotech) was added to each well and incubated at 37°C for 60 minutes.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Vero, LLC-MK2 and Huh-7 cells were used for the virus isolation in the biosafety level 3 (BSL-3) laboratory.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Huh-7</div><div>suggested: CLS Cat# 300156/p7178_HuH7, RRID:CVCL_0336)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Virus Preparation: Virus was amplified in Vero cell in an incubator at 37°C and 5% CO2 for 96 hours and the viral load was determined by qPCR assay.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: None</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • No conflict of interest statement was detected. If there are no conflicts, we encourage authors to explicit state so.
      • No funding statement was detected.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.02.03.429355: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: Both approvals were granted under the terms of the Infectious Disease Biobank’s ethics permission (reference 19/SC/0232) granted by the South Central Hampshire B Research Ethics Committee in 2019.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Fab/Fc ELISA: 96-well plates (Corning, 3690) were coated with goat anti-human Fc IgG antibody at 3 μg/mL overnight at 4°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human Fc IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The plates were washed twice in FACS buffer and stained with 50 μl/well of 1:200 dilution of PE-conjugated mouse anti-human IgG Fc antibody (BioLegend) on ice in dark for 1h.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Biotinylated Spike was expressed in 1L of HEK293F cells (Invitrogen) at a density of 1.5 × 106 cells ml-1.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293F</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2 (wild-type and mutants) and SARS-CoV pseudotyped virus preparation: Pseudotyped HIV virus incorporating the SARS-Cov-2 wild-type or mutants (D614G, N501Y, D614G+Del69/70 and B.1.1.7) or SARS-CoV spike protein was produced in a 10 cm dish seeded the day prior with 5×106 HEK293T/17 cells in 10 ml of complete Dulbecco’s Modified Eagle’s Medium (DMEM-C, 10% foetal bovine serum (FBS) and 1% Pen/Strep (100 IU/ml penicillin and 100 mg/ml streptomycin)).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T/17</div><div>suggested: ATCC Cat# CRL-11268, RRID:CVCL_1926)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Infectious virus strain and propagation: Vero-E6 cells (Cercopithecus aethiops derived epithelial kidney cells, provided by Prof Wendy Barclay, Imperial College London) cells were grown in Dulbecco’s modified Eagle’s medium (DMEM, Gibco) supplemented with GlutaMAX, 10% fetal bovine serum (FBS), 20 μg/mL gentamicin, and incubated at 37°C with 5% CO2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero-E6</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The media was removed from the pre-plated Vero-E6 cells and the serum-virus mixtures were added to the Vero E6 cells and incubated at 37°C for 24 h.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Gibson assembly products were directly transfected into HEK-293T cells and transformed under ampicillin selection.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK-293T</div><div>suggested: CCLV Cat# CCLV-RIE 1018, RRID:CVCL_0063)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">IgG expression and purification: Ab heavy and light plasmids were co-transfected at a 1:1 ratio into HEK-293F cells (Thermofisher) using PEI Max 40K (1mg/mL, linear polyethylenimine hydrochloride, Polysciences, Inc.) at a 3:1 ratio (PEI max:DNA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK-293F</div><div>suggested: RRID:CVCL_6642)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Monoclonal antibody binding to Spike using flow cytometry: HEK293T cells were plated in a 6-well plate (2×106 cells/well).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HeLa and HeLa-ACE2 cells alone and with SARS-CoV-2 Spike only were used as background and positive controls, respectively.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HeLa</div><div>suggested: CLS Cat# 300194/p772_HeLa, RRID:CVCL_0030)</div></div><div style="margin-bottom:8px"><div>HeLa-ACE2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">PBMCs were stained with live/dead (fixable Aqua Dead, Thermofisher), anti-CD3-APC/Cy7 (Biolegend), anti-CD8-APC-Cy7 (Biolegend), anti-CD14-BV510 (Biolegend), anti-CD19-PerCP-Cy5.5 (Biolegend), anti-IgM-PE (Biolegend), anti-IgD-Pacific Blue (Biolegend) and anti-IgG-PeCy7 (BD) and Spike-Alexa488 (Thermofisher Scientific, S32354) and Spike-APC (Thermofisher Scientific, S32362).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Thermofisher</div><div>suggested: (ThermoFisher; SL 8; Centrifuge, RRID:SCR_020809)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After another two washes, stained cells were analyzed using flow cytometry, and the binding data were generated by calculating the percent (%) PE-positive cells using FlowJo 10 software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The sequences were aligned with Clustal W and clustered via PhyML to produce maximum likelihood phylogenetic trees which were visualised and annotated using FigTree.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>PhyML</div><div>suggested: (PhyML, RRID:SCR_014629)</div></div><div style="margin-bottom:8px"><div>FigTree</div><div>suggested: (FigTree, RRID:SCR_008515)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.08.06.20169367: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">Consent: Participants or their legally authorized representatives completed electronic informed consent.<br>IRB: This study was approved by the University of Washington Human Subjects Institutional Review Board.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Gemini Biosciences, 100-110, lot H86W03J, pooled from 75 donors), and a CR3022 monoclonal antibody positive control dilution series starting at 1 ug/mL.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CR3022</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plates were then washed three times, and 50 μL of goat anti-human IgG-Fc horseradish peroxidase (HRP)-conjugated antibody (Bethyl Labs, A80-104P) diluted 1:3,000 in PBS-T containing 1% milk was added to each well and incubated for 1 hour at room temperature.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG-Fc</div><div>suggested: (Bethyl Cat# A80-104P, RRID:AB_67064)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The IgA secondary antibody was Peroxidase AffiniPure Goat Anti-Human Serum IgA, α chain specific (Jackson Labs, 109-035-011), and the IgM secondary antibody was goat Anti-Human IgM (μ-chain specific)–Peroxidase antibody (Sigma Aldrich, A6907); both were diluted 1:3000 in PBS-T containing 1 % milk.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>IgA</div><div>suggested: (Jackson ImmunoResearch Labs Cat# 109-035-011, RRID:AB_2337580)</div></div><div style="margin-bottom:8px"><div>Anti-Human Serum IgA</div><div>suggested: (Jackson ImmunoResearch Labs Cat# 109-035-011, RRID:AB_2337580)</div></div><div style="margin-bottom:8px"><div>IgM</div><div>suggested: (Thermo Fisher Scientific Cat# MA1-4803, RRID:AB_612248)</div></div><div style="margin-bottom:8px"><div>Anti-Human IgM</div><div>suggested: (Sigma-Aldrich Cat# A6907, RRID:AB_258318)</div></div><div style="margin-bottom:8px"><div>μ-chain specific)–Peroxidase</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Sociodemographic and clinical data were collected from electronic chart review and from participants via a data collection questionnaire (Project REDCap [24]) at the time of enrollment.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>REDCap</div><div>suggested: (REDCap, RRID:SCR_003445)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After calculating fraction infectivities, we used the neutcurve Python package (https://jbloomlab.github.io/neutcurve/) to calculate the plasma dilution that inhibited infection by 50% (IC50) by fitting a Hill curve with the bottom fixed at 0 and the top fixed at 1.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Python</div><div>suggested: (IPython, RRID:SCR_001658)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      The limitations of this study include the small number of samples, particularly in the asymptomatic and symptomatic hospitalized groups, and recruitment of participants from a single study site, which potentially limits the generalizability of these results. Furthermore, since symptom-onset date relies on individual recollections, it is difficult to precisely match the timing of blood draws across all participants. Additionally, we only had follow-up to about four months post-symptom onset and only measured plasma antibody responses. Further studies over longer time frames and with direct interrogation of plasma and memory B cells will be necessary to determine longer term durability of immunity to SARS-CoV-2, as well as its relationship to protection against re-infection. Despite these limitations, our study shows that titers of neutralizing and binding antibodies targeting SARS-CoV-2 spike remain detectable in most individuals out to >90 days post-symptom onset. While titers decline modestly from ~30 to >90 days post-symptom onset, we found that the dynamics of the antibody response to SARS-CoV-2 in the first several months following infection are consistent with what would be expected from knowledge of other acute viral infections [13-18].

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.06.23.167064: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      NIH rigor criteria are not applicable to paper type.

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells and viruses: VeroE6, HEK293T and A549 cells were obtained from ATCC and were maintained in Dulbecco’s modified Eagle medium (DMEM) containing 2 mM L-glutamine, non-essential amino acids, 100 U/ml penicillin, 100 μg/ml streptomycin and 10% fetal calf serum (DMEM complete).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>A549</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Calu3 cells were a kind gift from Dr. Manfred Frey, Mannheim and were maintained in DMEM complete supplemented with 10 mM sodium pyruvate and a final concentration of 20% FBS.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Calu3</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">A passage 4 working stock of this isolate was generated by passaging the virus twice in VeroE6 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VeroE6</div><div>suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Sample processing for cryo-EM: To generate the dataset for this study, 3 independent infections of cells grown on electron microscopy grids were done for A549-ACE2 cells and one infection on VeroE6 and Calu3 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>A549-ACE2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Primers for qPCR were designed using the Primer3 software44: ACE2 (forward) 5’-CACGAAGGTCCTCTGCACAA-3’, ACE2 (reverse) 5’-ATGCTAGGGTCCAGGGTTCT-3, SARS-CoV-2-N (forward) 5’-GCCTCTTCTCGTTCCTCATCAC-3’, SARS-CoV-2-N (reverse) 5’-AGCAGCATCACCGCCATTG-3’, HPRT (forward) 5’-CCTGGCGTCGTGATTAGTG-3’ and HPRT (reverse) 5’-ACACCCTTTCCAAATCCTCAG-3’.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Primer3</div><div>suggested: (Primer3, RRID:SCR_003139)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Individual projections were acquired in counting mode using dose fractionation. 10 – 20 individual frames per projections were aligned and summed on-the-fly using the SEMCCD plugin in SerialEM.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SerialEM</div><div>suggested: (SerialEM, RRID:SCR_017293)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Tomogram reconstruction and volume rendering: Tilt series (TS) were aligned and reconstructed with the IMOD software package48.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>IMOD</div><div>suggested: (IMOD, RRID:SCR_003297)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">This denoised tomogram was further processed with Amira 2019.3 (ThermoFisher Scientific) using the Membrane Enhancement Filter with a feature scale of 6.5 nm.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Amira</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For each individual S trimer, the nearest neighboring S trimer on the same virion was identified and the Euclidean distance was calculated using the pandas and numpy software libraries53,54.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>numpy</div><div>suggested: (NumPy, RRID:SCR_008633)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The RNA filament diameter was measured on the unbinned SIRT-like filtered reconstructed tomogram in FIJI by smoothing the image using gaussian blur (σ = 2 px) and measuring the line profiles perpendicular to RNA filaments using FIJI’s plot profile tool (10 pixels in width, 1.379 Å/pixel).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FIJI</div><div>suggested: (Fiji, RRID:SCR_002285)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.02.03.429555: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Proteins and antibodies: SARS-CoV-2 (438-516) S-RBD((HiS)6 and biotynilated human ACE2 have been purchased from Fisher Scientific (respective references 16534204 and 16545164).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ACE2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Monoclonal anti-6X His tag antibody has been purchased from ABCAM (reference ab18184, dilution 1/200).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-6X</div><div>suggested: (Abcam Cat# ab18184, RRID:AB_444306)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Anti α-tubulin antibody has been purchased from SIGMA (reference T6199, dilution 1/500).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Anti α-tubulin</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Secondary goat anti-mouse antibody coupled to AlexaFluor 488 has been purchase from Fisher Scientific (Reference Allo2g, dilution 1/400).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-mouse</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Bound proteins were detected by western blot using anti-His antibody and streptavidin-HRP conjugate (SIGMA, reference GERPN1231).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-His</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Lentiviral particles were produced by transient transfection of HEK293T(human embryonic kidney cells according to standard protocols.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T(human</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">DNA from two different cell clones (human 293T and K562 cells), containing a single integrated copy of the provirus, was used as a normalized cell line.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">DNA from a HEK cell line with one proviral insert (HEK-2C9) was used as a standard for quantification by the ΔCt method.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell imaging: For cell imaging 20 000 HEK293T and HEK293T-ACE2 cells were plated on glass coverslips pretreated with poly-L-Lysine solution 0.01% (SIGMA ref P4832) 5 minutes at room temperature.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For quantification of the S-RBD/ACE2 interaction in cellular context 45 000 HEK293T and HEK293T-ACE2 cells were incubated 45 minutes at 37°C in 100µl DMEM and increasing concentrations of RBD recombinant protein.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T-ACE2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data were analyzed with GraphPad Prism 5.01 software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Sensorgrams curves were plotted using Prism 5.0 software (Graphpad Software, La Jolla, CA) Cells and lentiviral vectors production: Lentivirus vector production was done by the service platform Vect’UB, (INSERM US 005</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Prism</div><div>suggested: (PRISM, RRID:SCR_005375)</div></div><div style="margin-bottom:8px"><div>Graphpad</div><div>suggested: (GraphPad, RRID:SCR_000306)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Epifluorescence microscopy was carried out on a Zeiss Axioimager Z1 driven by Metamorph.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Metamorph</div><div>suggested: None</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • No funding statement was detected.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.01.29.428442: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: UTMB is an AAALAC-accredited institution and all animal work was approved by the IACUC Committee of UTMB.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">The blinded tissue sections were semi-quantitatively scored for pathological lesions using the criteria described in Supplemental Table 1.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Pathogenicity of SARS-CoV-2 in hamsters: On day 0, seven week-old golden Syrian female hamsters (Envigo) were anesthetized with ketamine/xylazine, and 8 animals were exposed intransally to the targeted dose of 105 PFU of SARS-CoV-2 in a volume of 100 μl, while 4 animals were mock-infected with 100 μl 1X DPBS.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Antibodies: Monoclonal antibody CR3022 was produced by transient transfection of 293F cells with cDNA expression plasmids obtained from BEI resources.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Antibodies</div><div>suggested: (Imported from the IEDB Cat# CR3022, RRID:AB_2848080)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Monoclonal antibodies I1 and I14 against the VSV glycoprotein and monoclonal antibody 23H12 against the VSV matrix protein were purified from hybridoma supernatant by affinity chromatography on Protein G sepharose.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>I14 against the VSV glycoprotein</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The proteins were transferred to nitrocellulose membrane and probed with polyclonal rabbit serum against SARS-CoV S1 domain (Thermofisher, Cat No. PA5-81798 and PA5-81795), monoclonal antibodies I1 (8G5F11) and I14 (IE9F) against the VSV glycoprotein and monoclonal antibody 23H12 against VSV matrix protein provided by Douglas Lyles (Wake Forest University).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VSV glycoprotein</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After washing with DPBS the cells were incubated for 2 hours with monoclonal antibody CR3022 conjugated to Dylight 550 or a mixture of monoclonal antibodies I1 and I14 conjugated to Dylight 488.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>I14</div><div>suggested: (Rockland Cat# 200-401-I14, RRID:AB_2612206)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Antibody responses to SARS-CoV-2 spike protein (S1) were measured by an indirect ELISA as described previously(Kurup et al., 2015).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SARS-CoV-2 spike protein ( S1</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The secondary antibodies used in the ELISA are HRP-conjugated goat anti-syrian hamster IgG secondary antibody (Jackson immunoresearch, Cat# 107-035-142, 1:8000 in PBST) or mouse anti-hamster-IgG2/3-HRP (Southern Biotech, Cat# 1935-05, 1:8000 in PBST).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-syrian hamster IgG</div><div>suggested: (Jackson ImmunoResearch Labs Cat# 107-035-142, RRID:AB_2337454)</div></div><div style="margin-bottom:8px"><div>anti-hamster-IgG2/3-HRP</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Neutralizing antibody response: Sera collected from animals were tested for neutralizing capabilities against SARS-CoV-2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SARS-CoV-2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">As the secondary antibody, HRP-labeled goat anti-human IgG (SeraCare) was used at dilution 1:500.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The recombinant virus was recovered on 293T cells as described previously, filtered through an 0.22 μm filter and used to inoculate Vero (CCL-81, ATCC) or human BEAS-2B lung cells (gift from R. Plemper, University of Georgia).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>BEAS-2B</div><div>suggested: BCRJ Cat# 0395, RRID:CVCL_0168)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For immunofluorescence staining, Vero E6 cells were seeded on coverslips and infected at three different MOI ranging from 0.01 to 0.1 PFU.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: RRID:CVCL_XD71)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To assess viral replication of ConVac in vitro, Vero (CCL-81) cells were seeded in 6-well plates and infected next day at 34°C at an MOI of 5 and 0.05 PFU.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">UTMB is an AAALAC-accredited institution and all animal work was approved by the IACUC Committee of UTMB.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>UTMB</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data were analyzed with GraphPad Prism (Version 8.4.3) using 4-parameter nonlinear regression.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.01.28.21250598: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">Consent: COVID-19 patients and HCWs signed informed consents to give blood samples.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">Then, we randomly selected five positive pools per population from all regions, except for Jazan D population, for individual testing to obtain the average number of positive individual samples per population per region.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plates were washed, and 50 μl of 1:1000 diluted alkaline phosphatase labeled goat anti-human IgG secondary antibody (Thermo Fisher, Waltham, MA) were added and incubated for one hour at RT.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All statistical analyses were conducted using SAS 9.4 (SAS Institute Inc., Cary, NC) and GraphPad Prism V8 software (GraphPad Co.). Ethical Approval: The study was approved by the IRB in KAIMRC (Ministry of National Guard Health Affairs) for project number RC20-180.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SAS Institute</div><div>suggested: (Statistical Analysis System, RRID:SCR_008567)</div></div><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      This study has strengths of sampling largely populated, geographically distributed regions; but it has its limitation of using proxy samples and it had a pooling strategy that may not reflect precisely the seroprevalence; therefore, it reports seroprevalence estimation. In conclusion, this study estimates the national serological prevalence of COVID-19 in Saudi Arabia to be 11%, with an apparent disparity between regions. This warrants better vaccination programs and vaccination coverage to increase the immuned population.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.03.21.001628: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: Ethics and biosafety statement: All animal experiments were approved by the Institutional Animal Care and Use Committee of Rocky Mountain Laboratories, NIH and carried out by certified staff in an Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International accredited facility, according to the institution’s guidelines for animal use, following the guidelines and basic principles in the NIH Guide for the Care and Use of Laboratory Animals, the Animal Welfare Act, United States Department of Agriculture and the United States Public Health Service Policy on Humane Care and Use of Laboratory Animals.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">Histopathological analysis of tissue slides was performed by a board-certified veterinary pathologist blinded to the group assignment of the animals.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Study design: To evaluate the use of rhesus macaques as a model for SARS-CoV-2, eight adult rhesus macaques (4 males, 4 females) were inoculated via a combination of intranasal (0.5ml per nostril), intratracheal (</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To detect SARS-CoV-2 antigen, immunohistochemistry was performed using an anti-SARS nucleocapsid protein antibody (Novus Biologicals) at a 1:250 dilution.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS nucleocapsid protein</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2-specific antibodies were detected using anti-monkey IgG polyclonal antibody HRP-conjugated antibody (KPL), peroxidase-substrate reagent (KPL) and stop reagent (KPL)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-monkey IgG</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">VeroE6 cells were maintained in DMEM supplemented with 10% fetal calf serum, 1 mM L-glutamine, 50 U/ml penicillin and 50 μg/ml streptomycin.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VeroE6</div><div>suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)</div></div></td></tr></table>

      Results from OddPub: Thank you for sharing your data.


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.02.05.429566: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">Consent: Recovered patients and those with an active infection with SARS-CoV-2 were invited to participate and signed a consent letter at the moment of enrollment to the clinical trial NCT04384588.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Inclusion criteria for convalescent patient considered men and women previously confirmed with COVID-19 by PCR test and 21 or more days after symptoms had finished.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Recombinant proteins and secondary antibodies: Recombinant SARS-CoV-2 Nucleocapsid Protein with C-terminal His-tag (</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>His-tag</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For the immunodetection, the membranes were separately incubated with either HRP-conjugated secondary antibody anti-human IgG, anti-human IgA or anti-human IgM diluted at 1:20,000 (0.04 μg/ml) in blocking solution.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-human IgA</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-human IgM</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Later, each well was incubated at 20°C (±1°C) for 1h with 100 μL of a 20 ng/ml solution of the specific peroxidase-conjugated affiniPure anti-Human isotype antibody, anti-IgG (Fcβ fragment specific) (#709-035-098, Jackson Immuno-Research), anti-IgA (Frα fragment specific) (#109-035-011, Jackson Immuno-Research) and anti-IgM (μ chain) (#709-035-073, Jackson Immuno-Research).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-Human isotype antibody,</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-IgG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-IgA</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-IgM (μ chain)</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Immunofluorescence: HeLa cells (ATCC® CCL-2) were transient transfected with a mammalian expression vector expressing a Spike-GFPSpark tag codon optimized fusion SinoBiological VG40589-ACGLN in 10cm plates, 24 h after transfection ~ 8000 cells per well were deposited into 96 well optical plate (Themofisher), after 24 h incubation cells were washed with PBS (phosphate buffered saline solution) 1X 3 times and fixed with 4% paraformaldehyde at room temperature for 30 min.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HeLa</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pixels were quantified using Fiji Software (v.2.0.0, NIH) and exposition time was used as reference.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Fiji</div><div>suggested: (Fiji, RRID:SCR_002285)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">< Statistical analyses: Statistical analysis was performed using GraphPad Prism software, version 8.0.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      We understood the limitations of our work in the number of cases analyzed and the experimental strategy used; however, it provides information for some laboratories with limited resources to apply, exceptionally, basic research tools for monitoring COVID-19 cases during a pandemic.

      Results from TrialIdentifier: We found the following clinical trial numbers in your paper:<br><table><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Identifier</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Status</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Title</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04384588</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">COVID19-Convalescent Plasma for Treating Patients With Activ…</td></tr></table>


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.02.02.21250362: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: Approval for the study was granted by Institutional Ethics Committee Bio Medical Research Apollo Hospital, Bangalore.<br>Consent: Procedure: Bronchoscopy after informed consent was performed by 3 different operators.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistics: Data was tabulated and analysed using SPSS (ver. 25.0, SPSS Inc).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SPSS</div><div>suggested: (SPSS, RRID:SCR_002865)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      A fundamental limitation in the MV-CARDS patients during the pandemic was restricted suctioning due to aerosol risk, limiting many aspects of diagnosis and ventilator management. (1) Bronchoscopic inspection led to immediate changes including change of antibiotics, reduction of immunosuppression and anticoagulation, modification of the fluid strategy, ETT tube adjustment and detection of unexpected findings, such as a malignant mass (Table 2). Microbiologically, the Gram’s stain and subsequent culture reports were used to adjust antibiotics in line with standard principles. Another important result was proving COVID positivity in washings when earlier NP swabs were negative. Few studies have been published on bronchoscopy in severe COVID-19 patients. Torrego et al performed 101 bronchoscopies in 93 COVID-19 patients early in the pandemic. (4) The median duration from MV to procedure was 6.6 days (range 1-17). Bruyneel et al. performed 90 bronchoscopies in 32 ICU patients between 6 March and 21 April 2020. (5) Baron et al. performed 28 bronchoscopies between March 31 and June 2020 on 24 COVID-19 patients. (6) The median time [IQR] from MV to BAL was 16 [10-21] days. In our study, median symptom-onset (SO) to hospitalization duration was 7 (IQR;4-10) days, SO to MV was 10 days (7 – 13.2) and SO to bronchoscopy was 14 days (10-20), while MV to bronchoscopy was 2.5 days (1-6.5). The timing of bronchoscopy in our study was based on clinical indications, with the observation that l...

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.07.04.187757: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      NIH rigor criteria are not applicable to paper type.

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HEK293 cells (ATCC CRL-1573), and HEK-293T cells (CRL-3216 or CRL-11268) were cultured in DMEM supplemented with 10% heat-inactivated FBS, 1 mM sodium pyruvate, 20 mM GlutaMAX, 1×</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293</div><div>suggested: ATCC Cat# CRL-11268, RRID:CVCL_1926)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Calu3 cells (ATCC HTB-55) were maintained in EMEM supplemented with 10% FBS.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Calu3</div><div>suggested: ATCC Cat# HTB-55, RRID:CVCL_0609)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Caco2 cells (ATCC HTB-37) were maintained in EMEM supplemented with 20% FBS.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Caco2</div><div>suggested: ATCC Cat# HTB-37, RRID:CVCL_0025)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SUP-T1 [VB] cells (ATCC CRL-1942) were cultured in RPMI supplemented with 10% heat-inactivated FBS, 1mM sodium pyruvate</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SUP-T1</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Vero cells (ATCC CCL-81) were cultured in DMEM high glucose media containing 10% heat-inactivated fetal bovine serum, and 1X Penicillin/Streptomycin/L-Glutamine.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Virus production: 24 hrs prior to transfection, 6 × 105 HEK-293 cells were plated per well in 6 well plates.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK-293</div><div>suggested: CLS Cat# 300192/p777_HEK293, RRID:CVCL_0045)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">TMPRSS2 expressing SupT1 cells were then transduced with a second vector expressing ACE2, followed by puromycin selection at 1 ug/mL.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SupT1</div><div>suggested: BCRC Cat# 60191, RRID:CVCL_1714)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HEK293T cells were seeded overnight in DMEM high glucose media (Life Technologies) containing 10% heat-inactivated fetal bovine serum (Life Technologies), and Penicillin/-Streptomycin-L-Glutamine (Life Technologies).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Production of SARS-CoV-2 virus-like particles (VLPs): HEK-293T cells were cultured in DMEM supplemented with 10% heat-inactivated bovine serum, and transfected with pcDNA3.1 plasmids encoding the SARS-CoV-2 M, E, N, and S proteins, in different combinations, as indicated.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK-293T</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">These sequences were processed using a script importing biopython (Cock et al., 2009) to remove any gaps introduced by the alignment process and translate the sequence to protein space.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>biopython</div><div>suggested: (Biopython, RRID:SCR_007173)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The bresulting values were rendered as plots using matplotlib (Hunter, 2007).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>matplotlib</div><div>suggested: (MatPlotLib, RRID:SCR_008624)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The script for analyzing and plotting D614G variant frequency is available via GitHub: https://github.com/broadinstitute/sc2-variation-scripts The diversity of SNPs and their functional effects based on the same GISAID sequences and MAFFT alignment used to plot the frequency of D614G over time, with the 5’ and 3’ ends not masked.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MAFFT</div><div>suggested: (MAFFT, RRID:SCR_011811)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The VCF file with SNPs was annotated for functional effects using SnpEff (Cingolani et al., 2012).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SnpEff</div><div>suggested: (SnpEff, RRID:SCR_005191)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data was analyzed using FlowJo 10.5 (FlowJo, LLC, Ashland, OR)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The steady state analysis was performed using Scrubber software and the KD value was determined.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Scrubber</div><div>suggested: (Scrubber2, RRID:SCR_015745)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Local resolution was estimated using cryoSPARC to extend from 3Å to 6 Å</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>cryoSPARC</div><div>suggested: (cryoSPARC, RRID:SCR_016501)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Model building: Atomic models were prepared with Coot based on the resolved structure of D614 SARS-CoV-2 Spike (PDB: 6vxx and 6vsb).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Coot</div><div>suggested: (Coot, RRID:SCR_014222)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Real-space refinements were performed using PHENIX with secondary structure restraints.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>PHENIX</div><div>suggested: (Phenix, RRID:SCR_014224)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">MolProbity was used to evaluate the geometries of the structural model.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MolProbity</div><div>suggested: (MolProbity, RRID:SCR_014226)</div></div></td></tr></table>

      Results from OddPub: Thank you for sharing your code and data.


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: We found the following clinical trial numbers in your paper:<br><table><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Identifier</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Status</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Title</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04425629</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-Co…</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04426695</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-Co…</td></tr></table>


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.08.04.235002: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">Several veterinary pathologists independently examined slides and were blinded to the treatment groups. 2.9.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The neutralizing antibody titer was recorded as the highest serum dilution at which at least 50% of wells showed virus neutralization (NT50) based on the appearance of CPE observed under a microscope at 72 h post infection. 2.7. Detection of SARS-CoV-2 antibodies by indirect ELISA: To detect SARS-CoV-2 antibodies in sera, indirect ELISAs were performed with the recombinant viral proteins, nucleoprotein (N) and the receptor-binding domain (RBD), which were produced in-house.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>NT50</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The wells were washed 3 times with PBS-T, then 100 µl of Goat anti-Feline IgG (H+L) Secondary Antibody, HRP (ThermoFisher Scientific, catalogue number A18757, Waltham, MA, USA) diluted 1:2500 was added to each well and incubated for 1 h at room temperature.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-Feline IgG</div><div>suggested: (Thermo Fisher Scientific Cat# A18757, RRID:AB_2535534)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2-specific immunohistochemistry (IHC): For IHC, four-micron sections of formalin-fixed paraffin-embedded tissue were mounted on positively charged Superfrost® Plus slides and subjected to IHC using a SARS-CoV-2-specific anti-nucleocapsid mouse monoclonal antibody (clone 6F10, BioVision, Inc.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-nucleocapsid</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Sections were then incubated with the primary antibody (diluted at 1 µg/ml in Antibody Diluent [Dako, Carpinteria, CA]) for 30 min at room temperature, followed by a polymer-labeled goat anti-mouse IgG coupled with alkaline phosphatase (30 minutes; Powervision</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-mouse IgG</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The 200 µl per well of virus sera mixture was then cultured on VeroE6 cells in 96-well plates.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VeroE6</div><div>suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Sections from mock- and SARS-CoV-2-infected Vero cell pellets were used as negative and positive assay controls.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: CLS Cat# 605372/p622_VERO, RRID:CVCL_0059)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.02.17.431722: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">Consent: All study procedures were performed after informed consent.<br>IRB: The study was approved by the institutional review board of the Hong Kong West Cluster of the Hospital Authority of Hong Kong (approval number: UW20-169).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Sf9 cells (Spodoptera frugiperda ovarian cells, female) and High Five cells (Trichoplusia ni ovarian cells, female) were maintained in HyClone insect cell culture medium.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After extensive washing with PBS containing 0.1% Tween 20, each well in the plate was further incubated with the anti-human IgG secondary antibody (1:5000, Thermo Fisher Scientific) for 1 hour at 37°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Virus and Cell cultures: Vero and Vero E6 cells were maintained in DMEM medium supplemented with 10% fetal bovine serum (FBS), and 100 U mL−1 of Penicillin-Streptomycin.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: RRID:CVCL_XD71)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Sf9 cells (Spodoptera frugiperda ovarian cells, female) and High Five cells (Trichoplusia ni ovarian cells, female) were maintained in HyClone insect cell culture medium.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Sf9</div><div>suggested: CLS Cat# 604328/p700_Sf9, RRID:CVCL_0549)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Patient-derived SARS-CoV-2 (BetaCoV/Hong Kong/VM20001061/2020 [KH1]) and SARS-CoV (strain HK39849, SCoV) were passaged in Vero-E6 or Vero cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: CLS Cat# 605372/p622_VERO, RRID:CVCL_0059)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Mouse immunization: 6-10 weeks BALB/c mice were immunized with two rounds either 15ug NTD protein or 105 TCID50 live viruses together with 50 μL Addavax, via intraperitoneal (i.p.) route.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BALB/c</div><div>suggested: None</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.08.02.233536: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For the COVA1-16 IgG 1 antibody, suspension HEK293F cells (Invitrogen, cat no. R79007) were cultured in FreeStyle medium (Gibco) and co-transfected with the two IgG plasmids expressing the corresponding HC and LC in a 1:1 ratio at a density of 0.8-1.2 million cells/mL in a 1:3 ratio with 1 mg/L PEImax (Polysciences).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>COVA1-16 IgG 1</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Competition studies of antibodies with ACE-2 receptor: For competition assays, COVA1-16 IgG, CR3022 IgG, and human ACE2-Fc were all diluted to 250 nM.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>COVA1-16 IgG, CR3022 IgG</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pseudovirus neutralization assay: Neutralization assays were performed using SARS-CoV and SARS-CoV-2 S-pseudotyped HIV-1 virus and HEK-293T/ACE2 cells as described previously [59].</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK-293T/ACE2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In brief, pseudotyped virus was produced by co-transfecting expression plasmids of SARS-CoV S and SARS-COV-2Δ19 S proteins (GenBank; AAP33697.1 and MT449663.1, respectively) with an HIV backbone expressing NanoLuc luciferase (pHIV-1NL4-3 ΔEnv-NanoLuc) in HEK293T cells (ATCC, CRL-11268).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: ATCC Cat# CRL-11268, RRID:CVCL_1926)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Iterative model building and refinement were carried out in COOT [52] and PHENIX [53], respectively.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>COOT</div><div>suggested: (Coot, RRID:SCR_014222)</div></div><div style="margin-bottom:8px"><div>PHENIX</div><div>suggested: (Phenix, RRID:SCR_014224)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Micrographs were collected using Leginon [55] and the images were transferred to Appion for processing.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Leginon</div><div>suggested: (Leginon, RRID:SCR_016731)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Selected 3D classes were auto-refined on Relion and used to make figures with UCSF Chimera.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Relion</div><div>suggested: (RELION, RRID:SCR_016274)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Protein concentrations were determined by Nanodrop using the proteins peptidic molecular weight and extinction coefficient as determined by the online ExPASy software (ProtParam).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ExPASy</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The inhibitory concentration (IC50) was determined as the concentration of IgG or Fab that neutralized 50% of the pseudotyped virus using GraphPad Prism software (version 8.3.0).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Sequence conservation analysis: RBD protein sequences from SARS-CoV and SARS-related coronavirus (SARSr-CoV) strains were retrieved from the following accession codes: Multiple sequence alignment of the RBD sequences was performed by MUSCLE version 3.8.31 [60].</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MUSCLE</div><div>suggested: (MUSCLE, RRID:SCR_011812)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Sequence logos were generated by WebLogo [61].</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>WebLogo</div><div>suggested: (WEBLOGO, RRID:SCR_010236)</div></div></td></tr></table>

      Results from OddPub: Thank you for sharing your data.


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/135749: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      NIH rigor criteria are not applicable to paper type.

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">We used the highly inbred laboratory strain Drosophila melanogaster w1118, which was kept at 18°C on standard food (400 g of malt extract, 400 g of corn flour, 50 g of soy flour, 110 g of sugar beet syrup, 51 g of agar, 90 g of yeast extract, 31.5 ml of propionic acid and 7.5 g of Nipagin dissolved in 40 ml of Ethanol, water up to 5 l).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>w1118</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Intraspecific sexual dimorphism and effects of rearing conditions: Since most of the variation in shape was explained by differences between species (see Results), we split the analysis to further evaluate the effects of sex, rearing temperature, and density as well as potential interactions on wing shape within each species using Procrustes ANOVA in Geomorph (v. 3.3.1) (TableS2).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Geomorph</div><div>suggested: (geomorph, RRID:SCR_016482)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Magnitudes of sexual shape dimorphism were estimated using the Discriminant Function Analysis (DFA) and expressed in units of Procrustes distance using MorphoJ (version 1.06d).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MorphoJ</div><div>suggested: (MorphoJ, RRID:SCR_016483)</div></div></td></tr></table>

      Results from OddPub: Thank you for sharing your code.


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      However, despite these technical and analytical limitations, we could show that the three factors contributed additively to the observed shape variation and we confirmed that the size correction indeed removed the effect of centroid size on wing shape variation. Therefore, we are convinced that we could observe general trends, which will be briefly discussed separately for each factor. Sexual dimorphism: We observed a clear sexual shape dimorphism in all three species. While mostly wing width differed between females and males in C. capitata and D. melanogaster, the most obvious sexual differences in M. domestica was in wing length. According to a clear impact of sex on wing size (Siomava et al., 2016) (Fig. S2), we found a clear contribution of the allometric component to the shape difference between males and females in D. melanogaster. For instance, a shift of CuA1 along the wing margin as also described by (Bitner-Mathé and Klaczko, 1999), we could only detect when the allometric component was included. In general, exclusion of the allometric coefficient decreased the sexual shape dimorphism, suggesting that most of the observed shape differences could be explained by differences in wing size. In contrast, sex had only a minor effect on wing size in C. capitata and M. domestica (Siomava et al., 2016) (Fig. S2). Accordingly, the impact of the allometric component on wing shape was weak. For instance, the variation in the wing length that was explained by the allometric com...

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.02.18.431484: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: Animals: All animal procedures were approved by the Institutional Animal Care and Use Committees (IACUC) at the University of Michigan and Icahn School of Medicine at Mt. Sinai and were carried out in accordance with these guidelines. 6-8-week-old female C57Bl/6 mice (Charles River Laboratories) were housed in specific pathogen-free conditions.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Animals: All animal procedures were approved by the Institutional Animal Care and Use Committees (IACUC) at the University of Michigan and Icahn School of Medicine at Mt. Sinai and were carried out in accordance with these guidelines. 6-8-week-old female C57Bl/6 mice (Charles River Laboratories) were housed in specific pathogen-free conditions.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plates were washed three times with PBST (0.05% Tween20), and alkaline phosphatase conjugated secondary antibodies were added (goat-anti-mouse IgG, IgG1, IgG2b, or IgG2c Jackson Immuno Research Laboratories) diluted in PBS/0.1%BSA.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>IgG, IgG1</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were permeabilized with 0.1% TritonX100, washed and incubated with anti-SARS-CoV-2-nucleoprotein and anti-SARS-CoV-2-Spike monoclonal antibodies, mixed in 1:1 ratio, for 1.5h at RT.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-CoV-2-nucleoprotein</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-SARS-CoV-2-Spike</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After another wash, cells were incubated with HRP-conjugated goat-anti-mouse IgG secondary antibody for 1h at RT.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Anti-mouse SARS-CoV-2-nucleoprotein and anti-mouse SARS-CoV-2-spike antibodies were obtained from the Center for Therapeutic Antibody Development at the Icahn School of Medicine at Mount Sinai.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Anti-mouse SARS-CoV-2-nucleoprotein</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-mouse SARS-CoV-2-spike</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, SeV DI RNA from SeV-infected A549 cells was amplified using a 5’ primer with the T7 promoter and a 3’ primer with the hepatitis delta virus genomic ribozyme site followed by the T7 terminator.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>A549</div><div>suggested: NCI-DTP Cat# A549, RRID:CVCL_0023)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HEK293T cells expressing human angiotensin-converting enzyme 2 (293T-hACE2) were obtained from BEI resources and maintained in HEK293T medium: DMEM containing 4 mM L-glutamine, 4500 mg/L L-glucose, 1 mM sodium pyruvate and 1500 mg/L sodium bicarbonate, supplemented with 10% heat inactivated fetal bovine serum as previously described48.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: ATCC Cat# ACS-4500, RRID:CVCL_4V93)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Viruses: WT SARS-CoV-2: SARS-CoV-2 clinical isolate USA-WA1/2020 (BEI resources; NR-52281), was propagated by culture in Vero E6 cells as previously described (ref).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: RRID:CVCL_XD71)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">This DNA/PEI containing media was then distributed equally to 5-T150 flasks (Falcon) containing 293T cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: NCBI_Iran Cat# C498, RRID:CVCL_0063)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pseudovirus microneutralization (MNT) assays: 9×103 293T-hACE2 cells were seeded overnight on white clear bottom 96-well tissue culture plates in HEK293T medium.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T-hACE2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Animals: All animal procedures were approved by the Institutional Animal Care and Use Committees (IACUC) at the University of Michigan and Icahn School of Medicine at Mt. Sinai and were carried out in accordance with these guidelines. 6-8-week-old female C57Bl/6 mice (Charles River Laboratories) were housed in specific pathogen-free conditions.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>C57Bl/6</div><div>suggested: None</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.08.24.20180661: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">Consent: Each participant provided written consent to participate in the study which was performed according to the EU guidelines and the Declaration of Helsinki.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">Contamination: HEK293T cells expressing ACE2 were generated by lentiviral transduction with vector CSIB and selection in blasticidin S 8 All cell lines were routinely tested for the absence of mycoplasma.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Transduced cells were selected by FACS sorting 48 h later using the anti-EGFR antibody.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-EGFR</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The cell pellet was finally resuspended in a 1:200 dilution of mouse anti-human IgG1 Fc-PE (Ref.: 9054-09, Southern Biotech) and a 1:300 dilution of the Brilliant Violet 421™ anti-human EGFR Antibody (Ref.: 352911, Biolegend) in PBS-BSA.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG1</div><div>suggested: (SouthernBiotech Cat# 9054-09, RRID:AB_2796628)</div></div><div style="margin-bottom:8px"><div>anti-human EGFR</div><div>suggested: (BioLegend Cat# 352911, RRID:AB_2562213)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For multiplexing, the following antibodies were used (all from Cytognos, S.L.): FITC-labelled anti-IgG1, PE-labeled anti-IgG2, APC-labelled anti-IgG3, APCC750 labelled anti-IgG4, PEcy7-labelled anti-IgM andPerCPcy5.5-labelled anti-lgA (for IgA1 and lgA2).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-IgG1</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-IgG2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-IgG3</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-IgG4</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>PEcy7-labelled anti-IgM andPerCPcy5.5-labelled anti-lgA (for IgA1</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-IgM</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>lgA2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Bound antibodies were detected by incubation with mouse anti-human IgG1 secondary antibody coupled to horse-radish-peroxidase (HRP) (Southern Biotech) diluted 1/6,000 in 1% BSA in PBS which was then detected using an ABTS substrate solution (Invitrogen).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>horse-radish-peroxidase (HRP</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The nitrocellulose membrane was developed by ECL (Pierce) using PO-coupled mouse anti-human secondary antibodies (Southern Biotech).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human secondary antibodies (Southern Biotech).</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Human embryonic kidney HEK293T cells (ATCC CRL-3216) and human hepatocellular carcinoma HepG2 cells (ATCC HB-8065) were maintained in DMEM supplemented with 10% FBS in a CO2 incubator.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Lentiviral vector and Jurkat cell transduction: To express the full-length spike S protein of SARS-CoV2 we used the lentiviral vector based on the epHIV-7 plasmid that contains the truncated version of human EGFR (huEGFRt) that lacks the domains essential for ligand binding and tyrosine kinase activity described in Wang et al 9.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Jurkat</div><div>suggested: TKG Cat# TKG 0209, RRID:CVCL_0065)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For transduction, lentiviral-transducing supernatants were produced from transfected packaging HEK-293T cells as described previously 10.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK-293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Polybrene (8 μg/mL) was added to the viral supernatants prior to transduction of ACE2+HEK293T cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ACE2+HEK293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">A total of 3×105 MOLT-4 cells were plated on a P24 flat-bottom well 350 μL of DMEM and 350 μL of viral supernatant were added.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MOLT-4</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Jurkat-S cells were collected by centrifugation and resuspended in PBS at the same concentration.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Jurkat-S</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HepG2 cells were labelled with Cell Trace Violet (CTV, Invitrogen) for 5 min at 37°C in PBS; Jurkat-S were labelled with CFDA-SE (CFSE, Invitrogen) under the same conditions.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HepG2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Samples were then washed and labeled cells were analyzed on a FACSCalibur or FACSCanto II flow cytometer (Becton-Dickinson) and the data were analyzed with FlowJo software (BD).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FACSCalibur</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.08.01.20166553: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">Consent: Consecutive out-patients diagnosed at the same 4 hospitals prior to March 15th and on a convenience sample of later days were approached for consent to collect serum and saliva at 4–12 weeks PSO.<br>IRB: All samples were collected after Research Ethics Board (REB) review (see Sample section above for the individual REB approval numbers).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">No randomization was performed, since this is an observational study.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">This observational study focused on monitoring the levels of antibodies to SARS-CoV-2 antigens in serum and saliva of patients with confirmed SARS-CoV-2 infection.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SARS-CoV-2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After washing 4 times, 10 μl of one of the following secondary antibodies (all from Jackson ImmunoResearch) diluted in 1% BLOTTO in PBS-T were added at the indicated concentrations followed by incubation for 2 hr at room temperature: Goat anti-human IgG Fcy – HRP (#109-035-098; 1:40,000 or 0.2 ng per well), Goat anti-human IgM Fc5u – HRP (#109035-129; 1:12,000 or 0.66 ng per well) or Goat anti-human IgA a chain – HRP (#109-035-127; 1:10,000 or 0.8 ng per well).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG</div><div>suggested: (Jackson ImmunoResearch Labs Cat# 109-035-098, RRID:AB_2337586)</div></div><div style="margin-bottom:8px"><div>anti-human IgM</div><div>suggested: (Jackson ImmunoResearch Labs Cat# 109-035-129, RRID:AB_2337588)</div></div><div style="margin-bottom:8px"><div>anti-human IgA</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Antibodies used for the standard curves were: Human anti-spike S1 IgG (A02038, GenScript), anti-spike S1 IgM (A02046, GenScript) and Ab01680 anti-spike IgA (Ab01680-16, Absolute Antibody), all used at 0.5 to 10ng per well.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-spike S1 IgG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>A02038</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-spike S1 IgM</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>A02046</div><div>suggested: (GenWay Biotech Inc. Cat# GWB-A02046, RRID:AB_10276779)</div></div><div style="margin-bottom:8px"><div>anti-spike IgA</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Anti-human Ig antibody (Southern Biotech, 2010–01) diluted 1:1000 in PBS was added to 96-well Nunc MaxiSorp™ plates (ThermoFisher, 44-2404-21).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Anti-human Ig antibody</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>Anti-human Ig</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HRP-conjugated secondary antibodies against IgA, IgG, and IgM (goat anti-human IgA- and IgG-HRP, Southern Biotech, IgA: 2053–05, IgG: 2044–05, IgM: 2023–05) were added to the appropriate wells at 1:1000 in 2.5% BLOTTO and incubated for 1 hour at 37°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HRP-conjugated secondary antibodies against IgA, IgG, and IgM (goat anti-human IgA- and IgG-HRP, Southern Biotech, IgA: 2053–05, IgG: 2044–05, IgM: 2023–05)</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>HRP-conjugated secondary antibodies against IgA, IgG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>goat anti-human IgA-</div><div>suggested: (InvivoGen Cat# fab-iga, RRID:AB_11125122)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Horseradish peroxidase (HRP)-conjugated Goat anti human-IgG, IgA, and anti-IgM secondary antibodies (Southern Biotech, IgG: 2044–05, IgA: 2053–05, IgM: 2023–05) were added to wells at dilutions of 1:1000, 1:2000 and 1:1000 in 2.5% BLOTTO, respectively, and incubated for 1 hour at 37°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti human-IgG, IgA,</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti human-IgG, IgA</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-IgM</div><div>suggested: (SouthernBiotech Cat# 2023-01, RRID:AB_2795619)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For serum samples, seven multivariable linear regression models were constructed (one for each of anti-RBD IgA, anti-S IgA, anti-RBD IgG, anti-S IgG, anti-RBD IgM, anti-spike IgM, neutralizing antibody).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-RBD IgA</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-S IgA</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-RBD IgG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-S IgG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-RBD IgM</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-spike IgM</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Development and validation of manual colorimetric and automated chemiluminescent assays for monitoring RBD and spike trimers antibodies in serum or plasma. Fig. S2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>S2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Effect of heat versus detergent inactivation of saliva samples on the detection of anti-RBD antibodies in a manual, colourimetric ELISA. Fig. S5.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-RBD</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>S5</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To stabilize the spike protein in a trimeric form, the cDNA was cloned in-frame with the human resistin cDNA (aa 23–108) containing a C-terminal FLAG-(His)6 tag (Cricetulus griseus codon bias, GenScript) into a modified cumate-inducible pTT241 expression plasmid and transfected in CHO2353 cells (Stuible et al, manuscript in preparation) followed by methionine sulfoximine selection for 14 days to generate a stable CHO pool.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CHO2353</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Viral stock was expanded using Vero E6 as previously described such that stored aliquots of stock contain 2% FBS.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: RRID:CVCL_XD71)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Initial experiments were done with Triton X-100 (Sigma-Aldrich) serially diluted and applied to Vero-E6 cells in 96-well flat bottom plates to determine the minimum concentration required to prevent toxicity to cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero-E6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Spike trimer was expressed as follows: the SARS-CoV-2 spike sequence (aa 1–1208 from Genebank accession number MN908947 with the S1/S2 furin site (residues 682–685) mutated [RRAR->GGAS] and K986P / V987P stabilizing mutations was codon-optimized (Cricetulus griseus codon bias) and synthesized by Genscript.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Genebank</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">These analyses were performed in Prism (GraphPad), Version 8.3.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Prism</div><div>suggested: (PRISM, RRID:SCR_005375)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">References and Notes:</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Notes</div><div>suggested: None</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.02.14.431129: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Human β-coronavirus OC43 assay: The human beta-coronavirus OC43 assay in HeLa cells was performed as previously described.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HeLa</div><div>suggested: CLS Cat# 300194/p772_HeLa, RRID:CVCL_0030)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">[13] Human α-Coronavirus 229E assay: The human alpha-coronavirus 229E was purchased from Virapur (San Diego, CA) and propagated using MRC-5 human lung fibroblast cells (ATCC).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MRC-5</div><div>suggested: ICLC Cat# HL95001, RRID:CVCL_0440)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Huh7 cells (JCRB cell Bank) were cultured using DMEM media, supplemented with 10 % fetal bovine serum (FBS), 1% (v/v</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Huh7</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2 nanoluciferase assay in human ACE-2 expressing A549 cells: The SARS-CoV-2 nanoluciferase assay using A549 cells expressing the human ACE-2 receptor was performed in the laboratory of Pei-Yong Shi at the University of Texas, Medical Branch [14] on behalf of Aligos Therapeutics, Inc.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>A549</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2 3CLpro and human cathepsin L biochemical assays: The SARS-CoV-2 3CLpro and human cathepsin L assays were performed as previously described [12].</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SARS-CoV-2 3CLpro</div><div>suggested: None</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • No funding statement was detected.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.02.10.20248323: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: The study was approved by the Hospital Research Ethics Committee (REC-2020-012).<br>Consent: Participants provided written informed consent for collection of both oro/nasopharyngeal swabs and serum samples.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The anti-SARS-CoV-2 ELISA (IgG) requires a sample volume of 10μL for the detection of IgG antibody to SARS-CoV-2 (10μL diluted with 1mL of sample diluent).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-CoV-2 ELISA (IgG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>SARS-CoV-2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In addition, serum samples from all 137 study participants were tested on the Abbott Architect™ i2000SR instrument using the Abbott SARS-CoV-2 IgG75 assay following the manufacturer’s instructions.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Abbott Architect™</div><div>suggested: (Abbott ARCHITECT i1000sr System, RRID:SCR_019328)</div></div><div style="margin-bottom:8px"><div>Abbott</div><div>suggested: (Abbott, RRID:SCR_010477)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      However, the limitation of closed platform systems from a single supplier is around supply of reagents, analogous to the problems with reagents for PCR testing.27 The clinical performance of the Trinity Biotech Captia™ SARS-CoV-2-IgG kit in a healthcare worker population was evaluated as part of the CAST study. The Positive Percent Agreement (or estimated sensitivity) and the Negative Percent Agreement (or estimated specificity) were 95.92% and 100% respectively at >14 days post swab, providing a reliable and robust methodology for determining IgG levels in healthcare workers with impactful utility in the medium to long term management of the COVID-19 pandemic. There has been much discussion regarding antibody levels and their potential associated protection against SARS-CoV-2 re-infection. A study on SARS, a similar coronavirus to SARS-CoV-2, showed recovered individuals maintained neutralising antibodies for two years on average.28 In addition, antibody responses in individuals with laboratory-confirmed MERS-CoV infection lasted for at least 34 months after the outbreak.29 Long et al. and more recently Ward et al. have suggested a rapid decay of anti-SARS-CoV-2 IgG, although our findings do not support this assertion.30,31 Ward’s seroprevalence study on a large population in the U.K using lateral flow immunoassay testing found that healthcare workers along with ethnic minorities and care home workers were disproportionately affected by the pandemic with more positive test r...

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.09.21.20198309: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">Consent: Human subjects: Signed informed consent forms were obtained from all patients as per institutional ethical approvals obtained from the Unit of Biomedical Ethics in King Abdulaziz University Hospital (Reference No 245-20), the Institutional Review Board at the Ministry of Health, Saudi Arabia (IRB Numbers: H-02-K-076-0320-279 and H-02-K-076-0420-285), and the Global Center for Mass Gatherings Medicine, Saudi Arabia (GCMGM) (No. 20/03A).<br>IRB: Human subjects: Signed informed consent forms were obtained from all patients as per institutional ethical approvals obtained from the Unit of Biomedical Ethics in King Abdulaziz University Hospital (Reference No 245-20), the Institutional Review Board at the Ministry of Health, Saudi Arabia (IRB Numbers: H-02-K-076-0320-279 and H-02-K-076-0420-285), and the Global Center for Mass Gatherings Medicine, Saudi Arabia (GCMGM) (No. 20/03A).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After another washing, plates were incubated with HRP□conjugated goat anti□human IgG (H□+□L) or IgM antibodies (Jackson ImmunoResearch, West Grove, PA) for 1 h, washed again, and incubated with TMB (3,3’,5,5’-tetramethylbenzidine) substrate (KPL, Gaithersburg, MD) at room temperature for 30□min.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti□human IgG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>IgM</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To completely remove any excess amount of the rVSV-ΔG/G*-luciferase, 15 ml of DMEM containing rabbit polyclonal anti VSV-G antibody were added to the cells monolayer and incubated for 24 h at 37°C in 5% CO2 humidified incubator.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti VSV-G</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells: Baby Hamster kidney BHK-21/WI-2 cell line (Kerafast, EH1011) and African Green monkey kidney-derived Vero E6 cell line (ATCC, 1586) were cultured in Dulbecco’s modified essential medium (DMEM) contained 100 U/ml of penicillin, and 100 μg/ml of streptomycin and supplemented with 5 and 10% fetal bovine serum (FBS) in a 5% CO2 environment at 37°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BHK-21/WI-2</div><div>suggested: RRID:CVCL_HB78)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, a T-175 tissue culture flask of BHK21/WI-2 cells were transfected with 46 μg of pcDNA expressing codon-optimized full-length SARS-CoV-2 S protein (GenBank accession number: MN908947) using Lipofectamine ™ 2000 transfection reagent (Invitrogen).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BHK21/WI-2</div><div>suggested: RRID:CVCL_HB78)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Then, a 100 μl of the pseudovirus–serum mixtures were transferred onto Vero E6 cell monolayers and incubated at 37°C in a 5% CO2 humidified incubator for 24 h.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Median Inhibitory Concentration (IC50) neutralization titers were determined using four-parameter logistic (4PL) curve in GraphPad Prism V8 software (GraphPad Co.).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analysis: Statistical analyses and graphical presentations were conducted with GraphPad Prism version 8.0 software (</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.09.29.20193110: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: The human study was approved by the McGill University Health Centre (MUHC) Research Ethics Board #2021-6881.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Anti-B16-PDL1 antibody assay: Plasma was collected from heparinized murine peripheral blood by cetrifugation for 15 min at 2000g.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Anti-B16-PDL1</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Mice, aged 7-8 weeks, were implanted intradermally with 50,000 B16-PD-L1 melanoma cells that overexpress PD-L1.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>B16-PD-L1</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, 5×105 B16-PDL1 tumour cells were added to a 96-well plated, blocked with 10% FBS-PBS, and washed with PBS.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>B16-PDL1</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plasma samples were diluted 1:16 in PBS and were added to B16 cells in a volume of 100 μl, mixed and then incubated for 1 hour at 4°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>B16</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Mice: C57BL/6 mice were housed at the Hôpital Maisonneuve Rosemont animal facility (Montreal, QC, Canada).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>C57BL/6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">FACS analyses were performed by using FlowJo software or Cytobank for viSNE analyses.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div><div style="margin-bottom:8px"><div>Cytobank</div><div>suggested: (Cytobank, RRID:SCR_014043)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Quantification of retinal vasculature branch points was done with the use of the angiogenesis analyzer tool for ImageJ.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ImageJ</div><div>suggested: (ImageJ, RRID:SCR_003070)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on pages 41, 36 and 38. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.05.13.093195: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: NHPs – Animal experiment approval was provided by the Institutional Animal Care and Use Committee (IACUC) at Rocky Mountain Laboratories.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">NHPs – 9 adult rhesus macaques (8M, 1F) were randomly divided into two groups of six and three animals.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">Animals were scored daily by the same person who was blinded to study group allocations using a standardized scoring sheet.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The same calculation was used for diluting the sera to the same amounts of total IgG for further testing on different IgG subclasses with anti-mouse IgG subclass-specific antibodies (Abcam).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-mouse IgG subclass-specific antibodies ( Abcam) .</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Antibodies were detected using affinity-purified polyclonal antibody peroxidase-labeled goat-anti-monkey IgG (Seracare, 074-11-021) in casein and TMB 2-component peroxidase substrate (Seracare, 5120-0047), developed for 5-10 min, and reaction was stopped using stop solution (Seracare, 5150-0021) and read at 450 nm.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>IgG</div><div>suggested: (Thermo Fisher Scientific Cat# A300-450A-M, RRID:AB_2779227)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Specific anti-CoV immunoreactivity was detected using an in-house SARS-CoV-2 nucleocapsid protein rabbit antibody (Genscript) at a 1:1000 dilution.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SARS-CoV-2 nucleocapsid protein</div><div>suggested: (Bioss Cat# bsm-41414M, RRID:AB_2848129)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The virus was rescued and propagated in T-Rex 293 HEK cells (Invitrogen) which repress antigen expression during virus propagation.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK</div><div>suggested: CLS Cat# 300192/p777_HEK293, RRID:CVCL_0045)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Virus propagation was performed in VeroE6 cells in DMEM supplemented with 2% fetal bovine serum, 1 mM L-glutamine, 50 U/ml penicillin and 50 μg/ml streptomycin.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VeroE6</div><div>suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Study design animal experiments: Mice – Female BALB/cOlaHsd (BALB/c) (Envigo) and outbred Crl:CD1(ICR) (CD1) (Charles River) mice of at least 6 weeks of age, were immunized IM in the musculus tibialis with 6×109 VP of ChAdOx1 nCoV-19 unless otherwise stated.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BALB/cOlaHsd</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>BALB/c</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Sample acquisition was performed on a Fortessa (BD) and data analyzed in FlowJo v9 or FlowJo V10 (TreeStar).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr></table>

      Results from OddPub: Thank you for sharing your data.


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.01.28.21250716: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      No key resources detected.


      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      Our findings have limitations. The SES is calculated differently in each country, though the national ICBS classification correlative with metabolic disease13 making our findings generalizable. Also, in this study it is used as an ecological variable and is not indicative of individual health, yet this is a more appropriate representation of its implication on municipal vaccination. We did not have available data regarding active disease burden of population over 60, or the disease severity of active cases within municipalities. As data were aggregated we did not have available personal data regarding COVID-19 risk factors, though older age is the most important risk factor for severe COVID-1914. Finally, we were not able to remove the population aged over 60 who recovered or died from COVID-19 from the vaccination potential population in each municipality, though Israel has suffered from approximately 4,000 COVID-19 related deaths only, with approximately 5% of the population recovered from the disease hence this does not affect our findings. These data are an interim analysis based on the rates of the first dose of vaccination, and data of 2nd vaccination shot compliance are not yet available. The analysis time point, conducted 3 weeks following the initiation of vaccinations in Israel, aims at evaluating vaccination rollout and distribution as well as compliance and does not intend to evaluate vaccination efficacy in mitigating the pandemic. Moreover, as the mRNA vaccine l...

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.02.01.428871: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: The animal study protocols were approved by the Institutional Animal Care and Use Committee (IACUC) of University of Chicago.<br>IRB: This study was deemed exempt by the University of Chicago Institutional Review Board (IRB19-1942)</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">To evaluate the safety of the Nanotraps, 2 male and 2 female 6-10-week-old C57BL/6NHsd mice were intratracheally administered with 10 mg/kg Nanotrap-ACE2 in 50 μL PBS.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The pellet was resuspended in 100 μL PBS and incubated with biotinylated ACE2 (Bioss Antibodies) for 30 minutes on ice.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ACE2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">AF488-labeled anti-ACE2 antibody (Santa Cruz Biotechnology) was added to the Nanotrap-ACE2 for 30 minutes on ice and centrifuged at 5,000×g for 10 min, the pellet was washed with PBS for 3 times.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>AF488-labeled</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The differentiated THP-1 cells were harvested as dTHP-1 macrophages and maintained in RPMI supplemented with 10% FBS and 1% Penicillin-Streptomycin.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>THP-1</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After 24 hours, 3×107 FFU VSVdG*G-GFP virus was added to the HEK293T cells and incubated for another 48 hours.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Coculture was carried out in a macrophage to A549 cell ratio of 1:5. 4×104 A549 cells were seeded in an 18-well microslide (Vivid) overnight and 8×103 dTHP-1 macrophages were added onto the A549 cells for another 6 hours.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>A549</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In vitro cytotoxicity assay: A549 or HEK293T-ACE2 cells (both maintained in DMEM supplemented with 10% FBS and 1% Penicillin-Streptomycin) were seed in a 96-well plate at a density of 1×104 cells/well in 100 μL of culture medium overnight.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T-ACE2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">African green monkey kidney (Vero E6) cells were maintained in DMEM supplemented with 10% FBS and 1% Penicillin-Streptomycin.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To evaluate the safety of the Nanotraps, 2 male and 2 female 6-10-week-old C57BL/6NHsd mice were intratracheally administered with 10 mg/kg Nanotrap-ACE2 in 50 μL PBS.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>C57BL/6NHsd</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Line scans were performed in Fiji.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Fiji</div><div>suggested: (Fiji, RRID:SCR_002285)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The data were further analyzed by FlowJo (BD) and Prism (Graphpad) softwares.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div><div style="margin-bottom:8px"><div>Graphpad</div><div>suggested: (GraphPad, RRID:SCR_000306)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Image reconstruction videos were made in Imaris (Bitplane).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Imaris</div><div>suggested: (Imaris, RRID:SCR_007370)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.02.20.432092: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">Plaque numbers were scored in at least 3 replicates per dilution by independent readers blinded to the experimental group and the virus titers were determined by plaque-forming units (PFU) per milliliter. 4.6 Immunocytochemistry and fluorescence image analysis: hiPSC-CMs grown on 96-well plates were fixed using 4% PFA solution (Sigma-Aldrich) for 1 h and stored at 4°C until further processing.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After cell dissociation, cells were fixed with 1% paraformaldehyde (PFA), permeabilized with Triton 0.1% (Sigma Aldrich) and Saponin 0.1% (Sigma Aldrich), and stained with the antibodies anti-TNNT2 (1:2500; Thermo Fisher, MA5-12960) and anti-OCT4 (1:200, Thermo Fisher, MA5-14845).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-TNNT2</div><div>suggested: (Thermo Fisher Scientific Cat# MA5-12960, RRID:AB_11000742)</div></div><div style="margin-bottom:8px"><div>anti-OCT4</div><div>suggested: (Thermo Fisher Scientific Cat# MA5-14845, RRID:AB_10979606)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Primary antibodies were diluted in blocking solution and incubated at 4°C overnight, namely anti-SARS-CoV-2 convalescent serum from a recovered COVID-19 patient (1:1000); anti-SARS-CoV-2 spike protein monoclonal antibody (SP) (1:500, G632604 - Genetex); anti-cardiac troponin T (cTnT) (1:500, MA5-12960 - Invitrogen) and anti-Sigma1R B-5 (1:100, SC-137075 - Santa Cruz Biotechnology).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-CoV-2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-SARS-CoV-2 spike protein</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-cardiac troponin T ( cTnT )</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-Sigma1R</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Next, hiPSC-CMs were washed 3 times with PBS 1X and incubated with the secondary antibodies diluted in blocking solution: goat anti-Human Alexa Fluor 647 (1:400; A-21445 - Invitrogen) and goat anti-Mouse Alexa Fluor 488 (1:400; A-11001 - Invitrogen) for 1 h at room temperature.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-Human Alexa Fluor 647</div><div>suggested: (Molecular Probes Cat# A-21445, RRID:AB_2535862)</div></div><div style="margin-bottom:8px"><div>anti-Mouse</div><div>suggested: (Thermo Fisher Scientific Cat# A-11001, RRID:AB_2534069)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Membranes were then incubated overnight at 4°C with primary antibodies (anti-ACE2 (1:1000; MA5-32307 - Thermo Fisher),</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-ACE2</div><div>suggested: (Thermo Fisher Scientific Cat# MA5-32307, RRID:AB_2809589)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">anti-Sigma-1 R (1:500; SC-137075 - Santa Cruz Biotechnology), anti-actin (1:2000, MAB1501, Millipore); or anti-GAPDH (1:5000; AM4300 -Thermo Fisher) diluted in TBS-T with 5% non-fat milk.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-GAPDH</div><div>suggested: (Thermo Fisher Scientific Cat# AM4300, RRID:AB_2536381)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Then, membranes were washed and incubated with peroxidase-conjugated antibodies (goat anti-Mouse IgG (H+L), HRP-conjugate (1:10,000, G21040 -Molecular Probes) and Goat anti-Rabbit IgG (H+L) HRP- conjugate (1:10,000, G21234</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-Mouse IgG</div><div>suggested: (Thermo Fisher Scientific Cat# G-21040, RRID:AB_2536527)</div></div><div style="margin-bottom:8px"><div>anti-Rabbit IgG</div><div>suggested: (Thermo Fisher Scientific Cat# G-21234, RRID:AB_2536530)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">4.4 SARS-CoV-2 propagation: SARS-CoV-2 was expanded in Vero E6 cells from an isolate obtained from a nasopharyngeal swab of a confirmed case in Rio de Janeiro, Brazil (</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: RRID:CVCL_XD71)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After 100% confluence was reached, cells were kept in RPMI supplemented with B27 without insulin (both from Thermo Fisher, USA) and with 4 μM CHIR99021 (Merck Millipore Sigma, USA) for one day.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Merck Millipore Sigma</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">FC data was acquired using a Canto BD flow cytometer for each batch of differentiation and analyzed using the FlowJo Software considering 1%–2% of false-positive events.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Densitometry analysis was performed using ImageJ software Gel Analysis program and the values obtained represent the ratio of density between the immunodetected protein and the loading control (actin or GAPDH).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ImageJ</div><div>suggested: (ImageJ, RRID:SCR_003070)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Prism v8.0 (GraphPad) was used for data analysis and graphics, where statistical significance was accepted at P<0.05.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Prism</div><div>suggested: (PRISM, RRID:SCR_005375)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: We found the following clinical trial numbers in your paper:<br><table><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Identifier</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Status</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Title</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04349371</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Terminated</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Saved From COVID-19</td></tr></table>


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • No funding statement was detected.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.02.20.431855: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">Plaque numbers were scored in at least 3 replicates per dilution by independent readers blinded to the experimental group and the virus titers were determined by plaque-forming units (PFU) per milliliter. 2.5.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cardiomyocytes were incubated in primary antibodies diluted in a blocking buffer at 4° overnight (anti-SARS-CoV-2 convalescent serum from a positive COVID-19 patient (1:1000) and anti-cardiac troponin T (TNNT2) (1:500, MA5-12960 - Invitrogen).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-CoV-2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-cardiac troponin T (TNNT2</div><div>suggested: (Hytest Cat# RC4T19-RecChim406, RRID:AB_2889127)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Next, cardiomyocytes were incubated with the secondary antibody diluted in a blocking buffer: goat anti-Human Alexa Fluor 647 (1:400; A-21445 - Invitrogen) and goat anti-Mouse 594 (1:400; A-11032 - Invitrogen) for 1h.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-Human Alexa Fluor 647</div><div>suggested: (Molecular Probes Cat# A-21445, RRID:AB_2535862)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Membranes were incubated overnight at 4°C with primary antibodies anti-ACE2 (1: 1000; MA5-32307 - Thermo Fisher), anti-ACTIN (1: 2000; MAB1501, Millipore) diluted in TBS-T with 5% non-fat milk and anti-CB1 (1:500; SC-10066, Santa Cruz).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-ACE2</div><div>suggested: (Thermo Fisher Scientific Cat# MA5-32307, RRID:AB_2809589)</div></div><div style="margin-bottom:8px"><div>anti-ACTIN</div><div>suggested: (Millipore Cat# MAB1501, RRID:AB_2223041)</div></div><div style="margin-bottom:8px"><div>anti-CB1</div><div>suggested: (Santa Cruz Biotechnology Cat# sc-10066, RRID:AB_637711)</div></div><div style="margin-bottom:8px"><div>SC-10066</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Membranes were washed to be incubated with peroxidase-conjugated antibodies IgG (H + L), HRP-conjugate: goat anti-mouse (1: 10.000, G21040, Molecular Probes) goat anti-rabbit (1: 10.000, G21234, Molecular Probes) and rabbit anti-goat (1: 2.000, 61-1620, Invitrogen).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-mouse</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-rabbit</div><div>suggested: (Innovative Research Cat# G-21234, RRID:AB_1500696)</div></div><div style="margin-bottom:8px"><div>anti-goat</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2 titration: For virus titration, monolayers of Vero E6 cells (2 × 104 cell/well) in 96-well plates were infected with serial dilutions of supernatants containing SARS-CoV-2 for 1 hour at 37°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cytokine multiplex assay and LDH cytotoxicity assay: A multiplex biometric immunoassay containing fluorescent dyed microbeads was used for plasma cytokine measurement (Bio-Rad Laboratories, Hercules, CA, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Bio-Rad Laboratories</div><div>suggested: (Bio-Rad Laboratories, RRID:SCR_008426)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Next, membranes were blocked again and proceeded with the above-described steps. 2.11. Statistics: Statistical analyses were performed using GraphPadPrism software version 8.0 (GraphPad, EUA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.02.22.432218: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: Human ES cells were used following the Guidelines for Derivation and Utilization of Human Embryonic Stem Cells of the Ministry of Education, Culture, Sports, Science and Technology of Japan, and the study was approved by an independent ethics committee.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The virus was plaque-purified and propagated in Vero cells and stored at −80°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: CLS Cat# 605372/p622_VERO, RRID:CVCL_0059)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The ACE2- and TMPRSS2-expressing Ad vectors (Ad-ACE2 and Ad-TMPRSS2, respectively) were propagated in HEK293 cells (JCRB9068, JCRB Cell Bank).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">At day 2 (Vero cells) or day 4 (ACE2-iPS cells) after the infection, the viral RNA copy number in the cell culture supernatant was measured by qPCR.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ACE2-iPS</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Dilutions were placed onto the TMPRSS2/Vero cells in triplicate and incubated at 37°C for 96 hr.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>TMPRSS2/Vero</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Standard curves were prepared using SARS-CoV-2 RNA (105 copies/μL) purchased from Nihon Gene Research Laboratories.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Nihon Gene Research Laboratories</div><div>suggested: (University of Southern California; Los Angeles; USA, RRID:SCR_008093)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Adapter sequences and low-quality bases were trimmed from the raw reads by Cutadapt ver 1.14 (Martin, 2011).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Cutadapt</div><div>suggested: (cutadapt, RRID:SCR_011841)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The trimmed reads were mapped to the human reference genome sequences (hg38) using STAR ver 2.5.3a (Dobin et al., 2013) with the GENCODE (release 36, GRCh38.p13) (Frankish et al., 2019) gtf file.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>STAR</div><div>suggested: (STAR, RRID:SCR_015899)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The raw counts for protein-coding genes were calculated using htseq-count ver 0.12.4 (Anders et al., 2015) with the GENCODE gtf file.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GENCODE</div><div>suggested: (GENCODE, RRID:SCR_014966)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Gene expression levels were determined as transcripts per million (TPM) with DEseq2 (Love et al., 2014).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>DEseq2</div><div>suggested: (DESeq2, RRID:SCR_015687)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Raw data concerning this study were submitted under Gene Expression Omnibus (GEO) accession number GSE166990.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Gene Expression Omnibus</div><div>suggested: (Gene Expression Omnibus (GEO, RRID:SCR_005012)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analyses were performed using GraphPad Prism8 and 9.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: Thank you for sharing your data.


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.02.23.432569: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: All animal work was performed under the standards of the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health (NIH) and according to the Animal Welfare Act guidelines.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">General animal procedures: Syrian hamsters (aged 3-6 months old both male and female) were obtained from the Charles River, MA.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Controls of a validated SARS-CoV-2 antibody-negative, positive human serum, and an uninfected cell, were performed to ensure that virus neutralization was specific.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>antibody-negative</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The serum–virus mixes (200 μl total) were incubated at 37°C for 1 h, after which they were added dropwise onto confluent Vero E6 cell monolayers in six-well plates.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: RRID:CVCL_XD71)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Graphs were generated using GraphPad Prism, version 9.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">An unstained Syrian hamster lung section was used to create an autofluorescence signature that was subsequently removed from images using InForm software version 2.4.8 (Akoya Biosciences).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>InForm</div><div>suggested: (inForm, RRID:SCR_019155)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.02.22.432407: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Prior to the addition of virus, serial dilutions of antibodies against either the nucleocapsid (Genetex GTX632269) or spike proteins (polyclonal anti-spike, Abcam ab272504; anti-RBD, AcroBiosystems SAD-S35-100ug) of SARS-CoV-2 in a total volume of 60ul of VIM were made in a separate 96 well dilution plate to which 60 pfu/well of SARS-CoV-2 (USA-WA1/2020) was added for a final MOI of 0.05.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-spike ,</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-RBD</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Following incubation, samples were washed three times with 1XPBS+0.2% Triton-X100 for 5 minutes, prior to incubation with 1:1,000 anti-rabbit IgG secondary antibody (Rockland 611-141-122) for 1 hour.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-rabbit IgG</div><div>suggested: (Rockland Cat# 611-141-122, RRID:AB_1057564)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Determination of Viral Load: Raw 264.7 cells were seeded at a density of 2×106 cells/well in a 6-well plate (Geiner Bio-One 657165) and allowed to settle overnight at 37°C, 5% CO2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Raw 264.7</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Impact of MP Supernatants on Vero E6 Susceptibility to SARS-CoV-2: Vero E6 cells (ATCC VERO C1008) were cultured in DMEM containing, 4 mM L-glutamine, sodium pyruvate (Hyclone SH30243),</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: RRID:CVCL_XD71)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Prior to the addition of virus, serial dilutions of antibodies against either the nucleocapsid (Genetex GTX632269) or spike proteins (polyclonal anti-spike, Abcam ab272504; anti-RBD, AcroBiosystems SAD-S35-100ug) of SARS-CoV-2 in a total volume of 60ul of VIM were made in a separate 96 well dilution plate to which 60 pfu/well of SARS-CoV-2 (USA-WA1/2020) was added for a final MOI of 0.05.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>AcroBiosystems</div><div>suggested: (ACRObiosystems, RRID:SCR_012550)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Images were captured using a Zeiss LSM 710 confocal microscope and receptor expression quantitated using ImageJ.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ImageJ</div><div>suggested: (ImageJ, RRID:SCR_003070)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical Analysis: All graphical presentations of data and ANOVA analysis was conducted in GraphPad Prism 9.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.02.18.21251973: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: Research ethics approval was obtained from the South Central-Berkshire B Research Ethics Committee (IRAS ID: 283787).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">Since the first round of data collection in May 2020, in each subsequent round in each subsequent round between 150,000 and 175,000 randomly selected individuals ages 5 years and above, in England, have provided a self-administered throat and nose swab for RT-PCR testing for SARS-CoV-2.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      No key resources detected.


      Results from OddPub: Thank you for sharing your code and data.


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      Our study has a number of limitations. Because participation rates in our study may vary by a range of socio-demographic factors, it is possible that our sample is not fully representative of the base population, despite correcting for the sampling in our weighting procedure. However, unlike estimates based on symptomatic testing, we provide prevalence estimates among both symptomatic and non-symptomatic individuals from random samples of the population. Our study is therefore not subject to the biases driven by self-reporting, and health service capacity and performance present in similar data based only on tests of symptomatic individuals. We ask individuals to provide a self-administered throat and nose swab (parent/guardian for children ages 5 to 12 years) which may be less reliable than a swab administered by a health professional. However, we provide detailed instructions including video instructions, and have utilised the same approach across all rounds of REACT-1, so that within-study comparisons and trends in prevalence over time should be robust. In addition, we have established a cold chain from home to laboratory to preserve integrity of the samples, and use a single lab (with well-defined quality control procedures) to exclude between-laboratory variation. In conclusion, we have documented marked falls in prevalence in England during lockdown from January to February 2021. However, it should be noted that prevalence still remains high (prevalence now at a level l...

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.02.24.432203: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: Animals: All animal care and experimental procedures complied with the guidelines of Animal Care and were approved by Use Committee of the University of Perugia and by the Italian Minister of Health and Istituto Superiore di Sanità (Italy) and was in agreement with the European guidelines for use of experimental animals (permissions n. 583/2017-PR and 1126/2016-PR).<br>Consent: An informed consent was obtained by each donor for the use of the plasma sample remnants and the protocol was approved by the Ethical Committee of the University of Perugia: authorization n. 61843 (July 13,2020).<br>IRB: An informed consent was obtained by each donor for the use of the plasma sample remnants and the protocol was approved by the Ethical Committee of the University of Perugia: authorization n. 61843 (July 13,2020).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">After 8 days, Ahr+/+ and Ahr−/− HFD-F mice were randomized to receive HFD-F alone or plus Pelargonidin (5 mg/Kg/die) by oral gavage for remaining 7 weeks.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Briefly, according to this 8–10 weeks old male mice C57BL/6J wild-type and Ahr+/+ and Ahr−/− on C57BL/6J genetic background were administrated.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The program’s protocol included the quantitative analysis of the anti-SARS-CoV-2 IgG antibodies directed against the subunits (S1) and (S2) of the virus spike protein.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-CoV-2 IgG</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Transactivation Assay: For AhR-mediated transactivation, HepG2 cells were plated at 7.5 × 104 cells/well in a 24-well plate.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HepG2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell culture: Caco-2 cells, a human intestinal epithelial cell line (Sigma-Aldrich) was grown at 37 °C in D-MEM containing 10% FBS, 1% l-glutamine, and 1% penicillin/streptomycin.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Caco-2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2 yield reduction assay: Vero E6 cells (20,000 cells/well) were seeded in 96-well clear flat-bottom plates and incubated at 37°C with 5% CO2 for 24 h.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Mouse spleen macrophages purification: Spleens were collected from AhR+/+ and AhR−/− mice.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>AhR−/−</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">AhR knock out mice (Ahr−/−) on C57BL/6 background and their C57BL/6 congenic littermates wild type (Ahr+/+) were originally supplied by Charles River (Wilmington, MA, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>C57BL/6</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, according to this 8–10 weeks old male mice C57BL/6J wild-type and Ahr+/+ and Ahr−/− on C57BL/6J genetic background were administrated.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>C57BL/6J</div><div>suggested: RRID:IMSR_JAX:000664)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Primers were designed using the software PRIMER3 (http://frodo.wi.mit.edu/primer3/), using data published in the NCBI database.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>PRIMER3</div><div>suggested: (Primer3, RRID:SCR_003139)</div></div><div style="margin-bottom:8px"><div>NCBI</div><div>suggested: (NCBI, RRID:SCR_006472)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The receptor was treated with the Protein Preparation [34] tool implemented in Maestro ver.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Maestro</div><div>suggested: (Maestro, RRID:SCR_016748)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The docking procedure was realized with the Glide software package (Glide, version 7.1.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Glide</div><div>suggested: (Glide, RRID:SCR_000187)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • No funding statement was detected.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.02.24.432721: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      NIH rigor criteria are not applicable to paper type.

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">A custom reference database was generated based on the NCBI virus coronavirus genomes dataset (NCBI Resource Coordinators, 2018), which includes sequences from a large range of coronaviruses.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>NCBI Resource Coordinators</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Models were examined in turn and any position not covered by a higher priority model was added to the FoldX analysis pipeline.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FoldX</div><div>suggested: (FoldX, RRID:SCR_008522)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">It was filtered to exclude problematic sites using VCFTools, based on the annotation at https://github.com/W-L/ProblematicSites_SARS-CoV2/blob/master/problematic_sites_sarsCov2.vcf.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VCFTools</div><div>suggested: (VCFtools, RRID:SCR_001235)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The SARS-CoV-2 genome was sourced from Ensembl (Yates et al., 2020) and Tabix indexed.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Ensembl</div><div>suggested: (Ensembl, RRID:SCR_002344)</div></div></td></tr></table>

      Results from OddPub: Thank you for sharing your code.


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • No funding statement was detected.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.02.25.432136: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: Ethics statement: The study was approved by the Institutional Animal Ethics Committee and Institutional Biosafety Committee of ICMR-NIV, Pune with the approval no. of NIV/IAEC/2021/MCL/01 and NIVIBSC/05.01.2021/02 respectively.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Experiments in Syrian hamsters: Twenty-four (12 male and 12 female) Syrian hamsters of 8-10-week-old age were used for the pathogenicity experiment.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Enzyme-linked Immunosorbent Assay: The serum samples collected on day 3, 5, 7, 10 and 14 DPI were tested for IgG antibodies by hamster anti-SARS-CoV-2 IgG ELISA.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>IgG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-SARS-CoV-2 IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For antibody sub-typing, the same protocol was followed except that of the use of biotinylated anti-Syrian hamster IgG1 /IgG2 antibodies in 1:10000 dilution (BD biosciences, USA) and Streptavidin-horseradish peroxidase 1:8000 (Thermo-scientific, USA) for detection.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-Syrian hamster IgG1</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Hundred micro liters (μl) of the tissue homogenate/ swab specimens were added onto a 24-well plate with Vero CCL81 monolayers and incubated at 37°C for one hour.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero CCL81</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">0.1 ml of this mixture was added in a 24-well tissue culture plate containing a confluent monolayer of Vero CCL-81 cells with intermittent shaking.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero CCL-81</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Two hundred microliters of the tissue homogenate/ swab specimens were used for RNA extraction using MagMAX™</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MagMAX™</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data analysis: For analysis of the data, Graph pad Prism version 8.4.3 software was used.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Graph pad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      This finding is in contrary to the recent reports by NERVTAG which showed the evidences from analysis of multiple different datasets that infection with VOC 202012/01 is associated with an increased risk of hospitalization and death compared to infection with non-VOC, even though there are potential limitations in the datasets used which includes the representativeness, potential biases in case enrolment, confounders etc (17). The amount of virus shedding through the body secretions and excretions mainly contributes to the virus transmission. The high gRNA was observed in the nasal wash samples consistently during the first week post infection in VOC 202012/01 hamsters although comparable virus titers were observed with both variants in these samples. In conclusion, the intranasal infection with the SARS-CoV-2 VOC 202012/01 produced disease in hamsters characterized by body weight loss, infection of the upper and lower respiratory tract and mild lung pathology. No increased disease severity in terms of lung pathology could be observed in hamsters as speculated in humans with VOC 202012/01 but significant decrease in body weight was observed. There was no difference in the neutralization potential against D614G variant. The higher viral RNA load in nasal washes of the SARS-CoV-2 VOC-202012/01 infected hamsters could be a supporting evidence for the increased transmissibility reported with this strain. Further, transmissibility studies need to be explored.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.02.22.21252209: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: Severe COVID-19 was defined as having at least one of the following criteria at hospital admission : respiratory rate > 24 breaths/min or < 12 breaths/min, resting peripheral capillary oxygen saturation in ambient air < 90%, temperature > 40°C, systolic blood pressure < 100 mm Hg, or high lactate levels>2mmol/L.20–22 This observational study using routinely collected data received approval from the Institutional Review Board of the AP-HP clinical data warehouse (decision CSE-20-20_COVID19, IRB00011591, April 8th, 2020).<br>Consent: AP-HP clinical Data Warehouse initiatives ensure patient information and informed consent regarding the different approved studies through a transparency portal in accordance with European Regulation on data protection and authorization n°1980120 from National Commission for Information Technology and Civil Liberties (CNIL).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Medications with functional inhibition effect on acid sphingomyelinase (ASM): FIASMA medications were defined as having a substantial in vitro functional inhibition effect on ASM (i.e., a residual ASM activity lower than 50%), as detailed elsewhere,5–9 and were divided into the following classes according to their Anatomical Therapeutic Chemical (ATC) code:25 FIASMA alimentary tract and metabolism medications (e.g., loperamide); cardiovascular system medications, subdivided into calcium channel blockers (e.g., amlodipine) and other cardiovascular medications (e.g., carvedilol); nervous system medications, subdivided according to ATC codes into psychoanaleptic (e.g., amitriptyline) and psycholeptic medications (e.g., chlorpromazine); and respiratory system medications (e.g., desloratadine).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ATC</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">3 (R Project for Statistical Computing).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>R Project for Statistical</div><div>suggested: (R Project for Statistical Computing, RRID:SCR_001905)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      Our study has several limitations. First, there are two possible major inherent biases in observational studies: unmeasured confounding and confounding by indication. However, in the case of FIASMA medications, including several antidepressants and cardiovascular system medications, confounding by indication may typically result in increased adverse medical outcomes associated with these medications,49 not better outcomes as suggested by our findings. We tried to minimize the effects of confounding in several different ways. First, we used an analysis with inverse probability weighting to minimize the effects of confounding by indication,27,28 resulting in non-substantial between-group differences in clinical characteristics (all SMD<0.1) in both the IPW primary analysis and the Cox regression analysis in the matched analytic sample. Second, we performed multiple sensitivity analyses, which showed similar results. Finally, although some amount of unmeasured confounding may remain, our analyses adjusted for numerous potential confounders. Other limitations include missing data for some baseline characteristic variables (i.e., 11.5%), which might be explained by the overwhelming of all hospital units during the COVID-19 peak incidence, and different results might have been observed during a lower COVID-19 incidence period. However, imputation of missing data did not alter the significance of our results (data available on request). Second, inflation of type I error might have o...

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • No funding statement was detected.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.09.09.20191205: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      NIH rigor criteria are not applicable to paper type.

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2- specific antibodies were detected using phycoerythrin (PE)-conjugated mouse anti-human pan-IgG, IgG1, IgG2, IgG3, IgA1 or IgA2 (Southern Biotech) at 1.3μg/ml, 25μl per well.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human pan-IgG, IgG1</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>IgG2, IgG3</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>IgA1</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>IgA2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">RBD neutralising human IgG1 antibody (ACROBiosystems, USA) was included as a positive control, in addition to COVID-19 negative plasma and buffer only negative controls.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>human IgG1</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Monoclonal antibodies for surface staining included: CD19-ECD (J3-119) (Beckman Coulter), CD20 Alexa700 (2H7), IgM-BUV395 (G20-127), CD21-BUV737 (B-ly4), IgDCy7PE (IA6-2), IgG-BV786 (G18-145) (BD), CD14-BV510 (M5E2), CD3-BV510 (OKT3), CD8a-BV510 (RPA-T8), CD16-BV510 (3G8), CD10-BV510 (HI10a), CD27-BV605 (O323) (Biolegend), IgA-Vio450 (clone) (Miltenyi).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CD20</div><div>suggested: (BD Biosciences Cat# 740204, RRID:AB_2739954)</div></div><div style="margin-bottom:8px"><div>CD21-BUV737</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>CD14-BV510</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>CD3-BV510</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>OKT3</div><div>suggested: (BD Biosciences Cat# 566779, RRID:AB_2869862)</div></div><div style="margin-bottom:8px"><div>CD8a-BV510</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>CD16-BV510</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>CD10-BV510</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>CD27-BV605</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>IgA-Vio450</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Following stimulation, cells were washed, stained with Live/dead Blue viability dye (ThermoFisher), and a cocktail of monoclonal antibodies: CD27 BUV737 (L128), CD45RA PeCy7 (HI100), CD20 BUV805 (2H7), (BD Biosciences), CD3 BV510 (SK7), CD4 BV605 (RPA-T4), CD8 BV650 (RPA-T8)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CD27</div><div>suggested: (BD Biosciences Cat# 751682, RRID:AB_2875668)</div></div><div style="margin-bottom:8px"><div>CD45RA</div><div>suggested: (BD Biosciences Cat# 742052, RRID:AB_2871341)</div></div><div style="margin-bottom:8px"><div>CD3</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>CD4</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>CD8</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Microneutralisation Assay: SARS-CoV-2 isolate CoV/Australia/VIC01/202042 was passaged in Vero cells and stored at −80C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The ectodomain of SARS-CoV-2 (isolate WHU1;residues 1 – 1208) was synthesised with furin cleavage site removed and P986/987 stabilisation mutations45, a C-terminal T4 trimerisation domain, Avitag and His-tag, expressed in Expi293 cells and purified by Ni-NTA affinity and size-exclusion chromatography using a Superose 6 16/70 column (GE Healthcare).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Expi293</div><div>suggested: RRID:CVCL_D615)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Comparison of B and T cell frequencies at first and final sampling was performed using Wilcoxon Rank Sum test in GraphPad Prism 8.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on pages 52 and 31. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.08.24.20180877: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Secondary antibody buffer (100μL of 1 % milk diluted in PBS-T containing 1:500 goat anti-human-IgG-HRP; Invitrogen Part #: 31410) was added immediately following the washing procedure.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human-IgG-HRP</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2 RBD protein was produced by transient transfection of HEK293T cells cultured in 300 cm2 flasks.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Serological results from EUA approved antibody testing (Abbott Architect) performed in the WVUH clinical laboratory and ABO blood type were documented when available.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Abbott Architect</div><div>suggested: (Abbott ARCHITECT i1000sr System, RRID:SCR_019328)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Principal component and heatmap analysis: Serological data from patients tested for cytokine production and antibody production were pooled into Microsoft Excel and imported to ClustVis17.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Microsoft Excel</div><div>suggested: (Microsoft Excel, RRID:SCR_016137)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pearson correlation coefficients and p-values were calculated in GraphPad Prism using the “Correlation” analysis.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.05.11.088179: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Western Blotting: Western blotting was performed as described (Kobayashi et al., 2014; Konno et al., 2018; Nakano et al., 2017; Yamada et al., 2018) using an HRP-conjugated anti-HA rat monoclonal antibody (clone 3F10; Roche) and an anti-alpha-tubulin (TUBA)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-HA</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-alpha-tubulin</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Transfection, SeV Infection and Reporter Assay: HEK293 cells were transfected using PEI Max (Polysciences) according to the manufacturer’s protocol.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293</div><div>suggested: CLS Cat# 300192/p777_HEK293, RRID:CVCL_0045)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">We first aligned the viral genomes using the L-INS-i program of MAFFT version 7.453 (Katoh and Standley, 2013).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MAFFT</div><div>suggested: (MAFFT, RRID:SCR_011811)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">We visualized the tree using a FigTree software (http://tree.bio.ed.ac.uk/software/figtree).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FigTree</div><div>suggested: (FigTree, RRID:SCR_008515)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Nucleotide sequences were determined by a DNA sequencing service (Fasmac), and the sequence data were analyzed by Sequencher v5.1 software (Gene Codes Corporation)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Sequencher</div><div>suggested: (Sequencher, RRID:SCR_001528)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical Analysis: Data analyses were performed using Prism 7 (GraphPad Software).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Prism</div><div>suggested: (PRISM, RRID:SCR_005375)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.02.19.21252101: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">Ligation products were transformed into E. coli, and mini-preps of randomly selected colonies were screened via PCR for the presence of insert.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">Total incident UV-C irradiance was measured using an International Light Technologies (ILT) 2400 radiometer with a SED 220/U solar blind detector, W Quartz wide eye diffuser for cosine correction, and peak irradiance response NIST-traceable calibration.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The viral stock used in this study was established by thawing the Batch, diluting it 1:10,000 into incomplete DMEM (Gibco Cat# 11995-065, supplemented with 4.5 g/L D-glucose, 110 mg/L sodium pyruvate), and adding it to T175 flasks of confluent Vero cells (ATCC clone E6) for a one hour incubation period (37°C, 5% CO2), after which the supernatant was removed and replaced with complete DMEM (cDMEM; DMEM as above plus 4% heat-inactivated fetal bovine serum).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: CLS Cat# 605372/p622_VERO, RRID:CVCL_0059)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Graphing and Statistics: Graphs were prepared using either GraphPad Prism or Microsoft Excel programs; statistical analyses (including regression using the data analysis add-in to determine standard error of regression coefficients) were performed using these programs’ bundled software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div><div style="margin-bottom:8px"><div>Microsoft Excel</div><div>suggested: (Microsoft Excel, RRID:SCR_016137)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      This study provides the first rigorous UV222 dose response kinetics for SARS-CoV-2 in aqueous solution, but there are limitations that must be acknowledged. Most importantly, this study was conducted using virions suspended in aqueous solution. This is only a starting point for quantifying dose response kinetics for airborne virus disinfection that is most relevant for this virus, where many factors such as temperature, humidity, air flow dynamics, and UV reactor specifics will impact dose responses. Previous studies comparing disinfection kinetics of infectious agents in air at increasing relative humidity to those in water36–41 indicate that these water dose responses may present a conservative estimate of airborne disinfection kinetics because humidity in many indoor environments is conditioned to reduce infectious agent persistence One additional limitation of this study related to UV222 application in indoor environments is that the disinfection impact of any ozone production by vacuum UV wavelengths potentially emitted by the KrCl excilamp was not measured, but can likely be neglected due to high airflows in the biosafety cabinet and BSL3 facility. The negative air quality impacts and building material degradation by ozone potentially generated by these lamps, and the potential health hazards and building material solarization from wavelengths below 240 nm and the nonzero emission at wavelengths above 240 nm (Supplementary Figure S1), should also be considered when weig...

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.02.24.21252357: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">Consent: Briefly, participants were enrolled in the Emergency Department (ED) from Massachusetts General Hospital, Boston MA, from 3/24/2020 to 4/30/2020 during the first peak of the COVID-19 surge, with an institutional IRB-approved waiver of informed consent.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">(Addgene plasmid #86677), and pTRIP-SFFV-Hygro-2ATMPRSS2 were described in our recent publication 15. 293T ACE2/TMPRESS2 cell line was generated as described in our recent publication 15</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ACE2/TMPRESS2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">. 293T cells were seeded at 0.8 x 106 cells per well in a 6-well plate and were transfected the same day with a mix of DNA containing 1 μg psPAX, 1.6 μg pTRIP-SFFV-EGFP-NLS, and 0.4 μg pCMV-SARS2ΔC-gp41 using TransIT®-293 Transfection Reagent.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To transduce 293T ACE2 cells, the same protocol was followed, with a mix containing 1 μg psPAX, 1.6 μg pTRIPSFFV-Hygro-2A-TMPRSS2, and 0.4 μg pCMV-VSV-G.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ACE2</div><div>suggested: RRID:CVCL_DR94)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Medium was then removed from 293T ACE2/TMPRSS2 cells and replaced with 150 μl of the mix of plasma and pseudotyped lentivirus.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ACE2/TMPRSS2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Percentage GFP was quantified on a Cytoflex LX (Beckman Coulter), and data was analyzed with FlowJo.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Clinical data analyses, logistic regression and Cox proportion regression were performed on Stata (version 13.1) and figures were generated by Stata and GraphPad (Prism, version 9.0).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div><div style="margin-bottom:8px"><div>Prism</div><div>suggested: (PRISM, RRID:SCR_005375)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      Our study also has a few notable limitations. Although quite comprehensive, our proteomic database does not cover all the cytokines and proteins of interest in COVID-19 pathogenesis. We rely on a pre- existing proteomic database 17 and peripheral blood databases 26,28 to infer the origin of differentially expressed proteins, but do not have data on scRNA-Seq from this cohort to confirm the cellular source of some differentially expressed protein. Given the relatively high limits of detection of culture-based assays, we are unable to confirm whether the RNA detected in plasma samples are from viable, infective SARS-CoV-2 virions. In summary, we report the largest study to date that demonstrates SARS-CoV-2 viremia predicts severe COVID-19 disease outcomes and the likely role of systemic viral dissemination in mediating tissue damage, tissue fibrosis, hypercoagulable state, persistent elevation of proinflammatory markers, and higher viral entry factor expression. Our findings provide key insights into SARS-CoV-2 pathogenesis and identify potential therapeutic targets to mitigate COVID-19 disease severity. Methods Study participants Participant enrollment was described in our prior report 15. Briefly, participants were enrolled in the Emergency Department (ED) from Massachusetts General Hospital, Boston MA, from 3/24/2020 to 4/30/2020 during the first peak of the COVID-19 surge, with an institutional IRB-approved waiver of informed consent. Symptomatic participants of 18 years or...

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a protocol registration statement.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.08.19.258244: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">Consent: Serum samples from recovered COVID-19 patients: 6 serum samples from recovered COVID-19 patients were collected in the First Affiliated Hospital of Zhengzhou University with the patients’ written consent and was approved by the Ethics Committee of Zhengzhou University.<br>IACUC: All animals used in this study were maintained under specific pathogen-free conditions in Laboratory Animal Center of Zhengzhou University, and treatments was in accordance with the NIH Animal Care and Use Committee regulations.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">Animals: Female,12-week-old Syrian hamster were purchased from Vitalriver (Beijing), and randomly divided into 4 groups (n=9).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Antibodies used in this study were listed as the following, rabbit anti-RBD PAb (polyclonal antibody) (Sino Biological, #40592-T62), rabbit anti-Nucleocapsid PAb (Sino Biological, #40588-T62), mouse anti-GAPDH mAb (monoclonal antibody) (ProteinTech, 60004-1-Ig)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-RBD</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-Nucleocapsid</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-GAPDH</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Then cells were washed twice with cold PBS and stained with mouse anti-human HLA-A2-FITC antibody (Abcam) for 30 min on ice.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human HLA-A2-FITC</div><div>suggested: (MBL International Cat# K0186-4, RRID:AB_592228)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Sequence of human ACE2 and secreting gp96 (without “KDEL” motif of C terminal) were amplified from Suit2 and 293T cell respectively.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: NCBI_Iran Cat# C498, RRID:CVCL_0063)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells: Human kidney cell line HEK-293T and hamster kidney cell line BHK21 were purchased from Cell Bank of Type Culture Collection Committee of Chinese Academy of Sciences.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK-293T</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>BHK21</div><div>suggested: ATCC Cat# CRL-6282, RRID:CVCL_1914)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To generate BHK21-hACE2 or C-Vac overexpressing cells, 5×104 cells (500 μL) BHK21 or 293T-gp96-hFc cells were seeded into 24-well plates, then 1 ml supernatant containing proper lentivirus and 5 μg/ml polybrene (Sigma) was added.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T-gp96-hFc</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Group1-4 were vaccinated with 1×107 293T-gp96-hFc control cells, viable 293T-C-Vac cells, 293T-C-Vac cells treated with 5μg/ml mitomycin (MCE) for 4h and freeze-thaw treated 293T-C-Vac cells lysates, respectively.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T-C-Vac</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Subsequently, the fluorescence intensity of cells were analyzed using a BD FACSAria (BD Biosciences Immunocytometry Systems) after washed twice with cold PBS.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BD Biosciences Immunocytometry Systems</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistics analysis: All statistical tests were performed by Graphpad Prism 7 using Student’s t-test (unpaired, two-tailed).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Graphpad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.09.24.311977: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: These experiments were approved by the Anses/ENVA/UPEC ethic committee and the French Ministry of Research (Apafis n°24818-2020032710416319).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">(Mustela putorius furo, ten neutered males and five females Euroferrets, Denmark) and twenty-one 8-week old female hamsters (Mesocricetus auratus, strain RjHan:AURA - Janvier Labs, France) were used.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Specific antibody binding was detected by peroxydase-labelled Goat anti-Hamster IgG (H+L) (Invitrogen) and peroxydase-labelled Goat anti-Ferret IgG (H+L) (KPL), diluted 1:5000 and 1:100 respectively.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-Hamster IgG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-Ferret IgG</div><div>suggested: (Rockland Cat# 618-100-012, RRID:AB_218731)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Vero CCL-81 cells (passage 32, from ATCC, USA), grown at 80% confluence level were inoculated with 200µl micro-filtered elution.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CCL-81</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell supernatants (12 ml) were harvested at day 3 after inoculation and immediately used for passage 1 (P1) produced in T75 culture flasks containing Vero cells as previously described.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: CLS Cat# 605372/p622_VERO, RRID:CVCL_0059)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Virus titration: Viral load was determined for viral inoculum and for a subset of samples (list in the supplementary table) by plaque assay on VeroE6 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VeroE6</div><div>suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The efficiency, slope and correlation coefficient (R2) were determined with the Rotor Gene software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Rotor Gene</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">: Wilcoxon signed-rank test was performed by package stat in R (version 3.3.3) to compare viral RNA quantities in nasal washes between males and females ferrets and with GraphPad Prism v6 to compare the areas under the curves for the kinetics of viral presence in clinical samples and of weight changes from D0.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.09.24.311027: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: All mouse experiments were approved by the institutional animal care and use committee (IACUC) and were conducted according to international guidelines for animal studies.<br>IRB: Human COVID-19 convalescent serum samples: 41 human convalescent sera samples from recovered COVID-19 patients (table S1) were obtained from Public Health Clinical Center of Chengdu in Chengdu, China, under approved guidelines by the Institutional Review Board (IRB), and all patients had provided written informed consent before sera sample were collected.<br>Consent: Human COVID-19 convalescent serum samples: 41 human convalescent sera samples from recovered COVID-19 patients (table S1) were obtained from Public Health Clinical Center of Chengdu in Chengdu, China, under approved guidelines by the Institutional Review Board (IRB), and all patients had provided written informed consent before sera sample were collected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">Rhesus Macaques (3-6 years old) were randomized into 3 groups of 6 animals, and immunized intramuscularly with either PBS as a negative control, or 30 μg S-Trimer adjuvanted with 0.25 mL AS03, or 30 μg S-Trimer adjuvanted with 1.5 mg CpG 1018 plus 0.75 mg alum.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Animal studies, facilities and ethics statements: Specific pathogen-free (SPF) BALB/c female mice (6-8 weeks old) for immunogenicity studies were purchased from Chengdu Dossy Experimental Animals Co.,</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After washing 3 times with PBST, the plates were incubated with rabbit anti-Trimer-Tag antibody (Clover Biopharma) at 37°C for 1 h, followed by washing 3 times with PBST and then a 1:20000 dilution of goat anti-rabbit IgG-HRP (Southern Biotech).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-Trimer-Tag</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-rabbit IgG-HRP</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After washing 3 times with PBST, the plates were incubated with rabbit anti-Trimer-Tag antibody (Clover Biopharma) at 37°C for 1 h, followed by washing 3 times with PBST and then a 1:20000 dilution of goat anti-rabbit IgG-HRP (Southern Biotech).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-Trimer-Tag</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-rabbit IgG-HRP</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Then, freshly-trypsinized Vero-E6 cells were added to each well at 20000 cells/well.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero-E6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Animal studies, facilities and ethics statements: Specific pathogen-free (SPF) BALB/c female mice (6-8 weeks old) for immunogenicity studies were purchased from Chengdu Dossy Experimental Animals Co.,</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BALB/c</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Sprague Dawley (SD) rats immunogenicity studies were performed at JOINN Laboratories Inc. (Suzhou, China), and SD rats (6-9 weeks old) were purchased from Zhejiang Vital River Laboratory Animal Technology Co., Ltd. Studies with SD rats were compliant with the policies of JOINN Laboratories Inc., the Guide for the Care and Use of Laboratory Animals (8th Edition, Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council; National Academy Press; Washington, D.C., 2010), and the U.S. Department of Agriculture through the Animal Welfare Act (Public Law 99-198).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Sprague Dawley</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The expression vector was then stably transfected into GH-CHO (dhfr -/-) cell line and high expression clones were selected and adapted to SFM-4-CHO (Hyclone) serum free medium and ACE2-Fc was produced in 15 L bioreactors, as described for Endo180-Fc above.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>dhfr -/-</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After stepwise gene amplification with increasing concentrations (0.0–10 nM) of MTX (Sigma), the clones producing the highest S-Trimer titer were then adapted to SFM-4CHO serum-free medium (GE BioSciences).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GE BioSciences</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analysis: Statistical analyses were performed using the Prism 8.0 (GraphPad Software).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Prism</div><div>suggested: (PRISM, RRID:SCR_005375)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: We found the following clinical trial numbers in your paper:<br><table><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Identifier</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Status</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Title</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04405908</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Active, not recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">SCB-2019 as COVID-19 Vaccine</td></tr></table>


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.10.07.328302: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">Consent: IRCCS - Lazzaro Spallanzani Rome (IT) and Azienda Ospedaliera Universitaria Senese, Siena (IT) that provided samples from SARS-CoV-2 convalescent donors who gave their written consent.<br>IRB: The study was approved by local ethics committees (Parere 18_2020 in Rome and Parere 17065 in Siena) and conducted according to good clinical practice in accordance with the declaration of Helsinki (European Council 2001, US Code of Federal Regulations, ICH 1997).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">This study was unblinded and not randomized.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Blood samples were screened for SARS-CoV-2 RNA and for antibodies against HIV, HBV and HCV.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>antibodies against HIV</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>HCV</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">ELISA assay with S1 and S2 subunits of SARS-CoV-2 S-protein: The presence of S1- and S2-binding antibodies in culture supernatants of monoclonal S-protein-specific memory B cells was assessed by means of an ELISA assay implemented with the use of a commercial kit (ELISA Starter Accessory Kit, Catalogue No. E101; Bethyl Laboratories).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>S2-binding</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After an incubation of 1 h at 37°C, plates were washed and incubated with 25 μl/well secondary antibody (horseradish peroxidase (HRP)-conjugated goat anti-human IgG-Fc Fragment polyclonal antibody, diluted 1:10,000 in blocking buffer, Catalogue No. A80-104P; (Bethyl Laboratories) for 1 h at 37°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG-Fc</div><div>suggested: (Bethyl Cat# A80-104P, RRID:AB_67064)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">25 μL/well of alkaline phosphatase-conjugated goat anti-human IgG (Sigma-Aldrich) and IgA (Jackson Immuno Research) were used as secondary antibodies.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>alkaline phosphatase-conjugated goat anti-human IgG</div><div>suggested: (Jackson ImmunoResearch Labs Cat# 109-055-190, RRID:AB_2888997)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">PNPP (p-nitrophenyl phosphate) (Thermo Fisher) was used as soluble substrate to detect SARS-CoV-2 S-protein specific monoclonal antibodies and the final reaction was measured by using the Varioskan Lux Reader (Thermo Fisher Scientific) at a wavelength of 405 nm.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>( p-nitrophenyl phosphate )</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>p-nitrophenyl phosphate </div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Affinity evaluation of SARS-CoV-2 neutralizing antibodies: Anti-Human IgG Polyclonal Antibody (Southern Biotech 2040-01) was immobilized via amine group on two flow cells of a CM5 sensor chip.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SARS-CoV-2 neutralizing antibodies: Anti-Human IgG Polyclonal Antibody</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Following the capture of each mAb by the immobilized anti-human IgG antibody, different concentrations of SPIKE protein (20 μg/ml, 10 μg/ml, 5 μg/ml, 2.5 μg/ml and 1 μg/ml in HBS-EP+) were injected over both the blank flow cell and the flow cell containing the captured mAb for 180 sec at a flow rate of 80 μl/min.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For titration and neutralization tests of SARS-CoV-2, Vero E6 were seeded in 96-well plates (Sarstedt) at a density of 1,5×104 cells/well the day before the assay.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The protein was purified from filtered cell supernatants using NiNTA resin (GE Healtcare #11-0004-58)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GE Healtcare</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Results were analyzed by FlowJo (version 10)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.10.14.335893: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Mice were male, age-matched, and grouped for SARS-CoV-2 infection or IAV and SARS-CoV-2 co-infection.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Rabbit monoclonal antibody against ACE2 (Abclonal, A4612, 1:1000)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>A4612</div><div>suggested: (ABclonal Cat# A4612, RRID:AB_2863309)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">mouse monoclonal antibody against SARS-CoV Nucleoprotein (Sino Biological, 40143-MM05, 1:1000), anti-actin (Abclonal, 1:1000), were purchased commercially.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>mouse monoclonal antibody against SARS-CoV Nucleoprotein ( Sino Biological , 40143-MM05 , 1:1000) , anti-actin ( Abclonal , 1:1000)</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>antibody against SARS-CoV Nucleoprotein ( Sino Biological , 40143-MM05</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-actin</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Peroxidase-conjugated secondary antibodies (Antgene, 1: 5000) were applied accordingly followed by image development with Chemiluminescent HRP Substrate Kit (Millipore Corporation).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Antgene , 1: 5000</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>Antgene ,</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The primary antibodies used in this study were rabbit polyclonal antibody against ACE2 for immunofluorescence (Sino Biological, 10108-T26) and anti-influenza virus-NP (kindly provided by Prof. Ningshao Xia).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ACE2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-influenza virus-NP</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells and viruses: The 293T, A549, Huh-7, MDCK, and Vero E6, WI-38, WI-38 VA-13, and BEAS-2B were obtained from ATCC and maintained in Dulbecco’s modified Eagle’s medium (DMEM; Gibco) supplemented with 10% foetal bovine serum (FBS), Calu-3 (ATCC) was maintained in DMEM supplemented with 20% FBS.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>Huh-7</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>MDCK</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>WI-38</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>BEAS-2B</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>Calu-3</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">NCI-H292(ATCC) was maintained with RPMI-1640 (Gibco) supplemented with 20% FBS.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>NCI-H292</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Forty-eight hours post-transfection, 150 μl pseudotyped VSV-ΔG bearing VSV-G protein were used to infect Vero E6 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: RRID:CVCL_XD71)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">. Immunofluorescence: A549 cells were fixed and incubated with primary antibodies.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>A549</div><div>suggested: NCI-DTP Cat# A549, RRID:CVCL_0023)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">ACE2 knocking-down cells: Two sgRNAs targeting the hACE2 gene were designed under the protocol in http://chopchop.cbu.uib.no and commercially synthesized to clone in lenti-Cas9-blast vector (kindly provided by Prof. Hongbing Shu).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>http://chopchop.cbu.uib.no</div><div>suggested: (CHOPCHOP, RRID:SCR_015723)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Mice: The K18 hACE2 transgenic mice purchased from Gempharmatech were housed in ABSL-3 pathogen-free facilities under 12-h light-dark cycles with access to food and water.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Gempharmatech</div><div>suggested: (GemPharmatech, RRID:SCR_017239)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.08.22.20179754: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      NIH rigor criteria are not applicable to paper type.

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Samples were tested for SARS-CoV-2 RNA, whereas anthropic contamination was assessed searching for biological fluids of nose, mouth, gut through their microbiota traces by RT-PCR and/or NGS (Table 1). 2.2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>NGS</div><div>suggested: (PM4NGS, RRID:SCR_019164)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Approximately 200 μL lysozyme solution (20mg/mL Lisozima, 20 mM tris[hydroxymethyl]aminomethanehydrochloride at pH 8, 2mM ethylenediaminetetraacetic acid, and 1.2%TritonX-100; Sigma Aldrich, St Louis, USA) were added into the NAO Baskets and incubated a 37°C for 30 minutes.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>TritonX-100; Sigma Aldrich</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Raw sequence data was processed using an in-house pipeline that was built on the Galaxy platform and incorporated various software tools to evaluate the quality of the raw sequence data (FASTA/Q Information tools, Mothur).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Galaxy</div><div>suggested: (Galaxy, RRID:SCR_006281)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Demultiplexing was performed to remove PhiX sequences and sort sequences; moreover, to minimize sequencing errors and ensure sequence quality, the reads were trimmed based on the sequence quality score using Btrim (an average quality score of 30 from the ends, and remove reads that are less any 200 bp after end-trimming) (Kong, 2011).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Btrim</div><div>suggested: (Btrim, RRID:SCR_011836)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      Another limitation concerns the set of experimental conditions for RT-PCR and NGS. Primers and probes for selected bacterial genes from selected bacterial markers where chosen because of their feasibility and effectiveness, but we did not made comparisons with different sequences, indicators or reaction conditions for RT-PCR. The same concern can be raised for the NGS approach, which was adopted for the analysis of 16S rDNA amplicon sequencing, following standard protocols. A whole genome analysis would have been more informative. However, it would have also been more expensive for materials and bioinformatic analysis, being less appropriate for public health surveys on a larger scale. Finally, we used arbitrary thresholds to quantify droplets contamination based on CT values, proposing the highest sensibility for droplets detection. A lower threshold would have provided more specific data, or it could have been adapted to the different kind of transmission risks or expected hygiene levels in the different environments.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.07.31.230607: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      NIH rigor criteria are not applicable to paper type.

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Since this model is nested in the first (3-parameter) model, we used as test statistic the likelihood ratio 2Δl = 2(l1 - l0), where l0 is the log-likelihood under assumption H0 (3-parameter TN93 model estimating all the elements of the tree) and 11 is the log-likelihood under assumption H1 (6-parameter TN93 model with local differentiation of the parameters downstream of a node of interest).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>l1 - l0</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">We used program MAFFT [51] to generate these alignments.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MAFFT</div><div>suggested: (MAFFT, RRID:SCR_011811)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To this purpose, we developed a Python script to modify the JSON file used as input by the Auspice program.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Python</div><div>suggested: (IPython, RRID:SCR_001658)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • No funding statement was detected.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.05.24.20110346: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Viral culture: Vero E6 (African Green monkey kidney) and Caco2 (human colon carcinoma) cells were used to culture virus from air and environmental samples.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Caco2</div><div>suggested: CLS Cat# 300137/p1665_CaCo-2, RRID:CVCL_0025)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">A dilution series from solution containing 8.25×106 PFU/mL SARS-CoV-2 (titred by plaque assay in Vero cells) from 10-3 to 10-6 (covering Ct values from 26 to 36) was produced in DMEM and 50 μL inoculated in triplicate onto the surface of plastic (standard keyboard key) or stainless steel (2 × 1 × 0.2 cm) pieces.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">140 μL was used for RNA extraction and qPCR immediately (0 days post inoculation, dpi) and after incubation for 7 days in a 24-well plate with VeroE6 cells (7 dpi).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VeroE6</div><div>suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      However, a larger sample size is required to understand this risk Our study has important strengths and limitations. Strengths include our sampling strategy encompassing contemporaneous surface and air samples from a range of clinical services including both patient care and non-patient care areas, specifically, we included operating theatres and areas dedicated to known and potential AGPs; each sample was tested using PCR and also viral culture, and we performed laboratory viral culture experiments to quality our findings; the sampling was conducted during the peak of the pandemic (and so likely represents a worst-case scenario) in a European hospital group. Limitations include not collecting patient samples to better understand how our findings links to patient samples, particularly during tracheostomies and AGPs; no asymptomatic patient or staff testing ongoing at the time of sampling, which means patients and staff without known COVID-19 could have been shedding SARS-CoV-2 and this would explain the detection of SARS-CoV-2 RNA in non-patient care areas; challenges in interpreting the significance of samples with low viral loads,; a lack of resolution of particle sizes for contamination of the air; and no longitudinal sampling was performed so these findings represent a “snapshot”. Our findings may have implications for future policy and guidelines. Most international guidelines recommend enhanced surfaces disinfection during the management of COVID-19. For example, Public...

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.08.02.20166819: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">Plasma and serum were collected from hospitalized COVID-19 inpatients or ICU patients, OSU health care workers, and blinded convalescent plasma donors and analyzed in a blinded manner.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Antibodies used for Western blotting included anti-C9 (anti-rhodopsin) (Santa Cruz, #57432), anti-p24 (abcam, #ab63917), anti-β-actin (Sigma, #A1978) and secondary antibodies anti-Mouse IgG (Sigma, #A5278)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-C9</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-C9 ( anti-rhodopsin )</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-p24</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-β-actin</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-Mouse IgG</div><div>suggested: (Sigma-Aldrich Cat# A5278, RRID:AB_258232)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Secondary antibodies used for flow cytometry included FITC-conjugated anti-human IgG-Fc (Sigma,405 #F9512).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG-Fc</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After three washes with PBS plus 2% FBS, cells were incubated with FITC-conjugated anti-human IgG (1:200, Sigma, #F0257) secondary antibodies for 1 hr.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Following wash steps, wells were treated with 100 μl of HRP labeled anti-human-IgG tracer antibody (EDI, #31220), incubated at room temperature for 30 min, and again washed.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human-IgG tracer</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HEK293T (ATCC CRL-11268, RRID: CVCL_1926), HeLa (ATCC, CCL-2, RRID: CVCL_0030), HTX (a subclone of HT1080), A549 (ATCC, CCL-185, RRID: CVCL_0023) and Huh7.5 (RRID: CVCL_7927) cells were grown in Dulbecco’s modified Eagle’s medium (DMEM), supplemented with 1% penicillin/streptomycin and 10% (vol/vol) FBS.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>detected: (ATCC Cat# CRL-11268, RRID:CVCL_1926)</div></div><div style="margin-bottom:8px"><div>HeLa</div><div>detected: (BCRC Cat# 60005, RRID:CVCL_0030)</div></div><div style="margin-bottom:8px"><div>HT1080</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>A549</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>HTX a</div><div>detected: (BCRC Cat# 60074, RRID:CVCL_0023)</div></div><div style="margin-bottom:8px"><div>Huh7.5</div><div>detected: ( RRID:CVCL_7927)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Calu-3 (ATCC, gift of Stelle Cormet-Boyaka) were grown in Eagle’s Minimum Essential Medium (EMEM), supplemented with 1% penicillin/streptomycin and 10% (vol/vol) FBS.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Calu-3</div><div>suggested: KCLB Cat# 30055, RRID:CVCL_0609)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HEK293T/ACE2 cell line is a gift from Dr. Fang Li at the University of Minnesota. HeLa, A549, HTX and Huh7.5 cells stably expressing ACE2 were generated by transduction of pLenti-GFP vectors expressing ACE2 (OriGene, #RC208442L4), followed by puromycin selection (1 μg/mL) for 6 days.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T/ACE2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>HeLa</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>Huh7.5</div><div>suggested: RRID:CVCL_7927)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Production of intron-Gluc- or secNluc-based lentiviral pseudotypes bearing the S protein of SARS Coronaviruses and viral infection: For intron-Gluc- or secNluc-based pseudotyped lentiviral production, we transfected HEK293T cells with HIV-1-NL4.3 inGluc or secNluc vector plus a plasmid expressing the S protein or VSV-G in a 2:1 ratio using polyethylenimine (PEI).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Serum/virus mixtures were then used to infect confluent Vero-E6 cells for 1 h at 37°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero-E6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analyses were performed using GraphPad Prism 5.0 as follows: One-way Analysis of Variance (ANOVA) with Bonferroni’s post-tests was used to compute statistical significance between multiple groups for multiple comparison.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.08.26.266304: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">Contamination: HuH7 and MRC-5 cells were confirmed to be free of mycoplasma using the Venor® GeM Classic kit (Minerva Biolabs).</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Primary antibodies against the following proteins or peptides were used: anti β-actin (Santa Cruz, #sc-4778)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti β-actin</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, anti ATF3 (Santa Cruz, #sc-188), anti HERPUD1 antibody (Abnova, #H00009709-A01)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti ATF3</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti HERPUD1</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">anti CTH antibody (Cruz, #sc-374249),</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti CTH</div><div>suggested: (LSBio (LifeSpan Cat# LS-C80809, RRID:AB_2087504)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The following secondary antibodies were used: Dako P0447; polyclonal goat anti-mouse immunoglobulins/HRP, Dako P0448; polyclonal goat anti-rabbit immunoglobulins/HRP, Cy3-coupled anti rabbit (rb) IgG (dk, Merck Millipore, #AP182C), Dylight</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-mouse immunoglobulins/HRP</div><div>suggested: (Agilent Cat# P0447, RRID:AB_2617137)</div></div><div style="margin-bottom:8px"><div>anti-rabbit</div><div>suggested: (Millipore Cat# AP182C, RRID:AB_92588)</div></div><div style="margin-bottom:8px"><div>anti rabbit ( rb ) IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After immunoblotting (see below), membranes were stained with Coomassie brilliant blue and then hybridized with an anti puromycin antibody (Kerafast, #EQ0001) to detect puromycinylated polypetides.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti puromycin antibody ( Kerafast , #EQ0001</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After 2x washing, cells were fixed with 4% paraformaldehyde in PBS (Santa Cruz, #281692) for 5 min, washed 3x 10 min with Hank’s BSS (PAN, #PO4-32505), blocked with 10% normal donkey serum (Jackson ImmunoResearch, #017-000-121) for 20 min and incubated with primary and secondary antibodies diluted in Hank’s BSS containing 0.005% saponin (Sigma-Aldrich, #S4521-10G) for 2 h at room temperature.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>normal donkey serum</div><div>suggested: (Jackson ImmunoResearch Labs Cat# 017-000-121, RRID:AB_2337258)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Following 3 washing steps with Hank’s BSS containing 0.005% saponin, Cy3-conjugated (Millipore, #AP182C, 1:100) and Dylight488-conjugated (ImmunoReagents #DkxMu-003D488NHSX, 1:100) secondary antibodies were used.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>#AP182C</div><div>suggested: (Millipore Cat# AP182C, RRID:AB_92588)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">MRC-5 human embryonic lung fibroblasts ((ATCC, CCL-171)) were maintained in DMEM containing 1.5 g / l (w / v) NaHCO3 and complemented with 10% fetal calf serum (FCS; PAN Biotech Cat No. 1502-P110704), 2 mM L-glutamine, 100 U / ml penicillin and 100 μg / ml streptomycin, 1% minimum essential medium nonessential amino acids (100x MEM NEAA; Gibco Cat No 11140-035) and 1 mM sodium pyruvate (100 mM; Gibco 11360-039)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MRC-5 human embryonic lung fibroblasts</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Virus infections and assessments of antiviral activity: To analyze the antiviral activity of thapsigargin, HuH7 cells (for HCoV-229E, MERS-CoV), MRC-5 cells (for HCoV-229E) and Vero E6 (for SARS-CoV-2) were infected at the indicated multiplicities of infection (MOI) and incubated at 33°C (for HCoV-229E and SARS-CoV-2) or 37°C (for MERS-CoV) in the presence or absence of thapsigargin, or with the appropriate volume of solvent control (DMSO) as indicated.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: RRID:CVCL_XD71)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In brief, 1.2 x 104 HuH7 or 1 x 104 MRC-5 cells were seeded in 96-well plates for 24 hours and thereafter treated with DMSO, thapsigargin, virus alone or virus plus thapsigargin for 24 hours as indicated in the figure legends.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MRC-5</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For the data shown in Fig. 4 and 5, raw data from 96 LC-MS/MS runs (representing two independent experiments and three technical replicates per sample) were mapped to Homo sapiens (uniprot ID UP000005640 for HuH7 cells)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HuH7</div><div>suggested: CLS Cat# 300156/p7178_HuH7, RRID:CVCL_0336)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2 genome sequencing data have been submitted to the NCBI Short Read Archive repository under bioproject PRJNA658242 (SRA accession number SRP278165).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>NCBI Short Read Archive</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">EC50 values were calculated by non-linear regression analysis using GraphPad Prism 5.0 or 8.4.3 (GraphPad Software).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Quality control of RNA-seq reads was performed using the FastQC command line tool version 0.11.5 (https://www.bioinformatics.babraham.ac.uk/projects/fastqc/).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FastQC</div><div>suggested: (FastQC, RRID:SCR_014583)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Reads were aligned using STAR version 2.4.2a (Dobin et al, 2013) to an index based on the human genome version hg19.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>STAR</div><div>suggested: (STAR, RRID:SCR_015899)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The resulting bam files were imported into R (Team, 2015) (https://www.R-project.org/) and gene-specific read counts based on hg19 UCSC gene annotations were extracted using FeatureCounts from the R subread package version 1.24.2 (Liao et al, 2013).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FeatureCounts</div><div>suggested: (featureCounts, RRID:SCR_012919)</div></div><div style="margin-bottom:8px"><div>subread</div><div>suggested: (Subread, RRID:SCR_009803)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Detection of differentially expressed genes was done using DESeq2 version 1.14.1 (Love et al, 2014).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>DESeq2</div><div>suggested: (DESeq, RRID:SCR_000154)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">From the entire data set, only normalized read counts and ratio values for 166 gene IDs assigned to KEGG 04141 were extracted and further analyzed.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>KEGG</div><div>suggested: (KEGG, RRID:SCR_012773)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data analysis was performed using MaxQuant with the Andromeda search engine and Uniprot databases were used for annotating and assigning protein identifiers (Tyanova et al, 2016a).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MaxQuant</div><div>suggested: (MaxQuant, RRID:SCR_014485)</div></div><div style="margin-bottom:8px"><div>Uniprot</div><div>suggested: (UniProtKB, RRID:SCR_004426)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All subsequent filtering steps and heatmap representations were performed in Excel 2016 as described in the figure legends.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Excel</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Overrepresentation analyses were done using the gene IDs / gene names of differentially enriched proteins and Metascape software with the express settings (Zhou et al., 2019)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Metascape</div><div>suggested: (Metascape, RRID:SCR_016620)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Protein network data were extracted from the most recent version of STRING (Szklarczyk et al., 2019) and visualized with Cytoscape 3.8.0 (Cline et al, 2007).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>STRING</div><div>suggested: (STRING, RRID:SCR_005223)</div></div><div style="margin-bottom:8px"><div>Cytoscape</div><div>suggested: (Cytoscape, RRID:SCR_003032)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Mapping of ratio values on KEEG pathway 04141 was done with Pathview or Pathview Web software (Luo et al, 2017).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Pathview</div><div>suggested: (Pathview, RRID:SCR_002732)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Quantification and statistical analysis: Statistical parameters (t-tests, standard variations, confidence intervals, Pearson correlations) were calculated using SigmaPlot 11, GraphPad Prism 5.0 or 8.4.3 or Microsoft Excel 2016 in addition to the software tools mentioned above.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SigmaPlot</div><div>suggested: (SigmaPlot, RRID:SCR_003210)</div></div><div style="margin-bottom:8px"><div>Microsoft Excel</div><div>suggested: (Microsoft Excel, RRID:SCR_016137)</div></div></td></tr></table>

      Results from OddPub: Thank you for sharing your data.


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.08.25.20154252: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">from 20 blood donors (10 men and 10 women)</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">IgG specific for the Nucleocapsid Protein of SARSCoV-2 was detected in 150 l of plasma using the Abbott Architect SARS-CoV-2 IgG Assay (Illinois, U.S.A)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Abbott Architect</div><div>suggested: (Abbott ARCHITECT i1000sr System, RRID:SCR_019328)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analysis was performed with IBM SPSS version 20 (IBM, Armonk</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SPSS</div><div>suggested: (SPSS, RRID:SCR_002865)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      A limitation of our work is its observational nature, which precludes to infer causality. Nonetheless, the observed associations could serve as hypothesis generators, leading to the development of animal models to confirm the potential link between SARS-CoV-2 replication and the dysregulated host responses observed in severe COVID-19.

      Results from TrialIdentifier: We found the following clinical trial numbers in your paper:<br><table><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Identifier</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Status</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Title</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04457505</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">One Year Follow-ups of Patients Admitted to Spanish Intensiv…</td></tr></table>


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.08.29.20184358: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">The 30 controls included 20 females and 10 males, mean age of 41.7 ± 14.4.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">25 μL of 2 μg/mL biotinylated rabbit anti-hPAI-1 or biotinylated rabbit anti-htPA antibody (Molecular Innovations) was added to the plate, followed by incubating with phycoerythrin-conjugated streptavidin.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-hPAI-1</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-htPA</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data analysis was with GraphPad Prism software version 8.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      Our study has some limitations. We did not have access to fresh plasma samples each day of a patient’s hospitalization. PAI-1 and tPA levels were therefore not tested on a defined day of hospitalization, but rather when a plasma sample became available to the research laboratory. It should however be noted that when assessing correlations of PAI-1 and tPA with clinical variables, same-day laboratory and clinical status data were used. Due to research restrictions during the pandemic we were not allowed to recruit new healthy controls. Healthy controls were recruited during the pre-COVID-19 era and we were not able to match gender and age to COVID-19 patients. Future studies should endeavor to systematically track PAI-1 and tPA levels over the full course of hospitalization of COVID-19 patients and to compare with gender- and age-matched controls. We also recognize that tPA is not the sole activator of plasminogen, as uPA also plays a role in the fibrinolysis regulation and PAI-1 can also inhibit uPA17. Dysregulation of uPA and its receptor system have been implicated in the pathogenesis of pulmonary fibrosis and ARDS33,34. The role of uPA and its receptor in COVID-19 warrants further investigation. Because the COVID-19 associated prothrombotic risk is known, prophylactic anticoagulation has become part of standard COVID-19 treatment. High rates of thromboembolic events from early studies prompted some experts to recommend a more intensive dose of anticoagulation among COVID-1...

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.12.12.422516: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were permeabilized with 0.5% (v/v) Triton X-100/PBS, blocked with 4% (w/v) BSA/CMF-PBS at RT for 1 hr, incubated with 1:200 diluted anti-LINE-1 ORF1p mouse monoclonal antibody (clone 4H1, Sigma MABC1152, Lot 3493991), and then with 1:400 diluted Donkey-anti-Mouse-Alexa Fluor 594 second antibody (Invitrogen 21203)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-LINE-1</div><div>suggested: (LSBio (LifeSpan Cat# LS-C130455-100, RRID:AB_10847571)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Calu3 cells were obtained from ATCC (HTB-55) and cultured in EMEM (ATCC 30-2003) supplemented with 10% heat-inactivated FBS (Hyclone, SH30396.03) following ATCC’s method.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Calu3</div><div>suggested: ATCC Cat# HTB-55, RRID:CVCL_0609)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2 infection: SARS-CoV-2 USA-WA1/2020 (Gen Bank: MN985325.1) was obtained from BEI Resources and expanded and tittered on Vero cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: CLS Cat# 605372/p622_VERO, RRID:CVCL_0059)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For microglia stimulation, microglia differentiation media was exchanged with HEK293T media (DMEM + 10% heat-inactivated FBS + final 2mM L-Glutamine) and supplemented with 100 hg/ml lipopolysaccharide (LPS, Sigma Aldrich L4391-1MG) or PBS.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Recombinant DNA</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plasmid for HIV-1 reverse transcriptase expression: pCMV-dR8.2 dvpr was a gift from Bob Weinberg (Addgene plasmid # 8455; http://n2t.net/addgene:8455; RRID:Addgene_8455)41</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div></div><div>detected: RRID:Addgene_8455)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Addgene plasmid # 51288; http://n2t.net/addgene:51288; RRID:Addgene_51288)42; EF06R (5’UTR-LINE-1) was a gift from Eline Luning Prak (Addgene plasmid # 42940; http://n2t.net/addgene:42940; RRID:Addgene_42940)43.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div></div><div>detected: RRID:Addgene_51288)</div></div><div style="margin-bottom:8px"><div></div><div>detected: RRID:Addgene_42940)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">qPCR plots were generated with Prism 8 (Prism)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Prism</div><div>suggested: (PRISM, RRID:SCR_005375)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All figure panel images were prepared using FIJI software (ImageJ, NIH) and Adobe Illustrator 2020 (Adobe), showing deconvolved single z-slices.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ImageJ</div><div>suggested: (ImageJ, RRID:SCR_003070)</div></div><div style="margin-bottom:8px"><div>Adobe Illustrator</div><div>suggested: (Adobe Illustrator, RRID:SCR_010279)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To measure the LINE-1 ORF1p immuno-staining signal intensity, we projected cell optical sections (sum, 42 slices) with the “z projection” function in FIJI.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FIJI</div><div>suggested: (Fiji, RRID:SCR_002285)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To identify human – SARS-CoV-2 chimeric reads, raw sequencing reads were aligned to concatenated human and SARS-CoV-2 genomes plus transcriptomes by STAR (version 2.7.1a)47.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>STAR</div><div>suggested: (STAR, RRID:SCR_015899)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Differential expression was analyzed using EdgeR package (version 3.30.3)49,50 in R (version 4.0.3)46.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>EdgeR</div><div>suggested: (edgeR, RRID:SCR_012802)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">PMPs were harvested from suspension during medium exchange and plated in microglia differentiation media over 7-14 days to produce microglia like cell monocultures (Neurobasal (Life Technologies 21103049) supplemented with Gem21 NeuroPlex without Vitamin A (GeminiBio, 400-161)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>NeuroPlex</div><div>suggested: (NeuroPlex, RRID:SCR_016193)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.10.09.20209858: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">The sample IDs were composed of six characters generated randomly from the set of alphanumeric characters (a-zA-Z0-9) (random string generator https://www.random.org/strings/), excluding letters O, I, l, Z, Q and numbers 0, 1, 2, 9 to minimize human read errors.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Negative controls taken from patients prior to November 2019 were obtained from Naha Municipal Hospital from intravenous blood, and from a commercial serum pool (Human Serum from human male AB plasma, Sigma Aldrich H4522-100ML</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Protein purity was verified by SDS-PAGE and confirmed by Western blot with MonoRab™ Anti-His Tag (C-term) Antibody (Nr. 25B6E11, GenScript,</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Anti-His Tag (C-term</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Therefore, another threshold, calculated as 4-times the average blank, which has been demonstrated to be valid for identifying anti-SARS-CoV-2 antibody-positive samples was used instead (6).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-CoV-2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Contrast transfer function (CTF) estimation, particle picking and 2D classification were performed with RELION 3.1 (5)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>RELION</div><div>suggested: (RELION, RRID:SCR_016274)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Sequence alignments: The full-length sequences of SARS-CoV, MERS-CoV S protein (UniProt ID: P59594 and K9N5Q8, respectively) were aligned pairwise using ClustalW2 (8), against the SΔcs sequence (3)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ClustalW2</div><div>suggested: (ClustalW2, RRID:SCR_002909)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Figure preparation and digital processing: Images of protein gel and Western blot in Figure 1A were acquired by smartphone camera, cropped and adjusted for intensity level in Adobe Photoshop 2020 (Adobe Inc, USA)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Adobe Photoshop</div><div>suggested: (Adobe Photoshop, RRID:SCR_014199)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Graphs in Figures 2-5 were plotted with GraphPad Prism v8.4.3 (</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">(GraphPad Software, USA), using the scatter plot function (Figure 2).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.08.25.256339: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      NIH rigor criteria are not applicable to paper type.

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The extract of each lysed clone was applied as a 1:200 dilution (final concentration) in PBSTB (PBS supplemented with 0.1% Tween 20® and 0.2% (w/v) BSA, pH 7.4) together with 20 nM (final concentration) biotinylated spike protein domain, 1:400 (final concentration) of anti-6His-D2 HTRF antibody – FRET acceptor conjugate (Cisbio) and 1:400 (final concentration) of anti-strep-Tb antibody FRET donor conjugate (Cisbio, France) to a well of a 384-well plate and incubated for 120 min at 4°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>biotinylated spike protein domain</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-6His-D2 HTRF</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-strep-Tb</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Monoclonal antibodies against MERS-S (2), SARS-S or SARS2-S were included as a positive control(47).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MERS-S ( 2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Serum concentrations were determined by sandwich ELISA using RBD as capture reagent and an anti-His-tag antibody as detection reagent and using a standard curve.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-His-tag</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells and viruses: Vero E6 cells (African green monkey kidney cells, ATCC® CRL1586™) purchased from ATCC (Manassas, VA 20110 USA) were passaged in cell culture medium DMEM (FG0445) containing 10% FBS and supplements (2mM L-Glutamine, Non-essential amino acids and 100 U/ml Penicillin 100 μg/ml Streptomycin and HEPES, all from Biochrom, Berlin, Germany) at 37°C with CO2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: RRID:CVCL_XD71)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, HEK-293T cells were transfected with pCAGGS expression vectors encoding MERS-S, SARS-S or SARS2-S carrying a 16-, 28- or 18-a.a. cytoplasmic tail truncation, respectively.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK-293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Twenty-four hours later, supernatants containing SARS2-S pseudotyped VSV particles were harvested and titrated on African green monkey kidney Vero E6 (ATCC#CRL-1586) cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>E6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The raw data (relative light unit values) were exported to GraphPad Prism v8.01, and the % neutralization data were normalized to the untreated PsV signal.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Image processing: Movie stacks were manually inspected and then imported in Relion version 3.0.1(48).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Relion</div><div>suggested: (RELION, RRID:SCR_016274)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Drift and gain correction were performed with MotionCor2(49), and GCTF(50) was used to estimate the contrast transfer function for each movie.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MotionCor2</div><div>suggested: (MotionCor2, RRID:SCR_016499)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">, PyMOL (The PyMOL Molecular Graphics System, Version 2.0, Schrödinger, LLC) and BioRender (BioRender.com)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>PyMOL</div><div>suggested: (PyMOL, RRID:SCR_000305)</div></div><div style="margin-bottom:8px"><div>BioRender</div><div>suggested: (Biorender, RRID:SCR_018361)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">(Certara, Princeton, USA) or GraphPadPrism (GraphPad Software, La Jolla,USA) and non-compartmental analyses.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: Thank you for sharing your data.


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      A number of alternative molecules are being developed to complement and partially overcome this limitation of antibodies. Here we describe the generation of DARPin molecules - one prominent alternative to antibodies(30) amongst others(31–34) - that bind the SARS-CoV-2 spike protein. We tested a library of one trillion DARPin molecules and identified multiple DARPin molecules with different functionalities and binding specificities. By molecular linkage of individual DARPin molecules, we developed multi-DARPin molecules with low picomolar neutralizing activity and demonstrated their protective efficacy against SARS-CoV-2 infection in a hamster model. In particular, reduced lung tissue damage and reduced virus replication in the lower and upper respiratory tract were observed, the latter also being important for reducing virus shedding and transmission. The most advanced of those multi-DARPin molecules, MP0420 or ensovibep, is currently being studied in Phase 1. The most potent neutralizing mono-DARPin molecules were found to target the RBD, blocking the spike-ACE2 interaction necessary for infection. This finding is congruent with the identified epitopes of potent neutralizing antibodies obtained from COVID-19 patients(20, 35-39). Thus, the in vitro approach using DARPin molecules independently confirms that the ACE2 interaction site on the SARS-CoV-2 spike protein is one of the most vulnerable sites to block virus infection in cell culture. The single-chain binding domain nat...

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on pages 14 and 30. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.12.28.424533: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Chilled on ice, 100 μL of each sample was added to the VeroE6/TMPRSS2 cells that had been seeded in 96-well-plates at 5 × 104/100 μL/well a day before.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VeroE6/TMPRSS2</div><div>suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.12.28.424451: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">Consent: Samples were collected from convalescent donors who gave their written consent.<br>IRB: The study was approved by local ethics committees (Parere 18_2020 in Rome and Parere 17065 in Siena) and conducted according to good clinical practice in accordance with the declaration of Helsinki (European Council 2001, US Code of Federal Regulations, ICH 1997).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">This study was unblinded and not randomized.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Following, 25 μL/well of alkaline phosphatase-conjugated goat anti-human IgG (Sigma-Aldrich) was used as secondary antibodies.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In detail, two models of the PT188-EM spike NTD (residues 13-308) were built starting from two different cryo-EM structures of the wild type S protein as templates: (i) one bearing a completely resolved NTD (PDB ID: 7JJI (7)), which includes all the loops from N1 to N5, and (ii) one bound to the antibody 4A8 (PDB ID: 7C2L (8)), which presents only one small gap within the N5 loop.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>N5</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">18-24 hours before execution of the viral escape assay, plates and propagation flasks containing a standard concentration of Vero E6 cells were prepared in complete DMEM medium supplemented with 2% FBS and incubated at 37°C, 5% CO2 until use.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Sequenced reads were quality trimmed using Trimmomatic software during data analysis.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Trimmomatic</div><div>suggested: (Trimmomatic, RRID:SCR_011848)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Only good quality reads were mapped against SARS-CoV-2_human_ITA_INMI1_2020 GenBank: MT066156.1 using BWA software with default parameters.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BWA</div><div>suggested: (BWA, RRID:SCR_010910)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data were collected by the LightCycler software during the annealing phase of each cycle of amplification.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>LightCycler</div><div>suggested: (LightCycler Software, RRID:SCR_012155)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">CTF estimation and particle picking were performed using cisTEM (5), and particle stacks were exported to cryoSPARC v2 (6) for 2D classification, ab initio 3D reconstruction, and heterogeneous refinement.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>cryoSPARC</div><div>suggested: (cryoSPARC, RRID:SCR_016501)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The final set up was done with PSFGEN and VMD (16), whereas MD simulations were run on TACC Frontera computer facility using NAMD 2.14 (18) and CHARMM36m force fields to refine the models (19–21).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>NAMD</div><div>suggested: (NAMD, RRID:SCR_014894)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on page 17. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.08.26.266825: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The expression of the proteins was verified by SDS-PAGE and western blotting using a HRP-conjugated anti-Strep-tag antibody (dilution 1/20,000, iba lifesciences).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-Strep-tag</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For chicken samples, an anti-chicken conjugate (Rabbit anti-Chicken IgY (H+L) Secondary Antibody, HRP; ThermoFisher Scientific) diluted 1/10,000 was applied.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-Chicken IgY</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Expi293 cells were grown in suspension in Expi293 expression medium (ThermoFisher Scientific) at 37 °C, 8 % CO2, and 125 rpm.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Expi293</div><div>suggested: RRID:CVCL_D615)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Biotin was blocked by adding BioLock (iba lifesciences) as recommended, and the supernatant was purified using Strep-Tactin XT Superflow high capacity resin (iba lifesciences) according to the manufacturer’s instructions.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BioLock</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In addition, three sequential sera from a naturally SARS-CoV-2 infected cat were included (ProMED-mail, 2020).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ProMED-mail</div><div>suggested: (ProMed-Mail, RRID:SCR_010260)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All analyses and visualizations were performed using GraphPad Prism version 8.0 for Windows (GraphPad Software, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.01.27.428534: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">Consent: Donors gave written consent to have their blood drawn and authorized the unrestricted use of their blood samples by Immunome.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After that, cells were washed twice in PBS and stained with a goat anti-human ACE2 polyclonal antibody (R&D Systems, Cat # AF933) or isotype goat polyclonal isotype control (R&D Systems, Cat # AB-108-C) at 1:100 dilution for 30 minutes on ice.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human ACE2</div><div>suggested: (R and D Systems Cat# AF933, RRID:AB_355722)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Next, cells were washed twice and stained with Alexa Fluor 488-conjugated donkey anti-goat antibody (Jackson ImmunoResearch, Cat #705-545-147) at 1:200 dilution for 30 minutes on ice.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-goat</div><div>suggested: (Jackson ImmunoResearch Labs Cat# 705-545-147, RRID:AB_2336933)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HTRF Screening Assays: A homogeneous time-resolved fluorescence (hTRF) assay [26] comprised of terbium-labeled anti-human IgG (H+L) (Cisbio, custom label) donor and AF488-labeled anti-HIS (Cell Signaling, Cat # 14930S) acceptor antibodies was used to screen patient-derived antibodies for their binding to recombinantly produced SARS-CoV-2 antigens.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-HIS</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Flow cytometry-based cellular screens for antiviral antibodies: SARS-CoV-2 antigen sequences were cloned into pcDNA3.4 plasmids and transfected into 293F cells utilizing the Expi293 Expression System (Life Technologies, Cat # A14635) per manufacturer’s instructions.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>antiviral antibodies: SARS-CoV-2 antigen sequences</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>antiviral antibodies: SARS-CoV-2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">A cocktail of Fc-specific secondary antibodies consisting of AF647 goat-anti-human IgG (Jackson ImmunoResearch, Inc.)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>IgG</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HEK293 cells expressing human Angiotensin converting enzyme 2 (ACE2) (BPS Biosciences, Cat #79951) were cultured in EMEM containing 10% FBS and 5 mg/mL Puromycin to select for ACE2-expressing cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Immunoglobulin expression fragments were cloned into the pcDNA3.4-based vectors and expressed in 293F cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293F</div><div>suggested: RRID:CVCL_D615)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">100 mL of pseudovirus at various dilutions was added to ACE2-293T cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ACE2-293T</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells: 293TN Producer cell line (System Biosciences, Cat #LV900A-1) was maintained in DMEM containing 10% FBS.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Cells</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data were analyzed using FlowJo software (BD).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.08.30.20184309: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">Consent: Human samples collection: Upon informed consent, blood was taken by vein puncture and two BD Vacutainer CPT tubes of blood and one serum tube were collected per patient.<br>IRB: The COVID-19 collection and scientific use was approved by the Lisbon Academic Medical Center Ethics Committee (Ref. n.° 155/20) as was the staff screening (Ref. n.° 181/20).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Antibody measurements: Anti-SARS-CoV-2 ELISAs were performed as described previously [12].</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Anti-SARS-CoV-2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Serum samples were diluted in PBS-0.1%T + 1% non-fat milk powder, added (100 μl/well) and incubated for 1-2 hours at room temperature, washed with PBS-T 3x or 10x Hereafter several antibody isotypes, namely Total Ig, IgG, IgM and IgA anti-SARS-CoV2 were detected using horseradish peroxidase (HRP)-labelled goat anti-human IgG+IgM+IgA (Abcam, ab102420)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-CoV2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-human IgG+IgM+IgA</div><div>suggested: (Meridian Life Science Cat# W99549G, RRID:AB_152010)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, 24 hours prior to infection, Vero CCL81 cells grown in DMEM supplemented with 10% FBS were seeded at 20,000 per well in a 96-well plate.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero CCL81</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Media from Vero cells was substituted with the SARS-CoV-2pp/serum mix; plates were spinoculated by centrifugation at 1250rpm for 1 hr at 37°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analyses: A Kruskal-Wallis test (non-parametric test) was done to compare the geometric ratios between groups with a significance level of 0.05 (Dunn’s multiple comparisons test), student t test or two-way ANOVA were used as stated in the figure legends, calculated using GraphPad Prism 6.0 software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.04.22.055608: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: All the procedures and protocols used in this study were approved by an animal ethical committee, the Animal Welfare and Ethical Review Body (AWERB).<br>Consent: Recovered COVID-19 patient samples: Serum samples were donated to the Communicable Diseases Research Tissue Bank, Section of Virology, Imperial College London, following written informed consent, by patients who had been infected with SARS-CoV-2.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plates were incubated for 1 h at 37ºC, then washed and secondary antibody added at 1:2000 dilution in blocking buffer (100 μL/well) using either anti-mouse IgG-HRP, anti-mouse IgG1-HRP or anti-mouse IgG2a-HRP (Southern Biotech).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-mouse IgG-HRP</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-mouse IgG1-HRP</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-mouse IgG2a-HRP</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell Culture & saRNA Transfection: HEK293T/17 cells (ATCC) were cultured in complete Dulbecco’s Modified Eagle’s Medium (DMEM) (Gibco, Thermo Fisher Scientific) containing 10 % fetal bovine serum (FBS, Gibco, Thermo Fisher Scientific), 1 % L-glutamine and 1 % penicillin-streptomycin (Thermo Fisher Scientific) at 37°C, 5% CO₂.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T/17</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For the neutralization assay, heat-inactivated sera were first serially diluted and incubated with virus for 1 h, and then the serum-virus mixture was transferred into wells pre-seeded Caco2 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Caco2</div><div>suggested: CLS Cat# 300137/p1665_CaCo-2, RRID:CVCL_0025)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">7 Animals and immunizations: BALB/c mice aged 6-8 weeks old were placed into groups of n = 7 or 8.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BALB/c</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Samples were analyzed on a LSRForterssa (BD Biosciences) with FACSDiva software (BD Biosciences).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FACSDiva</div><div>suggested: (BD FACSDiva Software, RRID:SCR_001456)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">FlowJo LLC).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The IC50 neutralization was then calculated using GraphPad Prism (version 8.4).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.05.04.20090076: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">Consent: All study participants provided written and informed consent before enrolment.<br>IRB: The study was approved by the Ethics Committee of the Medical Faculty of the University of Bonn (approval number 085/20) and has been registered at the German Clinical Trials Register (https://www.drks.de, identification number DRKS00021306).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">Sampling was done randomly under the side condition that all 600 persons had different surnames, as it was assumed that different surnames were likely to indicate different households.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The data sheet (April 7, 2020) reports cross-reactivities with anti-SARS-CoV-1-IgG-antibodies, but not with MERS-CoV-, HCoV-229E-, HCoV-NL63-, HCoV-HKU1- or HCoV-OC43-IgG antibodies.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HCoV-OC43-IgG</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After incubation of 1 h at 37°C, 200 μl of each mixture were added to wells of a 24 well plate seated the day before with 1.5×105 Vero E6 cells/well.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: RRID:CVCL_XD71)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Study data were collected and managed using REDCap electronic data capture tools hosted at Institute for Medical Biometry, Informatics and Epidemiology13, 14. REDCap (Research Electronic Data Capture) is a secure, web-based software platform designed to support data capture for research studies, providing 1) an intuitive interface for validated data capture; 2) audit trails for tracking data manipulation and export procedures; 3) automated export procedures for seamless data downloads to common statistical packages; and 4) procedures for data integration and interoperability with external sources.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>REDCap</div><div>suggested: (REDCap, RRID:SCR_003445)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">R Foundation for Statistical Computing, Vienna, Austria) and version 9.4 of the SAS System for Windows (copyright © 2002-2012 by SAS Institute Inc., Cary, NC, USA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SAS Institute</div><div>suggested: (Statistical Analysis System, RRID:SCR_008567)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      However, with the limitations discussed above, the IFR calculated here remains a useful metric for other regions with higher or lower infection rates. If in a theoretical model the here calculated IFR is applied to Germany with currently approximately 6,575 SARS-CoV-2 associated deaths (May 2nd, 2020, RKI), the estimated number of infected in Germany would be higher than 1.8 Mio (i.e. 2.2% of the German population). It will be very important to determine the true average IFR for Germany. However, because of the currently low infection rate of approximately 2% (estimated based on IFR), an ELISA with 99% specificity will not provide reliable data. Therefore, under the current non-superspreading conditions, it is more reasonable to determine the IFR in high prevalence hotspots such as Heinsberg county. The data of the study reported here will serve as baseline for follow up studies on the delta of infections and deaths to identify the corresponding IFR under those changed conditions.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.05.19.20105999: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Samples were analyzed using the Bio-Rad iTaq Universal Probes One-Step kit in 20 μL reactions run at 50°C for 10 min, 95°C for 1 min followed by 40 cycles of 95°C for 10 s and 60°C for 30 s per the manufacturer’s recommendations.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Bio-Rad iTaq Universal Probes</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>iTaq</div><div>suggested: None</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      Jurisdictions can use primary sludge SARS-CoV-2 concentrations to preempt community outbreak dynamics or provide an additional basis for easing restrictions, especially when there are limitations in clinical testing. Raw wastewater and sludge-based surveillance is particularly useful for low and middle-income countries where clinical testing capacity is limited.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.05.20.20107813: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">Consent: All donors signed the informed consent approved by the National Research Center for Hematology ethical committee before the enrollment.<br>IACUC: Additionally, 10 healthy hematopoietic stem cell donor samples and 10 healthy donor serum samples were obtained from the blood bank with the approval of the local ethical committee.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">COVID-19 was confirmed either by positive SARS-CoV-2 RT-PCR test or retrospectively by the detection of anti-RBD antibodies.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-RBD</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After, plates were washed two times with PBS and then two times with PBS, containing 0.05% Tween-20, followed by incubation with biotinylated anti-human IFN-γ Detection antibody for 2h at room temperature (RT).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IFN-γ</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Next, the wells were washed 3 times and were incubated for one more hour with 100 μL of anti-human IgG monoclonal HRP-conjugated antibodies (supplied with RBD ELISA Kit).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Predicted proteasomal cleavage score of the C-terminal amino acid was estimated using NetChop 3.1 (Nielsen, Lundegaard et al. 2005).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>NetChop</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data were analyzed using FlowJo Software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr></table>

      Results from OddPub: Thank you for sharing your code and data.


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      Our findings are in line with that with acaveat that we observed the significant increase of SARS-CoV-2 S-protein reactive T-cells in healthy donors sampled during the COVID-19 pandemic (Figure 2c and 2d). Combined with the complete lack of SARS-CoV-2 specific antibodies in that group this suggests that some of the donors may have had contact with SARS-CoV-2 before blood sampling. Due to cross-reactivity induced by other coronaviruses their T cells might have protected them from developing the full scale infection. This is illustrated by the case of p1477 who is known to cohabited with COVID-19 patient but was negative in multiple PCR tests, did not have any COVID-19 typical or flu-like symptoms and had no detectable antibodies to any of the SARS-CoV-2 antigens. This hypothesis, although, needs to be validated on a larger cohort of donors. As others have shown before, we observed that significantly more CD4+ cells in convalescent donors express HLA-DR and CD38 (Braun, Loyal et al. 2020, Thevarajan, Nguyen et al. 2020). We have also shown the same tendency for CD8+ T cells, though the difference was not significant (Figure 2g). As was shown before (Weiskopf, Schmitz et al. 2020) the majority of SARS-CoV-2 specific CD4+ belonged to the TCM subpopulation while CD8+ were predominantly of TTE and TEM phenotype. In this work we used the IFNγ-secretion upon antigen stimulation as a criterion of antigen-specific cells. This approach might potentially miss some relevant T cells as the...

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on page 6. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.06.17.20134031: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: It was registered on Clinicaltrials.gov (NCT043235929) after approval by the referral Ethics Committee for the Coordinating Centre (University Hospital of Trieste, #CEUR-2020-Os-052).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Exposure to methylprednisolone (non-patented drug, ATC code H02AB04) complied with the following protocol: a loading dose of 80 mg iv at study entry (baseline), followed by an infusion of 80 mg/day in 240 mL normal saline at 10 mL/h for at least eight days, until achieving either a PaO2:FiO2 > 350 mmHg or a CRP < 20 mg/L.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ATC</div><div>suggested: None</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      After matching the expression changes induced by SARS-CoV2 in human lung tissue tissues and A549 lung cell line against the expression changes triggered by 5,694 FDA-approved drugs, methylprednisolone was found to be the drug with the greatest potential to revert the changes induced by COVID-19.[22] The safety profile reported in our study is consistent with the findings of multiple RCTs investigating prolonged corticosteroid treatment in thousands of patients with severe sepsis, septic shock and ARDS.[17] In these RCTs, hyperglycemia was transient in response to the initial loading bolus and did not impact negatively on outcome.[17] Viral shedding in both groups of our study was in agreement with international literature.[23, 24] Moreover, there is no evidence linking delayed viral clearance to worsened outcome in critically ill COVID-19 patients, and it is unlikely that it would have a greater negative impact than the host’s own cytokine storm.[25] The observational design of our study implies some obvious limitations, namely a possible restricted control over data collection and potential inclusion biases. However, internal validity was achieved by (1) the comparability of concurrent groups at baseline, (2). accounting for potential confounders into the multivariable Cox regression analyses, and (3) conducting sensitivity analysis to assess for potential bias in outcome ascertainment potentially influenced by medical decision making. Our study’s strengths include a prospec...

      Results from TrialIdentifier: We found the following clinical trial numbers in your paper:<br><table><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Identifier</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Status</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Title</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04323592</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Completed</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Methylprednisolone for Patients With COVID-19 Severe Acute R…</td></tr><tr style="background-color:#FF0000"><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT043235929</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Trial number did not resolve on clinicaltrials.gov. Is the number correct?</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NA</td></tr></table>


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.07.13.20152264: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      No key resources detected.


      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      These data were recorded as part of a comprehensive risk assessment process, which demonstrated no significant limitation of air flow through the chest drain circuit with the filter in-situ. Aerosols are typically generated by air moving across the surface of a liquid, with increasing air forces generating smaller particles. [1] This is consistent with the observations reported here in that unfiltered emissions of the smallest particles (0.3-0.5 microns) increased progressively from 1 to 3 to 5 L/minute. Our findings are also concordant with a recent study reported by Akhtar et al, in which a similar anti-viral filter was evaluated and produced a qualitative reduction in droplet emissions. However, droplet size, and therefore aerosolization potential were not examined. [8] These data support risk mitigation in patients with suspected or proven COVID-19, as recommended by the British Thoracic Society (BTS) [6] and the American Association for the Surgery of Trauma (AAST). [7] However, the absolute risk involved remains uncertain. Pleural effusion and pneumothorax appear uncommon complications of COVID-19 (occurring in ∼5% and ∼1% of cases, respectively [6][8]) and an aerosol-generating chest drain can clearly only be an infection risk if SARS-CoV-2 is a) present in any effusion drained (which may be of minimal volume in patients with pneumothorax and major air-leaks) and b) remains viable long enough to be aerosolised. Lescure [3] and Mei [4] have recently reported cases of SA...

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.07.13.20152884: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: Sample collection from human subjects: Samples collected at the State Hematology Institute Hemorio followed a protocol approved by the local ethics committee (CEP Hemorio; approval #4008095).<br>Consent: Samples collected at UFRJ COVID Screening and Diagnostic Center followed a protocol approved by the national ethics committee (CONEP, Brazil; protocol #30161620000005257; approval #3953368): subjects were initially interviewed and, if they accepted to participate, they signed the informed consent, answered a questionnaire (addressing demographic data, onset and type of symptoms, history of travel abroad, among other information) and had blood (venous blood and/or finger prick) and nasopharyngeal swab collected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Presence of S protein in the supernatants was determined by spot blots: 3 µL of each sample was applied to nitrocellulose membranes, serum of SARS-COV-2 convalescent patients (1:1000) was used as primary antibody, followed by incubation with anti-human IgG(Fc) HRP-labeled antibody (Sigma, #SAB3701282) and finally addition of chemiluminescent ECL reagent (BioRad).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG(Fc</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For Western blots, serum of SARS-COV-2 convalescent patients (1:1000) was used as primary antibody, followed by incubation with anti-human IgG (Fc) HRP-labeled antibody (Sigma, #SAB3701282) and then chemiluminescent ECL reagent (BioRad).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Next, 50 μL of 1:8000 goat anti-human IgG (Fc) HRP-labeled antibody (Sigma, #SAB3701282) was added to the plate and incubated for 1.5 hours at RT.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>1:8000 goat anti-human IgG</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Stable cell line generation: HEK293-3F6 cells (NRC Canada) growing in suspension in the chemically-defined, animal component-free HEK-TF (Xell AG) culture medium were stably transfected by lipofection using a broad-spectrum reagent (Lipofectamine 3000, Thermo Fisher) as described previously4.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293-3F6</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Virus-serum mixture was inoculated into confluent monolayers of Vero cells seeded in 12-well tissue culture plates.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: None</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.07.21.214759: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: All plasma samples were obtained under protocols approved by Institutional Review Boards at both institutions.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">Contamination: All cell lines have been tested negative for contamination with mycoplasma.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Antibody binding and ACE2 binding inhibition assay: A conformationally stabilized (6P) version of the SARS-CoV-2 S protein(25), appended at its C-terminus with a trimerization domain, a GGSGGn spacer sequence, NanoLuc luciferase, Strep-tag, HRV 3C protease cleavage site and 8XHis (S-6P-NanoLuc) was expressed and purified from the supernatant of 293T Expi cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ACE2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Mutants thereof were also expressed and purifies following substitution of sequences encoding the RBD that originated from the unmodified S-expression plasmids For antibody binding assays, 20ng, 40ng, or 80ng S-6P-NanoLuc (or mutants thereof) were mixed with 100ng of antibodies, C121, C135, or C144, \ diluted in LI-COR Intercept blocking buffer, in a total volume of 60μl/well in 96-well plate.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>C144</div><div>suggested: (Leinco Technologies Cat# C144, RRID:AB_2828501)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For ACE2-binding inhibition assays, 20ng of S-6P-NanoLuc was mixed with 100ng of antibodies, C121, C135 or C144, diluted in 3% goat serum/PBS, in a total volume of 50μl.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>C121</div><div>suggested: (Leinco Technologies Cat# C121, RRID:AB_2828361)</div></div><div style="margin-bottom:8px"><div>C135</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The half maximal inhibitory concentrations for plasma (NT50), and monoclonal antibodies (IC50) was calculated using 4-parameter nonlinear regression curve fit to raw or normalized infectivity data (GraphPad Prism).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>NT50</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell lines: HEK-293T cells and derivatives were cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) at 37°C and 5% CO2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK-293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, 293T cells were transfected with pHIVNLGagPol, pCCNanoLuc2AEGFP and a WT or mutant SARS-CoV-2 expression plasmid (pSARS-CoV-2Δ19) using polyethyleneimine.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After 30 minutes incubation, the mixture was incubated with 1×105 293T cells, or 293T/ACE2cl.22 cells for 2 hours at 4°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T/ACE2cl.22</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The PCR products were gel-purified and sequenced either using Sanger-sequencing or NGS as previously described (31).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>NGS</div><div>suggested: (PM4NGS, RRID:SCR_019164)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For analysis of NGS data, the raw paired-end reads were pre-processed to remove adapter sequences and trim low-quality reads (Phred quality score <20) using BBDuk.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Phred</div><div>suggested: (Phred, RRID:SCR_001017)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Information regarding RBD-specific variant frequencies, their corresponding P-values, and read depth were compiled using the Python programming language (version 3.7) running pandas (1.0.5), numpy (1.18.5), and matplotlib (3.2.2).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Python</div><div>suggested: (IPython, RRID:SCR_001658)</div></div><div style="margin-bottom:8px"><div>matplotlib</div><div>suggested: (MatPlotLib, RRID:SCR_008624)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The half maximal inhibitory concentrations for plasma (NT50), and monoclonal antibodies (IC50) was calculated using 4-parameter nonlinear regression curve fit to raw or normalized infectivity data (GraphPad Prism).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.03.27.20043752: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      NIH rigor criteria are not applicable to paper type.

      Table 2: Resources

      No key resources detected.


      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      The use of mobile military resources including the National Guard42–44 has the potential to address some capacity limitations, particularly given the differently timed epidemics across states. Other innovative strategies will need to be found, including the construction of temporary hospital facilities as was done in Wuhan,45 Washington state,46 and also New York.44,47 In this study, we have quantified the potential gap in physical resources, but there is an even larger potential gap in human resources (HR). Expanding bed capacity beyond licensed bed capacity may require an even larger increase in the HR to provide care. The average annual bed- day utilization rate in the US is 66% and ranges from 54% (Idaho) to 80% (Connecticut) by state. Most US hospitals are staffed appropriately at their usual capacity utilization rate, and expanding even up to, but then potentially well beyond, licensed capacity will require finding substantial additional HR. Strategies include increasing overtime, training operating room and community clinic staff in inpatient care or physician specialties in COVID-19 patient care, rehiring recently separated workers, and the use of volunteers. For example, UW Medicine has been fortunate that clinical faculty time can be redirected from research and teaching to clinical care during the COVID-19 surge. Other hospitals may not have this same ability. The most concerning HR bottleneck identified for UW Medicine is for ICU nurses, for which there are very l...

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.07.30.20165415: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">Consent: Written informed consent was obtained online from all participants.<br>IRB: All procedures involving human subjects/patients were approved by the UK London Bridge National Research Ethics Committee (Ref: 13/LO/1578) and the COVID-19 mental health questionnaire was approved by the same committee (as an amendment) on 6th April 2020.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Study design and setting: The study was conducted with participants from the PROTECT study.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>PROTECT</div><div>suggested: (ProTECT, RRID:SCR_004531)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      Limitations: One important limitation is the potential for bias in an on-line self-selecting sample. In particular we note the overrepresentation of women, white British people and those with a higher education, however because our analysis is focused on longitudinal patterns rather than prevalence there is still merit in identifying these trends within this sample. A second limitation is determining causation, a pervasive issue observational studies. Because the loneliness and physical activity questions were only taken during the pandemic it may be the case that worse mental health drove a decrease in physical activity and increase in loneliness. The wider literature has highlighted a causal relationship between higher physical activity levels and lower risk for major depressive disorder (but no causal relationship for the reverse) so in the context of this evidence it would be reasonable to hypothesise that maintaining physical activity during the pandemic may mitigate risk of mental health deterioration (25). A large randomised control trial would be needed to assess this but our findings pave the way for robust intervention testing. We are not aware of any studies which have conclusively shown a causal directional link between loneliness and mental health but the well-established link between the two is one of the reasons why loneliness is a critical policy area in the UK and internationally. Here we are able to show that for the first time that the association between l...

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.08.13.20173161: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: This study was approved by the University of Washington Institutional Review Board.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">The strains were then stratified by Pangolin lineage (A or B) (https://github.com/cov-lineages/pangolin) and 49 from lineage A and 59 from lineage B were randomly selected along with the Wuhan-Hu-1 reference genome (NC_045512.2) (25).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Neutralization Assays and Anti-Spike Antibody Testing: The presence of anti-Spike and neutralizing antibodies was analyzed in pre-departure sera samples from individuals that were positive in the Abbott assay screening through four different methods: Spike IgG ELISA, RBD ELISA, ACE2 blockade of binding ELISA, and pseudovirus neutralization.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Anti-Spike</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pooled sera collected from 2017-2018 from 75 individuals (Gemini Biosciences, 100-110, lot H86W03J) and CR3022 antibody (starting at 1/ug/mL, also diluted 4-fold) were included as negative and positive controls, respectively.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CR3022</div><div>suggested: (Imported from the IEDB Cat# CR3022, RRID:AB_2848080)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plates were again washed three times, and then 50μL of a 1:300 dilution of goat anti-human IgG-Fc horseradish peroxidase (HRP)-conjugated antibody (Bethyl Labs, A80-104P) in PBS-T containing 1% milk was added to each well and incubated for 1 hour at room temperature.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG-Fc</div><div>suggested: (Bethyl Cat# A80-104P, RRID:AB_67064)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Clinical testing of serum samples was performed using the Abbott Architect SARS-CoV-2 IgG assay (20).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Abbott Architect</div><div>suggested: (Abbott ARCHITECT i1000sr System, RRID:SCR_019328)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Sequencing reads are available at NCBI BioProject PRJNA610428 and sequence accessions are available in Supplemental Table 1.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BioProject</div><div>suggested: (NCBI BioProject, RRID:SCR_004801)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, sequencing reads were adapter- and quality-trimmed with BBDuk and mapped to the SARS-CoV-2 reference genome (NC_045512.2) using Bowtie 2 (23).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Bowtie</div><div>suggested: (Bowtie, RRID:SCR_005476)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Reads aligning to the SARS-CoV-2 reference genome were filtered using BBDuk and assembled with SPAdes (24).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SPAdes</div><div>suggested: (SPAdes, RRID:SCR_000131)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For samples that did not produce a genome through the automated pipeline, the mapped read assemblies were visualized in Geneious and a consensus genome was called manually.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Geneious</div><div>suggested: (Geneious, RRID:SCR_010519)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Sequences were aligned with MAFFT v7.453 (26) and a phylogenetic tree was constructed using FastTree (version 2.1.1) (27) with the 5’ and 3’UTRs masked.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MAFFT</div><div>suggested: (MAFFT, RRID:SCR_011811)</div></div><div style="margin-bottom:8px"><div>FastTree</div><div>suggested: (FastTree, RRID:SCR_015501)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Strains most closely related to the major outbreak clade were identified by searching against a custom BLASTN database containing all SARS-CoV-2 sequences in GISAID (accessed August 3, 2020).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BLASTN</div><div>suggested: (BLASTN, RRID:SCR_001598)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Neutralization Assays and Anti-Spike Antibody Testing: The presence of anti-Spike and neutralizing antibodies was analyzed in pre-departure sera samples from individuals that were positive in the Abbott assay screening through four different methods: Spike IgG ELISA, RBD ELISA, ACE2 blockade of binding ELISA, and pseudovirus neutralization.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Abbott</div><div>suggested: (Abbott, RRID:SCR_010477)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After calculating the fraction infectivity, we used the neutcurve Python package (https://jbloomlab.github.io/neutcurve/) to calculate the serum dilution that inhibited infection by 50% (IC50) by fitting a Hill curve with the bottom fixed at 0 and the top fixed at 1.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Python</div><div>suggested: (IPython, RRID:SCR_001658)</div></div></td></tr></table>

      Results from OddPub: Thank you for sharing your data.


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.05.28.122366: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      NIH rigor criteria are not applicable to paper type.

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The protein sequences of the non-recombinant regions SARS-CoV-2, SARS-CoV-1 and 67 closely related viruses with non-human hosts (bats and pangolins; Supplementary Table 6) were aligned using MAFFT version 7 (L-INS-i)54.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MAFFT</div><div>suggested: (MAFFT, RRID:SCR_011811)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Phylogenies for each codon alignment were inferred using RAxML with a GTR+G nucleotide substitution model55.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>RAxML</div><div>suggested: (RAxML, RRID:SCR_006086)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All selection analyses were performed in the HyPhy software package v.2.5.1456</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HyPhy</div><div>suggested: (HyPhy, RRID:SCR_016162)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Time-measured evolutionary histories for NRR1 and NRR2 were inferred using a Bayesian approach, implemented through the Markov chain Monte Carlo (MCMC) framework available in BEAST 1.1048.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BEAST</div><div>suggested: (BEAST, RRID:SCR_010228)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">We used the BEAGLE library v362 to increase computational performance.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BEAGLE</div><div>suggested: (BEAGLE, RRID:SCR_001789)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Trees were summarized as maximum clade credibility (MCC) trees using TreeAnnotator and visualized using FigTree.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FigTree</div><div>suggested: (FigTree, RRID:SCR_008515)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.09.15.20192765: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">The results were scored as positive or negative for IgM and IgG by two independent readers blinded to donor sample status.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The plates were again washed three times with PBS containing 0.05% Tween 20 (PBST) and banged on absorbent paper towels, and immediately anti-human horseradish peroxidase (HRP)-conjugated secondary antibodies for IgG (cat#A18817, Thermo Fisher, 1:2000), IgM (cat#A18841, Thermo Fisher, 1:8000), and IgA (Jackson Immunoresearch, cat#109-035-011, 1:2000) diluted in casein blocking buffer were added to the plates at 50μl per well for 30 minutes at room temperature.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human horseradish peroxidase ( HRP)-conjugated secondary antibodies for IgG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>cat#A18817</div><div>suggested: (Thermo Fisher Scientific Cat# A18841, RRID:AB_2535618)</div></div><div style="margin-bottom:8px"><div>cat#A18841</div><div>suggested: (Jackson ImmunoResearch Labs Cat# 109-035-011, RRID:AB_2337580)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Determination of the presence versus absence of SARS-CoV-2 reactive antibodies in samples and of Arbitrary Unit Values: First, the average ODs of corresponding ‘blank’ wells (sample diluent only in buffer only coated or antigen coated) on a given plate was subtracted from all wells with samples.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>antigen coated </div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">s DISCOVID IgM IgG LFD test was used to detect SARS-CoV-2 RBD specific IgM and IgG antibodies following manufacturer instructions.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>IgG</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Determination of Arbitrary Units: Data were analyzed using GraphPad Prism 8.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      However, a limitation of this assay is that it is currently considerably lower in throughput compared to other serological platforms. This protocol requires an operator for the manual wash steps, limiting the number of plates that can be run compared to automated methods, however, there is potential for throughput increase if automated washers/ELISA systems can be adapted to more closely mimic this protocol. Other important features of our approach include the inclusion of paired sample dilutions with buffer only coated wells to enable detection of true antigen-reactive signal and adjustment of the length of substrate incubation time based on standard curve development for OD standardization to enable direct comparison between samples on different plates. Quantification of relative antibody levels via Arbitrary Units (AU) or a similar method will be imperative for determining which convalescent samples have antibody levels sufficient for effective plasma transfer as well as other applications. However, while we believe this is a preferred approach for determining of relative output values within all samples, it is critical to note that the unique dynamics of the panoply of antibodies of varying affinities and isotypes within a given specimen causes inherent confounding factors to serologic readouts. For example, a specimen with a high level of SARS-CoV-2 RBD reactive IgM antibodies could have a lower detected signal for IgG and IgA due to IgM’s pentameric conformation blockin...

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.07.18.210161: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: Ethics approvals: Human studies were conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of Guy’s Hospital (reference 09/H0707/86), National Institutes of Health (approval numbers 7458, PACI, 13-H-0065 and 00-I-0159) and Imperial College London (approval number 12/WA/0196 ICHTB HTA license number 12275 to project R14098).<br>Consent: All patients provided informed written consent.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Where indicated, cells were activated in 96 well plates coated with antibodies against CD3 (OKT3, made inhouse by the Washington University hybridoma facility), CD3 + CD28 (CD28.2, Becton Dickinson) or CD3 + CD46 (TRA-2-10, a gift from John P Atkinson, Washington University, USA), all at 2μg/mL in sterile PBS overnight at 4C, in the presence and absence of a cell soluble cathepsin L inhibitor (ALX-260-133-M001 from Enzo Life Sciences, Exeter, UK) at 1μM final concentration.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CD3</div><div>suggested: (GeneTex Cat# GTX13464, RRID:AB_369206)</div></div><div style="margin-bottom:8px"><div>OKT3</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>CD28</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>TRA-2-10</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For surface staining we used the following antibodies: CD4 (OKT4, Thermo Fisher Scientific), IL-6 (MQ2-13A5, Biologend)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>OKT4</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>IL-6</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>MQ2-13A5</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For FACS sorting of memory CD4+ T cells, bulk CD4+ T cells enriched as described using RosetteSep Human CD4+ enrichment cocktail were stained with antibodies against CD4 (OKT4, Thermo Fisher Scientific), CD45RA (HI100, Biolegend), CD45RO (UCLH1, BD Biosciences) and CD25 (2A3, BD Biosciences) in MACS buffer at 4C for 30 min.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CD4</div><div>suggested: (Thermo Fisher Scientific Cat# MA1-42140, RRID:AB_2537291)</div></div><div style="margin-bottom:8px"><div>CD45RA</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>HI100</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>CD45RO</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>CD25</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Immunoblotting was performed according to standard protocols with initial blocking in PBS with 10% w/v clotting grade blocker (BioRad) or 3% w/v BSA (Sigma-Aldrich) and 0.1% v/v Tween20 (Sigma-Aldrich), followed by overnight incubation in primary antibodies: anti-VDR (D-6, Santa Cruz biotechnology) pSTAT3 (D3A7, Cell Signaling Technologies), STAT3 (124H6, Cell Signaling Technologies), Phospho-c-Jun (S63, R&D systems) or c-Jun (L70B11, Cell Signaling Technologies), followed by blocking and two hours incubation in appropriate HRP conjugated secondary anti-mouse or anti-rabbit antibodies (TrueBlot antibodies, Rockland).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-VDR</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>D-6</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pSTAT3</div><div>suggested: (Fluidigm Cat# 3158005, RRID:AB_2661827)</div></div><div style="margin-bottom:8px"><div>STAT3</div><div>suggested: (Cell Signaling Technology Cat# 9139, RRID:AB_331757)</div></div><div style="margin-bottom:8px"><div>Phospho-c-Jun ( S63</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>c-Jun ( L70B11</div><div>suggested: (Cell Signaling Technology Cat# 2315, RRID:AB_490780)</div></div><div style="margin-bottom:8px"><div>anti-mouse</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-rabbit</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Antibody against BACH2 (D3T3G, Cell Signaling Technologies, 1:5000 dilution) was added in blocking buffer and incubated with membranes overnight at 4C with rotation.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BACH2</div><div>suggested: (Cell Signaling Technology Cat# 80775, RRID:AB_2799961)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Human phospho-kinase antibody array: Array (Proteome Profiler Human Phospho-Kinase Array Kit, R&D systems) was carried out as per manufacturer’s protocol.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Human phospho-kinase</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Rabbit antibodies targeting H3K27Ac (ab4729, Abcam), c-JUN (60AB, Cell Signaling Technologies), and non-specific IgG (31235, Thermo Fisher Scientific) were used, together with pAG-MNase (123461, Addgene) for small DNA fragment generation.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>H3K27Ac</div><div>suggested: (Abcam Cat# ab4729, RRID:AB_2118291)</div></div><div style="margin-bottom:8px"><div>ab4729 , Abcam) ,</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>c-JUN</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>pAG-MNase ( 123461</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The samples were incubated with anti-CD3 (F7.2.38, Thermo Fisher Scientific) and anti-BACH2 (D3TG, Cell Signaling) primary antibodies overnight at 4C and washed in 0.01M PBS the next day.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-BACH2 ( D3TG , Cell Signaling )</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Alternatively, we used LEGENDplex Human Inflammation Panel 1 (13plex) (740808, BioLegend) following manufacturers protocol using an Invitrogen Attune NxT Flow Cytometer and analyzed using FlowJo v9 software (BD Biosciences).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">geNorm 6 gene kit, catalogue number ge-SY-6 from PrimerDesign UK) as housekeeping genes.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>geNorm</div><div>suggested: (geNORM, RRID:SCR_006763)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Hockey-stick plots of rank ordered stitched-enhancers plotted against VitD minus carrier H3K27Ac signal were produced in RStudio (ver. 1.2.5033</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>RStudio</div><div>suggested: (RStudio, RRID:SCR_000432)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The bowtie index for RSEM alignment was generated by ‘rsem-prepare-reference’ on all RefSeq genes, downloaded from UCSC table browser in April 2017.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>RefSeq</div><div>suggested: (RefSeq, RRID:SCR_003496)</div></div><div style="margin-bottom:8px"><div>UCSC table browser</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data were filtered to include only genes expressed at greater than 0.25 counts per million in at least 2 samples, TMM normalized within the edgeR package (v3.28.1), and differential expression performed using the glmQLFit and glmQLFTest functions in edgeR.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>edgeR</div><div>suggested: (edgeR, RRID:SCR_012802)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Confocal images were collected on a Zeiss 780 inverted confocal microscope at 40X with oil-immersion and analyzed using ImageJ software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ImageJ</div><div>suggested: (ImageJ, RRID:SCR_003070)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data presentation and statistical analysis: Figures were prepared using Adobe Illustrator (Adobe)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Adobe Illustrator</div><div>suggested: (Adobe Illustrator, RRID:SCR_010279)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical analysis and graphical visualizations were carried out in GraphPad Prism (v.8.4.0), XLstat biomed (v2017.4), DataGraph 4.5.1 (</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div><div style="margin-bottom:8px"><div>DataGraph</div><div>suggested: None</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on page 19. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.09.27.316174: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: All animal studies were reviewed and approved by the Institutional Animal Care and Use Committee at the University of Texas Medical Branch and were conducted according to the National Institutes of Health guidelines.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Hamster challenge experiments: Male and female Syrian golden hamsters were obtained from Charles River Laboratories at 6 weeks of age.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Antibody binding ELISA: The S1 subunit of the SARS-CoV-2 spike protein (amino acids 16-685) bearing a C-terminal histidine tag (ACRO Biosystems, Newark, NJ) was coated at 2 μg/ml on a Ni-NTA plate (Qiagen, Valencia, CA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SARS-CoV-2 spike protein (amino acids 16-685</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Antibody characterization: Kinetic interactions between the antibodies and His-tagged receptor binding domain (RBD, amino acids 319-537) (Acro Biosystems, Newark, NJ) protein was measured at 25°C using BIAcore T200 surface plasmon resonance (SPR) (GE Healthcare).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>His-tagged receptor binding domain (RBD, amino acids 319-537) (Acro Biosystems, Newark, NJ</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">STI-1499 or STI-2020 antibody was covalently immobilized on a CM5 sensor chip to approximately 500 and 100 resonance units (RU), respectively using standard N-hydroxysuccinimide/N-Ethyl-N′-(3-dimethylaminopropyl) carbodiimide hydrochloride (NHS/EDC) coupling methodology.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>STI-2020</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For antibody binding to the cells expressing the Spike proteins, the cells were dispensed into wells of a 96-well plate (25 μl per well), and an equal volume of 2x final concentration of serially-diluted anti-S1 antibody solution was added.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-S1</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Antibody treatments were administered intravenously (i.v.) with monoclonal antibodies (mAbs) against SARS-CoV-2 Spike, or isotype control mAb in up to 350 µl of sterile PBS at 1 hour-post inoculation.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SARS-CoV-2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HEK293 cells were transfected using FuGeneHD transfection reagent according to manufacturer’s protocol (Promega, Cat # E2311).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Vero E6 cells were plated to 96-well plates and incubated at 37° C, 5% CO2</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell based Spike binding assay: Mammalian expression vectors were constructed either by cloning of the synthesized gene encoding SARS-CoV-2 G614 Spike protein (UniprotKB, SPIKE-SARS2) or, for SARS-CoV-2 D614 Spike protein, via site-directed mutagenesis of the G614 Spike protein gene.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>UniprotKB</div><div>suggested: (UniProtKB, RRID:SCR_004426)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">A sigmoidal four-parameter logistic equation was used for fitting the MFI vs. mAb concentration data set to extract EC50 values (GraphPad Prism 8.3.0 software).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • No funding statement was detected.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.10.02.20204859: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">Consent: After giving informed consent, participants were instructed to provide 3-5 mL of saliva using the drooling method into a sterile tube without any stabilizer or solution.<br>IRB: The study was approved by the institutional review boards for both participating institutions.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2 Assay: Nucleic acid from individual specimens was extracted from 200 μL of Saliva/NP/MT specimens using the NucliSENS® easyMAG® platform (bioMérieux, Marcy l’Etoile, France) with an elution volume of 50 μL.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>NucliSENS®</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All statistical analyses were performed using GraphPad Prism version 8 (GraphPad Software, San Diego, CA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      The limitations for our study included the low number of positive participants, testing of symptomatic patients to determine an approach for screening the asymptomatic population, and the combined use of two collection sites (drive-through center and ED). The positive specimens include seven MT of the total 38 positives, to increase likelihood of participation in the study. All positive NP samples from the ED did not have a Ct value from the easyMAG/ABI 7500 platform, as not all samples were available for repeat testing. For this reason, only data from the easyMAG/ABI 7500 platform are included in the figures that compare Ct ranges. A challenge for all centers offering saliva testing is that some individuals may have difficulty producing adequate saliva for the test. Saliva is also a more challenging specimen for the laboratory staff to handle and requires judgement about thickness to ensure the correct volume is pipetted, with a chance of an under-pipetted sample, due to viscosity or bubbles, leading to a false-negative result, as well as increased likelihood of extraction failure. Initially, mucolyse was added to individual thick saliva specimens prior to extraction, but data obtained during our pooling validation showed that proteinase K digestion for individual thick samples prior to extraction was just as effective. Therefore, thick specimens and pooled specimens follow the same processing procedure. When evaluating the effectiveness of saliva collection, it is important...

      Results from TrialIdentifier: We found the following clinical trial numbers in your paper:<br><table><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Identifier</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Status</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Title</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04424446</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Saliva as Source of Detection for SARS-CoV-2</td></tr></table>


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a protocol registration statement.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2020.10.07.20208603: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">IRB: All testing and archiving of human specimens was approved by NYSDOH Institutional Review Board (IRB 20-021).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">The data was randomly separated into training (70%) and testing (30%) subsets.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">COVID-19 Serum Samples: Studies were performed on sera from clinical specimens submitted to the Wadsworth Center, New York State Department of Health for determination of antibody reactivity to SARS-CoV-2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SARS-CoV-2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Serum samples (25 µL at 1:100 dilution) and antigen-conjugated microspheres (25 µL at 5⨯104 microspheres/mL) were mixed and incubated 30 minutes at 37°C before washing and further incubation with phycoerythrin (PE)-conjugated secondary antibody.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>antigen-conjugated microspheres (25</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The PE-conjugated antibodies were chosen to specifically recognize, as indicated, total antibodies (pan-Ig), or, individually IgM, IgA, IgG, IgG1, IgG2, IgG3, IgG4.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>IgA, IgG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>IgG1</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>IgG2, IgG3</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>IgG4</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For the detection of SARS-CoV-2 neutralizing antibodies, 2-fold serially diluted test serum (100μl) was mixed with 100μl of 150-200 plaque forming units (PFUs) of SARS-CoV-2 (isolate USA-WA1/2020, BEI Resources, NR-52281) and incubated for 1 h at 37°C, 5% CO2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>NR-52281</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The virus:serum mixture (100μl) was applied to VeroE6 cells (C1008, ATCC CRL-1586) grown to 95-100% confluency in 6 well plates.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>VeroE6</div><div>suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)</div></div></td></tr></table>

      Results from OddPub: Thank you for sharing your code.


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      Limitations of Study: The size of our patient cohort enabled a robust analysis of the antibody response to SARS-CoV-2 in individuals with self-reported mild, moderate, or severe disease. However, the addition of samples from the of the full spectrum of COVID-19 presentation, including asymptomatic individuals, and non-survivors would significantly strengthen our study. The convalescent time-point at which this study was conducted allowed us to capture a large cohort that was with well documented clinical criteria. However, the late time-point (day 40 post onset) of this study weakens the predictive capacity of our analysis for earlier points during infection. In future studies we would like to follow a comprehensive cohort of individuals from COVID-19 symptom onset through and beyond recovery to assess how the early immune response influences both disease severity, and durable memory.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from rtransparent:
      • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
      • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
      • No protocol registration statement was detected.

      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. The vertex assignment vector has entries $\vec \tau_i$, where $i = 1, …, n$, for each of the vertices in the graph. For a given vertex $v_i \in \mathcal V$, the corresponding vertex assignment $\vec \tau_i$ defines which of the $K$ communities in which $v_i$ is a member. For instance, in a social network in which the vertices are students and the edges define whether two students are friends, a vertex assignment vector might denote the school in which each student learns. The matrix $\pmb B$ with entries $b_{kl}$ for $k, l = 1,…, K$ defines the probability of an edge existing between vertices which are in community $k$ with vertices which are in community $l$. For instance, in the social network example, one might select $\pmb B$ such that the diagonal entries $b_{kk}$ for $k = 1,…, K$ tend to exceed off-diagonal entries $b_{kl}$ where $k \neq l$ and $k,l = 1,…,K$. Further, the matrix $\pmb B$ is supposed to be symmetric; that is, for any $b_{kl}$, it is always the case that $b_{k,l} = b_{lk}$ for all $k = 1,…, K$. Intuitionally, this would correspond to the graph in which each of the The matrix $\pmb B$ defines that if vertex $v_i$ is in community $k$ and vetex $v_j$ is in community $l$, then an edge $e_{ij}$ or $e_{ji}$ exists between $v_i$ and $v_j$ with probability $b_{kl}=b_{lk}$. Fomally, we wite that $\pmb A \sim SBM_n(\vec \tau, \pmb B)$ if $A_{ij} | v_i = k, v_j = l \sim Bernoulli(b_{kl})$, or equivalently due to the symmetry of $\pmb B$, $A_{ji} | v_i = k, v_j = l \sim Bernoulli(b_{kl})$, for all $i,j \in 1,…,n$.

      too mathy

  2. Feb 2021
    1. Pastor-Barriuso, R., Pérez-Gómez, B., Hernán, M. A., Pérez-Olmeda, M., Yotti, R., Oteo-Iglesias, J., Sanmartín, J. L., León-Gómez, I., Fernández-García, A., Fernández-Navarro, P., Cruz, I., Martín, M., Delgado-Sanz, C., Larrea, N. F. de, Paniagua, J. L., Muñoz-Montalvo, J. F., Blanco, F., Larrauri, A., & Pollán, M. (2020). Infection fatality risk for SARS-CoV-2 in community dwelling population of Spain: Nationwide seroepidemiological study. BMJ, 371, m4509. https://doi.org/10.1136/bmj.m4509

    1. Aknin, L., Neve, J.-E. D., Dunn, E., Fancourt, D., Goldberg, E., Helliwell, J., Jones, S. P., Karam, E., Layard, R., Lyubomirsky, S., Rzepa, A., Saxena, S., Thornton, E., VanderWeele, T., Whillans, A., Zaki, J., Caman, O. K., & Amour, Y. B. (2021). A Review and Response to the Early Mental Health and Neurological Consequences of the COVID-19 Pandemic. PsyArXiv. https://doi.org/10.31234/osf.io/zw93g

    1. SciScore for 10.1101/2021.01.31.426979: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">VIRUS: Vero cells (ATCC®, CRL-1587, ATCC, Manassas, Virginia) were grown in Eagle’s Minimum Essential Medium (EMEM, Sigma-Aldrich, North Ryde, Australia, or Sigma-Aldrich, St. Louis, Missouri), supplemented with 1x non-essential amino acids (Gibco, Mount Waverley, Australia, or Thermo Fisher Scientific, 168 Third Avenue, Waltham, MA) and 10% heat-inactivated fetal bovine serum (FBS: Bovogen, Melbourne, Australia, or GE Healthcare Hyclone, Marlborough, MA).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Vero E6 cells (ATCC®, C1008) were grown in MEM/EBSS with L-Glutamine (Hyclone) supplemented with 1X non-essential amino acids (Gibco), 1 mM sodium pyruvate (Sigma-Aldrich), and 5% characterized fetal bovine serum (Hyclone).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: RRID:CVCL_XD71)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Virus stocks were prepared by growing virus in Vero 76 cells (ATCC CRL-1587) using media supplemented with 2% fetal bovine serum.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero 76</div><div>suggested: None</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: We found the following clinical trial numbers in your paper:<br><table><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Identifier</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Status</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Title</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04347954</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Completed</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for…</td></tr></table>


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from scite Reference Check: We found one citation with an erratum. We recommend checking the erratum to confirm that it does not impact the accuracy of your citation.

      <table style="border-collapse: collapse;"><tr><th style="min-width:95px; border: 1px solid lightgray; padding:2px">DOI</th><th style="min-width:95px; border: 1px solid lightgray; padding:2px">Status</th><th style="min-width:95px; border: 1px solid lightgray; padding:2px">Title</th></tr><tr><td style="min-width:95px; border: 1px solid lightgray; padding:2px">10.1136/bmjopen-2018-023118</td><td style="min-width:95px; border: 1px solid lightgray; padding:2px">Has correction</td><td style="min-width:95px; border: 1px solid lightgray; padding:2px">Evaluation of the safety of live attenuated influenza vaccin…</td></tr></table>
      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.01.31.428824: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      NIH rigor criteria are not applicable to paper type.

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Four rounds of panning were used to isolate scFvs binding both MERS S2 and SARS-2 spike using the following solutions coated on high binding plates: 2 μg/ml anti-c-myc tag antibody (Invitrogen) to eliminate phage expressing no or truncated scFv (Round 1), 2 μg/ml MERS S2 (Round 2), 2 μg/ml SARS-2 spike (Round 3), and 0.4 μg/ml SARS-2 spike (Round 4).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-c-myc tag</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Duplicate serial dilutions of each full-length antibody were allowed to bind each coat, and the secondary antibody solution was a 1:1200 dilution of goat-anti-human IgG Fc-HRP (SouthernBiotech).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>IgG Fc-HRP ( SouthernBiotech) .</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Western blot of antibody binding to coronavirus spike proteins: Purified coronavirus spike proteins (SARS-2 HexaPro, SARS-2, MERS, and HKU1) were reduced and boiled, and 50 ng of each was subjected to SDS-PAGE and transfer to PVDF membranes in quadruplicate.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HKU1</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To determine the affinity of 3A3 Fab by BLI, anti-human IgG Fc sensors were coated with the anti-foldon antibody identified in this work (3E11) at 20nM in kinetic buffer.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-foldon</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">MERS (18), HKU1 (18), and the SARS-2 variants HexaPro S2 (residues 697-1208 of the SARS-2 spike with an artificial signal peptide, proline substitutions at positions 817, 892, 899, 942, 986 and 987 and a C-terminal T4 fibritin domain, HRV3C cleavage site, 8xHisTag and TwinStrepTag), HexaPro RBD-locked-down (HexaPro with S383C-D985C substitutions), and aglycosylated HexaPro (HexaPro treated with Endo H overnight at 4 °C leaving only one N-acetylglucosamine attached to N-glycosylation site) as well as MERS S2-only (residues 763-1291 of MERS-2P with 8 additional stabilizing substitutions), MERS S2-apex-less (MERS S2-only construct with residues 811-824 replaced with GGSGGS and residues 1042-1073 replaced with a flexible linker) were expressed in Freestyle 293-F cells (ThermoFisher Scientific).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293-F</div><div>suggested: RRID:CVCL_6642)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">On day 2 after transfection, HEK-293T-hACE2 cells (BEI, NR-52511), which stably expresses human ACE2, were stained with 1 μM CellTrace Far Red dye (Invitrogen, Ex/Em: 630/661 nm) in PBS for 20 minutes at room temperature, then quenched with DMEM with 10% heat-inactivated FBS for 5 minutes, and resuspended in fresh media.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK-293T-hACE2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">expressing human ACE2 under an EF1a promoter was used to transduce HEK293T cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: NCBI_Iran Cat# C498, RRID:CVCL_0063)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Flow cytometry: On day 0, Expi-293 cells (ThermoFisher) were mock-transfected or transfected with pWT-SARS-2-spike (BEI NR-52514) or pD614G-SARS-2-spike (generated by site-directed mutagenesis).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Expi-293</div><div>suggested: RRID:CVCL_D615)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Murine immunization: Three BALB/c mice were immunized subcutaneously with 5μg pre-fusion stabilized MERS S2 and 20 μg of ODN1826 + 100 μl of 2X Sigma Adjuvant System</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BALB/c</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Images were collected with Zeiss LSM 710 confocal microscope (Carl Zeiss, Inc) and processed using ImageJ software (http://rsbweb.nih.gov/ij) (Fig. 2 and fig.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ImageJ</div><div>suggested: (ImageJ, RRID:SCR_003070)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The statistical significance of either HEK-ACE2 colocalization percentage or average cell size between different conditions was calculated with ANOVA using GraphPad Prism 7 (GraphPad Software).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Spectra were manually assessed, and figures were prepared using HD-eXplosion (40) and PyMOL (41).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>PyMOL</div><div>suggested: (PyMOL, RRID:SCR_000305)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were washed again, then scanned for AF647 (640 nm excitation, 670/30 bandpass emission) fluorescence on a BD Fortessa flow cytometer and analyzed with FlowJo (Fig. 6B).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      There are several limitations to this work as currently described. First, a structure showing the atomic details of 3A3 complexed with spike would provide additional insight into the mechanism of binding and neutralization. However, structures of antibodies bound to S2 are generally challenging to obtain with just one structure available of an antibody binding near the HR2 stem (28). It is possible that 3A3 binding distorts spike structure, disturbing otherwise ordered regions. Accordingly, additional efforts to better understanding the molecular underpinnings of 3A3/ spike interactions are underway. Second, while we have shown that 3A3 binds spike from all three highly pathogenic coronaviruses with similar affinities, we have only demonstrated its ability to neutralize SARS-2 spikes in vitro. Demonstration of broad neutralization in addition to broad recognition would increase the potential relevance of this epitope for future therapeutics. The 3A3 epitope is highly conserved, with pairwise comparisons showing between 56% and 100% identity to the SARS-2 epitope for MERS and SARS-1, respectively (fig. S14). Since 3A3 affinity for the least similar MERS spike is comparable to that for the SARS-2 spike and greater than for HKU1, it seems likely that binding and neutralization depend primarily on RBD position epitope accessibility. The most concerning emerging SARS-2 variants have one conservative substitution in this epitope in B.1.1.7, identified in the United Kingdom, and has...

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from scite Reference Check: We found one citation with an erratum. We recommend checking the erratum to confirm that it does not impact the accuracy of your citation.

      <table style="border-collapse: collapse;"><tr><th style="min-width:95px; border: 1px solid lightgray; padding:2px">DOI</th><th style="min-width:95px; border: 1px solid lightgray; padding:2px">Status</th><th style="min-width:95px; border: 1px solid lightgray; padding:2px">Title</th></tr><tr><td style="min-width:95px; border: 1px solid lightgray; padding:2px">10.1371/journal.ppat.1000863</td><td style="min-width:95px; border: 1px solid lightgray; padding:2px">Has correction</td><td style="min-width:95px; border: 1px solid lightgray; padding:2px">In Vitro Reconstitution of SARS-Coronavirus mRNA Cap Methyla…</td></tr></table>
      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.01.31.428851: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Transfection of virus encoding the DNA failed to generate replicative virus when electroporated into 293T cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: NCBI_Iran Cat# C498, RRID:CVCL_0063)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After removing growth medium Vero cells were infected with 200 μL of serially diluted virus containing medium at 37 °C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">DMEM containing 2% FBS was used for Vero cells and alphaMEM containing 10% FBS was used for HUH7 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HUH7</div><div>suggested: CLS Cat# 300156/p7178_HuH7, RRID:CVCL_0336)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.02.07.429299: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: All animal experiments were approved by the Institutional Animal Care and Use Committee of Wuhan Institute of Virology, Chinese Academy of Sciences (Ethics no. WIVA42202006).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">All animals were randomly divided into three groups: the control group (one animal, C1), prophylactic group (two animals, PA1 and PA2), and therapeutic group (two animals, AC1 and AC2).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Next, the libraries were labeled with streptavidin (SA)-phycoerythrin (PE) (eBioscience, 12-4317-8) and goat anti-mouse-Alexa Fluor 647 antibodies (Thermo Fisher Scientific, A-21235).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SA)-phycoerythrin ( PE</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-mouse-Alexa Fluor 647</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Measurement of antibody affinity by BLI: The affinity of mAbs for SARS-CoV-2 RBD/S1 and its mutants (SARS-CoV-2 RBD [ACRO, SPD-C52H3], SARS-CoV-2 S1 [ACRO, S1N-C52H4],</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SARS-CoV-2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>RBD/S1</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Vero E6 cells (ATCC, CRL-1586) were seeded in a 24-well plate (105 cells/well) and incubated at 37°C, in 5% CO2 for 16 h.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In brief, engineered CHO-K1 cells (100 μl/well) were seeded into 96-well plates at 5 × 105 cells/ml.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>CHO-K1</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">IC50 values were determined with Prism V8.0 software (GraphPad) using a four-parameter logistic curve fitting approach.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Prism</div><div>suggested: (PRISM, RRID:SCR_005375)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Finally, we collected the cell culture supernatants after 24 h of infection for viral RNA extraction with a QIAamp 96 Virus QIAcube HT Kit (Qiagen, 57731) and for viral RNA copy number detection in a CFX96 Touch Real-Time PCR Detection System (Bio-Rad Laboratories).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Bio-Rad Laboratories</div><div>suggested: (Bio-Rad Laboratories, RRID:SCR_008426)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data were processed using GraphPad Prism software (V8.0).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      Below is our point-by-point response:


      Reviewer #2 (Evidence, reproducibility and clarity (Required)):

      The manuscript of Lalanne and coworkers address the cellular responses to varied translation termination factor expression in Bacillus subtilis. The authors set-up a system to fine-tune the expression of release factor RF1, RF2 as well as PrmC that post-translationally modifies RF1/RF2 to maximize their catalytic hydrolysis activity. They then monitor the fitness costs associated with overexpression or depletion of the factor by following the changes in growth rate. The set-up is nicely illustrated in Figure 1. The results in Figure 2 show that overexpression of RF1 and RF2 has relatively modest effect on the growth rate compared to overexpression of PrmC that leads to dramatic growth rate reduction. By contrast, depletion of RF1 has a strong negative influence on fitness, whereas a similar level of depletion of RF2 had little influence on fitness. PrmC overexpression appears to be correlated with the induction of the sigmaB regulon, however, the authors do not manage to ascertain why this is. By contrast, RF2 depletion also results in the induction of the sigmaB regulon and the authors demonstrate convincingly that this is due to a termination defect within the rsbQ-rsbV operon that contains an overlapping start-stop AUGA

      A few points that the authors might consider discussing

      1. The natural abundance of each RF in bacteria in relation to the usage of different stop codons in different organisms.

      Response: We thank the reviewer for their suggestion. A correlation between RF abundance and stop codon usage across bacterial species has been previously reported (Korkmaz et al., 2014; Wei et al., 2016), which is corroborated by our quantification (see below). This correlation provides further evidence that the RF expression may be optimized to meet their demands in translation termination. We now include a new discussion in the main text (p. 9, lines 410-415): "Our data thus corroborate several previous lines of evidence suggesting that RF expression might be precisely tuned. First, it was found that the relative expression between RF1 and RF2 correlates with stop codon usage between different species (Korkmaz et al., 2014; Wei et al., 2016). For instance, B. subtilis has a higher abundance of RF1 and more frequent UAG usage compared to E. coli, suggesting that RF1’s expression setpoint meets translational demand (Methods).”

      Below we include additional analyses that may be of interests to the Reviewer.

      From our ribosome profiling quantification in E. coli, B. subtilis, C. crescentus, and V. natriegens (Lalanne et al., 2018), we can compare the relative usage of the three stop codons (frequency of stop codons weighted by expression) with abundances of RF1 and RF2:

      Despite the limited sample size, we find reasonable agreement with the expected correlation between codon usage and cognate RF abundance. In species with substantial differences between RF1 and RF2 abundances (E. coli and B. subtilis), the most heavily used non-UAA stop corresponds to the most highly expressed RF. This argues in favor of expression tuning of these important enzymes and is consistent with the growth optimization we directly observe.

      As a word of caution, although the low usage of UAG in E. coli and low expression of RF1 (reported long ago, e.g., (Adamski et al., 1994)) is well established, it should be noted that strain MG1655’s RF2 factor harbors a debilitating missense A246T mutation near its active site (Dinçbas-Renqvist et al., 2000), which potentially complicates interpretation of the expression of E. coli’s release factors [interestingly, we do not see any difference in RF1 and RF2 expression from ribosome profiling data in strain NCM3722, which contains the RF2 variant without the A246T mutation (JBL, unpublished data)].

      The role of the frameshifting mechanism in RF2 and how then RF1 levels are regulated.

      Response: We thank the reviewer to raising the interesting topic of release factor expression regulation. We have added a section in our discussion to comment on RF2 regulation (p. 9, lines 415-420).

      “Second, the gene encoding RF2 has a broadly conserved UGA-based frameshift event that autoregulates the expression based on its own activity (Baranov et al., 2002; Craigen and Caskey, 1986; Craigen et al., 1985). Interestingly, there are no reports of RF1 autoregulation to our knowledge, and we found that ectopic over- or under-expression does not affect its own promoter activity (Fig. S7). Therefore, a lack of autoregulation does not necessarily indicate that cells are less sensitive to small perturbations on its expression.”

      The statement above includes an additional analysis on RF1 regulation that was motivated by the Reviewer’s comment. In contrast to RF2, no definitive evidence exists on autoregulatory mechanisms for RF1. Following the Reviewer’s comment, we realized that our dataset allowed us to search for evidence of endogenous regulation in B. subtilis: our RF1 expression strain has a markerless deletion of prfA and prmC genes, leaving the surrounding regions, and notably the promoter, intact. As such, possible unbeknownst regulatory mechanisms at the promoter level could be identified in our RNA-seq data under steady-state perturbation of RF1 levels. Quantifying the expression of the 5’ untranslated region and operonic gene ywkF at the ablated prfAlocus (presented in Fig. S7, reproduced below), we find no significant changes in expression across over 30-fold range in RF1 expression, arguing against such transcriptional regulatory mechanisms. Although this does not rule out other regulatory mechanisms at the post-transcriptional level, no such mechanisms have been documented for RF1 to our knowledge.

      The authors observe queuing in front of the relevant stop codons upon RF depletion, however, do not discuss about readthrough events, which are usually competing with termination. Surprisingly, in this context the authors don't discuss the work from Mankin and coworkers showing sequestration of RFs from termination by peptides such as apideacin leads to translational readthrough.

      Response: We concur with the Reviewer about the importance of the recent work from Mankin et al. This paper was referenced in our original submission, but our literature management software improperly formatted its citation. The corrected reference to (Mangano et al., 2020) is now included in the revised manuscript.

      Translational readthrough is indeed clearly visible in our ribosome profiling data from acute CRISPRi knockdown of RF1/PrmC and RF2. Using an approach analogous to Mangano and Florin et al, we quantified readthrough as the ribosome footprint density downstream of the stop codon (+5 to +45 bp) to the density in the gene body for isolated genes (no codirectional genes within 55 bp). We find five-fold increase in the median readthrough for genes that are terminated by the RF under perturbation (shown in a new panel in the main text, Fig. 4b, reproduced below). This new analysis is included in the section regarding translational phenotypes identified from ribosome profiling under RF depletion, p. 7, lines 309-312.

      “The stop-codon-specific queuing is associated with translational readthrough downstream (Fig. 4b), consistent with a recent observation based on inhibition of peptide release by the antimicrobial apidaecin in E. coli (Mangano et al., 2020).”

      This additional analysis, in conjunction with (Mangano et al., 2020), also allows us to calibrate the depletion of RFs in our non steady-state CRISPRi perturbation. Given that apidaecin treatment (shown to lead to a nearly complete depletion of free RF in the cell) causes a >100-fold increase in readthrough, this suggests that our CRISPRi perturbation experiments only led to partial RF depletion at the moment of cell harvesting.

      The efficiency of translation termination is well-known to be dependent on the context of the stop codon. Do the authors also observe such a trend. Especially, UGAC for RF2, one would expect to observe high levels of readthrough upon RF2 depletion.

      Response: Further assessment of the sequence determinants that dictate susceptibility of certain genes and regulatory elements to RF perturbation is of great interest. We now include additional analyses for the effect of stop codon context on readthrough.

      In our RF2 CRISPRi knockdown data, stratifying the translational readthrough (data from Fig. 4b) by stop codon and its next nucleotide, we observe only a modest (≈2×, p“We also observed a trend of tetranucleotide-dependent (UGAN) readthrough for RF2 knockdowns (Methods, Appendix Fig. 2) consistent with previous characterizations (Poole et al., 1995).”

      As an additional point of interest, the importance of the 4th nucleotide in termination has not been studied outside of E. coli. Although indirect, one way to assess the influence of the 4th nucleotide is to determine the aggregated usage of each tetranucleotide stop signal by ribosome profiling. Interestingly, and as pointed out by the Reviewer, whereas E. coli (MG1655) displays a 16× increase in usage between the maximum UGAU (tetranucleotide usage 0.064) and minimum UGAC (tetranucleotide usage 0.004), no such difference is observed in B. subtilis (usage for UGAU and UGAC both at 0.015), suggesting that the immediate sequence context surrounding stop codons could have different consequences in different species.

      Reviewer #2 (Significance (Required)):

      Overall, the experiments are clearly performed and beautifully illustrated. Clearly, a lot of work has gone into this study but the end message that the cell regulates carefully RF concentrations is not surprising. Especially given that RF2 carefully regulates its own levels using an autoregulatory frameshifting mechanism. The major finding that the rsbQ-rsbV operon with the RF2 dependence leading to induction of the sigmaB regulon is in the end rather trivial since these regulators depend on RF2 for termination. Therefore, this manuscript is unlikely to have general interest to people in the translation field (such as myself) but rather those working in the field of synthetic biology.

      Response: We thank the Reviewer for their positive assessment of our presentation and experimental methods, and for their judgment that our work will be of interest to synthetic biologists.

      In our study, we used translation as a well-characterized system to interrogate the cellular response when enzyme concentrations are perturbed. Because the system is so well characterized, it allowed to ask whether the fitness effects are due to perturbations to the translation flux itself, or rather driven by spurious distal connections in the regulatory network. The end message we wish to convey is that enzyme expression is entrenched by spurious regulatory connections, suggesting that predictive bottom-up models of expression-fitness landscapes will require near-exhaustive characterization of parts.

      Although our focus is on the cellular response, there are several interesting findings related to translation. First, we show that even though RF1 and PrmC are not subject to the strict autoregulation as RF2 is, cell growth is similarly or even more sensitive to RF1 and PrmC abundance. Second, among the numerous regulators that depend on RF2 for termination, RbsV/RbsW is exceptionally sensitive to RF2 depletion (Fig. 4e). This result not only points to our incomplete understanding of translation regarding what makes this pair particularly susceptible, and further underscores the spurious nature of the cellular response to perturbations. We have expanded the discussions on the implication of these findings in the revised manuscript.


      Reviewer #3 (Evidence, reproducibility and clarity (Required)):

      In this paper, the authors use a combination of RNA sequencing, ribosome profiling and measurements of cellular composition and growth rate to gain insight into the multi-scale affects that perturbations to translation termination factors have on general physiological states and reproductive fitness using Bacillus subtilis as their model organism. Specifically, they find that perturbing the expression levels of peptide chain release factors in any direction has a negative effect on growth-rate. This negative effect was not due to a direct impact of the gene on the cell, but instead due to a chain of regulatory interactions that cause the activation of the general stress regulon. This leads to upregulation of a large chunk of the genome and an indirect impact on the expression of all other genes. Critically, the knock-on effects observed for the specific perturbations studied suggest that it may be difficult to predict expression-fitness landscapes of a cell, without carrying out a detailed mapping of all genes and the cell's physiological state.

      Overall, the core findings in the paper are well justified by the data presented and the experiments appear to have been rigorously carried out.

      Response: We thank the reviewer for their positive assessment.

      My only concern is that it is unclear if biological replicates of the ribosome profiling were performed. Also, biological replicates are mentioned for the RNA-seq data, but no data is shown. Even a simple graph demonstrating the expression levels across these would be useful to be assured of no issues in reproducibility given the complex processing of the data involved.

      Response: We now include additional analyses for biological replicates of RNA-seq and ribosome profiling experiments, which show the same high degree of reproducibility as we have demonstrated in previous studies (Johnson et al., 2020; Lalanne et al., 2018; Li et al., 2014).

      With respect to RNA-seq quantification, we compared our 6 wild-type datasets (biological replicates except for different inert inducer concentrations, using the same batch of conditioned MCC medium) against each other in all possible pairs. The data is now included as Appendix Fig. 1a (referred to in the main text, p. 4, line 138), and is reproduced below. Across pairs, the mRNA level quantification shows a median FC1090 (10th and 90th percentile in fold-change) between 0.86 to 1.16, and median R2 of log-transformed data at 0.99. These statistics showcasing reproducibility of our RNA-seq methodology are now included in our description of our RNA-seq approach in the Methods, p. S8, lines 313-320.

      Regarding ribosome profiling quantification, we now include comparisons between pairs of two replicates for wild type cells, and pairs of replicates wild-type with inert fluorescent protein expression, each pair of samples with their own batch of conditioned MCC medium. These samples were taken under different inducer concentrations, which are expected to affect the expression of two genes and not others. As indicated in Appendix Fig. 1b and reproduced below, the Pearson correlation of log-transformed footprint density is respectively of R2=0.98 and 0.99 (genes with >100 reads mapped), with a 10th to 90th percentile of fold-changes between 0.83 to 1.17, and 0.91 to 1.12. These results are described in the Methods, p. S9, lines 339-345.

      Related to this, I see no mention of data availability in the paper. For this study to be useful to others, providing the raw data (unprocessed) would be essential (ideally in a public repository).

      Response: We are sorry that the statement on data availability was buried in the original Methods section that was not a part of the merged PDF file. The raw sequencing data were submitted to Gene Expression Omnibus under the accession number GSE162169. The processed data, including fitness scores, mRNA levels, protein synthesis rates, were included as Supplementary Data Tables 1-9. We now moved the data availability statement to the main document at p. 12, lines 512-516.

      The presentation of the work is excellent, with very clear figures and text that helped guide the reader through the results. There were a few minor comments:

      1. Abstract: "in bacterium Bacillus subtilis" should read "in the bacterium Bacillus subtilis".

      Response: This typo is now corrected.

      Page 4: "found that under numerous ways" should read "found that under the numerous ways".

      Response: This typo is now corrected.

      The authors mention that changes in the expression level of RF1 impacted motility and biofilm genes, but not how this impacts fitness. Would they be able to experimentally identify origin of RF1 growth defects in the same way they did for PrmC? This is not essential for the main findings but would help strengthen the work.

      Response: The cause of the growth defect under RF1 knockdown is indeed interesting. We now present evidence ruling out the hypothesis that the growth defect is caused by the expression decrease for motility and biofilm genes.

      This hypothesis is driven by our result that ablation of SigB regulon rescues the fitness defect during PrmC overexpression (Fig. 3g) and by the observed downregulation of motility and lyt operons and upregulation of the eps operon during RF1 knockdown. To test this hypothesis, we used a strain without sigD (the motility sigma factor), which displays similar expression changes to what we observed in RF1 knockdown (Chai et al., 2009). Comparing the growth rates of wild-type to DsigD, we found only a slight difference (30% growth defect measured upon RF1 knockdown, it appears that transcriptional changes to the motility regulon can only partially explain of the RF1 growth defect. These results are discussed on p. 10, lines 459-463. Further assessment will constitute interesting future research avenues.

      It is difficult to know how generalisable the findings of this work are due to the very limited scope. It could be helpful for the authors in the discussion to consider and comment on how such approaches might be scaled-up to enable broader and more general studies of expression-fitness landscapes and where they will find most use.

      Response: Indeed, the spurious nature of the expression-fitness landscape makes it difficult to generalize the exact mechanisms that we described here to other proteins. However, what is generalizable is our conclusion that such spurious connections limit the feasibility of bottom-up models for predicting fitness landscapes unless one has near-exhaustive characterization of all parts.

      Our approach of mechanistic profiling of cell states under perturbations therefore provides a path forward that can be scaled up by recent developments in multiscale measurements. We now include a discussion for broader and more general studies on p. 11, lines 473-480.

      “Various strategies can now generate expression-fitness landscapes for a large number of genes in parallel, for example using suites of promoters (Keren et al., 2016), genome-scale library of inducible gene expression (Arita et al., 2021), or tunable CRISPR perturbations (Hawkins et al., 2020; Jost et al., 2020; Mathis et al., 2021). Together with the advent of single-cell transcriptomics in bacteria (Blattman et al., 2020; Imdahl et al., 2020; Kuchina et al., 2020), these methods open the possibility of dissecting the molecular underpinnings of expression-fitness landscapes genome-wide, and to comprehensively identify instances of regulatory entrenchment.”

      Reviewer #3 (Significance (Required)):

      This work has a number of contributions. Firstly, it demonstrates how to combine several complementary sequencing approaches to characterize in detail the transcriptional and translational state of a cell, as well as its overall growth rate to generate comprehensive expression-fitness maps. Secondly, it shows how the interwoven nature of cellular regulatory networks and the molecular interactions encoded within the genome can lead to cryptic responses in cellular behavior and fitness at a system-level that can only be understood by taking a detailed "bottom-up" approach. Finally, it suggests that some of these regulatory interactions may in fact "entrench" an organism's evolutionary path, by causing small genetic perturbations to propagate and potentially amplify their negative effect. While the results are compelling and well supported by experiments, the limited scope of the work makes it difficult to know whether this is in fact a rare or common occurrence. However, I do believe there is significance to these findings and that it will likely spur further studies to assess the generality of these findings.

      Overall, I believe the work will have a wide appeal covering areas such as Systems Biology, Gene Regulation, Evolution, Quantitative Biology, Sequencing, High-throughput Technologies.

      Response: We thank the reviewer for their assessment that our work will be of appeal to a broad audience.

      My field of expertise is in the quantitative measurement of core cellular processes (e.g. transcription and translation) using novel sequencing techniques and the application of this knowledge to biological design. As such, I believe I have sufficient expertise to review this paper in detail.

      Response references

      Adamski, F.M., McCaughan, K.K., Jørgensen, F., Kurland, C.G., and Tate, W.P. (1994). The concentration of polypeptide chain release factors 1 and 2 at different growth rates of Escherichia coli. J. Mol. Biol. 238, 302–308.

      Arita, Y., Kim, G., Li, Z., Friesen, H., Turco, G., Wang, R.Y., Climie, D., Usaj, M., Hotz, M., Stoops, E., et al. (2021). A genome-scale yeast library with inducible expression of individual genes. BioRxiv 2020.12.30.424776.

      Baranov, P. V, Gesteland, R.F., and Atkins, J.F. (2002). Release factor 2 frameshifting sites in different bacteria. 3, 373–377.

      Blattman, S.B., Jiang, W., Oikonomou, P., and Tavazoie, S. (2020). Prokaryotic single-cell RNA sequencing by in situ combinatorial indexing. Nat. Microbiol. 5, 1192–1201.

      Chai, Y., Normam, T., Kolter, R., and Losick, R. (2009). An epigenetic switch governing daughter cell separation in Bacillus subtilis. Genes Dev. 7824, 754–765.

      Craigen, W.J., and Caskey, C.T. (1986). Expression of peptide chain release factor 2 requires high-efficiency frameshift. Nature 322, 273–275.

      Craigen, W.J., Cook, R.G., Tate, W.P., and Caskey, C.T. (1985). Bacterial peptide chain release factors: Conserved primary structure and possible frameshift regulation of release factor 2. Proc. Natl. Acad. Sci. U. S. A. 82, 3616–3620.

      Dinçbas-Renqvist, V., Engström, Å., Mora, L., Heurgué-Hamard, V., Buckingham, R., and Ehrenberg, M. (2000). A post-translational modification in the GGQ motif of RF2 from Escherichia coli stimulates termination of translation. EMBO J. 19, 6900–6907.

      Hawkins, J.S., Silvis, M.R., Koo, B.M., Peters, J.M., Osadnik, H., Jost, M., Hearne, C.C., Weissman, J.S., Todor, H., and Gross, C.A. (2020). Mismatch-CRISPRi Reveals the Co-varying Expression-Fitness Relationships of Essential Genes in Escherichia coli and Bacillus subtilis. Cell Syst. 11, 523-535.e9.

      Imdahl, F., Vafadarnejad, E., Homberger, C., Saliba, A.E., and Vogel, J. (2020). Single-cell RNA-sequencing reports growth-condition-specific global transcriptomes of individual bacteria. Nat. Microbiol. 5, 1202–1206.

      Johnson, G.E., Lalanne, J.B., Peters, M.L., and Li, G.W. (2020). Functionally uncoupled transcription–translation in Bacillus subtilis. Nature 585, 124–128.

      Jost, M., Santos, D.A., Saunders, R.A., Horlbeck, M.A., Hawkins, J.S., Scaria, S.M., Norman, T.M., Hussmann, J.A., Liem, C.R., Gross, C.A., et al. (2020). Titrating gene expression using libraries of systematically attenuated CRISPR guide RNAs. Nat. Biotechnol. 38, 355–364.

      Keren, L., Hausser, J., Lotan-Pompan, M., Vainberg Slutskin, I., Alisar, H., Kaminski, S., Weinberger, A., Alon, U., Milo, R., and Segal, E. (2016). Massively Parallel Interrogation of the Effects of Gene Expression Levels on Fitness. Cell 166, 1282-1294.e18.

      Korkmaz, G., Holm, M., Wiens, T., and Sanyal, S. (2014). Comprehensive analysis of stop codon usage in bacteria and its correlation with release factor abundance. J. Biol. Chem. 289, 30334–30342.

      Kuchina, A., Brettner, L.M., Paleologu, L., Roco, C.M., Rosenberg, A.B., Carignano, A., Kibler, R., Hirano, M., William DePaolo, R., and Seelig, G. (2020). Microbial single-cell RNA sequencing by split-pool barcoding. Science (80-. ).

      Lalanne, J.B., Taggart, J.C., Guo, M.S., Herzel, L., Schieler, A., and Li, G.W. (2018). Evolutionary Convergence of Pathway-Specific Enzyme Expression Stoichiometry. Cell 749–761.

      Li, G.W., Burkhardt, D., Gross, C., and Weissman, J.S. (2014). Quantifying absolute protein synthesis rates reveals principles underlying allocation of cellular resources. Cell 157, 624–635.

      Mangano, K., Florin, T., Shao, X., Klepacki, D., Chelysheva, I., Ignatova, Z., Gao, Y., Mankin, A.S., and Vázquez-Laslop, N. (2020). Genome-wide effects of the antimicrobial peptide apidaecin on translation termination in bacteria. Elife 9, 1–24.

      Mathis, A.D., Otto, R.M., and Reynolds, K.A. (2021). A simplified strategy for titrating gene expression reveals new relationships between genotype, environment, and bacterial growth. Nucleic Acids Res. 49, e6.

      Poole, E.S., Brown, C.M., and Tate, W.P. (1995). The identity of the base following the stop codon determines the efficiency of in vivo translational termination in Escherichia coli. EMBO J. 14, 151–158.

      Wei, Y., Wang, J., and Xia, X. (2016). Coevolution between Stop Codon Usage and Release Factors in Bacterial Species. Mol. Biol. Evol. 33, 2357–2367.

    1. Wibmer, C. K., Ayres, F., Hermanus, T., Madzivhandila, M., Kgagudi, P., Lambson, B. E., Vermeulen, M., Berg, K. van den, Rossouw, T., Boswell, M., Ueckermann, V., Meiring, S., Gottberg, A. von, Cohen, C., Morris, L., Bhiman, J. N., & Moore, P. L. (2021). SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. BioRxiv, 2021.01.18.427166. https://doi.org/10.1101/2021.01.18.427166

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      Reviewer #1 (Evidence, reproducibility and clarity (Required)):

      **Summary:**

      This study of Nils Halberg and colleagues aims to characterize tumor-associated immune cell

      infiltrates in a mouse model of diet-induced obesity. Authors compared different syngeneic

      tumor cell lines for mammary adenocarcinoma and pancreatic ductal adenocarcinoma. Tumor

      infiltrating leukocytes were analyzed by a 36-parametric mass cytometry protocol. The authors

      put a lot of efforts in the generation of high-quality data by applying state-of-the-art methods for

      sample barcoding and batch analyses, removal of batch-specific variations and in the

      subsequent pipeline of data analysis. The clinical relevance of the topic addressed is well

      documented in several studies, showing a clear association between obesity and the

      development of several tumors, including those tumors investigated in this study.

      Main findings of this study can be summarized that in the model system used tumor-dependent

      differences in the qualitative and quantitative composition of immune cell infiltrates were

      observed. Unfortunately, the mouse model system used obviously did not reveal convincing

      data whether obesity may modulate the process of tumor infiltration.

      The manuscript is well written, quantity of figures is appropriately and of excellent quality and

      prior studies were referenced appropriately.

      In conclusion, authors made tremendous methodological and technical efforts to generate

      robust and high-quality mass cytometry data, but the overall outcome of the study remains

      limited in respect to shedding some new light how obesity is possibly involved in the qualitative

      and quantitative modulation of tumor-related immune cell infiltration.

      Authors’ Response: We thank the reviewer for their constructive and positive feedback as well

      as appreciation of our rigorous approach. We would however argue that our data significantly

      contributes to the understanding of how obesity affects tumor immunity. We believe that our

      systemic approach across multiple tumor systems highlights that i) it matters what model you

      choose, as each model have a separate response to the obesity challenge ii) for one model, the

      E0771 model, our data reflect obesity-dependent alterations to the CD8+ T-cells population.

      This was corroborated by a parallel publication by Rigel et al., 2020 as highlighted by the 2nd

      reviewer. That being said, we too, were surprised that the pro-inflammatory obese environment

      did not have more pronounced effects on the tumor immune infiltrates across the five models.

      **Major comments:**

      Due to the limited data really showing an association between obesity and immune cell

      infiltration of tumors investigated I would suggest that authors should change emphasis of their

      results more closely related to the findings of tumor-dependent immune cell infiltrations than

      obesity-related associations. So, the title of the study should be appropriately changed since

      "High dimensional immunotyping of the obese tumor micro-environment" rather implies

      analyses of spatial relationships of immune, tumor and fat cells by immunohistological analyses,

      which would indeed help to strengthen the outcome of this mass cytometry study.

      Authors’ Response: We appreciate the constructive suggestion. We did not intend the title to

      infer immunohistochemical analysis and apologize that was the case. We have therefore

      changed the title to “High dimensional immunotyping of tumors grown in obese and non-obese

      mice” in the revised version (line 1).

      Although all the efforts made in mass cytometry data generation are quite commendable in this

      study, basic statistical issues are not clearly addressed regarding the number of biological

      replicates. How many mice were treated per tumor cell line? According to figure 1B nine chow

      and eight HFD animals were used: does this mean that only one or two mice were analyzed per

      cell line, respectively? Please explain how many animals belong to each of the seven mouse

      cohorts.

      Authors’ Response: We agree that this was not clearly defined in the manuscript. We have

      updated Figure 1A and the corresponding legend to make it clearer. The mouse numbers,

      referred to as tumors, are also located in Table 3. In total 69 mice were used, distributed as:

      E0771_1 consists of 4 chow fed mice and 4 HFD mice (N=4/4, where N=chow/HFD, for a total

      of 8 mice)

      E0771_2 is N=5/4. Wnt1 is N=6/6. TeLi is N=5/5. C11_1 is N=5/4. C11_2 is N=5/5. UN-KC is N=5/6.

      Figure 1B shows representative mouse weights only. The female mice are from breast cancer

      cohort E0771_1 and the male mice are from pancreatic cancer cohort C11_1. We chose to only

      show representative data since diet-induced obesity is well established in the C57Bl/6 strain.

      Obviously, cell lines E07771 and C11 were analyzed as duplicates only. Regarding E0771,

      tumor growth was 31 and 23 days, respectively. So, large inter-individual differences in tumor

      growth were obvious and how this is reflected at the level of tumor infiltration? Therefore, please

      explain which criteria were used to decide when the tumors had to be removed. Furthermore,

      please indicate weight, viability and absolute cell number of each tumor sample in a

      supplementary table to get an impression about variability in tumor growth.

      Authors’ Response: The reviewer brings up an important point. The E0771 and C11 cohorts are

      included in the paper as combined cohorts. The individual C11 cohorts had too few tumors

      remaining after removal of samples with too low viability (as discussed below) to analyze

      separately. The E0771 cohorts are presented together as a representation of that tumor model.

      Data analysis for the E0771 cohorts separately shows comparable population abundance

      differences and obesity-dependent changes between chow and HFD tumors. The metacluster

      fold change for non-obese and obese tumors between E0771_1 and E0771_2 correlated with a

      R2 = 0.8586. Presenting the data combined provides a more concise view of the model.

      Removal of E0771 and C11 tumors in each individual cohort were time matched. E0771 tumors

      were continuously measured by caliper and removed before they reached 1 cm3 according to the

      local ethical guidelines. The E0771_2 cohort tumors had to be removed sooner as one tumor

      reached 1 cm3 earlier. We have reported the tumor mass in Figure 1C as that is a more accurate

      measurement of final tumor burden. Pancreatic tumors were removed based on optical imaging

      of luciferase expressing cancer cells and careful monitoring of mouse distress based on the

      grimace scale. The material and methods section has been updated to reflect this (line 556-558).

      Only pancreatic tumors had viability poor enough that they had to be excluded from analysis. A

      cutoff of CD45+ 5000 cells was set and applied to cells remaining following the gating strategy

      shown in Figure 1D. Therefore, CyTOF data for tumors with fewer than 5000 CD45+/Cisplatin

      negative cells were excluded from analysis as indicated with an X in Figure1C. As requested, we

      have included tumor weights and available viability measurements in new Table 5.

      **Minor comments:**

      The generation of orthotopic pancreatic cancer mouse models is technically challenging, and

      needs more complex imaging methods to monitor the growth of the implanted tumor cells.

      Furthermore, orthotopic implantation of tumor cells into the pancreas by surgery can also inflict

      significant physical trauma to the recipient animals. How authors have monitored tumor cell

      implantation?

      Authors’ Response: We agree that tracking tumor growth in the orthotopic pancreas cancer

      model is challenging. As mentioned above, these cells were engineered to express luciferase

      and optical imaging was used to monitor growth of the implanted cells. We did not report these

      numbers as we were unable to convincingly correct for possible light absorption by the

      enhanced adipose tissue mass in the high fat group. As such, these scans were used to

      estimate the end point.

      The number of CD45-positive cells per tumor sample is not given in the manuscript, but this

      information would be important to know, because it can be expected that most of the samples

      showed less than 20.000 cells. This relatively low number of total leukocytes would not allow a

      statistically significant profiling of rare cell subsets, such as DC's or MDSC's. This limitation

      should at least clearly addressed in the discussion section.

      Authors’ Response: The reviewer raises a great point. Since the cells were live cryopreserved

      and thawed before measuring CD45, we did not determine the total immune cell infiltrate. After

      thawing, the CD45+ cells accounted for roughly 1-12% of the total events collected across all

      batches leading to a total number of CD45+ cells ranging between 54,317 and 1,102,767 per

      batch. Numbers for each batch can be found in Table 3. After gating and exclusion of tumors

      with less than 5000 CD45+ cells, the remaining tumor data were equally sampled and 5206

      CD45+ cells were included in further analysis from each tumor. Overall, we were focused on

      broad phenotyping of the immune infiltrate and not on rare subsets. Some subsets had low

      abundance in some tumors and high abundance in others. Because the analysis was performed

      altogether, the overall phenotyping and clustering did not find any truly rare subsets. DCs and

      MDSC were not rare when assessed across the datasets. While we cannot characterize the

      subsets that are small in a specific tumor type, we can be confident in the characterization

      provided by the streamlined analysis of the data as a whole.

      According to table 2 authors have used 36 immune cell-related antigens including casp3, which

      was only used to exclude apoptotic cells from downstream analyses. But as written in the

      results section only 26 phenotyping markers were used to generate the viSNE map shown in

      Figure 3. In Figure 3C-F 30 markers were shown. Please explain this obvious inconsistency of

      markers used.

      Authors’ Response: Thank you for this question. Our goal here was to generate a viSNE map

      that best separated out immune cells by phenotype. Lineage markers and well-established

      phenotyping markers were therefore included to create the well separated viSNE map. It follows

      that some markers were not included: i) Markers that were used to gate the population of

      interest (CD45 and c-Cas3) were excluded from the viSNE input parameters.; ii) Markers that

      had relatively low signal were also excluded such as MHC-1 and CD117. Including negative

      markers is computationally costly, provides limited biological insight, and can produce a worse

      viSNE map by reducing cell separation due to shared lack of signal (Diggins et al., 2015); iii)

      Activation/ exhaustion markers were excluded from the viSNE analysis because the focus of the

      phenotyping was on major cell subsets and not on activation states. The hope was to observe

      differences in exhaustion marker expression between chow and HFD; and iv) CD5 was

      excluded because having two bright T cell markers skewed the map towards a more T cell

      dominant view. Markers with meaningful expression were reintroduced in the MEM analysis

      after the viSNE map was made. Exclusion of markers from viSNE analysis is a generally

      accepted practice and has been applied previously (Wogsland et al., 2017, Cheng et al., 2016,

      Huse et al., 2019, Leelatian et al., 2020, Doxie et al., 2018, Okamato et al., 2021, Henderson et

      al., 2020). The reasoning behind using the 26 phenotyping markers have been included in the

      revised manuscript (line 754 – 757)

      How viability of tumor samples was determined?

      Authors’ Response: Viability was measured at three points using membrane exclusion assays.

      Viability was first measured upon tumor dissociation using trypan blue and a Countess cell

      counter on the single cell suspension before freezing. Values were used to guide cell aliquoting

      for cryopreservation. Viability was again measured with trypan blue upon thaw in order to

      barcode and stain 3 million live cells per sample. Before fixation, cells were again stained for

      viability, this time with cisplatin, to exclude dead cells after data collection with gating. This has

      been added to the methods section (line 559-562)

      Cells were additionally stained for cleaved-Cas3 as an indicator of cells undergoing apoptosis.

      Only pancreatic tumors had viability poor enough that they had to be excluded form analysis.

      Tumors with fewer than 5000 CD45+ Cisplatin negative cells were excluded from analysis as

      indicated with an open X in Figure1C. The tumor count in parentheses in Table 3 indicates the

      tumors that were not excluded.

      Please indicate cell loss caused by cryopreservation of dispersed tumor tissue samples.

      Authors state that mainly neutrophilic granulocytes will be lost during cryopreservation, and that

      this would help to the "definitive identification and characterization of G-MDSC". But there are

      several reports showing that MDSC-subsets also behave very sensitive during cryopreservation

      and that it is recommended to analyze fresh samples if MDSC's are of particular interest (DOI:

      10.1177/1753425912463618; DOI: 10.1177/1753425912463618). This possible limitation

      should be discussed in the manuscript and not only highlighted as advantage on the way to

      identify MDSC-subsets.

      Authors’ Response: We thank the reviewer for this insightful comment. We agree that we likely

      lost some MDSC during the cryopreservation process as shown in the reference above. But

      since no neutrophils survive standard cryopreservation (Graham-Pole et al., 1977), the Ly6G

      positive cells in our analysis are G-MDSC and not neutrophils. We assume that any cell death

      related to cryopreservation would be consistent across samples, so although cell totals may be

      lower than in the tumor, abundance differences and phenotype can still be evaluated. We have

      included a discussion of this in the revised manuscript

      (line 408 – 410).

      In the Figure 1D X-axis named by "193Ir-NA" should be replaced by "193Ir-DNA".

      Authors’ Response: NA is shorthand for nucleic acid since the iridium intercalates into DNA

      and RNA. The figure legend has been updated to make this clear.

      Furthermore, please explain "(T)" in the figure legend. Percentages in the last two dot plots

      related to "all previous gates" are confusing: 20,44% of all DNA-containing single cells were

      finally intact, living CD45+ cells, i.e. almost 80% of cells were excluded because they were dead

      or apoptotic and this corresponds to 57,06% of intact, living CD45-positive cells related to all

      CD45-positive cells? How these percentages are related to the "Percent of CD45/total raw

      events" in the last column of Table 3?

      Authors’ Response: These are great points. Thank you for bringing them to our attention. This

      confusing notation has been removed since Figure 1D is a representative gating strategy. “All

      previous gates” means that the previous gates were all applied to the population showing in that

      plot. CyTOF data requires thorough gating to remove the events that are not representative of

      actual cells so yes, many events were removed before analysis. Even more cells were excluded

      here since our focus was on the CD45+ cells and not the cancer cells. The CD45+ cells

      indicated in Table 3 and visualized in Figure 1E can be calculated by summing the total gated

      CD45+ cells per Figure 1D for each batch and dividing that by the total number of events

      collected per batch. The summed CD45+ values and the total collected events are also in Table

      3.

      Authors claimed that "155Gd_IRF4" was changed to "155Gd", but it is not clear why to mention

      that IRF4 has been NOT used throughout the study? Please provide only those technical

      details, which are necessary to understand what has been done.

      Authors’ Response: We apologize for any confusion. This change was mentioned because

      most cohorts included the IRF4 channel while a two (C11_2 and Wnt_1) did not. The FCS files

      were changed to allow for simultaneous analysis. The IRF4 antibody did not work so there

      shouldn’t be any bleed into other channels in the samples that were stained with IRF4.

      According to general practice, we believe that it is important to make note of any manipulation to

      the FCS files.

      Re Figure 6: please explain the abbreviation "TNBC".

      Authors’ Response: We apologize for not explaining this abbreviation. TNBC is short for triple

      negative breast cancer. This has been corrected in the resubmitted version.

      Experiments done with TKO mice are not described in the Materials and Methods section. In

      particular, it would be important to know the number of replicates and the number of tumors

      grown in this model. It should be also discussed that the growth kinetics of tumors in chow and

      HFD TKO mice seem to be much faster as compared to wild type mice. Principally, the TKO

      model used here is only of limited value to clarify especially the role of CD8 cells since all other

      T- and B- cell subsets including NK cells are also absent in this knockout model and indirect

      effects caused by these cells cannot be excluded.

      Authors’ Response: We deeply apologize that the TKO experiments were not included in the

      Triple knockout (Rag2-/-::CD47-/-::Il2rg-/-; TKO) mice were purchased from Jackson Laboratories (Stock No: 025730).

      We agree with the reviewer it is an important point that the E0771 tumors overall grew faster in the TKO model. Ringel et al. 2020 saw similar results when depleting CD8 T cells in their MC38 model. Comparably, the most striking difference observed was that the tumor growth between obese and non-obese mice disappeared in the TKO mice.

      We have modified the results section to include these points (line 309-310). Reviewer #1 (Significance (Required)):

      material and methods section.

      experiment was performed with N=5/5. The description of the TKO model has been added to

      Orthotopic implantation and

      monitoring of E0771 and C11 cells were performed as with the wild type C57BL/6 mice. Each

      the methods section (line 520- 533) and number of mice used has been added to the figure

      legend.

      did not observe any major growth changes (overall growth rate and growth differences between

      obese and non-obese mice) in the TKO mice compared to the wild type mice.

      In the C11 model, interestingly, we

      We agree that the combined lack of B- and NK- cells in combination to the lack of T-cells

      exclude a direct conclusion on the effect of obesity-dependent alteration in T-cell phenotypes.

      Altogether, this study is a paragon that a single technology-based study alone, even when well-

      designed, is not sufficient to explore complex tumor microenvironment-immune cell interactions

      and that additional information on spatial relationships of cells and possibly single cell-based

      RNAseq techniques are necessary to shed new light on this ambitious topic. But there is no

      doubt that the potential of mass cytometry has been not fully exploited in this study and that a

      more focused view on particular cell types identified so far, such as macrophages or CD8 cells,

      by using as many immunophenotypic and functionally-related parameters as necessary would

      allow a more in depth-phenotyping of particular immune cell compartments.

      The significance of this subject would have been tremendously increased if human samples will

      be analyzed in a future confirmative study.

      Authors’ Response: Again, these are important insights. To what extend we have taken full

      advantage of the suspension mass cytometry technology is of course debatable. When we set

      out to perform these studies, we were compelled to take a broad approach rather than focusing

      on a single cell type for the following reasons: i) we had noticed extreme variability in immune

      targeted analysis through FACS of murine cancer models. Since we set out to demonstrate

      systemic effects of the obese environment rather than model-specific effects, the broad antibody

      panel made the most sense and ii) tumor immune infiltrates are known to be composed of

      multiple cell types and the effect of the obese state would likely affect multiple of these. To not

      bias ourselves this prompted us to design a rather broad immune panel. With the knowledge

      derived from this study and others (For example Rigel et al, Cell 2020 and Chung et all, Cell

      2020), new and more focused panels could be developed and implemented for future studies.

      We agree that the inclusion of human data would be of great value. We were, however, unable

      to obtain suitable human material that could be used for this suspension mass cytometry

      analysis. This was largely due to large inconsistencies in reported patient BMI and inadequate

      tumor freezing conditions.

      Even when I'm not a specialist in tumor biology, based on my expertise in the fields of chronic

      inflammation and cytometry, I'm convinced that the outlined way of generating

      immunophentypic data by single cell-based mass cytometry is of major interest not only for

      tumor biologists, but will be for sure recognized by a broad scientific community interested in the

      generation of single cell-based immunophenotypic data.

      Authors’ Response: Thank you for your helpful and supportive feedback. It is indeed our hope

      and motivation that the immunophenotyping platform presented herein will be broadly applicable

      to other cancer immunologists and fields.

      Reviewer #2

      (Evidence, reproducibility and clarity (Required)):

      Wogsland et al. apply herein mass cytometry (CyTOF) to investigate how obesity affects tumor

      immune infiltrates. They use several models of murine breast and pancreatic cancers and

      analyse their immune landscape thanks to an extended panel of 36 markers. They notably

      describe a decrease in CD8 T cells in one breast cancer model fed with high fat diet inducing

      obesity which favors tumor development.

      Overall, the report is clearly written and follows a very logical plan. Figures are also clear and

      nicely support the text. The mass cytometry approach appears quite original and could be

      relevant for many readers.

      Authors’ Response: We thank the referee for their constructive and positive comments on our work.

      The referee raises the general criticism that our study is descriptive.

      Nevertheless, some concerns have to be made and would need to be acknowledged by

      authors:

      -First of all, the paper appears very descriptive. Except at the end of the last figures, authors

      only establish of catalog of immune cells in different tumors. Even if the trueness of such

      observations is undisputable, their relevance to improve our understanding of tumor biology is

      clearly questionable.

      Authors’ Response:

      While we agree that the majority of the manuscript is focused on establishing a robust immune

      atlas in multiple tumor models grown in obese and non-obese mice, we believe that such work

      has important merit: i) our immune cell atlas of 5 transplant models will be a valuable resource

      for other cancer researchers interested in the immune-oncology field (as also highlighted by the

      first referee); ii) our findings clearly underscore the critical need to apply multiple cell lines in

      experimental setups when studying the interaction between tumors and immune cells –

      particularly in the obese setting; iii) we have implemented an analysis pipeline that is broadly

      applicable for high dimensional mass cytometry data that will be useful for future high-

      dimensional immunotyping efforts, iv) through our unbiased analysis pipeline we did identify

      obesity-dependent alterations to the CD8 cell population in the E0771 model. This finding was

      corroborated by the studies by Ringel et al., 2020. Collectively, we strongly believe that our

      studies will contribute to the advancement of our understanding of tumor biology.

      -Moreover, the major finding claimed in this study (CD8 T cells decrease in tumors from HFD

      mice) has been very recently published paper also providing mechanistic insights (Ringel et al.,

      Cell 2020). Authors could legitimately be disappointed but the interest of their study is sadly

      severely impacted by this prior publication. This key paper should be at least discussed and

      included in references.

      Authors’ Response: The paper by Ringel et al., was published after we originally submitted our

      manuscript for review and was therefore not referenced or discussed (Ringel et al., 2020). In the

      resubmitted version of the manuscript, we have included a thorough discussion of the paper’s

      findings in terms of consistencies and inconsistencies with our conclusions (line 545-463).

      -Finally, even if the initial strategy of integration of breast and pancreatic cancers was

      indubitably a good one, results reported in figures 5 & 6 clearly show a quite specific

      observation in the E0771 model. So in this context, integrating all these datasets do not improve

      the understanding of this phenotype

      Authors’ Response: We thank the referee for bringing up this point. Regardless of the outcome, we would strongly argue that the integrated approach to be advantageous to individual analysis. The integrated approach did not hinder new discoveries in any of the datasets – if anything, the integrated analysis pipeline developed herein would facilitate new discoveries that would be missed by repeating individual analysis. By integrating the datasets, we enabled the robust identification of more cell subsets. In particular cell types that displayed low abundance in some models. Those cells would have likely been hidden or even missed in a larger subset had the models been analyzed separately. As such, we maintain that the integrated approach is the correct and most biological meaningful to follow when given the possibility.

      Besides these quite general comments, few more specific points:

      -In Fig 2, the F4/80 signal appears very weak in all datasets except one (TeLi) with an almost

      flat curve for all the other ones. It asks the question of the reproducibility of the staining that

      could be only partially corrected with batch correction algorithms.

      Authors’ Response: The F4/80 peak in the TeLi cohort is indicative of a large F4/80

      population rather than a sign of signal intensity differences. TeLi tumors had much higher

      abundance of F4/80+ cells than did the other tumor types as can be seen in Figure 4B. For

      each mass cytometry run, we included a control sample to ensure equal staining patterns

      between the antibodies in each run.

      -Obesity is clearly known to be sex/hormone dependent as confirmed by authors themselves in

      their Fig 1B so again the global integration (both sex and 2 organs) strategy is disputable here.

      It is hard to know if there is no effect in the pancreas because of tissue or sex specificities.

      Authors’ Response: Thank you for the feedback. We specifically tried to show the different

      tumors side by side without making too many comparisons across tumor types because of the

      sex and tissue differences (as was noted in the results section of the manuscript, line 267). Both

      breast and pancreatic tumor models are relevant for studying the obesity cancer connection

      which is why we have worked to develop these models with different cancer types. Even with

      the sex and tissue differences, male and female mice became obese on a high fat diet, and

      tumors from both tissues grew larger on a high fat diet

      . It is our hope that this work will pave the

      way for future studies to interrogate these differences.

      -On Fig 1C, red dots are closed or open but explanation of this is lacking.

      Authors’ Response: Thank you for pointing this out. The figure legend has been updated. The

      X indicates a tumor that had too few live CD45+ cells to be included in the data CyTOF

      analysis. We apologize this was not clear.

      -Authors use 36 markers in their CyTOF panel but use only 26 for the dimension reduction

      without clearly explaining this choice. Should be amended. For example, why excluding CD5?

      Authors’ Response: Thank you for bringing this up. We have addressed these concerns in

      response to Reviewer #1 above.

      Reviewer #2 (Significance (Required)):

      Severly impaired by Ringel et al., Cell 2020

      Authors’ Response:

      It is clear that the study by Ringel et al., demonstrate new and important mechanistic insights

      into the connection between obesity, T-cell biology and tumor behavior. Our studies share many

      of the same conclusions on tumor immune cell infiltrate in obesity – particularly the T-cell finding

      in our E0771 model. However, we stipulate that our experimental approach and scientific

      questions differ. Our approach was to generate high-dimensional immune phenotyping atlas

      across multiple models to identify overarching obesity-dependent effects. The manuscript by

      Ringel et al., has a more mechanistic focus. The field would benefit from the additive insights

      from the two papers combined.

      Rebuttal References:

      CHENG, Y., WONG, M. T., VAN DER MAATEN, L. & NEWELL, E. W. 2016. Categorical Analysis of Human T Cell Heterogeneity with One-Dimensional Soli-Expression by Nonlinear Stochastic Embedding. The Journal of Immunology, 196, 924-932.

      DIGGINS, K. E., FERRELL, P. B., JR. & IRISH, J. M. 2015. Methods for discovery and characterization of cell subsets in high dimensional mass cytometry data. Methods, 82, 55-63.

      DOXIE, D. B., GREENPLATE, A. R., GANDELMAN, J. S., DIGGINS, K. E., ROE, C. E., DAHLMAN, K. B., SOSMAN, J. A., KELLEY, M. C. & IRISH, J. M. 2018. BRAF and MEK inhibitor therapy eliminates Nestin-expressing melanoma cells in human tumors. Pigment Cell & Melanoma Research, 31, 708-719.

      GRAHAM-POLE, J., DAVIE, M. & WILLOUGHBY, M. L. 1977. Cryopreservation of human granulocytes in liquid nitrogen. Journal of Clinical Pathology, 30, 758.

      HENDERSON, L. A., HOYT, K. J., LEE, P. Y., RAO, D. A., JONSSON, A. H., NGUYEN, J. P., RUTHERFORD, K., JULÉ, A. M., CHARBONNIER, L.-M., CASE, S., CHANG, M. H., COHEN, E. M., DEDEOGLU, F., FUHLBRIGGE, R. C., HALYABAR, O., HAZEN, M. M., JANSSEN, E., KIM, S., LO, J., LO, M. S., MEIDAN, E., SON, M. B. F., SUNDEL, R. P., STOLL, M. L., NUSBAUM, C., LEDERER, J. A., CHATILA, T. A. & NIGROVIC, P. A. 2020. Th17 reprogramming of T cells in systemic juvenile idiopathic arthritis. JCI Insight, 5.

      HUSE, K., WOGSLAND, C. E., POLIKOWSKY, H. G., DIGGINS, K. E., SMELAND, E. B., MYKLEBUST, J. H. & IRISH, J. M. 2019. Human Germinal Center B Cells Differ from Naïve and Memory B Cells in CD40 Expression and CD40L-Induced Signaling Response. Cytometry Part A, 95, 442-449.

      LEELATIAN, N., SINNAEVE, J., MISTRY, A. M., BARONE, S. M., BROCKMAN, A. A., DIGGINS, K. E., GREENPLATE, A. R., WEAVER, K. D., THOMPSON, R. C., CHAMBLESS, L. B., MOBLEY, B. C., IHRIE, R. A. & IRISH, J. M. 2020. Unsupervised machine learning reveals risk stratifying glioblastoma tumor cells. eLife, 9.

      OKAMATO, Y., GHOSH, T., OKAMOTO, T., SCHUYLER, R. P., SEIFERT, J., CHARRY, L. L., VISSER, A., FESER, M., FLEISCHER, C., PEDRICK, C., AUGUST, J., MOSS, L., BEMIS, E. A., NORRIS, J. M., KUHN, K. A., DEMORUELLE, M. K., DEANE, K. D., GHOSH, D., HOLERS, V. M. & HSIEH, E. W. Y. 2021. Subjects at-risk for future development of rheumatoid arthritis demonstrate a PAD4-and TLR-dependent enhanced histone H3 citrullination and proinflammatory cytokine production in CD14hi monocytes. Journal of Autoimmunity, 117, 102581.

      RINGEL, A. E., DRIJVERS, J. M., BAKER, G. J., CATOZZI, A., GARCÍA-CAÑAVERAS, J. C., GASSAWAY, B. M., MILLER, B. C., JUNEJA, V. R., NGUYEN, T. H., JOSHI, S., YAO, C.-H., YOON, H., SAGE, P. T., LAFLEUR, M. W., TROMBLEY, J. D., JACOBSON, C. A., MALIGA, Z., GYGI, S. P., SORGER, P. K., RABINOWITZ, J. D., SHARPE, A. H. & HAIGIS, M. C. 2020. Obesity Shapes Metabolism in the Tumor Microenvironment to Suppress Anti-Tumor Immunity. Cell, 183, 1848-1866.e26.

      WOGSLAND, C. E., GREENPLATE, A. R., KOLSTAD, A., MYKLEBUST, J. H., IRISH, J. M. & HUSE, K. 2017. Mass Cytometry of Follicular Lymphoma Tumors Reveals Intrinsic Heterogeneity in Proteins Including HLA-DR and a Deficit in Nonmalignant Plasmablast and Germinal Center B-Cell Populations. Cytometry B Clin Cytom, 92, 79-87.

    1. SciScore for 10.1101/2021.02.09.430547: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: Mouse work was approved by the QIMR Berghofer Medical Research Institute animal ethics committee (P3600, A2003-607).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Female mice were 8 weeks to 1 year old (age matched between groups) at the start of the experiment.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">Contamination: Cells were routinely checked for mycoplasma (MycoAlert Mycoplasma Detection Kit MycoAlert, Lonza) and FCS was assayed for endotoxin contamination before purchase (Johnson et al., 2005).</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">USA), HEK293T, AE17, and NIH-3T3 cells were cultured in medium comprising RPMI1640 (Gibco) supplemented with 10% fetal calf serum (FCS), penicillin (100 □IU/ml)/streptomycin (100□μg/ml) (Gibo/Life Technologies) and L-glutamine (2 mM) (Life Technologies).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>NIH-3T3</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The virus was determined to be mycoplasma free using co-culture with a non-permissive cell line (i.e. HeLa) and Hoechst staining as described (La Linn et al., 1995).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HeLa</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">CCID50 assays: Vero E6 cells were plated into 96 well flat bottom plates at 2×104 cells per well in 100 μl of medium.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Lentivirus production, titration and cell line transduction: ACE2 lentivirus was produced by co-transfection of HEK293T cells with the pCDH-ACE2 plasmid, VSV-G and Gag-Pol using Lipofectamine 2000 Reagent (Thermo Fisher Scientific) or Xfect Transfection Reagent (Takara Bio) as per manufacturer instructions.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Neutralization assay: Mouse serum was heat inactivated at 56°C for 30 min and incubated with 100 CCID50 SARS-CoV-2 for 2 hr at 37°C before adding 105 Vero cells/well in a 96 well plate to 200 μl.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell lines and SARS-CoV-2 culture: Vero E6 (C1008, ECACC, Wiltshire, England; Sigma Aldridge, St. Louis, MO,</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SARS-CoV-2 culture: Vero E6</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Mice intranasal lentivirus transduction and SARS-CoV-2 infection: C57BL/6J, IFNAR-/- (Swann et al., 2007) (originally provided by P. Hertzog, Monash University, Melbourne, VIC, Australia) and IL-28RA-/- (Ank et al., 2008; Galani et al., 2017) mice were bred in-house at QIMRB.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>C57BL/6J</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>IL-28RA-/-</div><div>suggested: RRID:IMSR_TIGM:IST11948G1)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">K18-hACE2 mice (McCray et al., 2007) were purchased from The Jackson Laboratory and bred in-house at QIMRB with C57BL/6J mice.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>K18-hACE2</div><div>suggested: RRID:IMSR_GPT:T037657)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell lines and SARS-CoV-2 culture: Vero E6 (C1008, ECACC, Wiltshire, England; Sigma Aldridge, St. Louis, MO,</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>England; Sigma Aldridge</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The quality of raw sequencing reads was assessed using FastQC (Simons, 2010) (v0.11.8) and trimmed using Cutadapt (Martin, 2011) (v2.3) to remove adapter sequences and low-quality bases.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FastQC</div><div>suggested: (FastQC, RRID:SCR_014583)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Trimmed reads were aligned using STAR (Dobin et al., 2013) (v2.7.1a) to a combined reference that included the mouse GRCm38 primary assembly and the GENCODE M23 gene model (Harrow et al., 2012), SARS-CoV-2 isolate Wuhan-Hu-1 (NC_045512.2; 29903 bp) and the human ACE2 mouse codon optimized sequence (2418 bp).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>STAR</div><div>suggested: (STAR, RRID:SCR_015899)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Analyses of K18-hACE2 and Ad5-hACE2 RNA-seq data: RNA-seq datasets generated from the Winkler et al. study (Winkler et al., 2020), and Sun et al. study (Sun et al., 2020a) were obtained from the Gene Expression Omnibus (GSE154104 and GSE150847 respectively) and trimmed using Cutadapt (v2.3).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Gene Expression Omnibus</div><div>suggested: (Gene Expression Omnibus (GEO, RRID:SCR_005012)</div></div><div style="margin-bottom:8px"><div>Cutadapt</div><div>suggested: (cutadapt, RRID:SCR_011841)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Mouse gene expression was estimated using RSEM (v1.3.0)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>RSEM</div><div>suggested: (RSEM, RRID:SCR_013027)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Reads aligned to SARS-CoV-2 and hACE2 were counted using SAMtools (v1.9)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SAMtools</div><div>suggested: (SAMTOOLS, RRID:SCR_002105)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Differential gene expression in the mouse was analyzed using EdgeR (3.22.3) and modelled using the likelihood ratio test, glmLRT().</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>EdgeR</div><div>suggested: (edgeR, RRID:SCR_012802)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Diseases and Functions and canonical pathways enriched in differentially expressed genes in direct and indirect interactions were investigated using Ingenuity Pathway Analysis (IPA) (QIAGEN).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Ingenuity Pathway Analysis</div><div>suggested: (Ingenuity Pathway Analysis, RRID:SCR_008653)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Network Analysis: Protein interaction networks of differentially expressed gene lists were visualized in Cytoscape (v3.7.2)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Cytoscape</div><div>suggested: (Cytoscape, RRID:SCR_003032)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Enrichment for biological processes, molecular functions, KEGG pathways and other gene ontology categories in DEG lists was elucidated using the STRING database (Szklarczyk et al., 2019) and GO enrichment analysis (Mi et al., 2019)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>KEGG</div><div>suggested: (KEGG, RRID:SCR_012773)</div></div><div style="margin-bottom:8px"><div>STRING</div><div>suggested: (STRING, RRID:SCR_005223)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">GSEA (Subramanian et al., 2005) was performed on a desktop application (GSEA v4.0.3) (http://www.broadinstitute.org/gsea/) using the “GSEAPreranked” module.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GSEA</div><div>suggested: (SeqGSEA, RRID:SCR_005724)</div></div><div style="margin-bottom:8px"><div>http://www.broadinstitute.org/gsea/</div><div>suggested: (Gene Set Enrichment Analysis, RRID:SCR_003199)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on page 25. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.


      Results from scite Reference Check: We found one citation with an erratum. We recommend checking the erratum to confirm that it does not impact the accuracy of your citation.

      <table style="border-collapse: collapse;"><tr><th style="min-width:95px; border: 1px solid lightgray; padding:2px">DOI</th><th style="min-width:95px; border: 1px solid lightgray; padding:2px">Status</th><th style="min-width:95px; border: 1px solid lightgray; padding:2px">Title</th></tr><tr><td style="min-width:95px; border: 1px solid lightgray; padding:2px">10.1371/journal.ppat.1003106</td><td style="min-width:95px; border: 1px solid lightgray; padding:2px">Has correction</td><td style="min-width:95px; border: 1px solid lightgray; padding:2px">Recombinant HIV Envelope Proteins Fail to Engage Germline Ve…</td></tr></table>
      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. SciScore for 10.1101/2021.02.12.430998: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">Consent: Written consent was obtained from all individuals and the study was approved by the local ethics committee (14/8/20).<br>IRB: Collection of plasma samples from COVID-19 patients treated at the intensive care unit was approved by the Ethic committee of the University Medicine Göttingen (SeptImmun Study 25/4/19 Ü)</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">Contamination: Further, cell lines were routinely tested for contamination by mycoplasma.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Production of recombinant human monoclonal antibodies against SARS-CoV-2 spike: VH and VL sequences of Regeneron antibodies Casirivimab/REGN10933, Imdevimab/REGN10987 and REGN10989 (Hansen et al., 2020) were cloned in pCMC3-untagged-NCV (SINO Biologics, Cat: CV011) and produced in 293T cells by SINO Biological (Beijing, China).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>REGN10989</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The human IgG1 isotype control antibodies IgG1/κ and IgG1/λ were produced by transfecting FreeStyle 293-F or 293T cells (Fisher Scientific, Schwerte, Germany, Cat. no. R790-07) with the respective plasmids using the protocol provided with the FreeStyle 293 Expression System (Thermo Fisher Scientific, Cat. no. K9000-01).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>human IgG1</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, 293T cells were stained with the recombinant human IgG1 antibodies in FACS buffer (PBS with 0.5% bovine serum albumin and 1 nmol sodium azide) for 20 minutes in ice, washed, incubated with an Alexa Fluor 647-labeled mouse monoclonal antibody against the human IgG1-Fc (Biolegend, San Diego, USA, cat #409320) and analyzed in a Gallios flow cytometer (Beckman Coulter, Brea, California, USA respectively)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>human IgG1-Fc</div><div>suggested: (Sino Biological Cat# 10702-MM01T-H, RRID:AB_2860221)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Finally, culture medium was added that was supplemented with anti-VSV-G antibody (culture supernatant from I1-hybridoma cells; ATCC no. CRL-2700; not added to cells expressing VSV-G).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-VSV-G</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The upper portion of the membrane was probed with anti-HA tag antibody (mouse, Sigma-Aldrich, H3663) diluted 1:1,000 in 5% skim milk solution, while the lower portion of the membrane was probed with anti-VSV matrix protein antibody (Kerafast, EB0011; loading control) diluted 1:2,500 in 5% skim milk solution.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-HA</div><div>suggested: (Sigma-Aldrich Cat# H3663, RRID:AB_262051)</div></div><div style="margin-bottom:8px"><div>anti-VSV matrix protein</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Following incubation over night at 4 °C, membranes were washed three times with PBS-T, before being probed with peroxidase-conjugated anti-mouse antibody (Dianova, 115-035-003, 1:5,000) for 1 h at room temperature.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-mouse</div><div>suggested: (Jackson ImmunoResearch Labs Cat# 115-035-003, RRID:AB_10015289)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell culture: All cell lines were incubated at 37 °C in a humidified atmosphere containing 5% CO2. 293T (human, kidney; ACC-635, DSMZ), Huh-7 (human, liver; JCRB0403, JCRB; kindly provided by Thomas Pietschmann, TWINCORE, Centre for Experimental and Clinical Infection Research, Hannover, Germany) and Vero76 cells (African green monkey, kidney; CRL-1586, ATCC; kindly provided by Andrea Maisner, Institute of Virology, Philipps University Marburg, Marburg, Germany) were cultivated in Dulbecco’s modified Eagle medium (DMEM) containing 10% fetal bovine serum (FCS, Biochrom), 100 U/ml of penicillin and 0.1 mg/ml of streptomycin (PAN-Biotech).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Huh-7</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>Vero76</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Caco-2 (human, intestine; HTB-37, ATCC) and Calu-3 cells (human, lung; HTB-55, ATCC; kindly provided by Stephan Ludwig, Institute of Virology, University of Münster, Germany) were cultivated in minimum essential medium supplemented with 10% FCS, 100 U/ml of penicillin and 0.1 mg/ml of streptomycin (PAN-Biotech), 1x non-essential amino acid solution (from 100x stock, PAA) and 1 mM sodium pyruvate (Thermo Fisher</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Caco-2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>HTB-37</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">A549 cells (human, lung; CRM-CCL-185, ATCC) were cultivated in DMEM/F-12 medium with Nutrient Mix (Thermo Fisher Scientific) supplemented with 10% FCS, 100 U/ml of penicillin and 0.1 mg/ml of streptomycin (PAN-Biotech).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>A549</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The following experimental set-ups were used: (i) In case of experiments comparing the efficiency cell entry by WT and mutant SARS-2-S, target cells were inoculated with 100 μl/well of the respective pseudotype particles; (ii) For investigation of inhibition of SARS-2-S-driven cell entry by the serine protease inhibitor Camostat mesylate, Calu-3 cells were preincubated for 1 h with medium (50 μl/well) containing either increasing concentrations of Camostat (0.5, 5 or 50 μM; Tocris) or dimethyl sulfoxide (solvent control) before the respective pseudotype particles were added on top; in order to assess the ability of sol-hACE2-Fc, patient sera and monoclonal antibodies to block SARS-2-S-driven cell entry, pseudotype particles were preincubated for 30 min with medium containing different dilutions of either sol-hACE2-Fc (1:20, 1:200, 1:2,000) or patient serum/plasma (serum: 1:50, 1:100, 1:200, 1:400, 1:800; plasma: 1:25, 1:100, 1:400, 1:1600, 1:6400), or with different concentrations of monoclonal antibody (5, 0.5, 0.05, 0.005, 0.0005 μg/ml), before being inoculated onto Vero76 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Calu-3</div><div>suggested: KCLB Cat# 30055, RRID:CVCL_0609)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Production of sol-hACE2-Fc: 293T cells were grown in a T-75 flask and transfected with 20 μg of sol-hACE2-Fc expression plasmid.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data normalization was done as follows: (i) In order to assess enhancement of S protein-driven pseudotype entry in BHK-21 cells following directed overexpression of hACE2, transduction was normalized against the assay background (which was determined by using rhabdoviral pseudotypes bearing no viral glycoprotein, set as 1); (ii) To compare efficiency of cell entry driven by the different S protein variants under study, transduction was normalized against SARS-2-S WT (set as 100%); (iii) For experiments investigating inhibitory effects exerted by sol-hACE2-Fc or Camostat Mesylate, patient serum/plasma samples or monoclonal antibodies, transduction was normalized against a reference sample (control-treated cells or pseudotypes, set as 100%).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>BHK-21</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Sequence alignments were performed using the Clustal Omega online tool (</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Clustal Omega</div><div>suggested: (Clustal Omega, RRID:SCR_001591)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Protein models were designed using the YASARA (http://www.yasara.org/index.html) and UCSF Chimera (version 1.14, developed by the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco) software packages, and are either based on PDB: 6XDG (Hansen et al., 2020) or on a template generated by modelling the SARS-2-S sequence on a published crystal structure (PDB: 6XR8, (Cai et al., 2020)) with the help of the SWISS-MODEL online tool (https://swissmodel.expasy.org/).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>YASARA</div><div>suggested: (YASARA, RRID:SCR_017591)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data normalization and statistical analysis: Data analysis was performed using Microsoft Excel as part of the Microsoft Office software package (version 2019, Microsoft Corporation) and GraphPad Prism 8 version 8.4.3 (GraphPad Software).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Microsoft Excel</div><div>suggested: (Microsoft Excel, RRID:SCR_016137)</div></div><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      The following limitations of our study need to be considered. We employed pseudotyped particles instead of authentic SARS-CoV-2 and we did not determine whether Y453F affects viral inhibition by T cell responses raised against SARS-CoV-2. Further, we did not investigate whether presence of Y453F in the SARS-CoV-2 S protein increases binding to mink ACE2. Nevertheless, our results suggest that the introduction of SARS-CoV-2 into mink allows the virus to acquire mutations that compromise viral control by the humoral immune response in humans. As a consequence, infection of mink and other animal species should be prevented and it should be continuously monitored whether SARS-CoV-2 amplification in other wild or domestic animals occurs and changes critical biological properties of the virus.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. Hodcroft, E. B., Domman, D. B., Oguntuyo, K., Snyder, D. J., Diest, M. V., Densmore, K. H., Schwalm, K. C., Femling, J., Carroll, J. L., Scott, R. S., Whyte, M. M., Edwards, M. D., Hull, N. C., Kevil, C. G., Vanchiere, J. A., Lee, B., Dinwiddie, D. L., Cooper, V. S., & Kamil, J. P. (2021). Emergence in late 2020 of multiple lineages of SARS-CoV-2 Spike protein variants affecting amino acid position 677. MedRxiv, 2021.02.12.21251658. https://doi.org/10.1101/2021.02.12.21251658

    1. SciScore for 10.1101/2021.02.10.430696: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">IACUC: Animals were housed and maintained as per National Institutes of Health (NIH) guidelines at the New Iberia Research Center (NIRC) of the University of Louisiana at Lafayette in accordance with the rules and regulations of the Committee on the Care and Use of Laboratory Animal Resources.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Animal subjects and experimentation: Thirty-three male rhesus macaques (Macaca mulatta) of Indian origin, aged 3 - 9 years were assigned to the study (Supplementary Table 1).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In wells with anti-human IgG capture antibody, human IgG control (SinoBiological, #HG1K) was serially diluted from 0.5-500 ng/mL in TBST in triplicate and 50 μL of each dilution incubated for 1 h.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The antibody-virus mixture was added to VeroE6 cell (C1008, ATCC, #CRL-1586</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>C1008</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">assay: Antibodies blocking the binding of SARS-CoV-2 Spike RBD to the angiotensin-converting enzyme 2 (ACE2) were detected with a V-PLEX SARS-CoV-2 Panel 2 (ACE2) Kit (Meso Scale Diagnostics) according to the manufacturer’s instructions.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ACE2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Luminex Isotype and FcR Binding Assay: To determine relative concentrations of antigen-specific antibody isotypes and Fc receptor binding activity, a Luminex isotype assay was performed as previously described39.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>antigen-specific</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Mouse-anti-rhesus antibody detectors were then added for each antibody isotype (IgG1, IgG2, IgG3, IgG4, IgA, NIH Nonhuman Primate Reagent Resource supported by AI126683 and OD010976).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>IgG1 , IgG2</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>IgG3 , IgG4</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Tertiary anti-mouse-IgG detector antibodies conjugated to PE were then added.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-mouse-IgG detector</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Systems serology: To quantify antibody functionality of plasma samples, bead-based assays were used to measure antibody-dependent cellular phagocytosis (ADCP), antibody-dependent neutrophil phagocytosis (ADNP) and antibody-dependent complement deposition (ADCD), as previously described40-43.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>antibody-dependent neutrophil phagocytosis ( ADNP</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>antibody-dependent complement deposition ( ADCD)</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2 spike protein (Hexapro antigen from Erica Ollmann Saphire, La Jallo for Immunology) was coupled to fluorescent streptavidin beads (Thermo Fisher) and incubated with sera samples to allow antibody binding to occur.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SARS-CoV-2 spike protein ( Hexapro antigen from Erica Ollmann Saphire , La Jallo for Immunology )</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>SARS-CoV-2 spike protein ( Hexapro antigen from Erica Ollmann Saphire ,</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After phagocytosis of immune complexes, neutrophils were stained with an anti-CD66b Pacific Blue detection antibody (Biolegend) prior to flow cytometry.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-CD66b</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For quantification of antibody-dependent NK cell activation, diluted plasma samples were incubated in Nunc MaxiSorp plates (Thermo Fisher Scientific) coated with antigen.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>antigen .</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Anti-S binding ELISA: SARS-CoV-2 Spike protein was produced in HEK293T cells (Atum, Newark, CA)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T</div><div>suggested: NCBI_Iran Cat# C498, RRID:CVCL_0063)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For neutralization assays, HEK-hACE2 cells were cultured in DMEM with 10% FBS (Hyclone) and 1% PenStrep with 8% CO2 in a 37°C incubator on poly-lysine (sigma) 96 well plates.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK-hACE2</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pseudovirions were produced in HEK293T/17 cells by co-transfection of a lentivirus backbone plasmid, a Spike-expressing plasmid, and a firefly Luc reporter gene plasmid.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>HEK293T/17</div><div>suggested: ATCC Cat# CRL-11268, RRID:CVCL_1926)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The furin cleavage site, a site with frequent culture adaptation in Vero E6 cells, harbored no polymorphisms at greater than 1% of sequence reads in this stock.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: RRID:CVCL_XD71)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For ADCP, cultured human monocytes (THP-1 cell line) were incubated with immune complexes, during which phagocytosis occurred.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>THP-1</div><div>suggested: CLS Cat# 300356/p804_THP-1, RRID:CVCL_0006)</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Animals were housed and maintained as per National Institutes of Health (NIH) guidelines at the New Iberia Research Center (NIRC) of the University of Louisiana at Lafayette in accordance with the rules and regulations of the Committee on the Care and Use of Laboratory Animal Resources.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>NIRC</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Alum (Alhydrogel 2%) was purchased from Croda Healthcare (Batch #0001610348).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Croda Healthcare</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plates were immediately read at 450 nm on a SpectraMax M5 plate reader (Molecular Devices) and data plotted and fit in Prism (GraphPad) using nonlinear regression sigmoidal, 4PL, X is log(concentration) to determine EC50 values from curve fits.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Prism</div><div>suggested: (PRISM, RRID:SCR_005375)</div></div><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All flow cytometry data were analyzed using Flowjo software v10 (TreeStar Inc.)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Flowjo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Before analysis, the PET images were Gaussian smoothed in OsiriX and smoothing was applied to raw data with a 3 x 3 matrix size and a matrix normalization value of 24.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>OsiriX</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">PET quantification values were organized in Microsoft Excel.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Microsoft Excel</div><div>suggested: (Microsoft Excel, RRID:SCR_016137)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All the statistical analyses were performed using GraphPad Prism v.9.0.0 or R version 3.6.1.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #1

      Evidence, reproducibility and clarity

      Summary:

      Provide a short summary of the findings and key conclusions (including methodology and model system(s) where appropriate). Please place your comments about significance in section 2.

      The authors resolved the biosynthesis of trehalose and alpha-glucan in Pseudomonas aeruginosa and the role of these two compounds in osmotic and desiccation stress.

      Major comments:

      • Are the key conclusions convincing?

      yes

      • Should the authors qualify some of their claims as preliminary or speculative, or remove them altogether?

      no

      • Would additional experiments be essential to support the claims of the paper? Request additional experiments only where necessary for the paper as it is, and do not ask authors to open new lines of experimentation.

      Not necessary, comprehensive coverage of research Topic

      • Are the suggested experiments realistic in terms of time and resources? It would help if you could add an estimated cost and time investment for substantial experiments.

      Not applicable

      • Are the data and the methods presented in such a way that they can be reproduced?

      yes

      • Are the experiments adequately replicated and statistical analysis adequate?

      Yes, everything is adequate but just one subtle concern: check the significance of the number of digits in the entries listed in Table S3. Revise Table S3.

      Minor comments:

      • Specific experimental issues that are easily addressable.

      not applicable (Table S3: see above)

      • Are prior studies referenced appropriately?

      No. Refs. 18- 32: The subjects of 'trehalose' and 'osmotic stress' have already been addressed in the Pseudomonas field and should be referenced. The authors cite work carried out on trehalose and osmotic stress on phylogenetically distant microorganisms, but do not cite related work from the Pseudomonas field which I consider to be inappropriate. Similarly, trehalose biosynthesis in Pseudomonas has not only been covered by refs. 47 and 48.

      • Are the text and figures clear and accurate?

      Extremely well written manuscript and prepared figures

      • Do you have suggestions that would help the authors improve the presentation of their data and conclusions?

      Revise the list of references and discuss more thoroughly your novel findings in the light of existing knowledge in the Pseudomonas field

      Significance

      2. Significance

      • Describe the nature and significance of the advance (e.g. conceptual, technical, clinical) for the field.

      Conceptual advance: The authors identified and characterized the enzymatic pathway of trehalose and alpha-glucan biosynthesis in Pseudomonas aeruginosa and its role to cope with osmotic and desiccation stress. The authors' conclusions do not correspond with recently published peers' work, hence they should discuss in more detail why they consider their data to be more accurate to discern the role of trehalose to contain desiccation and osmotic strass in P. aeruginosa.

      • Place the work in the context of the existing literature (provide references, where appropriate).

      Existing literature focusing on trehalose, osmotic stress, desiccation stress in the Pseudomonas field not cited by the authors

      Pazos-Rojas LA, Muñoz-Arenas LC, Rodríguez-Andrade O, López-Cruz LE, López- Ortega O, Lopes-Olivares F, Luna-Suarez S, Baez A, Morales-García YE, Quintero- Hernández V, Villalobos-López MA, De la Torre J, Muñoz-Rojas J. Desiccation- induced viable but nonculturable state in Pseudomonas putida KT2440, a survival strategy. PLoS One. 2019 Jul 19;14(7):e0219554. doi:10.1371/journal.pone.0219554.

      Wang T, Jia S, Dai K, Liu H, Wang R. Cloning and expression of a trehalose synthase from Pseudomonas putida KT2440 for the scale-up production of trehalose from maltose. Can J Microbiol. 2014 Sep;60(9):599-604. doi: 10.1139/cjm-2014-0330.

      Harty CE, Martins D, Doing G, Mould DL, Clay ME, Occhipinti P, Nguyen D, Hogan DA. Ethanol Stimulates Trehalose Production through a SpoT-DksA-AlgU-Dependent Pathway in Pseudomonas aeruginosa. J Bacteriol. 2019 May 22;201(12):e00794-18. doi: 10.1128/JB.00794-18.

      Cross M, Biberacher S, Park SY, Rajan S, Korhonen P, Gasser RB, Kim JS, Coster MJ, Hofmann A. Trehalose 6-phosphate phosphatases of Pseudomonas aeruginosa. FASEB J. 2018 Oct;32(10):5470-5482. doi: 10.1096/fj.201800500R.

      Wang T, Jia S, Dai K, Liu H, Wang R. Cloning and expression of a trehalose synthase from Pseudomonas putida KT2440 for the scale-up production of trehalose from maltose. Can J Microbiol. 2014 Sep;60(9):599-604. doi: 10.1139/cjm-2014-0330.

      Behrends V, Ryall B, Zlosnik JE, Speert DP, Bundy JG, Williams HD. Metabolic adaptations of Pseudomonas aeruginosa during cystic fibrosis chronic lung infections. Environ Microbiol. 2013 Feb;15(2):398-408. doi: 10.1111/j.1462-2920.2012.02840.x

      Behrends V, Ryall B, Wang X, Bundy JG, Williams HD. Metabolic profiling of Pseudomonas aeruginosa demonstrates that the anti-sigma factor MucA modulates osmotic stress tolerance. Mol Biosyst. 2010 Mar;6(3):562-9. doi: 10.1039/b918710c.

      Matthijs S, Koedam N, Cornelis P, De Greve H. The trehalose operon of Pseudomonas fluorescens ATCC 17400. Res Microbiol. 2000 Dec;151(10):845-51. doi: 10.1016/s0923-2508(00)01151-7.

      van der Werf MJ, Overkamp KM, Muilwijk B, Koek MM, van der Werff-van der Vat BJ, Jellema RH, Coulier L, Hankemeier T. Comprehensive analysis of the metabolome of Pseudomonas putida S12 grown on different carbon sources. Mol Biosyst. 2008 Apr;4(4):315-27. doi: 10.1039/b717340g.

      Hallsworth JE, Heim S, Timmis KN. Chaotropic solutes cause water stress in Pseudomonas putida. Environ Microbiol. 2003 Dec;5(12):1270-80. doi: 10.1111/j.1462-2920.2003.00478.x.

      Ball P, Hallsworth JE. Water structure and chaotropicity: their uses, abuses and biological implications. Phys Chem Chem Phys. 2015 Apr 7;17(13):8297-305. doi: 10.1039/c4cp04564e

      Cray JA, Russell JT, Timson DJ, Singhal RS, Hallsworth JE. A universal measure of chaotropicity and kosmotropicity. Environ Microbiol. 2013 Jan;15(1):287-96. doi: 10.1111/1462-2920.12018.

      Chin JP, Megaw J, Magill CL, Nowotarski K, Williams JP, Bhaganna P, Linton M, Patterson MF, Underwood GJ, Mswaka AY, Hallsworth JE. Solutes determine the temperature windows for microbial survival and growth. Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7835-40. doi: 10.1073/pnas.1000557107.

      These papers are of variable scientific quality, but the conceptual work by Hallsworth and the work by Behrens on the PA metabolome in CF lungs are worth discussing. All other work provides pieces of information on function and biosynthesis of trehalose up to now known by the Pseudomonas community. The authors resolved the function of the GlgA operon which will be definitely appreciated.

      Strengths of the manuscript:

      • Meticulously planned and carefully executed experiments, not a single experimental flaw • very high technical quality of experiments and primary data • comprehensive coverage of the research topic • excellent presentation in text and illustrations

      only weakness: • insufficient consideration of peers' published work on trehalose and its role in stress response in P. aeruginosa

      • State what audience might be interested in and influenced by the reported findings.

      Scientists working in the fields of glycoconjugate and carbohydrate research, biochemists, microbiologists with interest in metabolic pathways, stress response and/or Pseudomonas

      • Define your field of expertise with a few keywords to help the authors contextualize your point of view. Indicate if there are any parts of the paper that you do not have sufficient expertise to evaluate.

      Reviewer's expertise: Pseudomonas genomics and physiology, respiratory tract infections, solid background in biochemistry and molecular biology

    1. Reviewer #2 (Public Review):

      The manuscript "Archaeal chromatin 'slinkies' are inherently dynamic complexes with deflected DNA wrapping pathways" by Bowerman and colleagues describes a study of archaeasome dynamics combining molecular simulations, cryo-EM, and sedimentation velocity analytical ultracentrifugation. How chromatin evolved is a fundamental question in biology, marking a striking departure from the bacterial nucleoid. Indeed, ever since the first description of archaeal nucleosomes and histones HmfA/B (Sandman and Reeves mid-80s) from thermophilic archaea, this question has fascinated and puzzled the field.

      Recent work from the Luger lab figured out the organization of these archaeal chromatin fibers as a continuous loop structure. Here, the authors extend this question further. MD analyses show that Arc90 has two preferred states (closed and flexible ends), but the same 5T5K structure on 120 or 180 bp of DNA prefer a single state (closed). Sedimentation velocity analytical ultracentrifugation showed that Arc207 sediments slower than the H3 mononucleosome, implying that that Arc207 has a shape with higher anisotropy, resulting in excessive drag compared to a mononucleosome. Subsequently, high-resolution cryoEM showed that at least two distinct classes for Arc207 exist, where one class represents a 5-mer and another class represent a 7-mer. The latter has a unique shape in that the 7-mer forms an L-shape (or open clam) with a 3-mer hinging on a 4-mer.

      Overall, these data provide exciting structural insights into how archaeal chromatin is folded up at its basic unit level, which the authors describe as most fittingly as a "slinkie". Because so little is known about how nucleosomes evolved during the transition from archaea to eukaryotes, we found this interdisciplinary report well written and with compelling data, that will be of interest to the chromosome biology field at large. We suggest a minor revision in which a few technical points are addressed.

      Considerations:

      1) The cryoEM data showed two main groups of particles: 5-mer protecting 150 bp and a 7-mer protecting either 90bp or 120bp. A few times in the manuscript (both in the results and discussion section) the authors mention a 30-bp MNase digestion ladder is observed. The Mnase data should be included, as this provides evidence that the structures observed by cryoEM indeed represent physiological structures, especially if strong discrete bands are observed at 90, 120, and 150 bp.

      2) The two main classes found by cryoEM give the impression that adding dimers results in altered structures. The 7-mer shows an angled structure, which is interpreted as an open structure. The 5-mer shows a more uniform structure, which is interpreted as a closed structure. The former structure protects the full length of DNA on which HTkA histones were reconstituted, whereas the latter might be an incomplete reconstitution or a partially disassembled structure. It also raises the question if the length of the DNA is a limiting factor. What if HTkA was reconstituted on 170 bp or 307 bp instead? Would this in turn only permit the formation of the 5-mer on the 170 bp construct and two 5-mers on the 307 bp construct? The authors should consider addressing this point because the reconstitution might be constrained by the length of the DNA construct used. Indeed, a related topic might be AT content- what does archaeal DNA look like from the perspective of DNA sequence for chromatin (Jon Widom's group had a ChIPSeq paper on this a few years ago, just after his untimely passing).

      3) In the discussion the authors cite that in one archaeal species the Mg2+ concentration is ~120 mM, more than a magnitude greater than that tested in Figure 5. What happens to reconstituted archaeasomes at higher Mg+? This is relevant because in vivo, archaea are thought to have 10x the concentration of Mg+ (amongst other ions) relative to us humble eukaryotes who would probably die of kidney failure at those ionic concentrations. Indeed at high ionic conditions, eukaryotic chromatin can be made to precipitate out of solution (for e.g. 10mM Mg+, 3M NaCl). An AUC assay with higher Mg2+ concentrations seems a doable and physiologically relevant addition to the ms that would strengthen it. It is relevant to consider that in vivo structure in these halophilic and thermophilic organisms might be dependent on the concentration of various salts and temperature, it would be nice to read the authors' thoughts on this issue.

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      RESPONSE TO REVIEWERS

      We thank Review Commons and its three reviewers. Reviewers 2 and 3 provide detailed comments, which we address individually. Reviewer 1, however, gives a general critique of how we have approached asking how genome architecture affects the extent of evolution and the details of evolutionary trajectories. Our interpretation of their comments is that our approach and the one that they advocate represent two philosophically different, but complementary, views about how to study evolution in the laboratory. We begin by discussing this difference and then proceed to a point by point response to the three reviews.

      Reviewer 1

      Philosophical differences with Reviewer 1

      We interpret Reviewer 1’s comments as endorsing a formal, quantitative study of evolution that aims to explain the factors that control the rate at which fitness increases during experimental evolution. This approach derives from classical population genetics and aims to use a mixture of theory and experiment to uncover general principles that would allow rates of evolution and evolutionary trajectories, expressed as population fitness over time, to be predicted from quantitative parameters, such population sizes, mutation rates, distributions of the fitness effects of mutations (including their degree of dominance in diploids), and global descriptions of either general (e.g. diminishing returns) or allele-specific epistasis.

      This approach aims to predict how the average fitness trajectory should be affected by variations in these parameters and describe the variation, at the level of fitness, in the outcomes in a set of parallel experiments. This is an important approach and have previously used it to investigate how the strength of selection influences the advantage of mutators (Thompson, Desai, & Murray, 2006) and to produce and test theory that predicts how mutation rate and population size control the rate of evolution (Desai, Fisher, & Murray, 2007). Like every approach to evolution, this one has limitations: 1) if it doesn’t identify mutations or investigate phenotype other than fitness, it cannot reveal the biological and biochemical basis of adaptation or report on how variations in population genetic parameters (population size, haploids versus diploids, etc.) influence which genes acquire adaptive mutations, and 2) if the details of experiments (e.g. whether populations are clonal or contain standing variation, or which phenotypes are being selected for) have strong effects on the population genetic parameters, these must be measured before theoretical or empirical relationships could be used to predict the mean and variance of fitness trajectories produced by a given selection. A variety of evidence suggests that the second limitation is real. Examples include the absence of a universal finding that diploid populations evolve more slowly than haploids (discussed on Lines 437-442), even within the same experimental organism, and the finding that diminishing returns epistasis applies well to domesticated yeast evolving in a variety of laboratory environments (e. g. papers from the Desai lab, starting with (Kryazhimskiy, Rice, Jerison, & Desai, 2014) but not to the evolutionary repair experiments that we have conducted (Fumasoni & Murray, 2020; Hsieh, Makrantoni, Robertson, Marston, & Murray, 2020; Laan, Koschwanez, & Murray, 2015).

      The second approach to experimental evolution, which we, as molecular geneticists and cell biologists, predominantly take, is to follow the molecular and cell biological details of how organisms adapt to selective pressure. We subject organisms to defined selective forces, identify candidate causative mutations, test them by reconstructing the evolved mutations, individually and in combination, and perform additional experiments to ask how these mutations are increasing fitness. Because these experiments are performed on model organisms and often address phenotypes that have been studied by classical and molecular genetics, we can often say a good deal about the cell biological and biochemical mechanisms that increase fitness and this work can complement and extend what we know from classical and molecular genetics.

      The current manuscript and its predecessor are examples of finding causative mutations and asking how they improve fitness, with the first paper (Fumasoni & Murray, 2020) demonstrating how mutations in three functional modules could overcome most of the fitness cost of removing an important but non-essential protein and the current paper asking how alterations in genome architecture and dynamics (diploidy and eliminating double-strand break-dependent recombination) affect the extent to which populations increase in fitness and which genes and functional modules acquire mutations as they do so.

      By definition, such experiments are anecdotal: they report on how particular genotypes and genome architectures respond to particular selection pressures. Any individual set of experiments can produce conclusions about the effects of variables, such a population size, mutation rate, and genome architecture, on the mutations that increased fitness in response to the specific selection, but they can do more than lead to speculation and inference about what would happen in other experiments: speculation from the results of a single project and inferences from the combined results of multiple projects. Our interpretation is that the evolutionary repair experiments that we have performed, which have perturbed budding, DNA replication, and the linkage between sister chromatids do indeed lead to a common set of inferences: most of the selected mutations reduce or eliminate the function of genes, the interactions between the selected mutations are primarily additive, and the mutations cluster in a few functional modules.

      We believe that the population and molecular genetic approaches to experimental evolution are complementary and that a full understanding of evolution will require combining both of them. We think this will be especially true as we try to use the findings from laboratory studies to improve our understanding of evolution outside the lab, which takes place over longer periods, in more temporally and spatially variable environments, and is subject to variation in multiple population genetic and biological parameters.

      Reviewer #1 (Evidence, reproducibility and clarity (Required)): In their previous work the authors examined adaptation in response to replication stress in haploid yeast, via experimental evolution of batch cultures followed by sequencing. Here they extend this approach to include diploid and recombination-deficient strains to explore the role of genome architecture in evolution under replication stress. On the whole, a common set of functional modules are found to evolve under all genetic architectures. The authors discuss the molecular details of adaptation and use their findings to speculate on the determinants of adaptation rate.

      **SECTION A - Evidence, reproducibility and clarity** Experimental evolution can reveal adaptive pathways, but there are some challenges when applying this approach to compare genetic backgrounds or environments. They key challenge is that adaptation potentially depends on both the rate of mutation and the nature of selection. Distinct adaptation patterns between groups could therefore reflect differential mutation, selection, or both. The authors allude to this dichotomy but have very limited data to address it. The closest effort is engineering putatively-adaptive variants into all genetic background including those where they did not arise; the fact that such variants remain beneficial suggests they did not arise in certain backgrounds because of a lower mutation rate, but this is a difficult issue to tackle quantitatively.

      We agree, wholeheartedly, that adaptation depends on the combination of mutation rates and the nature of selection and our goal was to ask how the molecular nature of adaptation depends on genome architecture when three different architectures are subjected to the same selection: constitutive replication stress caused by removing an important component of replisome. We used a haploid strain as a baseline and compared it to two other strains chosen to influence either the effect of mutations (a diploid, where fully recessive mutations that were beneficial in the haploid would become neutral) or the rate of mutations (a recombination-defective strain that would be unable to use ectopic recombination to amplify segments of the genome). In both cases, we expected to see effects that are closer to qualitative than quantitative: the absence of fully recessive mutations in evolved diploids and absence of segmental amplification in the recombination-deficient haploid. We see both effects and they then allow us to ask two other questions: 1) does influencing the effect of a class of mutation (diploids) or preventing a class of mutation (recombination defect) have a major effect on the rate of evolution, and 2) do these differences affect which modules adaptive mutations occur in. As far as we can tell, the answer is no to both questions. We use “as far as we can tell” because our experiments do have limitations. First, the recombination-defective strain has a higher point mutation rate making it impossible to tell how much this elevation, rather than any other factor, accounts for it showing a greater fitness increase than the recombination-proficient haploid. Unfortunately, to our knowledge, it’s impossible to abolish recombination without affecting mutation rates. Second, we only experimentally tested a subset of the inferred causative mutations meaning that for many genes, our assertion that they are adaptive is a statistical inference and their assignment to a particular functional module is based on prior literature rather than our own experiments. In response to this criticism, we have now rephrased some of our sentences (see below).

      From mutation accumulation experiments, where the influence of selection is minimized, there is evidence that genetic architecture affects the rate and spectrum of spontaneous mutations. In this experiment, the allele used to eliminate recombination, rad52, will also increase the mutation rate generally. The diploid strain is also likely to have a distinct mutational profile--as a null expectation diploids should have twice the mutation rate of haploids. Recent evidence indicates the mutation rate difference between haploid and diploid yeast might be less than two-fold, but that there are additional differences in the mutation spectrum, including rates of structural change. The context for this study is therefore three genetic architectures likely to differ in multiple dimensions of their mutation profiles, but mutation rates are not measured directly.

      The reviewer is correct that we did not explicitly measure mutation rates, although the frequency of synonymous mutations (Figure 3-S1B) is a proxy for the point mutation rate as long as the majority of these mutations are assumed to be neutral. By this measure, the mutation rates for ctf4∆ haploids and ct4∆/ctf4∆ diploids, expressed per haploid genome, are close to each other (1.94 for haploids and 1.37 for diploids) but different enough to return p = 0.044 by Welch’s test, whereas the mutation rate for the recombination-deficient, ctf4∆ rad52∆ haploid is 4 to 5-fold higher (7.03). In contrast, we can infer that the ctf4∆ rad52∆ strain has much lower rates of segmental aneuploidy produced by recombination: we see only one such event in this strain in contrast to 16 in the ctf4∆ haploid and 44 in the ctf4∆/ctf4∆ diploid (Supplementary table 4), even though the amplification of the cohesin loader gene, SCC2, confers similar benefits in all three strains.

      The nature of selection on haploids and diploids is expected to differ because of dominance, but ploidy-specific selection is also possible. The authors discuss how recessive beneficial alleles may be less available to diploids, though this can be offset by relatively rapid loss of heterozygosity. However, diploids should also incur more mutations, all else being equal. The rate of beneficial mutation, as opposed to the rate of mutation generally, will depend on the mutational "target size" of fitness, and the authors findings recapitulate other literature (particularly regarding "compensatory" adaptation) that points to faster adaptation in genotypes with lower starting fitness.

      We agree with the reviewer and tried to make the point that which mutations are fixed is primarily determined by the product of the rate at which they occur and the benefit which they confer (lines 193-196). Evidence in budding yeast suggests that in diploid cells, removing one copy of most genes fails to produce a measurable fitness benefit (Deutschbauer et al., 2005), suggesting that losing one copy of many genesis purely recessive. If this was always the case, it would be very hard for such heterozygous, loss-of-function mutations to contribute to evolution in diploids: a mutation that inactivates one copy of a gene would have to rise to high enough frequency by genetic drift that homozygosis of this mutation mitotic recombination would have a significant probability. Instead we find that heterozygous mutations in some genes (inactivation of RAD9, what are likely to be hypomorphic mutations in SLD5) but not others (inactivation of IXR1) confer benefits in diploids that allow their frequency to rise much more rapidly by selection than they would by drift, allowing them to reach frequencies at which mitotic recombination becomes probable.

      There is ample literature on the above topics, particularly discussions of the evolutionary advantages of haploidy versus diploidy. While adaptation to replication stress provides a novel starting point for this investigation, much of the manuscript is devoted to long-standing questions that are not specific to replication stress. Unfortunately, the data the authors collected is not sufficient to shed light on these questions, because mutation and selection cannot be effectively distinguished. The Discussion states that "We find that the genes that acquire adaptive mutations, the frequency at which they are mutated, and the frequency at which these mutations are selected all differ between architectures but that mutations that confer strong benefits always lie in the same three modules" (line 379), but it is not clear that these statements are all supported by the data.

      The reviewer makes two points: we fail to make a significant contribution to long-standing questions about the evolutionary genetics of adaptation and the we make statements that are not supported by our data. On the first we disagree: unlike much of the previous work which compares the effects of mutation rates and population sizes on the rates of evolution, we sequence genomes, identify putative causative mutations, verify that they increase fitness, and test, by reconstruction, how their contribution to fitness is affected by fully characterized genome architectures. We know of no comparable work and we believe that this is a useful contribution to understanding evolution. In addition, some of the literature, for example the discussion of haploidy versus diploidy, has failed to reach a universal conclusion. On the second point, we realized that the statement that the reviewer quotes is stronger than it should be since we do not show “that mutations that confer strong benefits always lie in the same three modules”. What we do show is that mutations in all three modules are found in all three genome architectures (Figure 5), and that combining one mutation from each module (using mutations in genes that are found in that architecture) can reproduce the observed fitness increase in each architecture (Figure 6 B), but the reviewer is correct that we have not demonstrated that every clone from every population has an adaptive mutation in all three modules. We have therefore modified the quoted sentence as follows (altered wording underlined)

      "We find that the genes that acquire adaptive mutations, the frequency at which they are mutated, and the frequency at which these mutations are selected all differ between architectures but that mutations conferring strong benefits can occur in all three modules in each architecture" (Lines 405-408)

      Focusing on the more novel aspect of their experiment-the presence of replication stress-would arguably be a better approach. On this topic the authors have some interesting observations and speculation, but clear predictions are lacking. The introduction section could be redesigned to explicitly state why genome architecture might affect adaptation in response to replication stress in particular, rather than (or in addition to) adaptation generally. If there were no differences in mutation, does the nature of Ctf4 lead to predictions that the molecular basis of compensatory adaptation should differ among genome architectures? Without such predictions it will be difficult for readers to know whether the observation that different genome architectures follow similar adaptive paths is surprising or not.

      We believe that following this suggestion would diminish the paper. We set out to ask how genome architecture affected adaptation to the strong fitness defect produced by removing an important component of an essential process, DNA replication. We chose replication stress as an example of cell biological damage that cells would have to repair with the hope that the results would give general clues about evolutionary repair, rather than hoping that the experiment would inform us about how replication stress altered the types of mutation (e. g. point mutations versus segmental amplification) that were selected As we point out at the beginning of our response, we recognize that the result of any one such experiment must be anecdotal and any attempt to generalize must be described as speculation if it refers only to this one experiment, or inference if it refers to this experiment and other published work. In those cases where we discuss the effect of genome architecture on evolutionary trajectories, we can draw conclusions that apply to our own experiments, but can only speculate on adaptation to different selections. In others, where we see commonalities between our experiments and previous work on evolutionary repair (cite Review), we can make inferences about evolution to adapt to removing important proteins and speculate about other forms of selection. We have revised the discussion to make it clear where we conclude, where we speculate, and where we infer. We suspect that our finding that genome architecture has a larger effect on which genes acquire adaptive mutations than it does on which modules these mutations alter will generalize to other evolutionary repair experiments and may be true even more broadly.

      We deliberately did not make predictions about the effect of genome architecture on the rate at which population fitness increased or the mechanism of adaptation to replication stress because we believed that our ignorance and the diverging results of previous experiments was sufficient to make both exercises worthless. After the fact, we interpret our results to suggest that mutations that reduce the activity of components, such as Sld5, that are stably associated with replication forks should be semi-dominant, but we were not nearly smart enough to make such a specific prediction before the experiment began!

      **Minor comments:** Shifts in ploidy from diploid to haploid are less common than the reverse change, so the observation of such a shift (Fig. 1) should be discussed in more detail.

      We now mention that haploids becoming diploids is more common than the reverse transformation and point out that genome sequencing reveals that these strains are true haploids rather than aneuploids.

      “One diploid population (EVO14) gave rise to a population with a haploid genome content, suggesting a possible haploidization event during evolution. Sequencing revealed no aneuploidies as a potential explanation of this phenomenon. While diploidization has been recurrently observed during experimental evolution with budding yeast (Aleeza C. Gerstein & Otto, 2011; Aleeza C Gerstein, Chun, Grant, & Otto, 2006; Harari, Ram, Rappoport, Hadany, & Kupiec, 2018; Venkataram et al., 2016), reports of spontaneous haploidization events have been instead scarce. Given the difficulties introduced by the change of ploidy over the 1000 generations, we have excluded EVO14 from all our analyses.” (Lines 122-128)

      We believe that the most likely mechanism is that the strain sporulated to produce haploids that were fitter than their diploid parent, but because this event occurred in only one out of eight populations and the proposed explanation is pure speculation we have not included in the revised manuscript.

      Line 88 typo 'stains'.

      Fixed. Thank you.

      Reviewer #1 (Significance (Required)): **SECTION B - Significance** The novel aspect of this study is the combination of replication stress and genome architecture, but here the significance is limited by a lack of clear predictions on how these factors might interact. On the other hand, much of the manuscript is devoted to why adaptation might vary among genome architectures in general, but this long-standing and important question is not particularly well resolved by this experimental approach, which can't disentangle mutation and selection.

      Our belief is that quantitatively predicting how selection will change fitness is nearly impossible because we lack the detailed knowledge of population genetic parameters that apply to our experiments. Prediction is even harder if the goal is to identify which genes will fix adaptive mutations and understand how these mutations alter cellular phenotypes to increase fitness. Thus our approach is almost entirely empirical: we do experiments that alter interesting variables, collect data, and do our best to interpret them and suggest how the conclusions of individual experiments might generalize.

      The authors highlight the dichotomy when discussing the evolution of ploidy: "We suggest that... genome architecture affects two aspects of the mutations that produce adaptation: the frequency at which they occur and the selective advantage they confer" (line 399), but presenting this as a novel inference does not appropriately acknowledge prior research and discussion of these ideas; several relevant papers are cited by the authors in other contexts. It may be possible to recast these findings as a test of the role of genome architecture in adaptation generally, but the authors should clarify the limitations of experimental evolution and more fully consider the theory and data outlined in previous research. In particular, few studies can claim to directly compare mutation rates between genome architectures, and it is not obvious that the present study is an example of such.

      We have the disadvantage that the reviewer doesn’t identify the literature we fail to cite. To us the argument the reviewer quotes is self-evident. As we mention above, our goal was not to test either general or detailed predictions and the level at which we analyzed our experiment, especially demonstrating that mutations were causal and reconstructing them individually and in combination, is missing from previous work. Finally measuring mutation rates is supremely difficult: you either need good ways of following all possible forms of mutation, quantitatively and without selection, or you resort to selecting mutations with a particular phenotype and molecularly characterizing them, knowing that these assays may well give different ratios of the rates of different types of mutation at different loci. We do make and report one measure of mutation rate, the rate of synonymous mutation in protein coding genes, which we discuss above.

      Reviewer expertise: Evoutionary genetics; experimental evolution; mutation.

      Reviewer #2 (Evidence, reproducibility and clarity (Required)): **Summary** This manuscript investigates the effect of an organism's genotype (or, as the authors call it, an organism's 'genome architecture') on evolutionary trajectories. For this, the authors use Saccharomyces cerevisiae strains that experience some form of replication stress due to specific gene deletions, and that further differ in ploidy and/or the type of gene(s) deleted. They find the same three functional modules (DNA replication, DNA damage checkpoint, sister chromatid cohesion) are affected across the 3 different genotypes tested; although the specific genes that are mutated varies. **Major comments** This is a solid and exceptionally eloquent paper, comprising a large body of work that is in general well presented. That said, I do have some suggestions and questions. At several points in the manuscript, the authors should perhaps be more careful in their wording and avoid to overgeneralize data without providing additional evidence for these claims.

      We thank the reviewer for their constructive review and address their request for more careful wording below.

      • Some key points of the study are not entirely clear to me; possibly because the study builds upon a previous study that was recently published in eLife. Anyhow, I think it would be useful to clarify the following points a bit more:

        • Why exactly was ctf4∆ chosen as a model for replication stress? What is the evidence that ctf4∆ is a good model for replication stress? Without including some evidence for this, it is unclear how well the findings in this study really can be generalized to replication stress (which is what the authors do now).

      We described the reasons for choosing CTF4 deletion to mimic DNA replication stress in our previous eLife paper, to which we refer at. Nevertheless, the reviewer is right in asking us not to assume that the reader will have read our previous work. Briefly: DNA replication stress is a term that is loosely defined as the combination of the defects in DNA metabolism and the cellular response to these defects in cells whose replication has been substantially perturbed (Macheret & Halazonetis, 2015). Established methods in the field to induce DNA replication stress consist of either pharmacological treatments or genetic perturbation. Pharmacological treatments include hydroxyurea, which target the ribonucleotide reductase and hence stalls forks as a result of dNTP depletion (Crabbé et al., 2010), or aphidicolin, which directly inhibits polymerases α, ε and δ (Vesela, Chroma, Turi, & Mistrik, 2017b; Wilhelm et al., 2019). For genetic perturbation, the conditional depletion of replicative polymerases (Zheng, Zhang, Wu, Mieczkowski, & Petes, 2016) is frequently used. These methods are incompatible with experimental evolution, as cells can mutate the targets of replication inhibitors or alter the expression of genes that have been reduced in expression or activity. Removing an important but non-essential component of the replication machinery avoids these problems. We chose CTF4 deletion as a manipulation that affected the coordination of events at the replication fork: in the absence of Ctf4, the polα-primase complex is no longer physically bound to the replicative helicase, and thus the polymerase’s abundance at the replisome decreases (Tanaka et al., 2009). This manipulation achieves the same effects as polymerase depletion and replisome stalling, producing a constitutive DNA replication stress that can only be overcome by mutations in other genes. Multiple studies have shown that ctf4**D cells display replication intermediates commonly associated to DNA replication stress, such as the accumulation of ssDNA gaps and reversed forks (Abe et al., 2018; Fumasoni, Zwicky, Vanoli, Lopes, & Branzei, 2015), fork stalling (Fumasoni & Murray, 2020), checkpoint activation (Poli et al., 2012; Tanaka et al., 2009) and altered chromosome metabolism (Kouprina et al., 1992).

      We now justify our choice of deleting CTF4 at line 74:

      “DNA replication stress is often induced with drugs or by reducing the level of DNA polymerases (Crabbé et al., 2010; Vesela, Chroma, Turi, & Mistrik, 2017a; Wilhelm et al., 2019; Zheng et al., 2016). To avoid evolving drug resistance or increased polymerase expression, which would rapidly overcome DNA replication stress,** we deleted the CTF4 gene, which encodes a non-essential subunit of the DNA replication machinery (the replisome) (Kouprina NYu, Pashina, Nikolaishwili, Tsouladze, & Larionov, 1988). Ctf4 is a homo-trimer that functions as a structural hub within the replisome (Villa et al., 2016; Yuan et al., 2019) by binding to the replicative DNA helicase, primase (the enzyme that makes the RNA primers that initiate DNA replication), and other accessory factors (Gambus et al., 2009; Samora et al., 2016; Simon et al., 2014; Villa et al., 2016). In the absence of Ctf4, the Pol**a-primase and other lagging strand processing factors are poorly recruited to the replisome (Samora et al., 2016; Tanaka et al., 2009; Villa et al., 2016), causing several characteristic features of DNA replication stress, such as accumulation of single strand DNA (ssDNA) gaps (Abe et al., 2018; Fumasoni et al., 2015), reversed and stalled forks (Fumasoni & Murray, 2020; Fumasoni et al., 2015), cell cycle checkpoint activation (Poli et al., 2012; Tanaka et al., 2009) and altered chromosome metabolism (Hanna, Kroll, Lundblad, & Spencer, 2001; Kouprina et al., 1992). As a consequence of these defects, ctf4**D cells have substantially reduced reproductive fitness (Fumasoni & Murray, 2020).**”

      Would the authors expect to see similar routes of adaptation if a 'genomic architecture' with a less severe/other replication defect would have been used? I realize the last question is perhaps difficult to address without actually doing the experiment (which I am not suggesting the authors should do); I just want to point out that perhaps some data should not be over-generalized.

      We share the reviewer’s interest in asking whether different forms of DNA replication stress would lead to the same results described, and we plan to rigorously investigate this question in a separate paper. We note that the careful comparison between different forms of DNA replication stress has never been made and that authors studying this phenomenon often rely on a single perturbation to induce DNA replication stress (Crabbé et al., 2010; Wilhelm et al., 2019; Zheng et al., 2016). We agree that such a comparison will be useful, but we believe (as indicated by the reviewer) it will require an amount of work that goes beyond the scope of our study. To avoid over-generalization, we are using now using “a form of DNA replication stress” in lines 33, 244, 401, 414 and 461, to make it clear that our conclusions (as opposed to inferences and speculations) are restricted to the response to a single example of replication stress.

      Likewise, why was RAD52 selected as the gene to delete to affect homologous recombination? I understand that it is a key gene, but on the flipside, absence of RAD52 affects multiple cellular pathways and (as the authors also observe in their populations) also results in increased mutation rates which might confound some of the results.

      We aimed to observe the largest deficiency in DNA recombination possible and therefore chose to delete RAD52 because of its many roles in different forms of homologous recombination (Pâques & Haber, 1999) . The choice of other genes, such as RAD51, would have inhibited canonical double strand break (DSB) repair, but allowed other mechanisms that can rescue stalled replication forks (Ait Saada, Lambert, & Carr, 2018), such as break induced replication (BIR) or single strand annealing (SSA) (Ira & Haber, 2002).

      Our position regarding the inevitable increase in mutations rates obtained while working with genome maintenance process has been instead elaborated in response to reviewer #1 above.

      A sentence describing our choice to delete RAD52 has now been included at line 86:

      “…as well as from haploids impaired in homologous recombination due to the deletion of RAD52 (Figure 1A), which encodes a conserved enzyme required for pairing homologous DNA sequences during recombination (Pâques & Haber, 1999). Because Rad52 is involved in different forms of homologous recombination, it’s absence produces the most severe recombination defects and thus allows us to achieve the largest recombination defect achievable with a single gene deletion (Symington, 2002)..”

      Related to the first comment, it is also unclear to me how well the system chosen by the authors is representative of the replication stress experienced by tumor cells (as briefly touched upon in the final section of the discussion). Are some of the homologs key oncogenes that drive carcinogenesis?

      We should have been clearer. Our goal was to argue that the lesions and responses produced by replication stress in tumor cells, such as stalled replication forks and checkpoint activation, were similar to those seen in yeast cells lacking Ctf4. We did not mean to imply removing Ctf4 from yeast cells had the same effects on cell proliferation and survival as inactivating tumor suppressors and activating proto-oncogenes have in mammalian cells. Despite the difference between direct (removing Ctf4) and indirect effects on DNA replication (tumor cells), the replication intermediates (ssDNA, stalled and reversed forks), the cell cycle defects (G2/M delay), the genetic instability (increased mutagenesis and chromosome loss) and chromosome dynamics (late replication zones and chromosome bridges) generated by the absence of Ctf4 are similar to those observed in oncogene-induced DNA replication stress in mammalian cells (Kotsantis, Petermann, & Boulton, 2018). We therefore believe our experiments reveal evolutionary responses to a constitutive DNA replication stress that resembles the replication stress seen in cancer cells. Nevertheless, we agree that the comparison with cancer evolution remains speculative and we therefore avoided mentioning cancer in the title our paper or our conclusions, and only discuss it in a speculative section of the discussion.

      We have modified this section of the discussion as follows (line 554):

      “While generated through a different mechanism (unrestrained proliferation, rather than replisome perturbation), oncogene induced DNA replication stress produces cellular consequences (Kotsantis et al., 2018) which are remarkably similar to those seen in the absence of Ctf4, such as the accumulation of ssDNA, stalled and reversed forks (Abe et al., 2018; Fumasoni & Murray, 2020; Fumasoni et al., 2015), genetic instability (Fumasoni et al., 2015; Hanna et al., 2001; Kouprina et al., 1992) and DNA damage response activation (Poli et al., 2012; Tanaka et al., 2009). Based on these similarities we speculate that evolutionary adaptation to DNA replication stress could reduce its negative effects on cellular fitness and thus assist tumor evolution.”

      The authors should consider rephrasing some sentences regarding the occurrence of adaptive mutations. Sentences such as 'which genes are mutated depends on the selective advantage' (p1; lines 15-16); 'genome architecture controls the frequency at which mutations occur' (p15), "genome architecture controls which genes are mutated" (p1, line 20) makes it sound like the initial occurrence of mutations is not random, whereas in reality, the mutational landscape is the result of the combined effect of occurrence and fitness effect of the mutations, with the later rather than the former likely being the main driver behind the observed patterns.

      We thank the reviewer for asking for more precision in the above sentences, whose proposed changes we now list:

      “Mutations in individual genes are selected at different frequencies in different architectures, but the benefits these mutations confer are similar in all three architectures, and combinations of these mutations reproduce the fitness gains of evolved populations.” (Lines 13-15)

      “Genome architecture influences the distribution of adaptive mutants” (Line 277)

      "genome architecture influences the frequency at which mutations occur, the fitness benefit they confer, and the extent of overall adaptation." (Lines 462-463)

      Some important methodological information is missing or unclear in the manuscript:

      The authors should provide more details on how they decided which clones to select for sequencing. Did they select the biggest colonies; were colonies picked randomly, ...

      This following sentence is now reported in the materials and methods section (Line 603)

      “To capture the within-population genetic variability we selected the clones displaying the largest divergence of phenotypes in terms of resistance to genotoxic agents (methyl-methanesulfonate, hydroxyurea and camptothecin).”

      What is the population size during the evolution experiment?

      We now added the following sentence at line 599:

      “In this regime, the effective population size is calculated as N0 x g where N0 is the size of the population bottleneck at transfer and g is the number of generations achieved during a batch growth cycle and corresponds to approximately to 107 cells.”

      Sequencing of populations and clones: coverage should be mentioned

      The following sentence has now been added at line 616:

      “Clones and populations were sequenced at approximately the following depths: 25-30X for haploid clones, 50-60X for diploid clones, 50-60X for haploid populations and 120-130X for diploid populations.”

      Identification of mutations (p19, line 573): Is this really how the authors defined whether a variant is a mutation? Based on the definition given here, DNA mutations that lead to a synonymous mutation in the protein are not considered as mutations?

      We apologize for this typo. We do identify and consider synonymous mutations as evidenced by Figure 3-S1B. Now the sentence at line 626 correctly reports:

      “A variant that occurs between the ancestor and an evolved strain is labeled as a mutation if it either (1) causes a substitution in a coding sequence or (2) occurs in a regulatory region, defined as the 500 bp upstream and downstream of the coding sequence.”

      Perhaps the information can be found elsewhere, but the source data excel files for mutations is incomplete and should at the very least contain information on the type of mutation (eg. T->A), as well as the location of this mutation in the respective gene.

      Perhaps the reviewer is referring to Supplementary table 2, where we list the number of times a gene has been mutated in different populations (and thus summaries different types of mutations affecting the same gene). The information they request is reported in Supplementary table 1 for all the variants detected in populations and clones sequencing.

      **Minor comments** • While the author already cite several significant papers relevant for their manuscript, some other studies could also be included:

      We thank the reviewer for highlighting these references, which are now cited at line 28

      From the text in the abstract, it is unclear what the three genomic architectures (line 13) exactly are, the authors should consider spelling this out.

      In repose o the reviewer request for clarity we now propose the following change in line 13:

      “We asked how these trajectories depend on a population’s genome architecture by comparing the adaptation of haploids to that diploids and recombination deficient haploids.” (Lines 9-11)

      Can the authors speculate on why a homozygous ctf4D/ctf4D rad52D/rad52D would be lethal, and a haploid not?

      See below

      The authors note that a diploid ctf4D/ctf4D strain is less fit than its haploid counterpart. Why do the authors think this is the case?

      In response to the two previous questions, we now propose the following speculations that we include in the text (Line 97):

      “Diploid cells require twice as many forks as haploids and Ctf4-deficient diploids are thus more likely to have forks that cause severe cell-cycle delays or cell lethality. We speculate that this increased probability explains the more prominent fitness defect displayed by diploid cells. Interestingly, homologs of Ctf4 are absent in prokaryotes, where the primase is physically linked to the replicative helicase (Lu, Ratnakar, Mohanty, & Bastia, 1996) and Ctf4 is essential in the cells of eukaryotes with larger genomes such as chickens (Abe et al., 2018) and humans (Yoshizawa-Sugata & Masai, 2009). Rad52 is likely involved in rescuing stalled replication forks by recombination-dependent mechanisms (Fumasoni et al., 2015; Yeeles, Poli, Marians, & Pasero, 2013). We speculate that the absence of Rad52 increases the duration of these stalls and leads some of them to become double-stranded breaks resulting in cell lethality and explaining the decreased fitness of ctf4D rad52D haploid double mutants. In diploids ctf4D rad52D cells, which have twice as many chromosomes, the number of irreparably stalled fork may be sufficient to kill most of the cells in a population, thus explaining the unviability of the strain.”

      The authors passage their cells for 100 cycles and assume that this corresponds to around 1000 generations for each population. However, the fitness differences between the different starting strains (see also Figure 1B) are likely to cause considerable differences in number of generations between the different strains. Do the authors have more precise measurements of number of generations per population? If not, perhaps it should be noted that some lineages may have undergone more doublings than others, and perhaps also discuss if and how this could influence the results?

      In a batch culture regime, where populations are allowed to reach saturation after each dilution, the number of generations at each passage are dictated by the dilution factor (Van den Bergh, Swings, Fauvart, & Michiels, 2018). A dilution of 1:1000 from a saturated culture will allow for approximately 10 generations before populations reach a new saturated phase. As long as saturation is allowed to occur, this number is independent of the fitness of the cultured strains: Slower-dividing strains will simply employ more time to reach saturation after each dilution. At the beginning of the experiment, we had to dilute the ctf4D rad52**D strains being passaged every 48hrs instead of 24hrs. After generation 50, ctf4D rad52**D strains reached saturation within 24hrs and were then diluted daily. The total count considers the number of passages a culture has undergone, and not the number of days of culture, and thus should guarantee approximately the same number of generations in all three genome architectures.

      Panel A of figure 1A is somewhat confusing; as this seems to indicate that the ctf4∆ was introduced after strains were made, for example, haploid recombination deficient (which is not how these strains were constructed). Perhaps a better way of representing would be to have the indication of DNA replication stress pictured inside the yeast cells.

      We have modified Figure 1A to better represent the way the strains were constructed. For space reasons we have not represented a perturbed fork within each cell, but rather above all of them.

      Legend to Figure 1: is fitness expressed relative to haploid or diploid WT cells for the diploid strains?

      We apologize for having missed this detail in the figure legends. Throughout the figures, haploid and diploid cells were competed against reference strains with the same ploidy. We now add this sentence in Figure 1 and in the materials and methods (line 686).

      Figure 3: to improve readability of this figure, the authors could consider placing the legend of the different symbols (#, *,..) in the figure as well and not just in the figure legend.

      We now include the symbols legend in Figure 3.

      Figure 5 shows Indels, but if I am correct, these mutations are not discussed in the text; nor is it mentioned what the authors used as a cut-off to determine indels (the authors use the term 'small indels' without defining it)? For example, the data shown in Figure 3 and Figure 4 only includes SNPs and not indels (correct?) - but the indels should also be taken into account when investigating which modules are hit.

      Gapped alignments of the relatively long 150 paired-end reads in our data set permits the identification of small indels ranging in size from 1–55 bp using VarScan pileup2indels tool (Koboldt et al., 2012). All small indels (and the respective sequence affected) are listed together with SNPs in Supplementary table 1. Figure 3A, Figure 4 and Figure 5B are representation of ‘gene mutations’ which include both SNPs and small InDels. Large chromosomal Insertion and deletions, not detectable by short read gap alignment are instead identified using the VarScan pileup2copynumber tool (Koboldt et al., 2012), and are represented as amplifications or deletions in Figure 3B and 5C.

      The following sentence has been added to the material and methods at line 629:

      “Gapped alignments of the 150 paired-end reads in our data set permits the identification of small indels ranging in size from 1–55 bp using VarScan pileup2indels tool (Koboldt et al., 2012). All small indels (and the respective sequence affected) are listed together with SNPs in Supplementary table 1.”

      The following definition has been added in Figure legends 3A, 4 and 5A and B.

      “Gene mutations (SNPs and small InDels 1-55bp)”

      Figure 5 mentions: # gene mutations. So these are only the mutations in genes, and not in their up- or downstream regulatory regions?

      We use a broader definition of a gene, not restricted to the open reading frame, and including its regulatory regions. The following definition has been added to figure 5’s legend.

      “Frequency of SNPs and small InDels (1-55bp) affecting genes (Open reading frames and associated regulatory regions).”

      Figure 3-S1: labels of C panels are missing.

      Labels are now included in Figure 3-S1

      Figure 3-S1, panel B: why did the authors focus on synonymous mutations?

      The panel B is commented upon in line 186 and contrasted with panel A to argue that the increased number of mutations detected in ctf4∆ rad52∆ strains is due to a higher mutation rate(which is expected to increase synonymous mutations) instead of an higher number of adaptive mutations (which are less likely to be synonymous) being selected.

      Reviewer #2 (Significance (Required)): This is a solid and clearly written study, comprising a large body of work that is generally well presented and that will be of interest to scientists active in the field of (experimental) evolution and replication. However, many aspects studied in this manuscript have already been studied and reported before; including the recent eLife paper by the same group, as well as studies by other labs that have investigated how genome architecture / genotype affects evolutionary trajectories, the effect of ploidy on evolution, .... Because of this, I do feel that the authors should put their findings more in the context of existing literature context, including a general description of which results are truly novel, which confirm previous findings and which results seem to go against previous reports. This is already so at some points in the text, but I feel this could be done even more.

      We now rephrase the following paragraphs in our discussion to better highlight the main conclusions in contrast to the existing literature:

      “Engineering one mutation in each module into an ancestral strain lacking Ctf4 is enough to produce the evolved fitness increase in all three genomic architectures. Furthermore, engineering mutations in individual genes confer benefits in all three architectures (Fig. 6A) ,even in those where the mutations in these genes was rare, and combining these mutations recapitulated the evolved fitness increase in all three architectures (Fig. 6B). Altogether our results demonstrate the existence of a common pathway for yeast cells to adapt to a form of constitutive DNA replication stress.” (Lines 409-414)

      “Our results thus go against the trend of slower adaptation in diploids as compared to haploids reported by the majority other studies (A. C. Gerstein, Cleathero, Mandegar, & Otto, 2011; Marad, Buskirk, & Lang, 2018; Zeyl, Vanderford, & Carter, 2003). This effect is not limited to populations experiencing DNA replication stress (Figure 2A) but is also present in control wild-type populations (Figure 2B). Our results support the idea that the details of genotypes, selections, and experimental protocols can determine the effect of ploidy on adaptation.” (Lines 437-442)

      “Our results therefore agree with previous reports observing declining adaptability across strains with different initial fitness but largely fail to observe diminishing return epistasis as a potential justification of this phenomenon. Our experiments and two previous evolutionary repair experiments (Hsieh et al., 2020; Laan et al., 2015) both show interactions that are approximately additive between different selected mutations. The reasons for this difference are currently unknown.” (Lines 450-455)

      Additionally, I think the authors should be more careful not to over-generalize their findings, which come from only a few specific genetic manipulations that might not be representative for general replication stress. For example (p15), can the authors really claim that they have unraveled general principles of adaptation to constitutive DNA replication stress? Perhaps a better motivation of the choice of ctf4 as a model mutation for DNA replication stress could also help (see also my earlier comments). A similar comment applies to the molecular mechanisms affecting adaptation in diploid cells - what evidence do the authors have that their findings are not specific to the one specific type of diploid strain they used in their study? Adding a bit more background information or nuance for some of the claims would help tackle this issue.

      We now followed the suggestions made previously by the reviewer to justify our experimental choices better and to use a language that avoids over-generalizations.

      Field of expertise of this reviewer: genetics, evolution, genomics

      Reviewer #3 (Evidence, reproducibility and clarity (Required)): **Summary:** Here the authors carry out an evolution experiment, propagating replicate populations of the budding yeast with the CTF 4 gene deleted in three different genetic backgrounds: haploid , diploid and recombination deficient (RAD52 deletion). The authors find that the rate of evolution depends on the initial fitness of the different genetic backgrounds which is consistent with a repeated finding of evolution experiments: that beneficial mutations tend to have a smaller fitness effect in high fitness genetic backgrounds. Curiously even though the targets of selection tended to be specific to each of the three different genetic backgrounds, genetic reconstruction experiments showed beneficial mutations convert a fitness increase in all genetics backgrounds. The authors go on to provide a plausible explanation for why each of the three genetic backgrounds are predisposed to certain types of beneficial mutations. Overall, these results provide important context and caveats for an emerging consensus that genetic background determines the rate of evolution, a comprehensive molecular breakdown of adaptation to DNA replication stress and a mechanistic explanation for why different beneficial mutations are favoured in diploids, haploids and recombination deficient strains. This is a well-executed study that is beautifully presented and easy to follow. This will be of great interest to those in the experimental evolution community and the data an excellent resource.

      We thank reviewer #3 for emphasizing that reconstructed mutations are beneficial even in architectures where they were not ultimately detected at the end of the experiment. We have now highlighted this point in our conclusions as a response to the reviewer’s #1 and #2 request for more clarity regarding our novel findings.

      “We find that the genes that acquire adaptive mutations, the frequency at which they are mutated, and the frequency at which these mutations are selected all differ between architectures but that mutations that confer strong benefits can occur in all three modules in each architecture. Engineering one mutation in each module into an ancestral strain lacking Ctf4 is enough to produce the evolved fitness increase in all three genomic architectures. Furthermore, reconstruction of a panel of mutations into all three architectures proved they are adaptive even in architectures where the affected genes were not found significantly mutated by the end of the experiment. Altogether our results demonstrate the existence of a common pathway for yeast cells to adapt to a form of constitutive DNA replication stress.” (Lines 405-414)

      **Major comments:**

      • Are the key conclusions convincing? Yes, the convergent evolution analysis, fitness assays, and genetic reconstructions are sufficient to characterise the genetic causes of adaptation in this experiment, and are of the highest standard. The authors do particularly well to fully recover the fitness increases that evolved with their genetic reconstructions, which imparts a completeness to their understanding of what happened in their evolution experiment.
      • Should the authors qualify some of their claims as preliminary or speculative, or remove them altogether? No, in nearly all cases the authors make reasonable claims. One exception is on L419 in the discussion, where the authors speculate why some mutations do not follow diminishing returns epistasis, but this idea does not really have any basis (no citation or reasons to suggest that DNA repair genes are less connected with other genes in the genome). If the authors cannot support this statement, it should be removed, and instead write that is currently unknown why some individual mutations do not follow the pattern of diminishing returns.

      On reflection, we agree with the reviewer and now state,

      “Our results confirm previous reports observing declining adaptability across strains with different initial fitness but largely fail to observe diminishing return epistasis as a potential justification of this phenomenon. Our experiments and two previous evolutionary repair experiments (Hsieh et al., 2020; Laan et al., 2015) both show interactions that are approximately additive between different selected mutations. The reasons for this difference are currently unknown.

      A hypothesis, which would need experimental validation, could be that the different mutations have different degrees of epistatic interactions with the rest of the genome. Ixr1, whose mutation follows diminishing return epistasis, is a transcription factor that could in principle affect the expression of many other genes implicated in different cellular modules. Sld5, Scc2 and Rad9 instead, whose mutations have the same effect across different genome architectures, having more mechanistic roles in genome maintenance may have strong epistatic interactions only with a restricted number of cellular modules implicated with DNA metabolism.

      • Would additional experiments be essential to support the claims of the paper? No.
        • Are the data and the methods presented in such a way that they can be reproduced? Yes, but some more details are needed for the convergent evolution analysis, see minor comments.
        • Are the experiments adequately replicated and statistical analysis adequate? Yes, but some more statistic reporting in the main text or figure legends would be helpful, for example. L159: Please report the statistical test, test statistic and p value in the text or in the figure legend. Currently significance is indicated, but the methods do not specify the test.

      We apologize for the lack of clarity in the main text. The test used for all fitness analysis was only reported in the materials and methods as follow:

      “The P-values reported in figures are the result of t-tests assuming unequal variances (Welch’s test)”

      We now include the test and the associated p-value in line 184, and write the above sentence in all the relevant figures.

      This should also be done for the GO analysis shown in figure 3A.

      We thank reviewer #3 pointing out this omission. We now include the following section:

      “Gene ontology (GO) enrichment analysis:

      The list of genes with putatively selected mutations (Figure 3A) or homozygous mutations in diploids (Figure 4) were input as ‘multiple proteins’ in the STRING database, which reports on the network of interactions between the input genes (https://string-db.org). The GO term enrichment analysis provided by STRING are reported in Supplementary Table 3 and Supplementary Table 6 respectively. Briefly, the strength of the enrichment is calculated as Log10(O/E), where O is the number of ‘observed’ genes in the provided list (of length N) which belong to the GO-term, and E is the number of ‘expected’ genes we would expect to find matching the GO-term providing a list of the same length N made of randomly picked genes. P-values are computed using a Hypergeometric test and corrected for multiple testing using the Benjamini-Hochberg procedure. The resulting P-values are represented as ‘False discovery rate’ in the supplementary tables and describe the significance of the GO terms enrichment (Franceschini et al., 2013).”

      **Minor comments:**

      • Specific experimental issues that are easily addressable. Not a new experiment, but extra details are required. The authors carried out both clone and whole population sequencing. For their convergent evolution analysis, what is the criteria for a mutation to be included- ie, does it need to be fixed, have attained a certain frequency? This is important- if the criteria were low (say 5%), it would be important to know whether gene A had fixed in 4 populations, while gene B had attained a frequency of 10% in 5 populations. As it stands both would be described as examples of convergent evolution. This can be handled by providing these details in the methods.

      For the population sequencing we disregarded variants found at less than 25% and 35% of the reads in haploid and diploid populations respectively as we observed they were largely the product of alignment errors. All the variants found at frequencies higher than the thresholds indicated were used for the parallel evolution analysis. The frequency at which each individual variant was detected in each population is reported in Supplementary table 1, while the average frequency at which a gene has been found mutated across different populations is reported in Supplementary table 2. The reason why we didn’t solely focus on fixed mutations for our convergent evolution analysis was that from previous work we knew of the existence of clonal interference which kept the frequency of verified adaptive mutations that coexisted in the same population (e.g. ixr1 and sld5) well below 90% (Fumasoni & Murray, 2020).

      For clarity we now add the following sentence in the material and methods:

      “Variants found in less than 25% and 35% of the reads in haploid and diploid populations respectively were discarded, since many of these corresponded to misalignment of repeated regions. For clone sequencing, only variants found in more than 75% of the reads in haploids and 35% of the reads in diploids (to account for heterozygosity) were considered mutations. The frequency of the reads associated with all the variants detected are reported in Supplementary table 1”

      • Are prior studies referenced appropriately? I note that the authors use the term declining adaptability where as other papers use the term diminishing returns epistasis- I am sure the authors have good reasons for their choice of nomenclature but I think it would be helpful for their readers to connect this work to other work by mentioning that declining adaptability is also referred to as diminishing returns.

      We use both terms (for instance in line 446 and line 448) with a different meaning : By ‘declining adaptability’ we refer the phenomenon where more fit strains display lower adaptation rates than less fit ones. By ‘diminishing returns epistasis’ we refer to a possible explanation of such a phenomenon, where adaptive mutations have different fitness effects due to their ‘global’ epistatic interactions with other alleles. It has to be noted that ‘diminishing returns epistasis’ is not the only proposed explanation of the phenomenon of declining adaptability (Couce & Tenaillon, 2015). In our case, we do find evidence of declining adaptability but very limited evidence for diminishing return epistasis (only 1 mutation in 5 has a different fitness effect in different architectures).

      A reference the authors have missed: L419, as well as citing the Desai Lab bioxive paper, they should cite another theory paper that obtained similar conclusions. Lyons, D.M., et al. https://doi.org/10.1038/s41559-020-01286-y.

      We thank the reviewer for the suggested reference, which is now cited at line 450.

      • Are the text and figures clear and accurate? This paper is beautifully written and easy to follow, a lot of thought has gone into the figures which are aesthetically pleasing and easy to navigate.

        • Do you have suggestions that would help the authors improve the presentation of their data and conclusions? No.

        **Typos**

        L32 "do" should be "to" L95 analyzed L219 are the authors referring to ref 15 here? I think so, but please specify

      We thank the reviewer for carefully finding the typos, which are now all corrected.

      Reviewer #3 (Significance (Required)):

      • Describe the nature and significance of the advance (e.g. conceptual, technical, clinical) for the field. This paper is an important conceptual result and an immediate advance for basic research. The authors have done an outstanding job of showing the potential for the clinical translation of this research, especially regarding cancer biology.
      • Place the work in the context of the existing literature (provide references, where appropriate). This study follows up on and builds upon an earlier paper by these same authors published in E-life in 2020. Conceptually this work is most closely related to work in Michael Desai's, Sergey Kryazhimskiy's, Tim Coopers and Chris Marx's labs work looking at diminishing returns epistasis in yeast, and studies contrasting evolution of haploids and diploids led by Greg Lang's and Sarah Otto's labs.
      • State what audience might be interested in and influenced by the reported findings. This work will be of great interest to the Experimental evolution and molecular evolution communities and also of interest to those who study cancer genomics and DNA replication and repair.
      • Define your field of expertise with a few keywords to help the authors contextualize your point of view. Indicate if there are any parts of the paper that you do not have sufficient expertise to evaluate. Microbial experimental evolution.

      REFERENCES CITED IN THE REVIEW RESPONSE

      Abe, T., Kawasumi, R., Giannattasio, M., Dusi, S., Yoshimoto, Y., Miyata, K., … Branzei, D. (2018). AND-1 fork protection function prevents fork resection and is essential for proliferation. Nature Communications, 9(1), 3091. https://doi.org/10.1038/s41467-018-05586-7

      Ait Saada, A., Lambert, S. A. E., & Carr, A. M. (2018, November 1). Preserving replication fork integrity and competence via the homologous recombination pathway. DNA Repair. Elsevier B.V. https://doi.org/10.1016/j.dnarep.2018.08.017

      Couce, A., & Tenaillon, O. A. (2015). The rule of declining adaptability in microbial evolution experiments. Frontiers in Genetics, 6(MAR), 99. https://doi.org/10.3389/fgene.2015.00099

      Crabbé, L., Thomas, A., Pantesco, V., De Vos, J., Pasero, P., & Lengronne, A. (2010). Analysis of replication profiles reveals key role of RFC-Ctf18 in yeast replication stress response. Nature Structural & Molecular Biology, 17(11), 1391–1397. https://doi.org/10.1038/nsmb.1932

      Desai, M. M., Fisher, D. S., & Murray, A. W. (2007). The speed of evolution and maintenance of variation in asexual populations. Current Biology : CB, 17(5), 385–394. https://doi.org/10.1016/j.cub.2007.01.072

      Deutschbauer, A. M., Jaramillo, D. F., Proctor, M., Kumm, J., Hillenmeyer, M. E., Davis, R. W., … Giaever, G. (2005). Mechanisms of Haploinsufficiency Revealed by Genome-Wide Profiling in Yeast. Genetics, 169(4), 1915–1925. https://doi.org/10.1534/GENETICS.104.036871

      Franceschini, A., Szklarczyk, D., Frankild, S., Kuhn, M., Simonovic, M., Roth, A., … Jensen, L. J. (2013). STRING v9.1: Protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Research, 41(D1), D808. https://doi.org/10.1093/nar/gks1094

      Fumasoni, M., & Murray, A. W. (2020). The evolutionary plasticity of chromosome metabolism allows adaptation to constitutive DNA replication stress. ELife, 9. https://doi.org/10.7554/eLife.51963

      Fumasoni, M., Zwicky, K., Vanoli, F., Lopes, M., & Branzei, D. (2015). Error-Free DNA Damage Tolerance and Sister Chromatid Proximity during DNA Replication Rely on the Polα/Primase/Ctf4 Complex. Molecular Cell, 57(5), 812–823. https://doi.org/10.1016/j.molcel.2014.12.038

      Gambus, A., van Deursen, F., Polychronopoulos, D., Foltman, M., Jones, R. C., Edmondson, R. D., … Labib, K. (2009). A key role for Ctf4 in coupling the MCM2-7 helicase to DNA polymerase alpha within the eukaryotic replisome. EMBO J., 28(19), 2992–3004. https://doi.org/10.1038/emboj.2009.226

      Gerstein, A. C., Cleathero, L. A., Mandegar, M. A., & Otto, S. P. (2011). Haploids adapt faster than diploids across a range of environments. Journal of Evolutionary Biology, 24(3), 531–540. https://doi.org/10.1111/j.1420-9101.2010.02188.x

      Gerstein, Aleeza C., & Otto, S. P. (2011). Cryptic fitness advantage: Diploids invade haploid populations despite lacking any apparent advantage as measured by standard fitness assays. PLoS ONE, 6(12), 26599. https://doi.org/10.1371/journal.pone.0026599

      Gerstein, Aleeza C, Chun, H.-J. E., Grant, A., & Otto, S. P. (2006). Genomic Convergence toward Diploidy in Saccharomyces cerevisiae. PLoS Genetics, 2(9), e145. https://doi.org/10.1371/journal.pgen.0020145

      Hanna, J. S., Kroll, E. S., Lundblad, V., & Spencer, F. a. (2001). Saccharomyces cerevisiae CTF18 and CTF4 are required for sister chromatid cohesion. Mol Cell Biol., 21(9), 3144–3158. https://doi.org/10.1128/MCB.21.9.3144-3158.2001

      Harari, Y., Ram, Y., Rappoport, N., Hadany, L., & Kupiec, M. (2018). Spontaneous Changes in Ploidy Are Common in Yeast. Current Biology, 28(6), 825-835.e4. https://doi.org/10.1016/j.cub.2018.01.062

      Hsieh, Y. Y. P., Makrantoni, V., Robertson, D., Marston, A. L., & Murray, A. W. (2020). Evolutionary repair: Changes in multiple functional modules allow meiotic cohesin to support mitosis. PLoS Biology, 18(3), e3000635. https://doi.org/10.1371/journal.pbio.3000635

      Ira, G., & Haber, J. E. (2002). Characterization of RAD51-independent break-induced replication that acts preferentially with short homologous sequences. Molecular and Cellular Biology, 22(18), 6384–6392. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12192038

      Koboldt, D. C., Zhang, Q., Larson, D. E., Shen, D., McLellan, M. D., Lin, L., … Wilson, R. K. (2012). VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Research, 22(3), 568–576. https://doi.org/10.1101/gr.129684.111

      Kotsantis, P., Petermann, E., & Boulton, S. J. (2018, May 1). Mechanisms of oncogene-induced replication stress: Jigsaw falling into place. Cancer Discovery. American Association for Cancer Research Inc. https://doi.org/10.1158/2159-8290.CD-17-1461

      Kouprina, N., Kroll, E., Bannikov, V., Bliskovsky, V., Gizatullin, R., Kirillov, A., … et al. (1992). CTF4 (CHL15) mutants exhibit defective DNA metabolism in the yeast Saccharomyces cerevisiae. Mol Cell Biol., 12(12), 5736–5747. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/1341195

      Kouprina NYu, Pashina, O. B., Nikolaishwili, N. T., Tsouladze, A. M., & Larionov, V. L. (1988). Genetic control of chromosome stability in the yeast Saccharomyces cerevisiae. Yeast (Chichester, England), 4(4), 257–269. https://doi.org/10.1002/yea.320040404

      Kryazhimskiy, S., Rice, D. P., Jerison, E. R., & Desai, M. M. (2014). Microbial evolution. Global epistasis makes adaptation predictable despite sequence-level stochasticity. Science (New York, N.Y.), 344(6191), 1519–1522. https://doi.org/10.1126/science.1250939

      Laan, L., Koschwanez, J. H., & Murray, A. W. (2015). Evolutionary adaptation after crippling cell polarization follows reproducible trajectories. ELife, 4, e09638. https://doi.org/10.7554/eLife.09638

      Lu, Y. B., Ratnakar, P. V, Mohanty, B. K., & Bastia, D. (1996). Direct physical interaction between DnaG primase and DnaB helicase of Escherichia coli is necessary for optimal synthesis of primer RNA. Proc. Natl. Acad. Sci. USA, 93(23), 12902–12907. https://doi.org/10.1073/pnas.93.23.12902

      Macheret, M., & Halazonetis, T. D. (2015). DNA replication stress as a hallmark of cancer. Annu. Rev. Pathol. Mech. Dis., 10, 425–448. https://doi.org/10.1146/annurev-pathol-012414-040424

      Marad, D. A., Buskirk, S. W., & Lang, G. I. (2018). Altered access to beneficial mutations slows adaptation and biases fixed mutations in diploids. Nature Ecology & Evolution, 2(5), 882–889. https://doi.org/10.1038/s41559-018-0503-9

      Pâques, F., & Haber, J. E. (1999). Multiple pathways of recombination induced by double-strand breaks in Saccharomyces cerevisiae. Microbiology and Molecular Biology Reviews : MMBR, 63(2), 349–404. https://doi.org/

      Poli, J., Tsaponina, O., Crabbé, L., Keszthelyi, A., Pantesco, V., Chabes, A., … Rothstein, R. (2012). dNTP pools determine fork progression and origin usage under replication stress. EMBO J., 31(4), 883–894. https://doi.org/10.1038/emboj.2011.470

      Samora, C. P., Saksouk, J., Goswami, P., Wade, B. O., Singleton, M. R., Bates, P. A., … Masai, H. (2016). Ctf4 Links DNA Replication with Sister Chromatid Cohesion Establishment by Recruiting the Chl1 Helicase to the Replisome. Molecular Cell, 63(3), 371–384. https://doi.org/10.1016/j.molcel.2016.05.036

      Simon, A. C., Zhou, J. C., Perera, R. L., van Deursen, F., Evrin, C., Ivanova, M. E., … Pellegrini, L. (2014). A Ctf4 trimer couples the CMG helicase to DNA polymerase alpha in the eukaryotic replisome. Nature, 510(7504), 293–297. https://doi.org/10.1038/nature13234

      Symington, L. S. (2002). Role of RAD52 Epistasis Group Genes in Homologous Recombination and Double-Strand Break Repair. Microbiology and Molecular Biology Reviews, 66(4), 630–670. https://doi.org/10.1128/mmbr.66.4.630-670.2002

      Tanaka, H., Katou, Y., Yagura, M., Saitoh, K., Itoh, T., Araki, H., … Shirahige, K. (2009). Ctf4 coordinates the progression of helicase and DNA polymerase alpha. Genes to Cells, 14(7), 807–820. https://doi.org/10.1111/j.1365-2443.2009.01310.x

      Thompson, D. A., Desai, M. M., & Murray, A. W. (2006). Ploidy controls the success of mutators and nature of mutations during budding yeast evolution. Current Biology : CB, 16(16), 1581–1590. https://doi.org/10.1016/j.cub.2006.06.070

      Van den Bergh, B., Swings, T., Fauvart, M., & Michiels, J. (2018). Experimental Design, Population Dynamics, and Diversity in Microbial Experimental Evolution. Microbiol Mol Biol Rev., 82(3), e00008-18. https://doi.org/10.1128/MMBR.00008-18

      Venkataram, S., Dunn, B., Li, Y., Agarwala, A., Chang, J., Ebel, E. R., … Petrov, D. A. (2016). Development of a Comprehensive Genotype-to-Fitness Map of Adaptation-Driving Mutations in Yeast. Cell, 166(6), 1585-1596.e22. https://doi.org/10.1016/J.CELL.2016.08.002

      Vesela, E., Chroma, K., Turi, Z., & Mistrik, M. (2017a). Common Chemical Inductors of Replication Stress: Focus on Cell‐Based Studies. Biomolecules, 7(1), 19. https://doi.org/10.3390/biom7010019

      Vesela, E., Chroma, K., Turi, Z., & Mistrik, M. (2017b, February 21). Common chemical inductors of replication stress: Focus on cell-based studies. Biomolecules. MDPI AG. https://doi.org/10.3390/biom7010019

      Villa, F., Simon, A. C., Ortiz Bazan, M. A., Kilkenny, M. L., Wirthensohn, D., Wightman, M., … Dutta, A. (2016). Ctf4 Is a Hub in the Eukaryotic Replisome that Links Multiple CIP-Box Proteins to the CMG Helicase. Molecular Cell, 63(3), 385–396. https://doi.org/10.1016/j.molcel.2016.06.009

      Wilhelm, T., Olziersky, A. M., Harry, D., De Sousa, F., Vassal, H., Eskat, A., & Meraldi, P. (2019). Mild replication stress causes chromosome mis-segregation via premature centriole disengagement. Nature Communications, 10(1), 1–14. https://doi.org/10.1038/s41467-019-11584-0

      Yeeles, J. T., Poli, J., Marians, K. J., & Pasero, P. (2013). Rescuing stalled or damaged replication forks. Cold Spring Harbor Perspectives in Biology, 5(5), a012815. https://doi.org/10.1101/cshperspect.a012815

      Yoshizawa-Sugata, N., & Masai, H. (2009). Roles of human AND-1 in chromosome transactions in S phase. J Biol Chem., 284(31), 20718–20728. https://doi.org/10.1074/jbc.M806711200

      Yuan, Z., Georgescu, R., Santos, R. de L. A., Zhang, D., Bai, L., Yao, N. Y., … Li, H. (2019). Ctf4 organizes sister replisomes and Pol α into a replication factory. ELife, 8, e47405. https://doi.org/10.7554/eLife.47405

      Zeyl, C., Vanderford, T., & Carter, M. (2003). An Evolutionary Advantage of Haploidy in Large Yeast Populations. Science, 299(5606), 555–558. https://doi.org/10.1126/SCIENCE.1078417

      Zheng, D.-Q., Zhang, K., Wu, X.-C., Mieczkowski, P. A., & Petes, T. D. (2016). Global analysis of genomic instability caused by DNA replication stress in Saccharomyces cerevisiae. Proc Natl Acad Sci U S A., 113(50), E8114–E8121. https://doi.org/10.1073/pnas.1618129113

    1. The “posterior” head of Smedβ-catenin-a(RNAi) and SmedDvl-a/b(RNAi) animals contained a characteristically anterior nervous system and gut as did the “anterior” head (Fig. 1H,I,L,M). In contrast, the “anterior” tail of SmedAPC(RNAi) animals was devoid of discernible brain tissue and exhibited posterior structures as did the “posterior” tail (Fig. 1J,N).

      Researchers examined the regerated structures beyond the surface level by examing two organs of the CNS. The presence or lack there of indicated the degree of the erroneous regeneration, and isolate the genes relationship to the development of those structures. Missing here is a description of the viability of the animals in their post amputated state, or the number of animals that survived amputation.

    1. Author Response:

      Summary:

      While the work addresses an interesting research question, several shortcomings have been raised by three independent reviewers. A first issue is the lack of theoretical clarity and linkage with prior work, as discussed by Reviewer 1 and Reviewer 2. A second critical set of concerns is raised by all reviewers with the need for several additional analyses to nail down the interpretations proposed by the authors. Reviewer 2 specifically raised concerns regarding the interpretability of activation in auditory cortices, while Reviewer 3 provides insights on the MVPA analysis and suggests the possible use of RSA to clarify the main findings.

      While we respect the editor’s decision, we think that all points raised by Reviewer 1 and Reviewer 3 can be easily addressed through editing of the text and additional analyses. As we describe below, these revisions do not undermine the findings reported in our study – instead, they improve the clarity of the manuscript and further demonstrate that our results are genuine and robust. Furthermore, we believe that points raised by Reviewer 2 are based on misunderstanding. Differences in auditory properties across sound categories in our experiment cannot explain the pattern of results reported. Thus, additional analyses in the auditory cortex, proposed by Reviewer 2, can neither support nor undermine the claims made in our study. Nevertheless, we performed all the analyses suggested by the Reviewer 2.

      We also want to stress that all reviewers find our study timely and interesting for broad readership. Furthermore, Reviewer 1 and Reviewer 3 made a number of positive comments on study methodology. Overall, we believe that there are no doubts regarding the novelty and importance of our study, and that we are able to address all additional methodological concerns raised by the reviewers.

      Reviewer #1:

      Bola and colleagues asked whether the coupling in perception-action systems may be reflected in early representations of the face. The authors used fMRI to assess the responses of the human occipital temporal cortex (FFA in particular) to the presentation of emotional (laughing/crying), non-emotional (yawning/sneezing), speech (Chinese), object and animal sounds of congenitally blind and sighted participants. The authors present a detailed set of independent and direct univariate and multivariate contrasts, which highlight a striking difference of engagement to facial expressions in the OTC of the congenitally blind compared to the sighted participants. The specificity of facial expression sounds in OTC for the congenitally blind is well captured in the final MVPA analysis presented in Fig.5.

      We would like to thank the reviewer for an overall positive assessment of our work.

      -The use of "transparency of mapping" is rather metaphorical and hand-wavy for a non-expert audience. If the issue relates to the notion of compatibility of representational formats, then it should be expressed formally.

      Following the reviewer’s suggestion, we revised the introduction and clarified what we mean by “transparency of mapping”, and how this concept might be related to the compatibility of representations computed in different areas of the brain. As is now extensively explained, we propose that shape features of inanimate objects are directly relevant to our actions. In contrast, a relationship between shape and relevant actions is much less clear in the case of most animate objects. We hypothesized that this inherent difference between the inanimate and the animate domain, combined with evolutionary pressures for quick, accurate, and efficient object-directed responses, resulted in the inanimate vOTC areas being more strongly coupled with the action system, both in terms of manipulability and navigation, than the animate vOTC areas. The stronger coupling is likely to be reflected in the format of vOTC shape representation of inanimate objects being more compatible with the format of representations computed in the action system.

      -The theoretical stance of the authors does not clearly predict why blind individuals should show more precise emotional expressions in FFA as compared to sighted - as the authors start addressing in their Discussion. In the context of the action-perception loop, it is even more surprising considering that the sighted have direct training and visual access to the facial gestures of interlocutors, which they can internalize. Can the authors entertain alternative scenarios such as the need to rely on mental imagery for congenitally blind for instance?

      We agree that our approach does not predict the difference between the blind and the sighted subjects, and we openly discuss this in the discussion: “An unexpected finding in our study is the clear difference in vOTC univariate response to facial expression sounds across the congenitally blind and the sighted group”. We also propose an explanation of this unexpected difference. Specifically, we suggest that the interactions between the action system and the animate areas in the vOTC are relatively weak, even in the case of facial expressions – thus, they can be captured mostly in blind individuals, whose visual areas are known to increase their sensitivity to non-visual stimulation. This explanation can account for this unexpected between-group difference and is consistent with our theoretical proposal.

      The “mental imagery account” can be, in our opinion, divided into two distinct hypotheses. One version of this account would be to assume that the representation of animate entities typically computed in the vOTC (i.e., also in sighted people) can be activated through visual mental imagery (as suggested by several previous studies), and that this would affect our between-group comparisons. In that case, however, we should observe an effect opposite to that obtained in our study – namely, the activation in the vOTC animate areas should be stronger in the sighted subjects, since they, but not the congenitally blind participants, can create visual mental images (as the reviewer pointed out). This is clearly not what we observed. A second version of the mental imagery account would be to assume representational plasticity in the vOTC of blind individuals – that is, to assume that vOTC animate areas in this population switch from representing visually, face-related information to representing motor mental imagery, which presumably they can generate just like sighted individuals. However, such an account does not, on its own, explain why the animate vOTC areas in the congenitally blind participants are more strongly activated than they are in the sighted subjects, who can generate both visual and motor mental imagery. Based on these considerations, we do not think that the mental imagery account provides a sufficient explanation. Nonetheless, it is certainly a factor worth considering, which we add in a revised discussion of the reported results. Similar reasoning can be applied to other accounts which assume that the observed difference between the blind and the sighted group is a result of representational plasticity in this region in the blind group. Such accounts would need to propose a plausible dimension, different than face shape and its relation to the action system, that is captured by the animate vOTC areas in blind individuals. Since the effect we report is independent of auditory, emotional, social or linguistic dimensions present in our stimuli, it is hard to say what this dimension might be.

      We now elaborate on these important points in the Discussion section.

      Reviewer #2:

      The study by Bola and colleagues tested the specific hypothesis that visual shape representations can be reliably activated through different sensory modalities only when they systematically map onto action system computations. To this aim, the authors scanned a group of congenitally blind individuals and a group of sighted controls while subjects listened to multiple sound categories.

      While I find the study of general interest, I think that there are main methodological limitations, which do not allow to support the general claim.

      We would like to thank the reviewer for this assessment. Below, we argue that the results presented in the paper support our claim, and that they cannot be explained by alternative accounts described by the reviewer.

      Main concerns

      1) Auditory stimuli have been equalized to have the same RMS (-20 dB). In my opinion, this is not a sufficient control. As shown in Figure 3 - figure supplement 1, the different sound categories elicited extremely different patterns of response in A1. This is clearly linked to intrinsic sound properties. In my opinion without a precise characterization of sound properties across categories, it is not possible to conclude that the observed effects in face responsive regions (incidentally, as assessed using an atlas and not a localizer) are explained by the different category types. On the stimulus side, authors should at least provide (a) spectrograms and (b) envelope dynamics; in case sound properties would differ across categories all results might have a confound associated to stimuli selection.

      We now present spectrograms and waveforms for sounds used in the study in the Methods section. We did not present this information in the original version of the paper because, in our opinion, it is quite obvious that sounds from different categories will differ in terms of their auditory properties – after all, this is why we can distinguish among human speech, animal sounds or object sounds. Thus, differences in sound properties across conditions are an inherent characteristic of every study comparing sounds from several domains or semantic categories (e.g., human vs. non-human), including our own study. We now clarify this issue in the Methods section of the manuscript.

      Having said that, we believe that differences in acoustic properties across sound categories cannot explain the results in the vOTC, reported in our work. We report that, in blind subjects, the vOTC face areas respond more strongly to sounds of emotional facial expressions and non-emotional facial expressions than to speech sounds, animal sounds and object sounds. These brain areas did not show differential responses to two expression categories or to three other sound categories. To explain this pattern of results, the “acoustic confound account” would need to assume that there is some special auditory property that differentiate both types of expression sounds, but does not differentiate sound categories in any other comparison. Moreover, this account would need to further assume that this is precisely the auditory dimension to which the vOTC face areas are sensitive, while being insensitive to other auditory characteristics, different across the other sound categories (e.g., across object sounds and animal sounds, or expression sounds and speech sounds - as the reviewer pointed out, all categories are acoustically very different, as indicated by the activation of A1). We find this account extremely unlikely. We now comment on these points in the Methods and the Results section.

      2) More on the same point: the authors use the activation of A1 as a further validation of the results in face selective areas. Page 16 line 304 "We observed activation pattern that was the same for the blind and the sighted subjects, and markedly different from the pattern that was observed in the fusiform gyrus in the blind group (see Fig. 1D). This suggests that the effects detected in this region in the blind subjects were not driven by the differences in acoustic characteristics of sounds, as such characteristics are likely to be captured by activation patterns of the primary auditory cortex." It is the opinion of this reader that this control, despite being important, does not support the claim. A1 is certainly a good region to show how basic sound properties are mapped. However, the same type of analysis should be performed in higher auditory areas, as STS. If result patterns would be similar to the FFA region, I guess that the current interpretation of results would not hold.

      As we discuss above, we believe that the explanation of the results observed in the vOTC in terms of “acoustic confound” does not hold, even without any empirical analysis in the auditory cortex. The analysis in A1 was planned to clearly illustrate this point and to support interpretation of potential unexpected pattern of results across sound categories (such an unexpected pattern was not observed).

      However, per reviewer’s request, we performed an ROI analysis also in the STS. Specifically, we chose two ROIs – a broad and bilateral ROI covering the whole STS, and a more constrained ROI covering the right posterior STS (rpSTS), known to be a part of the face processing network and to respond primarily to dynamic aspects of the face shape. As can be seen in Supplementary Materials, the broad STS ROI pattern of responses is markedly different from the one observed in the FFA. Particularly, the magnitude of the STS activation is clearly different for speech sounds, animal sounds, and objects sounds, in both the blind and the sighted group. In the case of the FFA, the activation magnitudes for these three sound categories were indistinguishable. Furthermore, in the blind group, the STS showed stronger activation for emotional facial expression sounds than for non-emotional expression sounds. Again, such a difference was not observed in the FFA (if anything, the FFA showed slightly stronger activation for non-emotional expression sounds in the blind group). The pattern of the rpSTS responses is more similar to the responses observed in the FFA. This is exactly what can be expected based on our hypothesis that the FFA in the blind group is sensitive primarily to dynamic facial reconfigurations, with transparent link between the motoric and visual shape representations. Overall, we think that the pattern of results observed in the auditory cortex is fully in line with our hypothesis – the auditory regions (A1 and STS, defined broadly) show responses that are different than the responses observed in the FFA (one may hypothesize that responses in the auditory regions are driven by low-level auditory features of stimuli to a larger extent); the rpSTS, which is specialized in the processing of dynamic aspects of the face shape, shows the pattern of responses that is more similar to the pattern of responses observed in the FFA. Importantly, the responses in the rpSTS were not different across subject groups. As we describe below, this is the pattern of results that was observed also in MVPA. We now report all the above-described results in the paper.

      3) Linked to the previous point. Given that the authors implemented a MPVA pipeline at the ROI level, it is important to perform the same analysis in both groups, but especially in the blind, in areas such as STS as well as in a control region, engaged by the task (with signal) to check the specificity of the FFA activation.

      Per reviewer’s request, we additionally performed the MVPA in three control regions. Firstly, we performed the analysis in the auditory cortex, defined as A1 and the STS combined. We treated this area as a positive control – particularly, given the acoustic differences between sound categories, we expected to successfully decode all sound categories from the activity of this ROI. Secondly, we performed the analysis in the parahippocampal place area (PPA). We treated the PPA as a negative control – given that this area does not seem to contain much information about animate entities, we did not expect to find effects there for most of our comparisons. Furthermore, as the PPA is the vOTC area bordering the FFA, the negative results in this area would be a proof of spatial specificity of our results. Thirdly, we performed the analysis in the rpSTS – here, we expected to observe the results similar to the ones observed in the FFA, for the reasons provided above. We now present the results of these analyses as supplementary figures.

      We were able to successfully distinguish all sound categories, in both groups, based on the activation of the auditory cortex (all p = 0.001; the lowest value that can be achieved in our permutation analysis). Furthermore, based on the activation of this area, we were able to classify specific facial expressions, specific speech sounds, and the gender of the actor, in contrast to the result from the FFA, where the decoding of facial expressions was the only positive result.

      As expected, the decoding of animate sound categories was generally not successful in the PPA. However, as one might expect, activation of this area allowed us, to some extent, to distinguish object sounds from animate sounds – especially in the blind group. Furthermore, based on the PPA activation, we were not able to classify specific facial expressions, speech sounds, or the gender of the actor. These results confirm that the results reported for the FFA are specific to only certain parts of the brain and even certain parts of the vOTC.

      As can be expected, the results in the rpSTS were the most similar to the results observed in the FFA – while the activation of this region was diagnostic of all categorical distinctions, the more detailed analysis showed that this region represented differences between specific facial expressions, but not between the speech sounds or the gender of actors acting the expressions (the similar pattern of results was observed in both groups). This is the same specificity that the FFA in blind people show.

      Finally, we would like to stress that the difference between results observed in the FFA and the PPA is yet another argument against interpreting the results in the FFA as being driven by auditory properties of stimuli – the issue that we discussed in details above. We do not see the reason why putative acoustic influences on the vOTC responses in the blind group should be present in the FFA, but not in the PPA.

      4) I find the manuscript rather biased with regard to the literature. This is a topic which has been extensively investigated in the past. For instance, the manuscript does not include relevant references for the present context, such as:

      Plaza, P., Renier, L., De Volder, A., & Rauschecker, J. (2015). Seeing faces with your ears activates the left fusiform face area, especially when you're blind. Journal of vision, 15(12), 197-197.

      Kitada, R., Okamoto, Y., Sasaki, A. T., Kochiyama, T., Miyahara, M., Lederman, S. J., & Sadato, N. (2013). Early visual experience and the recognition of basic facial expressions: involvement of the middle temporal and inferior frontal gyri during haptic identification by the early blind. Frontiers in human neuroscience, 7, 7.

      Pietrini, P., Furey, M. L., Ricciardi, E., Gobbini, M. I., Wu, W. H. C., Cohen, L., ... & Haxby, J. V. (2004). Beyond sensory images: Object-based representation in the human ventral pathway. Proceedings of the National Academy of Sciences, 101(15), 5658-5663.

      The first reference listed by the reviewer is actually a conference abstract. Thus, we feel that it would be premature to give it comparable weight to peer-reviewed papers. Furthermore, based on the abstract, without the published paper, we cannot assess the robustness of the results and their relevance to our study (particularly, it is unclear whether some effects were observed in the right FFA, and whether a statistically significant difference between blind and sighted subjects was detected).

      In the second reference, the authors did not observe effects in the FFA in the visual version of their experiment with sighted subjects, at the threshold of p < 0.05, corrected for multiple comparisons. In our opinion, this makes the null result of the tactile experiment, reported for the FFA, hard to interpret – thus, while the paper is very interesting in certain contexts, it is not particularly informative when it comes to the question addressed here.

      While the third reference reports interesting results, it does not investigate preference for inanimate objects or animate objects in the vOTC, which is the main topic of our paper (only comparisons vs. rest and between- and within-category correlations are reported). Furthermore, based on that study, we cannot conclude whether effects reported for faces are found in the face areas or in other parts of the vOTC (no analyses in specific vOTC areas were reported).

      These were the reasons why we did not refer to these materials in the previous version of the manuscript. Importantly, none of them compel us to revise our claims, and we refer to a number of other papers, directly relevant to the question we are interested in – that is, the difference between vOTC animate and inanimate areas in sensitivity to non-visual stimulation. Nevertheless, we agree that referring to materials suggested by the reviewer might be informative for non-expert readers – thus, we cite them in the revised version of our paper.

      Reviewer #3:

      Bola and colleagues set out to test the hypothesis that vOT domain specific organization is due to the evolutionary pressure to couple visual representations and downstream computations (e.g., action programs). A prediction of such theory is that cross-modal activations (e.g., response in FFA to face-related sounds) should be detected as a function of the transparency of such coupling (e.g., sounds associated with facial expression > speech).

      To this end, the Authors compared brain activity of 20 congenitally blind and 22 sighted subjects undergoing fMRI while performing a semantic judgment task (i.e., is it produced by a human?) on sounds belonging to 5 different categories (emotional and non-emotional facial expressions, speech, object sounds and animal sounds).The results indicate preferential response to sounds associated with facial expressions (vs. speech or animal/objects sounds) in the fusiform gyrus of blind individuals regardless of the emotional content.

      The issue tackled is relevant and timely for the field, and the method chosen (i.e., clinical model + univariate and multivariate fMRI analyses) well suited to address it. The analyses performed are overall sound and the paper clear and exhaustive.

      We thank the reviewer for this positive assessment.

      1) While I overall understand why the Authors would choose a broader ROI for multivariate (vs. univariate) analyses, I believe it would be appropriate to show both analyses on both ROIs. In particular, the fact that the ROI used for the univariate analyses is right-hemisphere only, while the multivariate one is bilateral should be (at least) discussed.

      We shortly discuss this issue in the Methods section: “The reason behind broader and bilateral ROI definition was that the multivariate analysis relies on dispersed and subthreshold activation and deactivation patterns, which might be well represented also by cross-talk between hemispheres (for example, a certain subcategory might be represented by activation of the right FFA and deactivation of the left analog of this area).”

      Constraining the FFA ROI in the multivariate analysis (i.e., using the same ROI as was used in the univariate analysis) makes the results slightly weaker, in both groups. However, the pattern of results is qualitatively comparable. Slight decrease in statistical power can be expected, for the reasons described in the Methods and cited above:

      Similarly, using broader FFA ROI in the univariate analysis (i.e., using the same ROI as was used in the multivariate analysis) results in qualitatively comparable, but slightly weaker effects in the blind group and no change in sighted subjects (no difference between sound categories). Again, this is expectable – visual studies show that the functional sensitivity to face-related stimuli is weaker in the left counterpart of the FFA than in the right FFA. This is also the case in our data - using broader and bilateral ROI essentially averages a stronger effect in the right FFA and a more subtle effect in the left counterpart of the FFA.

      We now clarify this issue in the Methods section.

      2) The significance of the multivariate results is established testing the cross-validated classification accuracy against chance-level with t-tests. Did these tests consider the hypothetical chance level based on class number? A permutation scheme assessing the null distribution would be advisable. In general, more details should be provided with respect to the multivariate analyses performed, for instance the confusion matrix in Figure 5B is never mentioned in the text.

      Yes, the chance level was calculated in a standard way, by dividing 100 % by the number of conditions/classes included in the analysis (note that all stimulus classes were presented equal number of times). To respond to the reviewer’s comment, we used a permutation approach to recalculate significances of all MVPA analyses reported in the paper (note that the whole-brain univariate analyses are already performed within the permutation framework). To this aim, we reran each analysis 1000 times with condition labels randomized and compared the actual result of this analysis with the null distribution created in this way (see the Methods section for details). We replicated all results reported in the paper. We now report this new analysis in the manuscript, changing the figure legends and the Methods section accordingly.

      The confusion matrix was not mentioned in the text because it is not a separate analysis. As explained in the figure legend, it is just a graphical representation of classifiers performance (i.e., its choices for specific stimulus classes) during the decoding analysis reported in Fig. 5A. To clarify this, we now briefly mention the graph presented in Fig. 5B in the main text.

      3) I wonder whether a representational similarity approach could be useful in better delineating similarity/differences in blind vs. sighted participants sounds representations in vOT. Such analysis could also help further exploring potential graded effects: i.e., sounds associated with facial expression (face related, with salient link to movement) > speech (face related, with less salient link with movement) > animals sounds (non-human face related) > object sounds (not face related at all). The above-mentioned confusion matrix could be the starting point of such investigation.

      We thank the reviewer for this interesting suggestion. In response to this comment, we performed an additional RSA analysis, aimed at investigating graded similarity in the FFA response patterns, across categories used in the experiment. Based on our hypothesis, we created a simple theoretical model assuming that responses to both types of facial expression sounds are the most similar to each other (animate sounds with high shape-action mapping transparency), somewhat similar to speech sounds (animate sounds with weaker shape-action mapping transparency), and the least similar to animal and object sounds (animate sounds with no clear shape-action mapping transparency and inanimate sounds). We observed a significant correlation between this theoretical model and FFA response patterns in the blind group (pFDR = 0.012), but not in the sighted group pFDR = 0.223). We believe that the RSA analysis further supports our visual-shape-to-action mapping conjecture, at least when it comes to blind subjects (see the Discussion section for our interpretation of the observed differences between the blind and the sighted subjects). We describe this new analysis in the revised text.

    1. \*-(+.+#'4"#-#B')/'+*1$'),1-*+"6('-#'81&#-3/)+11)31-7#"'B*1-')610*3*4'+*1$9@"'+A(+"#*-8/-81(#.'$0*$+"#!'("*$,+1$(4"11)(+"#53#'+/-#071+"'(+*4F'$0'4'--1+9@#'4"#-(F$#&+"'+*3+"#*-(+/0#$+((+/67)#01$+"#+#(++"#*-1&$H17(&#-#'+-*(F9@"*(,'B#+#'4"#-('(+-1$,61+*B'+*1$+1#$(/-#+"#*-(+/0#$+(8'((#0.#(8#4*'))5'(+"#_-#'+E#4#((*1$7'++#-#0+"#)'71-6'-F#+9C++"#('6#+*6#.*3+"#*-(+/0#$+(1/+8#-31-6#0+"#*-8##-(.+#'4"#-('$0'06*$*(+-'+1-(41/)0-#4#*B#71$/(#(13/8+1lS.RRR9%351/'00+"1(#81&#-3/)*$4#$+*B#(+1+"##B*0#$4#*$+"#4'(#:+"#"*,"$/67#-13#-'(/-#('$0+"#'7$1-6'))5"*,"+#(+(41-#(:+"#-#&#-#,-1/$0(31-(/(8*4*1$+"'+31/-+"L,-'0#+#'4"#-(.71&*$,#*+"#-+13#'-1-+1,-##0."'041--#4+#0+"#*-(+/0#$+(A#?'6(

      This shows how these "correction" algorithms do more harm than good, because they promote fear in teachers, since if their students do not perform well then they lose their jobs and livelihood. This pressures them to do actions like correcting their students' exams, even though the student does not fully understand the exam topics/material.

    2. !*+"1/+3##07'4F."1&#B#-.'(+'+*(+*4')#$,*$#4'$41$+*$/#(8*$$*$,1/+3'/)+5'$00'6',*$,'$')5(*(&"*)#$#B#-)#'-$*$,3-16*+(6*(+'F#(9D'$513+"#!DJ(%A))7#0*(4/((*$,*$+"*(711F.*$4)/0*$,+"#!'("*$,+1$(4"11)0*(+-*4+A(B')/#L'00#0610#).7#"'B#)*F#+"'+9@"#50#3*$#+"#*-1&$-#')*+5'$0/(#*++1H/(+*35+"#*--#(/)+(9@"*(+58#13610#)*((#)3L8#-8#+/'+*$,."*,")50#(+-/4+*B#:'$0B#-541661$9

      A problem with most of these algorithms is that there is no human giving them feedback. This is dangerous, since there is no way that the algorithm can fix itself.

    3. !5(14F*.1341/-(#.3#)++"#$/67#-(&#-#"1--*7)5/$3'*-.'$0("#&'$+#0+1F$1&&"#-#+"#54'6#3-169`%01$A++"*$F'$51$#/$0#-(+110+"#6.a("#)'+#-+1)06#9]1&41/)0',110+#'4"#-,#+(/4"0*(6')(41-#(b!"'+&'(+"#B')/#L'00#0610#)6#'(/-*$,b

      Another problem with these algorithms is that they are not transparent on how they work and what metrics they use to make their decisions.

    4. %3&#"'07##$4)#'-L"#'0#0.&#'))&1/)0"'B#+'F#$'(+#87'4F'++"*(81*$++13*,/-#1/+"1&6'+""'07##$6*(/(#0'$0"1&&#41/)08-#B#$+'(*6*)'-4'+'(+-18"#*$+"#3/+/-#9

      This can relate to Basart and Serra's argument, since they both claimed that engineers should be more aware of their contribution to the output an organization has. If O'Neil and other mathematicians realized the adverse effects of their work, they could have correct it and saved thousands of people from losing their livelihoods after the 2008 Housing Crisis.

    1. SciScore for 10.1101/2021.01.27.21250559: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">Array probing: Serum or plasma samples were first heat inactivated at 56°C for one hour59 then tested at 1:100 dilution in 0.05% PBS-Tween supplemented with 1% (w/v) bovine serum albumin (BSA) and transferred into 96-well plates in a randomized layout.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">Samples were screened in a blinded fashion at a dilution of 1:80 with ultraviolet (UV) microscopy by clinical laboratory staff (A.G. and J.G.) who have extensive experience in the interpretation of ANA patterns.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In addition, prototype human plasma samples derived from participants with autoimmune diseases with known reactivity patterns (e.g. ds-DNA, Scl-70, centromere, SSA, SSB, cardiolipin, whole histones, and RNP, all purchased from ImmunoVision; also from Stanford Autoimmune Diseases Biobank, and OMRF); APS-1, IPEX, PAP, or AMI associated with anti-IFN- γ blocking antibodies; as well as normal human sera (ImmunoVision, Product # HNP-0300, certified to be nonreactive to Hep-2 cell lysates at a titer of 1:100), were used for validation.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SSB</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-IFN-</div><div>suggested: (Novus Cat# NB100-78214, RRID:AB_1084710)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Additional controls included samples from five healthy donors and three de-identified patients known to have clinically elevated PR3 and MPO antibody levels.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MPO</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">ANAs were detected using a FITC- conjugated goat anti-human IgG antibody following vendor instructions.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Goat anti-human IgG-HRP (Cat# 109-035-008, Jackson ImmunoResearch Laboratories, West Grove, PA) was diluted 1:10,000 with sample dilution buffer and 50 μl of secondary antibody was added to each well.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Goat anti-human IgG-HRP</div><div>suggested: (Santa Cruz Biotechnology Cat# sc-2907, RRID:AB_650497)</div></div><div style="margin-bottom:8px"><div>anti-human IgG-HRP</div><div>suggested: (Santa Cruz Biotechnology Cat# sc-2769, RRID:AB_656966)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Antibodies were considered “positive” if MFI was > 5 SD above the average MFI for HC for that antigen, and MFI was >3,000 units, a threshold which is more stringent than commonly published in related literature21.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>antigen,</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">ELISA and antibody number data were visualized in GraphPad Prism v.9.0.0 (86).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ELISA</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In addition, prototype human plasma samples derived from participants with autoimmune diseases with known reactivity patterns (e.g. ds-DNA, Scl-70, centromere, SSA, SSB, cardiolipin, whole histones, and RNP, all purchased from ImmunoVision; also from Stanford Autoimmune Diseases Biobank, and OMRF); APS-1, IPEX, PAP, or AMI associated with anti-IFN- γ blocking antibodies; as well as normal human sera (ImmunoVision, Product # HNP-0300, certified to be nonreactive to Hep-2 cell lysates at a titer of 1:100), were used for validation.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Hep-2</div><div>suggested: None</div></div></td></tr><tr><th style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</th></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">In addition, prototype human plasma samples derived from participants with autoimmune diseases with known reactivity patterns (e.g. ds-DNA, Scl-70, centromere, SSA, SSB, cardiolipin, whole histones, and RNP, all purchased from ImmunoVision; also from Stanford Autoimmune Diseases Biobank, and OMRF); APS-1, IPEX, PAP, or AMI associated with anti-IFN- γ blocking antibodies; as well as normal human sera (ImmunoVision, Product # HNP-0300, certified to be nonreactive to Hep-2 cell lysates at a titer of 1:100), were used for validation.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>ImmunoVision</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Images were acquired with a Hamamatsu ORCA- ER B&W CCD Digital Camera controlled with Metamorph V7.10.3.390 software and 1×1 camera binning.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Metamorph</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">ELISA and antibody number data were visualized in GraphPad Prism v.9.0.0 (86).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad Prism</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Upon publication of this study in a peer-reviewed journal, deidentified array data will be uploaded to the Gene Expression Omnibus (GEO) database.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Gene Expression Omnibus</div><div>suggested: (Gene Expression Omnibus (GEO, RRID:SCR_005012)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
      Many studies of hospitalized COVID-19 patients, including our study, suffer from important limitations. First, confounding variables exist including heterogeneous demographics, medications at hospitalization, individualized treatment approaches, and, in some cases, unknown history of pre- existing medical or autoimmune conditions. Second, “Day 0” is not day 0 of infection but instead refers to a time point most proximate to hospitalization. Our viral array results (Figs. 4 and 5) confirm that the time between initial infection and sample acquisition was heterogeneous, potentially confounding interpretation of autoantibody and ACA results. Third, not all antigens (e.g., lipids, hydrophobic proteins and carbohydrates) are compatible with our screening methodology, and as a result we have certainly missed some reactivities. Fourth, we did not include patients who were asymptomatic, had mild COVID-19, were vaccinated for SARS-CoV-2, had other severe viral illnesses, or were children. Finally, our analysis was limited to hospitalized patients during acute illness, with follow up times of days rather than months or years. Although beyond the scope of these studies, our data generate many more questions that need to be addressed in the coming years – questions that can only be answered by generating large cohorts of prospectively enrolled subjects with new-onset viral syndromes, including patients with COVID-19, respiratory illnesses which resemble COVID-19, and subjects enrolled in...

      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on page 75. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.


      Results from scite Reference Check: We found no unreliable references.


      <footer>

      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

      </footer>

    1. l t h o u g h t h e s e c u l t u r e s o f p a r t i c i p a t i o n a r e b e c o m i n g m o r e c o m m o n , t h e y a r e not equally accessed. Recent research has shown that despite the emerging cultural image of the average youth as constantly connected and technologically savvy, those who can actually create digital media or interactive environments are in the minority

      flashbacks to me trying to become tiktok famous but failing

  3. Jan 2021
    1. SciScore for 10.1101/2021.01.21.21249623: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Viral isolation and production: SARS-CoV-2 strains were isolated in the African green monkey kidney cell line, Vero E6.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero E6</div><div>suggested: RRID:CVCL_XD71)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">When cell density reached approximately 80%, cells were rinsed once with MEM medium supplemented with 2% FBS, then 50 to 100 µl of SARS-CoV-2-positive swab specimen was mixed with 2 mL MEM 2% FBS and layered on the Vero cell monolayer.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Vero</div><div>suggested: CLS Cat# 605372/p622_VERO, RRID:CVCL_0059)</div></div></td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, cells were cultured in a 25 cm2 flask containing 5 ml of Eagle medium (MEM: Gibco/Invitrogen, Carlsbad, CA, USA) supplemented with 5% heat-inactivated fetal bovine serum (FBS), 2 mmol/L L-Glutamine, 1 mmol/L sodium pyruvate, 100 U/mL of penicillin, 100 µg/mL of streptomycin and 0.5 µg/mL of Amphotericin B (PAN Biotech, Aidenbach, Germany), at 37°C under a 5% CO2 atmosphere.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Gibco/Invitrogen</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Nanopore (MinION) Sequencing and Analysis: Genomes were sequenced from viruses originally infecting four independent patients.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MinION</div><div>suggested: (MinION, RRID:SCR_017985)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Geneious v9.1.8[13] was used to inspect and curate mapped sequence data.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Geneious</div><div>suggested: (Geneious, RRID:SCR_010519)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Sequencing was performed on the MiSeq platform, with 1 * 170 bp single end reads.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MiSeq</div><div>suggested: (A5-miseq, RRID:SCR_012148)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Sequences were quality trimmed and adapters removed using Trimmomatic v0.39.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Trimmomatic</div><div>suggested: (Trimmomatic, RRID:SCR_011848)</div></div></td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.


      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from scite Reference Check: We found no unreliable references.


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

    1. SciScore for 10.1101/2021.01.15.426911: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">Consent: Informed consent was obtained from all participants and the study was conducted in accordance with Good Clinical Practice.<br>IRB: The study visits and blood draws were reviewed and approved under the National Institutes of Health’s Federalwide Assurance (FWA00005897), in accordance with Federal regulations 45 CFR 46 and 21 CFR 5 by the NIH Intramural Research Program IRB committee (IRB# 99CC0168, Collection and Distribution of Blood Components from Healthy Donors for In Vitro Research Use) and by the Institutional Review Board of the Rockefeller University (IRB# DRO-1006, Peripheral Blood of Coronavirus Survivors to Identify Virus-Neutralizing Antibodies).</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">Contamination: Cells were periodically tested for contamination with mycoplasma or retroviruses. rVSV/SARS-CoV-2/GFP chimeric virus stocks were generated by infecting 293T/ACE2.cl22 cells.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Study participants: To isolate and characterize anti-SARS-CoV-2 RBD antibodies from vaccinees, a cohort of 20 individuals that participated in either the Moderna or Pfizer-BioNTech phase 3 vaccine clinical trials and did not report prior history of SARS-CoV-2 infection was recruited at the NIH Blood Center and the Rockefeller University Hospital for blood donation.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-CoV-2 RBD</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>Pfizer-BioNTech phase 3</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plates were washed 6 times with washing buffer and then incubated with anti-human IgG, IgM or IgA secondary antibody conjugated to horseradish peroxidase (HRP) (Jackson Immuno Research</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human IgG</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>IgA</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The half-maximal neutralization titers for plasma (NT50) or half-maximal and 90% inhibitory concentrations for monoclonal antibodies (IC50 and IC90, respectively) were determined using four-parameter nonlinear regression (least squares regression method without weighting; constraints: top=1, bottom=0) (GraphPad Prism).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>IC90</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The enriched B cells were incubated in FACS buffer (1× PBS, 2% FCS, 1 mM EDTA) with the following anti-human antibodies (all at 1:200 dilution): anti-CD20-PECy7 (BD Biosciences, 335793), anti-CD3-APC-eFluro 780 (Invitrogen, 47-0037-41)</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-human</div><div>suggested: (GenWay Biotech Inc. Cat# 18-202-335793-0.1 mg, RRID:AB_1981874)</div></div><div style="margin-bottom:8px"><div>anti-CD20-PECy7</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>anti-CD3-APC-eFluro 780</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The frequency distributions of human V genes in anti-SARS-CoV-2 antibodies from this study was compared to 131,284,220 IgH and IgL sequences generated by 50 and downloaded from cAb-Rep 51, a database of human shared BCR clonotypes available at https://cab-rep.c2b2.columbia.edu/.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>anti-SARS-CoV-2</div><div>suggested: (Thermo Fisher Scientific Cat# 51-6490-82, RRID:AB_2884044)</div></div></td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were periodically tested for contamination with mycoplasma or retroviruses. rVSV/SARS-CoV-2/GFP chimeric virus stocks were generated by infecting 293T/ACE2.cl22 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T/ACE2.cl22</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Then, the virus-antibody mixtures were incubated with 5× 105 293T/ACE2cl.22 cells in 6-well plates.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T/ACE2cl.22</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, 293T cells were transfected with pNL4-3DEnv-nanoluc and pSARS-CoV-2-SΔ19 and pseudotyped virus stocks were harvested 48 hours after transfection, filtered and stored at −80°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>293T</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The study visits and blood draws were reviewed and approved under the National Institutes of Health’s Federalwide Assurance (FWA00005897), in accordance with Federal regulations 45 CFR 46 and 21 CFR 5 by the NIH Intramural Research Program IRB committee (IRB# 99CC0168, Collection and Distribution of Blood Components from Healthy Donors for In Vitro Research Use) and by the Institutional Review Board of the Rockefeller University (IRB# DRO-1006, Peripheral Blood of Coronavirus Survivors to Identify Virus-Neutralizing Antibodies).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>NIH Intramural Research Program</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The average of its signal was used for normalization of all of the other values on the same plate with Excel software before calculating the area under the curve using Prism V8.4 (GraphPad).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Excel</div><div>suggested: None</div></div><div style="margin-bottom:8px"><div>Prism</div><div>suggested: (PRISM, RRID:SCR_005375)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For monoclonal antibodies, the EC50 was determined using four-parameter nonlinear regression (GraphPad Prism V8.4).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>GraphPad</div><div>suggested: (GraphPad Prism, RRID:SCR_002798)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For analysis of the sequencing data, the raw paired-end reads were pre-processed to remove trim adapter sequences and to remove low-quality reads (Phred quality score < 20) using BBDuk.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Phred</div><div>suggested: (Phred, RRID:SCR_001017)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2 pseudotype neutralization assays: Plasma or monoclonal antibodies from vaccine recipients were four-fold or five-fold serially diluted and then incubated with SARS-CoV-2 pseudotyped HIV-1 reporter virus for 1 h at 37 °C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Plasma</div><div>suggested: None</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Single CD3-CD8-CD14-CD16-CD20+Ova-RBD-PE+RBD-AF647+ B cells were sorted into individual wells of 96-well plates containing 4 μl of lysis buffer (0.5× PBS, 10 mM DTT, 3,000 units/ml RNasin Ribonuclease Inhibitors (Promega, N2615) per well using a FACS Aria III and FACSDiva software (Becton Dickinson) for acquisition and FlowJo for analysis.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>FACSDiva</div><div>suggested: (BD FACSDiva Software, RRID:SCR_001456)</div></div><div style="margin-bottom:8px"><div>FlowJo</div><div>suggested: (FlowJo, RRID:SCR_008520)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Sequence analysis was performed using MacVector.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>MacVector</div><div>suggested: (MacVector, RRID:SCR_015700)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data were collected using SerialEM automated data collection software44 and movies were recorded with a K3 camera (Gatan).</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>SerialEM</div><div>suggested: (SerialEM, RRID:SCR_017293)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The non-dose-weighted images were used to estimate CTF parameters using cryoSPARC implementation of the Patch CTF job.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>cryoSPARC</div><div>suggested: (cryoSPARC, RRID:SCR_016501)</div></div></td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Models were then refined into cryo-EM maps by rigid body and real space refinement in Phenix47 If the resolution allowed, partial CDR3 loops were built manually in Coot48 and then refined using real-space refinement in Phenix.</td><td style="min-width:100px;border-bottom:1px solid lightgray"><div style="margin-bottom:8px"><div>Phenix</div><div>suggested: (Phenix, RRID:SCR_014224)</div></div></td></tr></table>

      Results from OddPub: Thank you for sharing your code and data.


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.


      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      Results from scite Reference Check: We found no unreliable references.


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

    2. SciScore for 10.1101/2021.01.15.426911: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">Informed consent was obtained from all participants and the study was conducted in accordance with Good Clinical Practice.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Ages of the analyzed volunteers ranged from 29-69 years (median 43); ( 60%) were male and 8 (40%) female. 16 participants identified as Caucasian, 2 as Hispanic, and as African American or Asian, respectively.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">Cells were periodically tested for contamination with mycoplasma or retroviruses. rVSV/SARS-CoV-2/GFP chimeric virus stocks were generated by infecting 293T/ACE2.cl22 cells.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To isolate and characterize anti-SARS-CoV-2 RBD antibodies from vaccinees, a cohort of 20 individuals that participated in either the Moderna or Pfizer-BioNTech phase 3 vaccine clinical trials and did not report prior history of SARS-CoV-2 infection was recruited at the NIH Blood Center and the Rockefeller University Hospital for blood donation.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-SARS-CoV-2 RBD</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>Pfizer-BioNTech phase 3</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plates were washed 6 times with washing buffer and then incubated with anti-human IgG, IgM or IgA secondary antibody conjugated to horseradish peroxidase (HRP) (Jackson Immuno Research 109-036-088</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human IgG</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>IgA</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The half-maximal neutralization titers for plasma (NT50) or half-maximal and 90% inhibitory concentrations for monoclonal antibodies (IC50 and IC90, respectively) were determined using four-parameter nonlinear regression (least squares regression method without weighting; constraints: top=1, bottom=0) (GraphPad Prism).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>IC90</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The enriched B cells were incubated in FACS buffer (1× PBS, 2% FCS, 1 mM EDTA) with the following anti-human antibodies (all at 1:200 dilution): anti-CD20-PECy7 (BD Biosciences, 335793), anti-CD3-APC-eFluro 780 (Invitrogen, 47-0037-41), anti-CD8-APC-eFluor (Invitrogen, 47-0086-42)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human</div> <div>suggested: (GenWay Biotech Inc. Cat# 18-202-335793-0.1 mg, RRID:AB_1981874)</div> </div> <div style="margin-bottom:8px"> <div>anti-CD20-PECy7</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-CD3-APC-eFluro 780</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-CD8-APC-eFluor</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The frequency distributions of human V genes in anti-SARS-CoV-2 antibodies from this study was compared to 131,284,220 IgH and IgL sequences generated by 50 and downloaded from cAb-Rep 51, a database of human shared BCR clonotypes available at https://cab- rep.c2b2.columbia.edu/.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-SARS-CoV-2</div> <div>suggested: (Thermo Fisher Scientific Cat# 51-6490-82, RRID:AB_2884044)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Average of two or more experiments. g-i, Correlations of plasma antibodies measurements. g, Normalized AUC for IgG anti-S plotted against normalized AUC for IgG anti-RBD. h, Normalized AUC for IgM anti-S plotted against normalized AUC for IgM anti-RBD. i, Normalized AUC for IgA anti-S plotted against normalized AUC for IgA anti-RBD.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Normalized AUC for IgG</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>plotted against normalized AUC for IgG anti-RBD . h , Normalized AUC for IgM</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>plotted against normalized AUC for IgM anti-RBD . i , Normalized AUC for IgA</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-RBD</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The number of antibody sequences (IGVH and IGVL) evaluated for each participant are n=68 (MOD1), n=45 (MOD2), n=117 (MOD3), n=123 (MOD4), n=110 (MOD6), n=109 (MOD7), n=144 (MOD8), n=102 (MOD9), n=132 (PFZ10), n=109 (MOD11), n=91 (PFZ12), n=78 (C001), n=66 (C003), and n=115 (C004). b, Distribution of the hydrophobicity GRAVY scores at the IGH CDR3 compared to a public database (see Methods for statistical analysis).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>MOD3</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>MOD4</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>MOD7</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>MOD8</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>MOD9</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>PFZ10</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>MOD11</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>PFZ12</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>C001</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>C003</div> <div>suggested: (GenWay Biotech Inc. Cat# GWB-22C003, RRID:AB_10283528)</div> </div> <div style="margin-bottom:8px"> <div>C004</div> <div>suggested: (Creative Diagnostics Cat# DMABH-C004, RRID:AB_2528444)</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were periodically tested for contamination with mycoplasma or retroviruses. rVSV/SARS-CoV-2/GFP chimeric virus stocks were generated by infecting 293T/ACE2.cl22 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>293T/ACE2.cl22</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Then, the virus-antibody mixtures were incubated with 5× 105 293T/ACE2cl.22 cells in 6-well plates.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>293T/ACE2cl.22</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, 293T cells were transfected with pNL4-3DEnv-nanoluc and pSARS-CoV-2- SΔ19 and pseudotyped virus stocks were harvested 48 hours after transfection, filtered and stored at -80℃.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>293T</div> <div>suggested: RRID:CVCL_H376)</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The study visits and blood draws were reviewed and approved under the National Institutes of Health’s Federalwide Assurance (FWA00005897), in accordance with Federal regulations 45 CFR 46 and 21 CFR 5 by the NIH Intramural Research Program IRB committee (IRB# 99CC0168, Collection and Distribution of Blood Components from Healthy Donors for In Vitro Research Use) and by the Institutional Review Board of the Rockefeller University (IRB# DRO-1006, Peripheral Blood of Coronavirus Survivors to Identify Virus-</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>NIH Intramural Research Program</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The average of its signal was used for normalization of all of the other values on the same plate with Excel software before calculating the area under the curve using Prism V8.4 (GraphPad).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Excel</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>Prism</div> <div>suggested: (PRISM, RRID:SCR_005375)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For monoclonal antibodies, the EC50 was determined using four-parameter nonlinear regression (GraphPad Prism V8.4).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>GraphPad</div> <div>suggested: (GraphPad Prism, RRID:SCR_002798)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For analysis of the sequencing data, the raw paired-end reads were pre-processed to remove trim adapter sequences and to remove low-quality reads (Phred quality score < 20) using BBDuk.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Phred</div> <div>suggested: (Phred, RRID:SCR_001017)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Single CD3−CD8−CD14−CD16−CD20+Ova−RBD-PE+RBD-AF647+ B cells were sorted into individual wells of 96-well plates containing 4 μl of lysis buffer (0.5× PBS, 10 mM DTT, 3,000 units/ml RNasin Ribonuclease Inhibitors (Promega, N2615) per well using a FACS Aria III and FACSDiva software (Becton Dickinson) for acquisition and FlowJo for analysis.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>FACSDiva</div> <div>suggested: (BD FACSDiva Software, RRID:SCR_001456)</div> </div> <div style="margin-bottom:8px"> <div>FlowJo</div> <div>suggested: (FlowJo, RRID:SCR_008520)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Sequence analysis was performed using MacVector.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>MacVector</div> <div>suggested: (MacVector, RRID:SCR_015700)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data were collected using SerialEM automated data collection software44 and movies were recorded with a K3 camera (Gatan).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>SerialEM</div> <div>suggested: (SerialEM, RRID:SCR_017293)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For all datasets, cryo-EM movies were patch motion corrected for beam- induced motion including dose-weighting within cryoSPARC v2.1545 after binning super resolution movies.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>cryoSPARC</div> <div>suggested: (cryoSPARC, RRID:SCR_016501)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Models were then refined into cryo-EM maps by rigid body and real space refinement in Phenix47 If the resolution allowed, partial CDR3 loops were built manually in Coot48 and then refined using real-space refinement in Phenix.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Phenix</div> <div>suggested: (Phenix, RRID:SCR_014224)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data availability statement: Data presentation Figures arranged in Adobe Illustrator 2020.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Adobe Illustrator</div> <div>suggested: (Adobe Illustrator, RRID:SCR_010279)</div> </div> </td></tr></table>

      Results from OddPub: Thank you for sharing your data.


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.


      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

    1. SciScore for 10.1101/2021.01.19.427330: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Analysis of sequence reads We aligned reads to the MN908947.3 reference genome with BWA-MEM version 0.7.1539.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>BWA-MEM</div> <div>suggested: (Sniffles, RRID:SCR_017619)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">We identified single nucleotide variants with iVar 1.2.1 using the following parameters: sample with viral load ≥ 103 copies/μL; sample with consensus genome length of ≥ 29000; sample with ≥ 80% of genome sites above 200x coverage; iSNV frequency threshold of 2%; read depth of ≥ 100 at iSNV sites; ≥ 10 reads with average Phred score of > 35 supporting a given iSNV; iVar p-value of < 0.0001.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Phred</div> <div>suggested: (Phred, RRID:SCR_001017)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">To generate a phylogenetic tree, we aligned consensus genomes with MUSCLE 3.8.31 and masked positions that are known to commonly exhibit homoplasies or sequencing errors41.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>MUSCLE</div> <div>suggested: (MUSCLE, RRID:SCR_011812)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">We generated a maximum likelihood phylogeny with IQ-TREE, using a GTR model and ultrafast bootstrap replicates42,43.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>IQ-TREE</div> <div>suggested: (IQ-TREE, RRID:SCR_017254)</div> </div> </td></tr></table>

      Results from OddPub: Thank you for sharing your data.


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.


      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

    1. SciScore for 10.1101/2021.01.13.426628: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">Animals, inoculation and sampling All animals were handled in accordance with the Animal Welfare Act Amendments (7 U.S. Code §2131 to §2156) and all study procedures were reviewed and approved by the Institutional Animal Care and Use Committee at the National Animal Disease Center (IACUC approval number ARS-2020-861).</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">At 24 h post-inoculation, cells were fixed with 3.7% formaldehyde for 30 min at room temperature, permeabilized with 0.2% Triton X-100 (in Phosphate Buffered Saline [PBS]) and subjected to an immunofluorescence assay (IFA) using a monoclonal antibody (MAb) antiACE2 (Sigma-Aldrich), and then incubated with a goat anti-rabbit IgG (goat anti-rabbit IgG, Alexa Fluor 488®), and using a monoclonal antibody (MAb) anti-SARS-CoV-2 nucleoprotein (N) (clone B6G11) produced and characterized in Dr.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>antiACE2</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-rabbit IgG</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-SARS-CoV-2 nucleoprotein (N</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Diel’s laboratory, and then incubated with a goat anti-mouse IgG secondary antibody (goat anti-mouse IgG, Alexa Fluor® 594), and Nuclear counterstain was performed with DAPI, and visualized under a fluorescence microscope.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-mouse IgG</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Fluorescent beads were coupled with the anti-equine IL-4 antibody, clone 25 (RRID: AB_2737308) as previously described (65).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-equine IL-4</div> <div>detected: (Dr. Bettina Wagner - Cornell University Cat# IL4 25, RRID:AB_2737308)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The assay was detected using a biotinylated mouse anti-goat IgG (H+L) (RRID: AB_2339061, Jackson Immunoresearch Laboratories, West Grove, PA) cross-reactive with deer immunoglobulin.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>mouse anti-goat IgG H+L</div> <div>detected: (Jackson ImmunoResearch Labs Cat# 205-065-108, RRID:AB_2339061)</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The SARS-CoV-2 isolate TGR/NY/20 obtained from a Malayan tiger naturally infected with SARS-CoV-2 and presenting with respiratory disease compatible with SARS-CoV-2 infection (22) was propagated in Vero CCL-81 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Vero CCL-81</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell susceptibility and growth curves The susceptibility and kinetics of replication of the SARS-CoV-2 in DL cells was assessed in vitro and compared to virus replication in Vero E6 and Vero E6/TMPRSS2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Vero E6</div> <div>suggested: RRID:CVCL_XD71)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Positive samples were subjected to end point titrations by limiting dilution using the Vero E6/TMPRSS2 cells and virus titers were determined using the Spearman and Karber’s method and expressed as TCID50.ml-1.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Vero E6/TMPRSS2</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Following incubation of serum and virus, 50 µl of a cell suspension of Vero cells was added to each well of a 96-well plate and incubated for 48 h at 37 °C with 5% CO2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Vero</div> <div>suggested: None</div> </div> </td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.


      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

    1. SciScore for 10.1101/2021.01.11.426080: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      NIH rigor criteria are not applicable to paper type.

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The plates were incubated at room temperature (RT) for 1 h and then washed three times with washing buffer (PBS + 0.05 % tween 20), the ELISA plates with N protein coating were washed additionally once with high salt PBST (Phosphate buffer with 500 mM NaCl and 0.05 % Tween 20) and incubated with biotinylated anti-hamster IgG antibody (Sigma) for another 1 h and washed subsequently with the washing buffer and incubated further with Avidin-HRP (Sigma) for 45 min at RT.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-hamster IgG</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>Avidin-HRP</div> <div>suggested: (R and D Systems Cat# A-115, RRID:AB_10992927)</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Virus preparation and determination of viral titers SARS-Related Coronavirus 2, Isolate USA-WA1/2020 virus was used as challenge strain, which was grown and titrated in Vero E6 cell line grown in Dulbecco’s Modified Eagle Medium (DMEM) complete media containing 4.5 g/L D-glucose, 100,000 U/L Penicillin-</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Vero E6</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">TCID50 For TCID50 determination, 50 µl of homogenized lung supernatant samples were incubated with confluent Vero-E6 cells in 96-well plates as described previously (Chan et al., 2020).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Vero-E6</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Intracelluar anti-mouse IFN-γ (XMG1.2) (BioLegend) staining was then carried out after fixing the cells in Cytofix solution and permeabilization with 1X Perm/Wash Buffer using kit (BD Biosciences; # 554714) for 20 min in dark at RT.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>BD Biosciences</div> <div>suggested: (BD Biosciences, RRID:SCR_013311)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cells were then washed and acquired on FACS Canto II and were analysed with FlowJo software (Tree star) as previously described (Malik et al., 2017)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>FlowJo</div> <div>suggested: (FlowJo, RRID:SCR_008520)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The web-based tool ClustVis was used to create the sample PCA plots to check the clustering of biological samples (ClustVis: a web tool for visualizing clustering of multivariate data using Principal Component Analysis and heatmap) (Metsalu and Vilo, 2015).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>ClustVis</div> <div>suggested: (ClustVis, RRID:SCR_017133)</div> </div> </td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.


      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: Please consider improving the rainbow (“jet”) colormap used on pages 6, 8, 12, 36, 47, 48, 49, 50 and 52. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

    1. SciScore for 10.1101/2021.01.04.21249236: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">Investigators were blinded to generation patient information of data raw from and blood health and status plasma at the samples.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Antibody clones and vendors used anti-hHLA-DR (G46-6) (1:400</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-hHLA-DR ( G46-6 )</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After three washes with PBS-T (PBS with 0.1% Tween-20) and 50 μl of HRP anti-Human IgG Antibody (GenScript #A00166, 1:5,000) or anti-Human IgM-Peroxidase</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-Human IgG</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-Human IgM-Peroxidase</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All clinical data were obtained using EPIC EHR and REDCap 9.3.6 software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>REDCap</div> <div>suggested: (REDCap, RRID:SCR_003445)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">FlowJo software version 10.6 (tree Star) was used for data analysis.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>FlowJo</div> <div>suggested: (FlowJo, RRID:SCR_008520)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical and data analyses Statistical and data analyses were performed using Jmp Pro 15.0.0 (SAS Institute), and GraphPad Prism 8.4.3.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>SAS Institute</div> <div>suggested: (Statistical Analysis System, RRID:SCR_008567)</div> </div> <div style="margin-bottom:8px"> <div>GraphPad Prism</div> <div>suggested: (GraphPad Prism, RRID:SCR_002798)</div> </div> </td></tr></table>

      Results from OddPub: Thank you for sharing your data.


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.


      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

    1. SciScore for 10.1101/2020.12.31.425021: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">We then used deep sequencing to measure the frequency of each RBD mutation in the initial population and the antibody-escape FACS bin.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>antibody-escape FACS bin.</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After the serum incubations, the libraries were secondarily labeled with 1:100 FITC-conjugated anti-MYC antibody (Immunology Consultants Lab, CYMC-45F) to label for RBD expression and 1:200 Alexa-647- or DyLight-405-conjugated goat anti-human-IgA+IgG+IgM (Jackson ImmunoResearch 109-605-064 or 109-475-064, respectively) to label for bound serum antibodies.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-MYC</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-human-IgA+IgG+IgM</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">A magnet was used to separate antibodies that bind RBD from the supernatant, and the supernatant (the post-RBD antibody depletion sample) was removed.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>post-RBD</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Dilution series of the “synthetic” sera comprised of the anti-RBD antibody rREGN10987 ​(Hansen et al., 2020)​ or anti-NTD antibody 4A8 ​(Chi et al., 2020)​ and pooled pre-pandemic human sera from 2017-2018 (Gemini Biosciences; nos. 100–110, lot H86W03J; pooled from 75 donors) were performed such that the anti-spike antibody was present at a highest concentration of 0.25 μg/mL.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-NTD</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-spike</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Pre-pandemic serum alone, without anti-RBD antibody depletion, was used as a negative control, averaged over 2 replicates.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-RBD</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Serum is a unique identifier for each serum mapped, PID is the patient ID from ​(Crawford et al., 2020a)​, subject is the simpler patient identifier used for patients in the current study, the selection serum dilution indicates the reciprocal dilution at which each selection was performed (i.e., 500 is a 1:500 dilution of serum) and the 4 rightmost columns indicate the percentage of each population of cells that fell into the antibody-escape selection gate for the duplicate mutant libraries (lib1 and lib2) and for cells expressing unmutated RBD and incubated with the same dilution of serum as the mutant libraries (WT 1x) or 10-fold less serum (WT 0.1x).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>antibody-escape</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">6e5 293T cells per well were seeded in 6-well plates in 2 mL D10 growth media (DMEM with 10% heat-inactivated FBS, 2 mM l-glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>293T</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Depletion of RBD-binding antibodies from polyclonal sera Magnetic beads conjugated to the SARS-CoV-2 RBD (AcroBiosystems, MBS-K002) were prepared according to the manufacturer’s protocol.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>AcroBiosystems</div> <div>suggested: (ACRObiosystems, RRID:SCR_012550)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">There are no corresponding raw FACSDiva gating plots for expt_36 (subject K (day 29)) in ​Figure S2​.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>FACSDiva</div> <div>suggested: (BD FACSDiva Software, RRID:SCR_001456)</div> </div> </td></tr></table>

      Results from OddPub: Thank you for sharing your data.


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:

      There are several limitations to our study. Most importantly, we only examined mutations to the RBD. While we and others ​(Piccoli et al., 2020; Steffen et al., 2020)​ have shown that RBD-binding antibodies contribute the majority of the serum neutralizing activity of most convalescent human sera and plasma, antibodies also target other regions of the spike. For example, mutations and deletions in the NTD can affect serum antibody neutralization ​(Andreano et al., 2020; Kemp et al., 2020b; Liu et al., 2020a; McCarthy et al., 2020; Voss et al., 2020)​, and are certainly of great importance. In addition, we only mapped samples from 11 individuals at two time points. Given the substantial inter- and intra-individual heterogeneity, mapping more samples may identify additional sites of importance. On a technical level, we assayed binding of antibodies to isolated RBD expressed by yeast, which implies several limitations. First, we are unable to map the effects of mutations that alter the spike’s overall conformation or affect antibodies spanning quaternary epitopes ​(Barnes et al., 2020a)​. Second, our mapping likely overestimates the contributions of antibodies that bind epitopes that are more accessible on isolated RBD than in the context of full spike (e.g., F456). Finally, the N-linked glycans on yeast-expressed proteins are more mannose-rich than those on mammalian-expressed proteins (Hamilton et al., 2003)​, which could affect measurements of how N-linked glycans affect anti...


      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  4. myjurnal.poltekkes-kdi.ac.id myjurnal.poltekkes-kdi.ac.id
    1. Nama: Nening Terapi oksigen hiperbarik (HBOT) Terapi Oksigen Hiperbarik (HBOT) adalah suatu terapi dengan pemberian oksigen konsentrasi 100% dan tekanan lebih dari 1 atmosfer absolut (ATA), yang dilakukan di ruang udara bertekanan tinggi/ruang hiperbarik dengan tekanan lebih dari 1 atmosfer (Atm). Regimen HBO (hiperbarik oksigen) menggunakan tekanan 1,5 hingga 2,5 Atm untuk durasi 30 hingga 90 menit, yang dapat diulang beberapa kali. Waktu antara dan jumlah total sesi berulang sangat bervariasi. Tujuan terapi oksigen hiperbarik untuk perawatan dan pengobatan beberapa penyakit seperti emboli intravaskular, penyakit dekompresi, infeksi anaerob, keracunan CO (Shahriari, Khooshideh, & Heidari, 2014).

      Ruang Hiperbarik Ruang hiperbarik dapat terdiri dari dua jenis: tunggal atau ganda. Sementara tekanan terjadi di tempat duduk tunggal melalui oksigen dan peningkatan tekanan bersifat sistemik, ruang multiplace diberi tekanan dengan udara dan oksigen disuplai kepada pasien melalui masker, helm, atau tabung endotrakeal, tergantung kasusnya. (Gill & Bell, 2004)

      Indikasi Terapi Oksigen Hiperbarik Penting untuk mengetahui indikasi untuk terapi hiperbarik. Indikasi meliputi penyakit dekompresi, emboli udara, keracunan karbon monoksida, cedera, anemia kehilangan darah akut, abses intrakranial, luka bakar termal, fasciitis nekrotikans, gas gangren, dan kehilangan pendengaran akut. Kondisi tersebut perlu mendapat perawatan terapi oksigen hiperbarik. Pada umunya pusat hiperbarik merawat pasien dengan dengan kondisi non- alergi seperti penyembuhan luka yang buruk, cedera radiasi yang tertunda, osteomielitis kronis dan flap. Sangat penting bagi tim medis yang merawat untuk mengenali indikasi hiperbarik yang muncul. (Chen et al., 2019)

      D. Indikasi Terapi Oksigen Hiperbarik menurut (Mathieu et al., 2017) Keracunan karbon monoksida (CO) Merekomendasikan HBOT dalam pengobatan keracunan CO (rekomendasi Tipe 1, bukti Level B). • Merekomendasikan 100% oksigen segera diterapkan pada orang yang keracunan CO sebagai pengobatan pertolongan pertama (rekomendasi Tipe 1, bukti Level C). • Merekomendasikan HBOT untuk setiap orang yang keracunan CO yang disertai dengan adanya perubahan kesadaran, tanda- tanda klinis gangguan neurologis, jantung, pernapasan atau psikologis dan tingkat karbokshaemoglobin pada saat masuk rumah sakit (rekomendasi Tipe 1, bukti Level B). • Merekomendasikan HBOT pada wanita hamil yang keracunan CO apa pun gejala klinis mereka dan tingkat karboksihemoglobin saat masuk rumah sakit (rekomendasi Tipe 1, bukti Level B). • Sebaiknya merawat pasien dengan keracunan CO minor baik dengan oksigen normobarik 12 jam atau HBOT (rekomendasi Tipe 3, bukti Level B). • Tdak merekomendasikan perawatan dengan pasien tanpa gejala HBOT yang terlihat lebih dari 24 jam setelah akhir paparan CO (rekomendasi Tipe 1, bukti Level C)

      Fraktur terbuka dengan crush injury

      • Merekomendasikan HBOT dalam pengobatan fraktur terbuka dan/ atau dengan crush injury (Rekomendasi Tipe 1, bukti Level B). • Merekomendasikan aplikasi awal HBOT setelah fraktur terbuka parah karena dapat mengurangi komplikasi seperti nekrosis jaringan dan infeksi. Cedera Gustilo 3B dan 3C dianggap sebagai indikasi untuk HBOT dan cedera yang kurang parah harus dipertimbangkan untuk perawatan ketika terdapat faktor risiko terkait host atau cedera (rekomendasi Tipe 1, bukti Level B). • Menyarankan bahwa HBOT dapat memberikan manfaat pada crush injury dengan luka terbuka tanpa fraktur, di mana viabilitas jaringan berisiko atau di mana ada risiko infeksi yang signifikan (rekomendasi Tipe 2, bukti Level C). • Sebaiknya memberikan HBOT untuk crush injury/ cedera tertutup di mana viabilitas jaringan secara klinis dinilai berisiko (rekomendasi Tipe 3, bukti Level C). • Sebaiknya memberikan HBOT untuk crush injury/ cedera tertutup di mana ada potensi sindrom kompartemen, tetapi yang tidak memerlukan fasciotomi dan dimungkinkan untuk memantau kemajuan dan respons terhadap pengobatan baik secara klinis atau melalui tekanan kompartemen atau pemantauan oksigenasi (Rekomendasi Tipe 3, bukti Level C). • Merekomendasikan bahwa pusat HBOT yang merawat crush injury harus memiliki peralatan untuk pengukuran oksimetri transkutan (TCOM) di bawah tekanan karena ini memiliki nilai prediksi dalam beberapa situasi (Rekomendasi Tipe 1, bukti Level B

      D. Radionekrosis/lesi yang disebabkan oleh radiasi • Merekomendasikan HBOT dalam pengobatan osteoradionekrosis mandibula (Rekomendasi Tipe 1, bukti Level B). • Merekomendasikan HBOT untuk pencegahan osteoradionekrosis mandibula setelah pencabutan gigi (rekomendasi Tipe 1, bukti Level B). • Merekomendasikan HBOT dalam pengobatan sistitis radiasi hemoragik (Rekomendasi Tipe 1, bukti Level B). • Merekomendasikan HBOT dalam pengobatan proktitis radiasi (rekomendasi Tipe 1, bukti Level A). • Menyarankan HBOT dalam pengobatan osteoradionekrosis tulang selain mandibula (Rekomendasi Tipe 2, bukti Level C). • Menyarankan HBOT untuk mencegah kehilangan implan osseointegrasi pada tulang yang diradiasi (Rekomendasi Tipe 2, bukti Level C). • Menyarankan HBOT dalam pengobatan radionekrosis jaringan lunak (selain sistitis dan proktitis), khususnya di daerah kepala dan leher (rekomendasi Tipe 2, bukti Level C). • Sebaiknya menggunakan HBOT untuk mengobati atau mencegah lesi yang diinduksi radio dari laring (Rekomendasi Tipe 3, bukti Level C). • Sebaiknya menggunakan HBOT dalam pengobatan lesi yang diinduksi radio dari sistem saraf pusat (Rekomendasi Tipe 3, bukti Level C).

      Penyakit dekompresi merupakan kondisi yang terjadi pada saat aliran darah di dalam tubuh terhambat, dikarenakan perubahan tekanan udara. Perubahan tekanan ini dapat terjadi akibat penerbangan, menyelam, atau hal lain yang mengakibatkan terjadinya perubahan tekanan udara secara drastis. Perubahan tekanan udara di luar tubuh yang tiba-tiba dapat menyebabkan timbulnya gelembung udara di dalam pembuluh darah atau emboli.

      Efek HBOT didasarkan pada regulasi gas, dan efek fisiologis dan biokimia dari hiperoksia. Hukum Boyle menyatakan bahwa pada suhu konstan, tekanan dan volume gas berbanding terbalik. Ini adalah dasar untuk semua terapi hiperbarik. Hukum Boyle menjelaskan tentang hubungan tekanan gas dan volume gas. Tekanan gas berbanding terbalik dengan volume gas. Bila tekanan semakin besar maka volume akan semakin kecil. Prinsip ini digunakan pada kasus-kasus penyakit dekompresi dan emboli gas. Pada penyakit dekompresi, terjadi gelembung-gelembung nitrogen (nitrogen bubbles) sehingga terjadi penyumbatan pembuluh darah akibat gelembung ini.

      Oksigen yang ditangkap dengan bernapas juga bervariasi selama perawatan di ruang hiperbarik, karena, selama penurunan ke kedalaman, tekanan oksigen intraalveolar meningkat; Ini terjadi sebagai respons fisiologis yang merespons hukum Boyle dan hukum Dalton. Hukum Boyle menyatakan bahwa, pada suhu konstan, tekanan gas berbanding terbalik dengan volumenya, sementara hukum Dalton menyatakan bahwa dalam campuran gas setiap elemen memberikan tekanan yang sebanding dengan fraksinya dari total volume; hukum-hukum ini menjelaskan efek dari tekanan parsial oksigen dan intraalveolar tersedia. (Balestra et al., 2016).

      Mekanisme Hbit Reactive Oxygen Species (ROS) Prinsip dari terapi oksigen hiperbarik adalah membantu tubuh untuk memperbaiki jaringan yang rusak dengan meningkatkan aliran oksigen ke jaringan tubuh. Terapi oksigen hiperbarik akan menyebabkan darah menyerap oksigen lebih banyak akibat peningkatan tekanan oksigen di dalam paru￾paru yang dimanipulasi oleh ruangan hiperbarik. Dengan konsentrasi oksigen yang lebih tinggi dari normal, tubuh akan terpicu untuk memperbaiki jaringan yang rusak lebih cepat dari biasanya. Terapi oksigen hiperbarik (HBOT) memberikan oksigen di bawah tekanan untuk meningkatkan kadar oksigen jaringan. Oksigen diberikan 2-3 kali lebih tinggi dari tekanan atmosfer, dan didistribusikan di sekitar area yang terinfeksi; sehingga memungkinkan terjadinya proses penyembuhan alami tubuh dan memperbaiki fungsi jaringan. HBOT juga merangsang kaskade transduksi sinyal dengan meningkatkan oksigen reaktif dan spesies nitrogen, maka jaringan akan melepaskan prostaglandin, oksida nitrat, dan sitokin yang menunjukkan respons patofisiologis terhadap luka, pembedahan, dan infeksi. HBOT diketahui sebagai terapi untuk mengobati penyakit dekompresi, gangren, atau keracunan karbon monoksida. (Al-Waili & Butler, 2006; Gandhi et al., 2018).

      ROS dipandang berbahaya karena potensinya menyebabkan kerusakan pada lipid, protein, dan DNA (Alfadda & Sallam, 2012), tetapi secara ilmiah ROS sangat penting dalam pensinyalan dan pengaturan sel, contoh, dalam sel endotel, ROS adalah penyebab utama dari banyak patologi vaskular, seperti disfungsi endotel diabetes dan hiperpietik, di sisi lain, angiogenesis dan vasorelaxasi yang bergantung pada endotelium berada di bawah kendali redoks. Karena sifatnya yang aktif dan berumur pendek, ROS harus dihasilkan di kompartemen subseluler yang tepat yang dekat dengan molekul yang dimodifikasi dalam proses pensinyalan dan pengaturan sel yang bergantung pada ROS. (Craige, Kant, & Keaney Jr, 2015).

      Di permukaan laut konsentrasi oksigen plasma adalah 3 ml/l. Jaringan saat istirahat membutuhkan sekitar 60 ml oksigen per liter aliran darah (dengan asumsi perfusi normal) untuk mempertahankan metabolisme seluler yang normal, meskipun persyaratan bervariasi di antara jaringan. Pada tekanan 3 atmosfer (304 kPa) oksigen terlarut mendekati 60 ml/l plasma, yang hampir mencukupi untuk memasok kebutuhan oksigen total istirahat dari banyak jaringan tanpa kontribusi dari oksigen yang terikat dengan hemoglobin. Ini memiliki keuntungan dalam situasi seperti keracunan karbon monoksida atau anemia berat di mana sulit melakukan crossmatching atau keyakinan agama mencegah transfusi darah (Leach et al., 1998).

      Fungsi HBOT Secara umum dapat dibagi menjadi dua jenis efek, fisiologis dan farmakologis, kadang terjadi tumpang tindih. Oksigen dapat dianggap sebagai unsur alami yang penting untuk kehidupan, dan sebagai obat yang digunakan untuk mengubah patologi penyakit. HBOT menggunakan oksigen sebagai obat dan oleh karena itu, memiliki protokol dosis yang tepat, indeks terapi, dan efek samping yang perlu dipahami agar dapat digunakan dengan aman dan efektif. (Kahle & Cooper, 2019; Maslova & Klimova, 2012). Terapi Oksigen hiperbarik fungsi HBOT sangat kompleks. Akan mengurangi ukuran gelembung gas dalam cairan (darah). Sehingga meningkatkan kapasitas pembawa oksigen darah melalui peningkatan konsentrasi oksigen plasma menjadi sekitar 7%. Adanya bakteriostatik dan bakteriosidal pada tekanan dan oksigenasi yang lebih tinggi. Oksigen hiperbarik akan meningkatkan neovaskularisasi arteri dan mengurangi edema jaringan, yang akan menghambat berbagai eksotoksin seperti racun alfa dan beta yang terkait dengan infeksi nekrotikans. Pengobatan hiperbarik akan meningkatkan difusi oksigen lebih lanjut dalam jaringan dengan jarak sekitar empat kali jarak perfusi normal. Sehingga akan menyebabkan terjadi difusi oksigen dari lingkungan yang kaya oksigen ke lingkungan oksigen yang buruk seperti dengan luka iskemik dan anggota badan. Hukum Boyle adalah dasar untuk efektivitas dalam penyakit dekompresi dan emboli udara. Permukaan terlalu cepat dari penyelaman bawah laut yang dalam akan menghasilkan presipitasi gelembung nitrogen dalam darah. Ini akan menghasilkan persendian yang sangat menyakitkan, tikungan, dan bahkan kematian. (Fife et al., 2016; Jones & Wyatt, 2019)

      Bahaya dan kontraindikasi terapi oksigen hiperbarik kontraindikasi mutlak untuk perawatan hiperbarik adalah pneumotoraks yang tidak diobati. Kontraindikasi relatif lainnya adalah jika pasien menggunakan agen kemoterapi tertentu seperti Adriamycin dan Cisplatinum atau Antabuse. Masalah lain yang menjadi perhatian adalah pasien berventilasi, pasien dengan hipertensi yang tidak terkontrol, dan penderita diabetes. Masalah dengan pasien berventilasi adalah varian dalam volume udara dan tekanan dan masalah barotrauma. Gula darah serum sering jatuh saat menyelam. Oleh karena itu, disarankan untuk memastikan glukosa serum pada pasien dengan diabetes berada pada sisi yang tinggi sebelum menyelam (Cho et al., 2018). Efek samping negatif dari menerima O2 bertekanan, akan terjadi cedera stres oksidatif, kerusakan DNA, metabolisme seluler, pengaktifan koagulasi, disfungsi endotel, neurotoksisitas akut, dan toksisitas paru, gangguan metabolisme sel, mengaktifkan koagulasi, disfungsi endotel, neurotoksisitas akut dan toksisitas paru. (Chen et al., 2019).Alasan mengapa HBOT tidak boleh diberikan pada interval yang jauh lebih sering dan dalam sesi yang lebih lama adalah potensi risiko keracunan oksigen (Körpınar & Uzun, 2019) Risiko oksigen hiperbarik; Bahaya kebakaran; Komplikasi fatal yang paling umum. Fitur umum; Claustrophobi, Miopia yang dapat dibalik, Kelelahan, Sakit kepala, Muntah. Barotrauma; Kerusakan telinga, Kerusakan sinus, Telinga tengah yang pecah, Kerusakan paru-paru. Toksisitas oksigen; Otak, Kejang, Psikologi. Paru-paru, Edema paru, perdarahan, Toksisitas paru, Gagal pernafasan (mungkin tidak dapat dikembalikan ketika terjadi fibrosis topulmoner). Penyakit dekompresi; Penyakit dekompresi, Pneumotoraks, Emboli gas. (Chen et al., 2019; Leach et al., 1998; Thom, 2009; Stephen R Thom, 2011)

    2. A.Definisi Terapi oksigen hiperbarik (HBOT) Terapi Oksigen Hiperbarik (HBOT) adalah suatu terapi dengan pemberian oksigen konsentrasi 100% dan tekanan lebih dari 1 atmosfer absolut (ATA), yang dilakukan di ruang udara bertekanan tinggi/ruang hiperbarik dengan tekanan lebih dari 1 atmosfer (Atm). Regimen HBO (hiperbarik oksigen) menggunakan tekanan 1,5 hingga 2,5 Atm untuk durasi 30 hingga 90 menit, yang dapat diulang beberapa kali. Waktu antara dan jumlah total sesi berulang sangat bervariasi. Tujuan terapi oksigen hiperbarik untuk perawatan dan pengobatan beberapa penyakit seperti emboli intravaskular, penyakit dekompresi, infeksi anaerob, keracunan CO (Shahriari, Khooshideh, & Heidari, 2014).

      B.Ruang Hiperbarik Ruang hiperbarik dapat terdiri dari dua jenis: tunggal atau ganda. Sementara tekanan terjadi di tempat duduk tunggal melalui oksigen dan peningkatan tekanan bersifat sistemik, ruang multiplace diberi tekanan dengan udara dan oksigen disuplai kepada pasien melalui masker, helm, atau tabung endotrakeal, tergantung kasusnya. (Gill & Bell, 2004)

      C. Indikasi Terapi Oksigen Hiperbarik Penting untuk mengetahui indikasi untuk terapi hiperbarik. Indikasi meliputi penyakit dekompresi, emboli udara, keracunan karbon monoksida, cedera, anemia kehilangan darah akut, abses intrakranial, luka bakar termal, fasciitis nekrotikans, gas gangren, dan kehilangan pendengaran akut. Kondisi tersebut perlu mendapat perawatan terapi oksigen hiperbarik. Pada umunya pusat hiperbarik merawat pasien dengan dengan kondisi non- alergi seperti penyembuhan luka yang buruk, cedera radiasi yang tertunda, osteomielitis kronis dan flap. Sangat penting bagi tim medis yang merawat untuk mengenali indikasi hiperbarik yang muncul. (Chen et al., 2019)

      D. Indikasi Terapi Oksigen Hiperbarik menurut (Mathieu et al., 2017) Keracunan karbon monoksida (CO) Merekomendasikan HBOT dalam pengobatan keracunan CO (rekomendasi Tipe 1, bukti Level B). • Merekomendasikan 100% oksigen segera diterapkan pada orang yang keracunan CO sebagai pengobatan pertolongan pertama (rekomendasi Tipe 1, bukti Level C). • Merekomendasikan HBOT untuk setiap orang yang keracunan CO yang disertai dengan adanya perubahan kesadaran, tanda- tanda klinis gangguan neurologis, jantung, pernapasan atau psikologis dan tingkat karbokshaemoglobin pada saat masuk rumah sakit (rekomendasi Tipe 1, bukti Level B). • Merekomendasikan HBOT pada wanita hamil yang keracunan CO apa pun gejala klinis mereka dan tingkat karboksihemoglobin saat masuk rumah sakit (rekomendasi Tipe 1, bukti Level B). • Sebaiknya merawat pasien dengan keracunan CO minor baik dengan oksigen normobarik 12 jam atau HBOT (rekomendasi Tipe 3, bukti Level B). • Tdak merekomendasikan perawatan dengan pasien tanpa gejala HBOT yang terlihat lebih dari 24 jam setelah akhir paparan CO (rekomendasi Tipe 1, bukti Level C)

      Fraktur terbuka dengan crush injury

      • Merekomendasikan HBOT dalam pengobatan fraktur terbuka dan/ atau dengan crush injury (Rekomendasi Tipe 1, bukti Level B). • Merekomendasikan aplikasi awal HBOT setelah fraktur terbuka parah karena dapat mengurangi komplikasi seperti nekrosis jaringan dan infeksi. Cedera Gustilo 3B dan 3C dianggap sebagai indikasi untuk HBOT dan cedera yang kurang parah harus dipertimbangkan untuk perawatan ketika terdapat faktor risiko terkait host atau cedera (rekomendasi Tipe 1, bukti Level B). • Menyarankan bahwa HBOT dapat memberikan manfaat pada crush injury dengan luka terbuka tanpa fraktur, di mana viabilitas jaringan berisiko atau di mana ada risiko infeksi yang signifikan (rekomendasi Tipe 2, bukti Level C). • Sebaiknya memberikan HBOT untuk crush injury/ cedera tertutup di mana viabilitas jaringan secara klinis dinilai berisiko (rekomendasi Tipe 3, bukti Level C). • Sebaiknya memberikan HBOT untuk crush injury/ cedera tertutup di mana ada potensi sindrom kompartemen, tetapi yang tidak memerlukan fasciotomi dan dimungkinkan untuk memantau kemajuan dan respons terhadap pengobatan baik secara klinis atau melalui tekanan kompartemen atau pemantauan oksigenasi (Rekomendasi Tipe 3, bukti Level C). • Merekomendasikan bahwa pusat HBOT yang merawat crush injury harus memiliki peralatan untuk pengukuran oksimetri transkutan (TCOM) di bawah tekanan karena ini memiliki nilai prediksi dalam beberapa situasi (Rekomendasi Tipe 1, bukti Level B

      D. Radionekrosis/lesi yang disebabkan oleh radiasi • Merekomendasikan HBOT dalam pengobatan osteoradionekrosis mandibula (Rekomendasi Tipe 1, bukti Level B). • Merekomendasikan HBOT untuk pencegahan osteoradionekrosis mandibula setelah pencabutan gigi (rekomendasi Tipe 1, bukti Level B). • Merekomendasikan HBOT dalam pengobatan sistitis radiasi hemoragik (Rekomendasi Tipe 1, bukti Level B). • Merekomendasikan HBOT dalam pengobatan proktitis radiasi (rekomendasi Tipe 1, bukti Level A). • Menyarankan HBOT dalam pengobatan osteoradionekrosis tulang selain mandibula (Rekomendasi Tipe 2, bukti Level C). • Menyarankan HBOT untuk mencegah kehilangan implan osseointegrasi pada tulang yang diradiasi (Rekomendasi Tipe 2, bukti Level C). • Menyarankan HBOT dalam pengobatan radionekrosis jaringan lunak (selain sistitis dan proktitis), khususnya di daerah kepala dan leher (rekomendasi Tipe 2, bukti Level C). • Sebaiknya menggunakan HBOT untuk mengobati atau mencegah lesi yang diinduksi radio dari laring (Rekomendasi Tipe 3, bukti Level C). • Sebaiknya menggunakan HBOT dalam pengobatan lesi yang diinduksi radio dari sistem saraf pusat (Rekomendasi Tipe 3, bukti Level C).

      E. Penyakit Dekompresi (DCI)

      Penyakit dekompresi merupakan kondisi yang terjadi pada saat aliran darah di dalam tubuh terhambat, dikarenakan perubahan tekanan udara. Perubahan tekanan ini dapat terjadi akibat penerbangan, menyelam, atau hal lain yang mengakibatkan terjadinya perubahan tekanan udara secara drastis. Perubahan tekanan udara di luar tubuh yang tiba-tiba dapat menyebabkan timbulnya gelembung udara di dalam pembuluh darah atau emboli.

      F. DASAR FISIOLOGIS TERAPI OKSIGEN HIPERBARIK

      Efek HBOT didasarkan pada regulasi gas, dan efek fisiologis dan biokimia dari hiperoksia. Hukum Boyle menyatakan bahwa pada suhu konstan, tekanan dan volume gas berbanding terbalik. Ini adalah dasar untuk semua terapi hiperbarik. Hukum Boyle menjelaskan tentang hubungan tekanan gas dan volume gas. Tekanan gas berbanding terbalik dengan volume gas. Bila tekanan semakin besar maka volume akan semakin kecil. Prinsip ini digunakan pada kasus-kasus penyakit dekompresi dan emboli gas. Pada penyakit dekompresi, terjadi gelembung-gelembung nitrogen (nitrogen bubbles) sehingga terjadi penyumbatan pembuluh darah akibat gelembung ini.

      Oksigen yang ditangkap dengan bernapas juga bervariasi selama perawatan di ruang hiperbarik, karena, selama penurunan ke kedalaman, tekanan oksigen intraalveolar meningkat; Ini terjadi sebagai respons fisiologis yang merespons hukum Boyle dan hukum Dalton. Hukum Boyle menyatakan bahwa, pada suhu konstan, tekanan gas berbanding terbalik dengan volumenya, sementara hukum Dalton menyatakan bahwa dalam campuran gas setiap elemen memberikan tekanan yang sebanding dengan fraksinya dari total volume; hukum-hukum ini menjelaskan efek dari tekanan parsial oksigen dan intraalveolar tersedia. (Balestra et al., 2016).

      G. MEKANISME HBOT

      Reactive Oxygen Species (ROS) Prinsip dari terapi oksigen hiperbarik adalah membantu tubuh untuk memperbaiki jaringan yang rusak dengan meningkatkan aliran oksigen ke jaringan tubuh. Terapi oksigen hiperbarik akan menyebabkan darah menyerap oksigen lebih banyak akibat peningkatan tekanan oksigen di dalam paru￾paru yang dimanipulasi oleh ruangan hiperbarik. Dengan konsentrasi oksigen yang lebih tinggi dari normal, tubuh akan terpicu untuk memperbaiki jaringan yang rusak lebih cepat dari biasanya. Terapi oksigen hiperbarik (HBOT) memberikan oksigen di bawah tekanan untuk meningkatkan kadar oksigen jaringan. Oksigen diberikan 2-3 kali lebih tinggi dari tekanan atmosfer, dan didistribusikan di sekitar area yang terinfeksi; sehingga memungkinkan terjadinya proses penyembuhan alami tubuh dan memperbaiki fungsi jaringan. HBOT juga merangsang kaskade transduksi sinyal dengan meningkatkan oksigen reaktif dan spesies nitrogen, maka jaringan akan melepaskan prostaglandin, oksida nitrat, dan sitokin yang menunjukkan respons patofisiologis terhadap luka, pembedahan, dan infeksi. HBOT diketahui sebagai terapi untuk mengobati penyakit dekompresi, gangren, atau keracunan karbon monoksida. (Al-Waili & Butler, 2006; Gandhi et al., 2018).

      ROS dipandang berbahaya karena potensinya menyebabkan kerusakan pada lipid, protein, dan DNA (Alfadda & Sallam, 2012), tetapi secara ilmiah ROS sangat penting dalam pensinyalan dan pengaturan sel, contoh, dalam sel endotel, ROS adalah penyebab utama dari banyak patologi vaskular, seperti disfungsi endotel diabetes dan hiperpietik, di sisi lain, angiogenesis dan vasorelaxasi yang bergantung pada endotelium berada di bawah kendali redoks. Karena sifatnya yang aktif dan berumur pendek, ROS harus dihasilkan di kompartemen subseluler yang tepat yang dekat dengan molekul yang dimodifikasi dalam proses pensinyalan dan pengaturan sel yang bergantung pada ROS. (Craige, Kant, & Keaney Jr, 2015).

      H. FISIOLOGIS, DAN FARMAKOLOGIS GAS HIPERBARIK

      Di permukaan laut konsentrasi oksigen plasma adalah 3 ml/l. Jaringan saat istirahat membutuhkan sekitar 60 ml oksigen per liter aliran darah (dengan asumsi perfusi normal) untuk mempertahankan metabolisme seluler yang normal, meskipun persyaratan bervariasi di antara jaringan. Pada tekanan 3 atmosfer (304 kPa) oksigen terlarut mendekati 60 ml/l plasma, yang hampir mencukupi untuk memasok kebutuhan oksigen total istirahat dari banyak jaringan tanpa kontribusi dari oksigen yang terikat dengan hemoglobin. Ini memiliki keuntungan dalam situasi seperti keracunan karbon monoksida atau anemia berat di mana sulit melakukan crossmatching atau keyakinan agama mencegah transfusi darah (Leach et al., 1998).

      Fungsi HBOT Secara umum dapat dibagi menjadi dua jenis efek, fisiologis dan farmakologis, kadang terjadi tumpang tindih. Oksigen dapat dianggap sebagai unsur alami yang penting untuk kehidupan, dan sebagai obat yang digunakan untuk mengubah patologi penyakit. HBOT menggunakan oksigen sebagai obat dan oleh karena itu, memiliki protokol dosis yang tepat, indeks terapi, dan efek samping yang perlu dipahami agar dapat digunakan dengan aman dan efektif. (Kahle & Cooper, 2019; Maslova & Klimova, 2012)

      I.FUNGSI/MANFAAT (HBOT)

      Terapi Oksigen hiperbarik fungsi HBOT sangat kompleks. Akan mengurangi ukuran gelembung gas dalam cairan (darah). Sehingga meningkatkan kapasitas pembawa oksigen darah melalui peningkatan konsentrasi oksigen plasma menjadi sekitar 7%. Adanya bakteriostatik dan bakteriosidal pada tekanan dan oksigenasi yang lebih tinggi. Oksigen hiperbarik akan meningkatkan neovaskularisasi arteri dan mengurangi edema jaringan, yang akan menghambat berbagai eksotoksin seperti racun alfa dan beta yang terkait dengan infeksi nekrotikans. Pengobatan hiperbarik akan meningkatkan difusi oksigen lebih lanjut dalam jaringan dengan jarak sekitar empat kali jarak perfusi normal. Sehingga akan menyebabkan terjadi difusi oksigen dari lingkungan yang kaya oksigen ke lingkungan oksigen yang buruk seperti dengan luka iskemik dan anggota badan. Hukum Boyle adalah dasar untuk efektivitas dalam penyakit dekompresi dan emboli udara. Permukaan terlalu cepat dari penyelaman bawah laut yang dalam akan menghasilkan presipitasi gelembung nitrogen dalam darah. Ini akan menghasilkan persendian yang sangat menyakitkan, tikungan, dan bahkan kematian. (Fife et al., 2016; Jones & Wyatt, 2019)

      J.BAHAYA DAN KONTRAINDIKASI Terapi oksigen hiperbarik

      kontraindikasi mutlak untuk perawatan hiperbarik adalah pneumotoraks yang tidak diobati. Kontraindikasi relatif lainnya adalah jika pasien menggunakan agen kemoterapi tertentu seperti Adriamycin dan Cisplatinum atau Antabuse. Masalah lain yang menjadi perhatian adalah pasien berventilasi, pasien dengan hipertensi yang tidak terkontrol, dan penderita diabetes. Masalah dengan pasien berventilasi adalah varian dalam volume udara dan tekanan dan masalah barotrauma. Gula darah serum sering jatuh saat menyelam. Oleh karena itu, disarankan untuk memastikan glukosa serum pada pasien dengan diabetes berada pada sisi yang tinggi sebelum menyelam (Cho et al., 2018). Efek samping negatif dari menerima O2 bertekanan, akan terjadi cedera stres oksidatif, kerusakan DNA, metabolisme seluler, pengaktifan koagulasi, disfungsi endotel, neurotoksisitas akut, dan toksisitas paru, gangguan metabolisme sel, mengaktifkan koagulasi, disfungsi endotel, neurotoksisitas akut dan toksisitas paru. (Chen et al., 2019).

      Alasan mengapa HBOT tidak boleh diberikan pada interval yang jauh lebih sering dan dalam sesi yang lebih lama adalah potensi risiko keracunan oksigen (Körpınar & Uzun, 2019) Risiko oksigen hiperbarik; Bahaya kebakaran; Komplikasi fatal yang paling umum. Fitur umum; Claustrophobi, Miopia yang dapat dibalik, Kelelahan, Sakit kepala, Muntah. Barotrauma; Kerusakan telinga, Kerusakan sinus, Telinga tengah yang pecah, Kerusakan paru-paru. Toksisitas oksigen; Otak, Kejang, Psikologi. Paru-paru, Edema paru, perdarahan, Toksisitas paru, Gagal pernafasan (mungkin tidak dapat dikembalikan ketika terjadi fibrosis topulmoner). Penyakit dekompresi; Penyakit dekompresi, Pneumotoraks, Emboli gas. (Chen et al., 2019; Leach et al., 1998; Thom, 2009; Stephen R Thom, 2011).

    3. Terapi Oksigen Hiperbarik (HBOT) semakin sering digunakan di berbagai bidang medis, perawatan, dan praktik kesehatan. Menjadi intervensi penting dengan mekanisme tindakan yang tidak dipahami dengan baik. Terapi Oksigen Hiperbarik adalah salah satu metode p engobatan yang dilakukan dengan menyediakan 100% oksigen murni yang dihirup oleh pasien di ruangan khusus dengan udara bertekanan tinggi. Tekanan udara yang meningkat pada ruang Hiperbarik menyebabkan paru pasien menyerap lebih banyak oksigen daripada bias anya, yang dapat membantu menyembuhkan berbagai penyakit. Diharapkan adanya kajian ilmiah, ulasan dan diskusi tentang terapi heperbaric dan pencarian literatur tentang penggunaannya dapat bermanfaat bagi tim medis baik perawat, dokter, pekerja kesehatan la innya dan masyarakat, sehingga mereka dapat meningkatkan pengetahuan, berdasarkan fisiologi, patologi, fisika, farmakologi, manfaat, indikasi dan perawatan tentang terapi hiperbarik sehingga dapat diterapkan dalam berbagai bidang yang diperlukan.

      Ruang Hiperbarik Ruang hiperbarik dapat terdiri dari dua jenis: tunggal atau ganda. Sementara tekanan terjadi di tempat duduk tunggal melalui oksigen dan peningkatan tekanan bersifat sistemik, ruang multiplace diberi tekanan dengan udara dan oksigen disuplai kepada pasien melalui masker, helm, atau tabung endotrakeal, tergantung kasusnya. (Gill & Bell, 2004)

      Indikasi Terapi Oksigen Hiperbarik Penting untuk mengetahui indikasi terapi hiperbarik. Indikasi meliputi penyakit dekompresi, emboli udara, keracunan karbon monoksida, cedera, anemia kehilangan darah akut, abses intrakranial, luka bakar termal, fasciitis nekrotikans, gas gangren, dan kehilangan pendengaran akut.

      Indikasi Terapi Oksigen Hiperbarik menurut (Mathieu et al., 2017) Keracunan karbon monoksida (CO) Keracunan karbon monoksida dapat terjadi ketika seseorang menghirup gas karbon monoksida yang menyebabkan penyerapan oksigen oleh darah terganggu. Terapi oksigen hiperbarik dapat mengatasi kondisi ini dengan cara menghilangkan karbon monoksida dari dalam darah dengan pemberian oksigen murni bertekanan tinggi. • Merekomendasikan HBOT dalam pengobatan keracunan CO (rekomendasi Tipe 1, bukti Level B). • Merekomendasikan 100% oksigen segera diterapkan pada orang yang keracunan CO sebagai pengobatan pertolongan pertama (rekomendasi Tipe 1, bukti Level C). • Merekomendasikan HBOT untuk setiap orang yang keracunan CO yang disertai dengan adanya perubahan kesadaran, tanda- tanda klinis gangguan neurologis, jantung, pernapasan atau psikologis dan tingkat karbokshaemoglobin pada saat masuk rumah sakit • Merekomendasikan HBOT pada wanita hamil yang keracunan CO apa pun gejala klinis mereka dan tingkat karboksihemoglobin saat masuk rumah sakit (rekomendasi Tipe 1, bukti Level B). • Sebaiknya merawat pasien dengan keracunan CO minor baik dengan oksigen normobarik 12 jam atau HBOT (rekomendasi Tipe 3, bukti Level B). • Tdak merekomendasikan perawatan dengan pasien tanpa gejala HBOT yang terlihat lebih dari 24 jam setelah akhir paparan CO (rekomendasi Tipe 1, bukti Level C).

      Penyakit Dekompresi (DCI) Penyakit dekompresi merupakan kondisi yang terjadi pada saat aliran darah di dalam tubuh terhambat, dikarenakan perubahan tekanan udara. Perubahan tekanan ini dapat terjadi akibat penerbangan, menyelam, atau hal lain yang mengakibatkan terjadinya perubahan tekanan udara secara drastis. Perubahan tekanan udara di luar tubuh yang tiba-tiba dapat menyebabkan timbulnya gelembung udara di dalam pembuluh darah atau emboli. Terapi oksigen hiperbarik dapat mengecilkan gelembung di dalam pembuluh darah akibat perubahan tekanan. 186 p-ISSN: 2083-0840: E-ISSN: 2622-5905 Volume 11, Nomor 2, Desember 2019 • Merekomendasikan HBOT dalam pengobatan DCI (Rekomendasi Tipe 1, bukti Level C). • Merekomendasikan 100% normobarik oksigen pertolongan pertama (rekomendasi Tipe 1, bukti Level C). • Merekomendasikan resusitasi cairan intravena dengan larutan kristaloid yang tidak mengandung glukosa (Rekomendasi Tipe 1, bukti Level C). • Merekomendasikan tabel terapi kompresi HBOT⁄ (Tabel Perawatan Angkatan Laut AS 6 atau helium / oksigen (Heliox) Comex Cx30 atau yang setara) untuk pengobatan awal DCI (Rekomendasi Tipe 1, bukti Level C). • Merekomendasikan tabel pengobatan HBOT yang sesuai untuk manifestasi residual DCI (rekomendasi Tipe 1, bukti Level C). • Merekomendasikan penggunaan heparin dengan berat molekul rendah untuk profilaksis trombosis vena dalam untuk kasus DCI yang lumpuh atau lumpuh (rekomendasi Tipe 1, bukti Level C). • Menyarankan penggunaan tabel lignocaine (lidocaine) dan rekompresi Heliox untuk DCI neurologis yang serius (rekomendasi Tipe 2, bukti Level C). • Menyarankan tenoxicam oral (atau NSAID serupa) untuk kasus DCI yang dipilih dengan tepat (Rekomendasi Tipe 2, bukti Level B).

      FISIOLOGIS, DAN FARMAKOLOGIS GAS HIPERBARIK 194 Di permukaan oksigen plasma adalah 3 ml/l. Jaringan saat istirahat membutuhkan sekitar 60 ml oksigen per liter aliran darah (dengan asumsi perfusi normal) untuk mempertahankan metabolisme seluler yang normal, meskipun persyaratan bervariasi di antara jaringan. Pada tekanan 3 atmosfer (304 kPa) oksigen terlarut mendekati 60 ml/l plasma, yang hampir mencukupi untuk memasok kebutuhan oksigen total istirahat dari banyak jaringan tanpa kontribusi dari oksigen yang terikat dengan hemoglobin. Ini memiliki keuntungan dalam situasi seperti keracunan karbon monoksida atau anemia berat di mana sulit melakukan crossmatching atau keyakinan agama mencegah transfusi darah (Leach et al., 1998).

      Fungsi HBOT Secara umum dapat dibagi menjadi dua jenis efek, fisiologis dan farmakologis, kadang terjadi tumpang tindih. Oksigen dapat dianggap sebagai unsur alami yang penting untuk kehidupan, dan sebagai obat yang digunakan untuk mengubah patologi penyakit. HBOT menggunakan oksigen sebagai obat dan oleh karena itu, memiliki protokol dosis yang tepat, indeks terapi, dan efek samping yang perlu dipahami agar dapat digunakan dengan aman dan efektif

      Efek Fisiologis Dalam kondisi normal di permukaan laut, udara terdiri dari sekitar 21% oksigen yang menghasilkan tekanan oksigen alveolar (PAO2) sekitar 100 mmHg. Dalam kondisi ini, hemoglobin plasma hampir seluruhnya jenuh, dan oksigen plasma terlarut minimal.Oleh karena itu, dengan asumsi konsentrasi hemoglobin 12 g/dL, kandungan oksigen darah gabungan dalam seluruh darah adalah sekitar 16,2 mL O2/dL. Dalam kondisi hiperbarik yang menghirup oksigen 100% pada 3 atmospheric absolut (ATA), nilai PAO2 meningkat menjadi sekitar 2280 mmHg; dan menurut hukum Henry, kandungan oksigen gabungan dalam darah lengkap meningkat menjadi 23,0 mL O2 / dL. Peningkatan 42% dari baseline ini hampir seluruhnya berasal dari peningkatan oksigen yang terlarut dalam plasma. Peningkatan pasokan oksigen dan tekanan oksigen arteri membentuk dasar HBOT (Lambertsen, 1988; Oh et al., 2008; Rothfuss & Speit, 2002)

      Terapi Oksigen hiperbarik fungsi HBOT sangat kompleks. Akan mengurangi ukuran gelembung gas dalam cairan (darah). Sehingga meningkatkan kapasitas pembawa oksigen darah melalui peningkatan konsentrasi oksigen plasma menjadi sekitar 7%. Adanya bakteriostatik dan bakteriosidal pada tekanan dan oksigenasi yang lebih tinggi. Oksigen hiperbarik akan meningkatkan neovaskularisasi arteri dan mengurangi edema jaringan, yang akan menghambat berbagai eksotoksin seperti racun alfa dan beta yang terkait dengan infeksi nekrotikans. Pengobatan hiperbarik akan meningkatkan difusi oksigen lebih lanjut dalam jaringan dengan jarak sekitar empat kali jarak perfusi normal. Sehingga akan menyebabkan terjadi difusi oksigen dari lingkungan yang kaya oksigen ke lingkungan oksigen yang buruk seperti dengan luka iskemik dan anggota badan. Hukum Boyle adalah dasar untuk efektivitas dalam penyakit dekompresi dan emboli udara. Permukaan terlalu cepat dari penyelaman bawah laut yang dalam akan menghasilkan presipitasi gelembung nitrogen dalam darah. Ini akan menghasilkan persendian yang sangat menyakitkan, tikungan, dan bahkan kematian. (Fife et al., 2016; Jones & Wyatt, 2019). Tujuan pengobatan adalah untuk mencegah pembentukan gelembung nitrogen sehingga berkurang ukurannya dan kembali larut. Hal yang sama berlaku untuk perawatan emboli udara. Peningkatan tekanan yang diberikan oleh terapi medis hiperbarik akan mengurangi gelembung gas tersebut.

      BAHAYA DAN KONTRAINDIKASI Terapi oksigen hiperbarik kontraindikasi mutlak untuk perawatan hiperbarik adalah pneumotoraks yang tidak diobati. Kontraindikasi relatif lainnya adalah jika pasien menggunakan agen kemoterapi tertentu seperti Adriamycin dan Cisplatinum atau Antabuse. Masalah lain yang menjadi perhatian adalah pasien berventilasi, pasien dengan hipertensi yang tidak terkontrol, dan penderita diabetes. Masalah dengan pasien berventilasi adalah varian dalam volume udara dan tekanan dan masalah barotrauma. Gula darah serum sering jatuh saat menyelam. Oleh karena itu, disarankan untuk memastikan glukosa serum pada pasien dengan diabetes berada pada sisi yang tinggi sebelum menyelam (Cho et al., 2018). Efek samping negatif dari menerima O2 bertekanan, akan terjadi cedera stres oksidatif, kerusakan DNA, metabolisme seluler, pengaktifan koagulasi, disfungsi endotel, neurotoksisitas akut, dan toksisitas paru, gangguan metabolisme sel, mengaktifkan koagulasi, disfungsi endotel

    4. A.Definisi Terapi oksigen hiperbarik (HBOT) Terapi Oksigen Hiperbarik (HBOT) adalah suatu terapi dengan pemberian oksigen konsentrasi 100% dan tekanan lebih dari 1 atmosfer absolut (ATA), yang dilakukan di ruang udara bertekanan tinggi/ruang hiperbarik dengan tekanan lebih dari 1 atmosfer (Atm). Regimen HBO (hiperbarik oksigen) menggunakan tekanan 1,5 hingga 2,5 Atm untuk durasi 30 hingga 90 menit, yang dapat diulang beberapa kali. Waktu antara dan jumlah total sesi berulang sangat bervariasi. Tujuan terapi oksigen hiperbarik untuk perawatan dan pengobatan beberapa penyakit seperti emboli intravaskular, penyakit dekompresi, infeksi anaerob, keracunan CO (Shahriari, Khooshideh, & Heidari, 2014).

      B.Ruang Hiperbarik Ruang hiperbarik dapat terdiri dari dua jenis: tunggal atau ganda. Sementara tekanan terjadi di tempat duduk tunggal melalui oksigen dan peningkatan tekanan bersifat sistemik, ruang multiplace diberi tekanan dengan udara dan oksigen disuplai kepada pasien melalui masker, helm, atau tabung endotrakeal, tergantung kasusnya. (Gill & Bell, 2004)

      C. Indikasi Terapi Oksigen Hiperbarik Penting untuk mengetahui indikasi untuk terapi hiperbarik. Indikasi meliputi penyakit dekompresi, emboli udara, keracunan karbon monoksida, cedera, anemia kehilangan darah akut, abses intrakranial, luka bakar termal, fasciitis nekrotikans, gas gangren, dan kehilangan pendengaran akut. Kondisi tersebut perlu mendapat perawatan terapi oksigen hiperbarik. Pada umunya pusat hiperbarik merawat pasien dengan dengan kondisi non- alergi seperti penyembuhan luka yang buruk, cedera radiasi yang tertunda, osteomielitis kronis dan flap. Sangat penting bagi tim medis yang merawat untuk mengenali indikasi hiperbarik yang muncul. (Chen et al., 2019)

      D. Indikasi Terapi Oksigen Hiperbarik menurut (Mathieu et al., 2017) Keracunan karbon monoksida (CO) Merekomendasikan HBOT dalam pengobatan keracunan CO (rekomendasi Tipe 1, bukti Level B). • Merekomendasikan 100% oksigen segera diterapkan pada orang yang keracunan CO sebagai pengobatan pertolongan pertama (rekomendasi Tipe 1, bukti Level C). • Merekomendasikan HBOT untuk setiap orang yang keracunan CO yang disertai dengan adanya perubahan kesadaran, tanda- tanda klinis gangguan neurologis, jantung, pernapasan atau psikologis dan tingkat karbokshaemoglobin pada saat masuk rumah sakit (rekomendasi Tipe 1, bukti Level B). • Merekomendasikan HBOT pada wanita hamil yang keracunan CO apa pun gejala klinis mereka dan tingkat karboksihemoglobin saat masuk rumah sakit (rekomendasi Tipe 1, bukti Level B). • Sebaiknya merawat pasien dengan keracunan CO minor baik dengan oksigen normobarik 12 jam atau HBOT (rekomendasi Tipe 3, bukti Level B). • Tdak merekomendasikan perawatan dengan pasien tanpa gejala HBOT yang terlihat lebih dari 24 jam setelah akhir paparan CO (rekomendasi Tipe 1, bukti Level C)

      Fraktur terbuka dengan crush injury

      • Merekomendasikan HBOT dalam pengobatan fraktur terbuka dan/ atau dengan crush injury (Rekomendasi Tipe 1, bukti Level B). • Merekomendasikan aplikasi awal HBOT setelah fraktur terbuka parah karena dapat mengurangi komplikasi seperti nekrosis jaringan dan infeksi. Cedera Gustilo 3B dan 3C dianggap sebagai indikasi untuk HBOT dan cedera yang kurang parah harus dipertimbangkan untuk perawatan ketika terdapat faktor risiko terkait host atau cedera (rekomendasi Tipe 1, bukti Level B). • Menyarankan bahwa HBOT dapat memberikan manfaat pada crush injury dengan luka terbuka tanpa fraktur, di mana viabilitas jaringan berisiko atau di mana ada risiko infeksi yang signifikan (rekomendasi Tipe 2, bukti Level C). • Sebaiknya memberikan HBOT untuk crush injury/ cedera tertutup di mana viabilitas jaringan secara klinis dinilai berisiko (rekomendasi Tipe 3, bukti Level C). • Sebaiknya memberikan HBOT untuk crush injury/ cedera tertutup di mana ada potensi sindrom kompartemen, tetapi yang tidak memerlukan fasciotomi dan dimungkinkan untuk memantau kemajuan dan respons terhadap pengobatan baik secara klinis atau melalui tekanan kompartemen atau pemantauan oksigenasi (Rekomendasi Tipe 3, bukti Level C). • Merekomendasikan bahwa pusat HBOT yang merawat crush injury harus memiliki peralatan untuk pengukuran oksimetri transkutan (TCOM) di bawah tekanan karena ini memiliki nilai prediksi dalam beberapa situasi (Rekomendasi Tipe 1, bukti Level B

      D. Radionekrosis/lesi yang disebabkan oleh radiasi • Merekomendasikan HBOT dalam pengobatan osteoradionekrosis mandibula (Rekomendasi Tipe 1, bukti Level B). • Merekomendasikan HBOT untuk pencegahan osteoradionekrosis mandibula setelah pencabutan gigi (rekomendasi Tipe 1, bukti Level B). • Merekomendasikan HBOT dalam pengobatan sistitis radiasi hemoragik (Rekomendasi Tipe 1, bukti Level B). • Merekomendasikan HBOT dalam pengobatan proktitis radiasi (rekomendasi Tipe 1, bukti Level A). • Menyarankan HBOT dalam pengobatan osteoradionekrosis tulang selain mandibula (Rekomendasi Tipe 2, bukti Level C). • Menyarankan HBOT untuk mencegah kehilangan implan osseointegrasi pada tulang yang diradiasi (Rekomendasi Tipe 2, bukti Level C). • Menyarankan HBOT dalam pengobatan radionekrosis jaringan lunak (selain sistitis dan proktitis), khususnya di daerah kepala dan leher (rekomendasi Tipe 2, bukti Level C). • Sebaiknya menggunakan HBOT untuk mengobati atau mencegah lesi yang diinduksi radio dari laring (Rekomendasi Tipe 3, bukti Level C). • Sebaiknya menggunakan HBOT dalam pengobatan lesi yang diinduksi radio dari sistem saraf pusat (Rekomendasi Tipe 3, bukti Level C).

      E. Penyakit Dekompresi (DCI)

      Penyakit dekompresi merupakan kondisi yang terjadi pada saat aliran darah di dalam tubuh terhambat, dikarenakan perubahan tekanan udara. Perubahan tekanan ini dapat terjadi akibat penerbangan, menyelam, atau hal lain yang mengakibatkan terjadinya perubahan tekanan udara secara drastis. Perubahan tekanan udara di luar tubuh yang tiba-tiba dapat menyebabkan timbulnya gelembung udara di dalam pembuluh darah atau emboli.

      F. DASAR FISIOLOGIS TERAPI OKSIGEN HIPERBARIK

      Efek HBOT didasarkan pada regulasi gas, dan efek fisiologis dan biokimia dari hiperoksia. Hukum Boyle menyatakan bahwa pada suhu konstan, tekanan dan volume gas berbanding terbalik. Ini adalah dasar untuk semua terapi hiperbarik. Hukum Boyle menjelaskan tentang hubungan tekanan gas dan volume gas. Tekanan gas berbanding terbalik dengan volume gas. Bila tekanan semakin besar maka volume akan semakin kecil. Prinsip ini digunakan pada kasus-kasus penyakit dekompresi dan emboli gas. Pada penyakit dekompresi, terjadi gelembung-gelembung nitrogen (nitrogen bubbles) sehingga terjadi penyumbatan pembuluh darah akibat gelembung ini.

      Oksigen yang ditangkap dengan bernapas juga bervariasi selama perawatan di ruang hiperbarik, karena, selama penurunan ke kedalaman, tekanan oksigen intraalveolar meningkat; Ini terjadi sebagai respons fisiologis yang merespons hukum Boyle dan hukum Dalton. Hukum Boyle menyatakan bahwa, pada suhu konstan, tekanan gas berbanding terbalik dengan volumenya, sementara hukum Dalton menyatakan bahwa dalam campuran gas setiap elemen memberikan tekanan yang sebanding dengan fraksinya dari total volume; hukum-hukum ini menjelaskan efek dari tekanan parsial oksigen dan intraalveolar tersedia. (Balestra et al., 2016).

      G. MEKANISME HBOT

      Reactive Oxygen Species (ROS) Prinsip dari terapi oksigen hiperbarik adalah membantu tubuh untuk memperbaiki jaringan yang rusak dengan meningkatkan aliran oksigen ke jaringan tubuh. Terapi oksigen hiperbarik akan menyebabkan darah menyerap oksigen lebih banyak akibat peningkatan tekanan oksigen di dalam paru￾paru yang dimanipulasi oleh ruangan hiperbarik. Dengan konsentrasi oksigen yang lebih tinggi dari normal, tubuh akan terpicu untuk memperbaiki jaringan yang rusak lebih cepat dari biasanya. Terapi oksigen hiperbarik (HBOT) memberikan oksigen di bawah tekanan untuk meningkatkan kadar oksigen jaringan. Oksigen diberikan 2-3 kali lebih tinggi dari tekanan atmosfer, dan didistribusikan di sekitar area yang terinfeksi; sehingga memungkinkan terjadinya proses penyembuhan alami tubuh dan memperbaiki fungsi jaringan. HBOT juga merangsang kaskade transduksi sinyal dengan meningkatkan oksigen reaktif dan spesies nitrogen, maka jaringan akan melepaskan prostaglandin, oksida nitrat, dan sitokin yang menunjukkan respons patofisiologis terhadap luka, pembedahan, dan infeksi. HBOT diketahui sebagai terapi untuk mengobati penyakit dekompresi, gangren, atau keracunan karbon monoksida. (Al-Waili & Butler, 2006; Gandhi et al., 2018).

      ROS dipandang berbahaya karena potensinya menyebabkan kerusakan pada lipid, protein, dan DNA (Alfadda & Sallam, 2012), tetapi secara ilmiah ROS sangat penting dalam pensinyalan dan pengaturan sel, contoh, dalam sel endotel, ROS adalah penyebab utama dari banyak patologi vaskular, seperti disfungsi endotel diabetes dan hiperpietik, di sisi lain, angiogenesis dan vasorelaxasi yang bergantung pada endotelium berada di bawah kendali redoks. Karena sifatnya yang aktif dan berumur pendek, ROS harus dihasilkan di kompartemen subseluler yang tepat yang dekat dengan molekul yang dimodifikasi dalam proses pensinyalan dan pengaturan sel yang bergantung pada ROS. (Craige, Kant, & Keaney Jr, 2015).

      H. FISIOLOGIS, DAN FARMAKOLOGIS GAS HIPERBARIK

      Di permukaan laut konsentrasi oksigen plasma adalah 3 ml/l. Jaringan saat istirahat membutuhkan sekitar 60 ml oksigen per liter aliran darah (dengan asumsi perfusi normal) untuk mempertahankan metabolisme seluler yang normal, meskipun persyaratan bervariasi di antara jaringan. Pada tekanan 3 atmosfer (304 kPa) oksigen terlarut mendekati 60 ml/l plasma, yang hampir mencukupi untuk memasok kebutuhan oksigen total istirahat dari banyak jaringan tanpa kontribusi dari oksigen yang terikat dengan hemoglobin. Ini memiliki keuntungan dalam situasi seperti keracunan karbon monoksida atau anemia berat di mana sulit melakukan crossmatching atau keyakinan agama mencegah transfusi darah (Leach et al., 1998).

      Fungsi HBOT Secara umum dapat dibagi menjadi dua jenis efek, fisiologis dan farmakologis, kadang terjadi tumpang tindih. Oksigen dapat dianggap sebagai unsur alami yang penting untuk kehidupan, dan sebagai obat yang digunakan untuk mengubah patologi penyakit. HBOT menggunakan oksigen sebagai obat dan oleh karena itu, memiliki protokol dosis yang tepat, indeks terapi, dan efek samping yang perlu dipahami agar dapat digunakan dengan aman dan efektif. (Kahle & Cooper, 2019; Maslova & Klimova, 2012)

      I.FUNGSI/MANFAAT (HBOT)

      Terapi Oksigen hiperbarik fungsi HBOT sangat kompleks. Akan mengurangi ukuran gelembung gas dalam cairan (darah). Sehingga meningkatkan kapasitas pembawa oksigen darah melalui peningkatan konsentrasi oksigen plasma menjadi sekitar 7%. Adanya bakteriostatik dan bakteriosidal pada tekanan dan oksigenasi yang lebih tinggi. Oksigen hiperbarik akan meningkatkan neovaskularisasi arteri dan mengurangi edema jaringan, yang akan menghambat berbagai eksotoksin seperti racun alfa dan beta yang terkait dengan infeksi nekrotikans. Pengobatan hiperbarik akan meningkatkan difusi oksigen lebih lanjut dalam jaringan dengan jarak sekitar empat kali jarak perfusi normal. Sehingga akan menyebabkan terjadi difusi oksigen dari lingkungan yang kaya oksigen ke lingkungan oksigen yang buruk seperti dengan luka iskemik dan anggota badan. Hukum Boyle adalah dasar untuk efektivitas dalam penyakit dekompresi dan emboli udara. Permukaan terlalu cepat dari penyelaman bawah laut yang dalam akan menghasilkan presipitasi gelembung nitrogen dalam darah. Ini akan menghasilkan persendian yang sangat menyakitkan, tikungan, dan bahkan kematian. (Fife et al., 2016; Jones & Wyatt, 2019)

      J.BAHAYA DAN KONTRAINDIKASI Terapi oksigen hiperbarik

      kontraindikasi mutlak untuk perawatan hiperbarik adalah pneumotoraks yang tidak diobati. Kontraindikasi relatif lainnya adalah jika pasien menggunakan agen kemoterapi tertentu seperti Adriamycin dan Cisplatinum atau Antabuse. Masalah lain yang menjadi perhatian adalah pasien berventilasi, pasien dengan hipertensi yang tidak terkontrol, dan penderita diabetes. Masalah dengan pasien berventilasi adalah varian dalam volume udara dan tekanan dan masalah barotrauma. Gula darah serum sering jatuh saat menyelam. Oleh karena itu, disarankan untuk memastikan glukosa serum pada pasien dengan diabetes berada pada sisi yang tinggi sebelum menyelam (Cho et al., 2018). Efek samping negatif dari menerima O2 bertekanan, akan terjadi cedera stres oksidatif, kerusakan DNA, metabolisme seluler, pengaktifan koagulasi, disfungsi endotel, neurotoksisitas akut, dan toksisitas paru, gangguan metabolisme sel, mengaktifkan koagulasi, disfungsi endotel, neurotoksisitas akut dan toksisitas paru. (Chen et al., 2019).

      Alasan mengapa HBOT tidak boleh diberikan pada interval yang jauh lebih sering dan dalam sesi yang lebih lama adalah potensi risiko keracunan oksigen (Körpınar & Uzun, 2019) Risiko oksigen hiperbarik; Bahaya kebakaran; Komplikasi fatal yang paling umum. Fitur umum; Claustrophobi, Miopia yang dapat dibalik, Kelelahan, Sakit kepala, Muntah. Barotrauma; Kerusakan telinga, Kerusakan sinus, Telinga tengah yang pecah, Kerusakan paru-paru. Toksisitas oksigen; Otak, Kejang, Psikologi. Paru-paru, Edema paru, perdarahan, Toksisitas paru, Gagal pernafasan (mungkin tidak dapat dikembalikan ketika terjadi fibrosis topulmoner). Penyakit dekompresi; Penyakit dekompresi, Pneumotoraks, Emboli gas. (Chen et al., 2019; Leach et al., 1998; Thom, 2009; Stephen R Thom, 2011).

  5. Dec 2020
    1. SciScore for 10.1101/2020.12.28.424565: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">Materials and Methods Ethics statement Approval of animal experiments was obtained from the Institutional Animal Care and Use Committee of the Rocky Mountain Laboratories.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Inoculation experiments Four to six-week-old female Syrian hamsters (ENVIGO) were inoculated (12 animals per route) either intranasally (I.N.), via aerosol exposure or via exposure to a fomite.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Using GenScript U864YFA140-4/CB2093 NP-1 (1:1000) specific anti-CoV immunoreactivity was detected using the Vector Laboratories ImPress VR anti-rabbit IgG polymer (# MP-6401) as secondary antibody.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>NP-1</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-rabbit IgG</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Spike-specific antibodies were detected with goat anti-hamster IgG Fc (horseradish peroxidase (HRP)- conjugated, Abcam) for 1 h at RT and visualized with KPL TMB 2-component peroxidase substrate kit (SeraCare, 5120-0047).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-hamster IgG</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cytokine analysis Cytokine concentrations were determined using a commercial hamster ELISA kit for TNF-α, INF-γ, IL-6, IL-4, and IL-10 available at antibodies.com, according to the manufacturer’s instructions (antibodies.com; A74292, A74590, A74291, A74027, A75096).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>TNF-α</div> <div>suggested: (Bio-Rad Cat# M6000007NY, RRID:AB_2784537)</div> </div> <div style="margin-bottom:8px"> <div>INF-γ</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>IL-6</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>IL-4</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>A74590</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>A74291</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Virus propagation was performed in VeroE6 cells in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 2% foetal bovine serum (FBS), 2 mM L-glutamine, 100 U/mL penicillin and μg/mL streptomycin.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>VeroE6</div> <div>suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Statistical Analysis Heatmaps and correlation graphs were made in R [64] using pheatmap [65] and corrplot [66] packages.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>pheatmap</div> <div>suggested: (pheatmap, RRID:SCR_016418)</div> </div> </td></tr></table>

      Results from OddPub: Thank you for sharing your data.


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.


      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      Reviewer #1 The authors study allostery with a beautiful genotype-phenotype experiment to study the fitness landscape of an allosteric lac repressor protein. The authors make a mutational library using error prone pcr and measure the impact on antibiotic resistance protein expression at varying levels of ligand, IPTG, expression. After measuring the impact of mutations authors fill-in the missing data using a neural net model. This type of dose response is not standard in the field, but the richness of their data and the discovery of the "band pass" phenomena prove its worth here splendidly. Using this mixed experimental/predicted data the authors explore how each mutation alters the different parameters of a hill equation fit of a dose response curve. Using higher order mutational space the authors look at how mutations can qualitatively switch phenotypes to inverted or band-stop dose-response curves. To validate and further explore a band-stop novel phenotype, the authors focused on a triple mutant and made all combinations of the 3 mutations. The authors find that only one mutation alone alters the dose-response and only in combination does a band-stop behavior present itself. Overall this paper is a fantastic data heavy dive into the allosteric fitness landscape of protein. Overall, the data presented in this paper is thoroughly collected and analyzed making the conclusions well-based. We do not think additional experiments nor substantial changes are needed apart from including basic experimental details and more biophysical rationale/speculation as discussed in further detail below.

      The authors do a genotype-phenotype experiment that requires extensive deep sequencing experiments. However, right now quite a bit of basic statistics on the sequencing is missing. Baseline library quality is somewhat shown in supplementary fig 2 but the figure is hard to interpret. It would be good to have a table that states how many of all possible mutations at different mutation depths (single, double, etc) there are. Similarly, sequencing statistics are missing- it would be useful to know how many reads were acquired and how much sequencing depth that corresponds to. This is particularly important for barcode assignment to phenotype in the long-read sequencing. In addition, a synonymous mutation comparison is mentioned but in my reading that data is not presented in the supplemental figures section.

      We thank the reviewer for this succinct summary of the manuscript and the results. We appreciate the reviewer identifying data of interest that were not included in the original manuscript. We agree that this information is necessary to consider the results. Specific changes are summarized in the comments below.

      The paper is very much written from an "old school" allostery perspective with static end point structures that are mutually exclusive - eg. p5l10 "relative ligand-binding affinity between the two conformations" - however, an ensemble of conformations is likely needed to explain their data. This is especially true for the bandpass and inverted phenotypes they observe. The work by Hilser et al is of particular importance in this area. We would invite the authors to speculate more freely about the molecular origins of their findings.

      We agree with the suggestions to adopt a modern allosteric perspective. We have changed the language throughout the manuscript to align with the ensemble model of allostery. We continue to frame results using the Monad-Wyman-Changeaux model, which reliably predicts LacI activity from biophysical parameters and is not exclusive of more modern models of allostery.

      **Minor** There are a number of small modifications. In general this paper is very technical and could use with some explanation and discussion for relevance to make the manuscript more approachable for a broader audience. P1L23: Ligand binding at one site causes a conformational change that affects the activity of another > not necessarily true - and related to using more "modern" statistical mechanical language for describing allostery.

      We agree with the reviewer’s comment. We have addressed this comment by adopting language in line with more modern view of allostery, for example:

      “With allosteric regulation, ligand binding at one site on a biomolecule changes the activity of another, often distal, site. Switching between active and inactive states provides a sense-and-response function that defines the allosteric phenotype.”

      P2L20: The core experiment of this paper is a selection using a mutational library. In the main body the authors mention the library was created using mutagenic pcr but leave it at that. More details on what sort of mutagenic pcr was used in the main body would be useful. According to the methods error prone pcr was used. Why use er-pcr vs deep point mutational libraries? Presumably to sample higher order phenotype? Rationale should be included. Were there preliminary experiments that helped calibrate the mutation level?

      We agree that justifying the decision to use error-prone PCR for library construction would be helpful. To explain this decision, we have added to the main text to explain this decision and to reflect on the consequences.

      “We used error-prone PCR across the full lacI CDS to investigate the effects of higher-order substitutions spread across the entire LacI sequence and structure.”

      And

      Novel phenotypes emerged at mutational distances greater than one amino acid substitution, highlighting the value in sampling a broader genotype space with higher-order mutations. Furthermore, the untargeted, random mutagenesis approach used here was critical for finding these novel phenotypes, as the genotypes required for these novel phenotypes were unpredictable.”

      P2L20: Baseline library statistics would be great in a table for coverage, diversity, etc especially as this was done by error prone pcr vs a more saturated library generation method. This is present in sup fig2 but it's a bit complicated.

      To more clearly convey the diversity within the library, we have included a heatmap of amino acid substitution counts found within the library (Supplementary Fig. 4). Additionally, we have added Supplementary Table 1, which lists the distribution of mutational distances of LacI variants found within the library, and the corresponding coverage of all possible mutations for each mutational distance.

      P2L26: How were FACS gates drawn? This is in support fig17 - should be pointed to here.

      We agree that a better description of the FACS process would be helpful. To address this we have included Supplementary Fig. 2, showing flow cytometry measurements of the library before and after FACS. Additionally, we have extended the description of the FACS process:

      “The initial library had a bimodal distribution of G__­0, as indicated by flow cytometry results, with a mode at low fluorescence (near G__­0 of wildtype LacI), and mode at higher gene expression. To generate a library in which most of the LacI variants could function as allosteric repressors, we used fluorescence activated cell sorting (FACS) to select the portion of the library with low fluorescence in the absence of ligand, gating at the bifurcation of the two modes (Sony SH800S Cell Sorter, Supplementary Fig. 2).”

      __

      P3L4: Where is the figure/data for the synonymous SNP mutations? This should be in the supplement.

      We agree this data is necessary to support the claim that LacI function was not impacted by synonymous mutations. We have included a new Supplementary Fig. 9, which shows the distribution of Hill equation parameters for LacI variants that code for the wild-type amino acid sequence, but with non-identical coding DNA sequences. Additionally, we included the results of a statistical analysis in the main text, this analysis compared all synonymous sequences in the library:

      “__We compared the distributions of the resulting Hill equation parameters between two sets of variants: 39 variants with exactly the wild-type coding DNA sequence for LacI (but with different DNA barcodes) and 310 variants with synonymous nucleotide changes (i.e. the wild-type amino acid sequence, but a non-wild-type DNA coding sequence). Using the Kolmogorov-Smirnov test, we found no significant differences between the two sets (p-values of 0.71, 0.40, 0.28, and 0.17 for G0, G∞, EC50, and n respectively, Supplementary Fig. 9).” __

      P3L20: The authors use a ML learning deep neural network to predict variant that were not covered in the screen. However, the library generation method is using error prone pcr meaning there could multiple mutations resulting in the same amino acid change. The models performance was determined by looking at withheld data however error prone pcr could result in multiple nonsynomymous mutations of the same amino acid. For testing were mutations truly withheld or was there overlap? Because several mutations are being represented by different codon combinations. Was the withheld data for the machine learning withholding specific substitutions?

      We thank the reviewer for identifying the need to clarify this critical data analysis. Data was held-out at the amino acid level, and so no overlap between the training and testing datasets occurred. We have clarified the description of the method in the main text:

      “We calculated RMSE using only held-out data not used in the model training, and the split between held-out data and training data was chosen so that all variants with a specific amino acid sequence appear in only one of the two sets.”


      In addition, higher order protein interactions are complicated and idiosyncratic. I am surprised how well the neural net performs on higher order substitutions. P4L4: Authors find mutations at the dimer/tetramer interfaces but don't mention whether polymerization is required. is dimerization required for dna binding? Tetramerization?

      We agree with the reviewer that, overall, a description of LacI structure and function would improve messaging the reported results. As such, we have added Supplementary Table 2, which defines the structural features discussed throughout the manuscript. Additionally, we have strived to describe the relevant structural and functional role of specific amino acids that are discussed in the text. Finally, we have also added a paragraph to the main text that summarizes the structure and function of LacI.

      “The LacI protein has 360 amino acids arranged into three structural domains__22–24__. The first 62 N-terminal amino acids form the DNA-binding domain, comprising a helix-turn-helix DNA-binding motif and a hinge that connects the DNA-binding motif and the core domain. The core domain, comprising amino acid positions 63-324, is divided into two structural subdomains: the N-terminal core and the C-terminal core. The full core domain forms the ligand-binding pocket, core-pivot region, and dimer interface. The tetramerization domain comprises the final 30 amino acids and includes a flexible linker and an 18 amino acid α-helix (Fig. 3, Supplementary Table 2). Naturally, LacI functions as a dimer of dimers: Two LacI monomers form a symmetric dimer that further assembles into a tetramer (a dimer of dimers).”

      P4L8: Substitutions near the dimer interface both impact g0 and ec50, which authors say is consistent with a change in the allosteric constant. Can authors explain their thinking more in the paper to make it easier to follow? Are the any mutations in this area that only impact g0 or ec50 alone? Why may these specific residues modify dimerization?

      We agree that a more in-depth discussion on the possible mechanisms behind these phenotypic changes would improve the manuscript. We have added discussion throughout the subsection “Effects of amino acid substitutions on LacI phenotype,” we believe this added discussion improve the manuscript and clarify the relationship between the observed allosteric phenotypes and the molecular mechanisms behind them. W

      Overall, we have made a number of changes in the manuscript that we hope will address these concerns.

      P4L8: The authors discuss the allosteric constant extensively within the paper but do not explain it. It would be helpful to have an explanation of this to improve readability. This explanation should include the statistical mechanical basis of it and some speculation about the ways it manifests biophysically.

      The allosteric constant is a critical concept, and we agree that it must be defined and discussed clearly throughout the manuscript. We have greatly expanded the discussion of the effects of single amino acid substitutions, and in the process we give examples of biochemical changes in the protein, and how they may affect the allosteric constant. We think this added text improves the manuscript and helps clarify the allosteric constant and the biomolecular processes that affect it.

      P4L1-16: Authors see mutations in the dimerization region that impact either G0 and Gsaturated in combination with Ec50 but not g0 and gsaturated together. Maybe we do not fully understand the hill equation but why are there no mutations that impact both g0 and gsaturated seen in support fig 13c? Why would mutations in the same region potentially impacting dimerization impact either g0 or gsaturated? What might be the mechanism behind divergent responses?

      It is important to recognize that the dimer interface does not just support the formation of dimers. There are many points of contact along the dimer interface that change when LacI switches between the active and inactive states. So, the dimer interface also helps regulate the balance between the active and inactive states. Our results show that different substitutions near the dimer interface can push this balance either toward the active or inactive states to varying degrees. We’ve added text throughout the description of single-substitutions effects to give specific examples and added a new paragraph at the end of that section to provide additional discussion and context. With regard to the more specific question of changes to both G0 and Ginf, the models indicate that simultaneous changes to those Hill Equation parameters requires an unusual combination of biophysical changes. To clarify this point, we added a short paragraph to the text:

      “None of the single amino substitutions measured in the library simultaneously decrease __G∞ and increase G0 (Supplementary Fig. 20c). This is not surprising, since substitutions that shift the biophysics to favor the active state tend to decrease G∞ while those that favor the inactive state tend to increase G0, and the biophysical models2,14,15 indicate that only a combination of parameter changes can cause both modifications to the dose-response. The library did, however, contain several multi-substitution variants with simultaneously decrease __G∞ and increase G0. These inverted variants, and their associated substitutions are discussed below.”


      P4L29: for interpretability it would be good to explain what log-additive effect means in the context of allostery.

      We agree that this information would be useful to the reader and have added additional text to explain log-additivity. We thank the reviewer for pointing out this oversight.

      “Combining multiple substitutions in a single protein almost always has a log-additive effect on EC50. That is, the proportional effects of two individual amino acid substitutions on the EC50 can be multiplied together. For example, if substitution A results in a 3-fold change, and substitution B results in a 2-fold change, the double substitution, AB, behaving log-additively, results in a 6-fold change__.”__

      P4L34-P5L19: This section is wonderful. Really cool results and interesting structural overlap! P5L34 Helix 9 of the protein is mentioned but it's functional relevance is not. This is common throughout the paper - it would be useful for there to be an overview somewhere to help the reader contextualize the results with known structural role of these elements.

      We agree with the reviewer that this information would help to contextualize the results. We have made a number of changes to address this. First, we have added Supplementary Table 2, which describes the structural features of LacI. Second, we have added a paragraph overviewing the structure and function of LacI. Third, we have expanded the section “the effects of individual amino acid substitutions on the function of LacI” to discuss the structural or biochemical impact of specific substitutions. We thank the reviewer for this suggestion.

      P5L39: The authors identified a triple mutant with the band-stop phenotype then made all combination of the triple mutant. Of particular interest is R195H/G265D which is nearly the same as the triple mutant. It would be nice if the positions of each of these mutations and have some discussion to begin to rationalize this phenotype, even if to point out how far apart they are and that there is no easy structural rationale!

      We appreciate the reviewer highlighting this area of interest. We have added structural information to Fig. 6, which indicates to position of the amino acid substitutions that result in the band-stop phenotype, as well as a small discussion in the main text:

      “To further investigate the band-stop phenotype, we chose a strong band-stop LacI variant with only three amino acid substitutions (R195H/G265D/A337D). These three positions are distributed distally on the periphery of the C-terminal core domain, and the role that each of these substitutions plays in the emergence of the band-stop phenotype is unclear.”

      P6L9: There should be more discussion of the significance of this work directly compared to what is known. For instance, negative cooperativity is mentioned as an explanation for bi-phasic dose response but this idea is not explained. Why would the relevant free energy changes be more entropic? Another example is the reverse-TetR phenotype observed by Hillen et al.

      We agree that more discussion is necessary to frame the results reported in the manuscript. To address this, we have added additional discussion throughout the manuscript that relates the results to the current understanding of allostery. Also, in the Conclusion, we added specific examples that lead us to link the ideas of bi-phasic dose response, negative cooperativity, and entropy/disorder. We believe these additions have improved the manuscript and we thank the reviewer for this suggestion.

      P6L28: The authors mention that phenotypes exist with genotypes that are discoverable with genotype-phenotype landscapes. This study due to the constraints of error prone pcr were somewhat limited. How big is the phenotypic landscape? Is it worth doing a more systematic study? What is the optimal experimental design: Single mutations, doubles, random - where is there the most information. How far can you drift before your machine learning model breaks down? How robust would it be to indels?

      The reviewer raises some excellent questions here, some of which are appropriate subjects for future work. The optimal experimental design depends on the objective: If the goal is to understand every possible mutation, a systematic site-saturation approach would be more appropriate. However, the landscape of a natural protein is limited by its wild-type DNA coding sequence, and so some substitutions are inaccessible (due to the arrangement of the codon table). The approach we took allowed to us characterize most of the accessible amino acid substitutions, while also allowing us to identify novel functions that would not have been identified with other approaches. We have added a little to the main text to discuss this (below). With regard to the DNN model, in the manuscript (SI Fig. 14), we show how the predictive accuracy degrades with mutational distance from the wild-type. It is possible that the type of DNN that we used could handle indels, since it effectively encodes each variant as a set of step-wise changes from the wild-type. But as with all machine-learning methods, it would require training with a dataset that included indels.

      “Novel phenotypes emerged at mutational distances greater than one amino acid substitution, highlighting the value in sampling a broader genotype space with higher-order mutations. Furthermore, the untargeted, random mutagenesis approach used here was critical for finding these novel phenotypes, as the genotypes required for these novel phenotypes were unpredictable.”

      Figures: Sup figs 3-7: The comparison of library-based results and single mutants is a great example of how to validate genotype-phenotype experiments!

      Thank you.

      Supp fig 5.: Missing figure number.

      We appreciate the reviewer catching this error and have attempted to properly label all figures and tables in this revision. Thank you.

      Supp fig7: G0 appears to have very poor fit between library vs single mutant version. Why might this be? R^2 would likely be better to report here as opposed to RMSE as RMSE is sensitize to the magnitude of the data such that you cannot directly compare RMSE of say 'n' to G0.

      We agree that these are important discussion points and have addressed this concern with an expanded discussion in the main text, as well as the addition of coefficient of correlation (R^2) in the caption for Figure 2 (previously supplementary figure 7). We believe these additions contribute meaningfully to the manuscript, and they address the concerns of the reviewer. The additional text reads:

      “We compared the Hill equation parameters from the library-scale measurement to those same parameters determined from flow cytometry measurements for each of the chemically synthesized LacI variants (Fig. 2). This served as a check of the new library-scale method’s overall ability to measure dose-response curves with quantitative accuracy. The accuracy for each Hill equation parameter in the library-scale measurement was: 4-fold for G0, 1.5-fold for G∞, 1.8-fold for EC50, and ± 0.28 for n. For G0, G∞, and EC50, we calculated the accuracy as: __, where __ is the root-mean-square difference between the logarithm of each parameter from the library-scale and cytometry measurements. For n, we calculated the accuracy simply as the root-mean-square difference between the library-scale and cytometry results. The accuracy for the gene expression levels (G0 and G∞) was better at higher gene expression levels (typical for G∞) than at low gene expression levels (typical for G0), which is expected based on the non-linearity of the fitness impact of tetracycline (Supplementary Figs. 10-11). Measurements of the Hill coefficient, n, had high relative uncertainties for both barcode-sequencing and flow cytometry, and so the parameter n was not used in any quantitative analysis.”

      Sup fig13c: it is somewhat surprising that mutations only appear to effect g0 and not gsaturated. This implies that basal and saturated activity are not coupled. Is this expected? Why or why not?

      This comment is partially addressed with a response above (P4L1-16). Coupled gene expression increases do occur, especially with substitutions at the start codon that result in fewer copies of LacI in the cell. In this instance, both G0 and G∞ are increased. Otherwise, changes to multiple biophysical parameters are required to increase both G0 and G∞.

      Reviewer #1 (Significance (Required)): Allostery is hard to comprehend because it involves many interacting residues propagating information across a protein. The Monod-Wyman-Changeux (MWC) and Koshland, Nemethy, and Filmer (KNF) models have been a long standing framework to explain much of allostery, however recent formulations have focused on the role of the conformational ensemble and a grounding in statistical mechanics. This manuscript focuses on the functional impact of mutations and therefore contribution of the amino acids to regulation. The authors unbiased approach of combining a dose-response curve and mutational library generation let them fit every mutant to a hill equation. This approach let the authors identify the allosteric phenotype of all measured mutations! The authors found inverted phenotypes which happen in homologs of this protein but most interesting is the strange and idiosyncratic 'Band-stop' phenotype. The band-stop phenotype is bi-phasic that will hopefully be followed up with further studies to explain the mechanism. This manuscript is a fascinating exploration of the adaptability of allosteric landscapes with just a handful of mutations. Genotype-phenotype experiments allow sampling immense mutational space to study complex phenotypes such as allostery. However, a challenge with these experiments is that allostery and other complicated phenomena come from immense fitness landscapes altering different parameters of the hill equation. The authors approach of using a simple error prone pcr library combined with many ligand concentrations allowed them to sample a very large space somewhat sparsely. However, they were able to predict this data by training and using a neural net model. I think this is a clever way to fill in the gaps that are inherent to somewhat sparse sampling from error prone pcr. The experimental design of the dose response is especially elegant and a great model for how to do these experiments. With some small improvements for readability, this manuscript will surely find broad interest to the genotype-phenotype, protein science, allostery, structural biology, and biophysics fields. We were prompted to do this by Review Commons and are posting our submitted review here: Willow Coyote-Maestas has relevant expertise in high throughput screening, protein engineering, genotype-phenotype experiments, protein allostery, dating mining, and machine learning. James Fraser has expertise in structural biology, genotype-phenotype experiments, protein allostery, protein dynamics, protein evolution, etc.

      Reviewer #2 (Evidence, reproducibility and clarity (Required)): The authors use deep mutational scanning to infer the dose-response curves of ~60,000 variants of the LacI repressor and so provide an unprecedently systematic dataset of how mutations affect an allosteric protein. Overall this is an interesting dataset that highlights the potential of mutational scanning for rapidly identifying diverse variants of proteins with desired or unexpected activities for synthetic biology/bioengineering. The relatively common inverted phenotypes and their sequence diversity is interesting, as is the identification of several hundred genotypes with non-sigmoidal band-stop dose-response curves and their enrichment in specific protein regions. A weakness of the study is that some of the parameter estimates seem to have high uncertainty and this is not clearly presented or the impact on the conclusions analysed. A second shortcoming is that there is little mechanistic insight beyond the enrichments of mutations with different effects in different regions of the protein. But as a first overview of the diversity of mutational effects on the dose-response curve of an allosteric protein, this is an important dataset and analysis. **Comments** **Data quality and reproducibility** "The flow cytometry results confirmed both the qualitative and quantitative accuracy of the new method (Supplementary Figs. 3-7)"

      • There need to be quantitative measures of accuracy in the text here for the different parameters.

      We believe this comment is addressed along with the following two comments.

      • Sup fig 7 panels should be main text panels - they are vital for understanding the data quality In particular, the G0 parameter estimates from the library appear to have a lower bound ie they provide no information below a cytometry Go of ~10^4. This is an important caveat and needs to be highlighted in the main text. The Hill parameter (n) estimate for wt (dark gray) replicate barcodes is extremely variable - why is this?

      • In general there is not a clear enough presentation of the uncertainty and biases in the parameter estimations which seem to be rather different for the 4 parameters. Only the EC50 parameter seems to correlate very well with the independent measurements.

      We thank the reviewer for identifying a need for more information on the accuracy of this method. So, we have moved Supplementary Fig. 7 to the main text (Fig 2 in the revised manuscript) and have added coefficients of correlation to each Hill equation parameter in that figure caption. Furthermore, we have added new data (Supplementary Fig. 11), which shows the uncertainty associated with different gene expression levels. Finally, we have added a discussion on the accuracy of this method for each parameter of the Hill equation to the main text. Estimation of the Hill coefficient (n) from data is often highly uncertain and variable, because that parameter estimate can be highly sensitive to random measurement errors at a single point on the curve. The estimate for the wild type appears to be highly variable because the plot contains 53 replicate measurements. So, the plotted variability represents approximately 2 standard deviations. The spread of wild-type results in the plot is consistent with the stated RMSE for the Hill coefficient. Furthermore, the Hill coefficient is not used in any of the additional quantitative analysis in our manuscript, partially because of its relatively high measurement uncertainty, but also because, based on the biophysical models, it is not as informative of the underlying biophysical changes.

      “We compared the Hill equation parameters from the library-scale measurement to those same parameters determined from flow cytometry measurements for each of the chemically synthesized LacI variants (Fig. 2). This served as a check of the new library-scale method’s overall ability to measure dose-response curves with quantitative accuracy. The accuracy for each Hill equation parameter in the library-scale measurement was: 4-fold for G0, 1.5-fold for G∞, 1.8-fold for EC50, and ± 0.28 for n. For G0, G∞, and EC50, we calculated the accuracy as: "exp" ["RMSE" ("ln" ("x" ))], where "RMSE" ("ln" ("x" )) is the root-mean-square difference between the logarithm of each parameter from the library-scale and cytometry measurements. For n, we calculated the accuracy simply as the root-mean-square difference between the library-scale and cytometry results. The accuracy for the gene expression levels (G0 and G∞) was better at higher gene expression levels (typical for G∞) than at low gene expression levels (typical for G0), which is expected based on the non-linearity of the fitness impact of tetracycline (Supplementary Figs. 10-11). Measurements of the Hill coefficient, n, had high relative uncertainties for both barcode-sequencing and flow cytometry, and so the parameter n was not used in any quantitative analysis.”

      • The genotypes in the mutagenesis library contain a mean of 4.4 aa substitutions and the authors us a neural network to estimate 3 of the Hill equation parameters (with uncertainties) for the 1991/2110 of the single aa mutations. It would be useful to have an independent experimental evaluation of the reliability of these inferred single aa mutational effects by performing facs on a panel of single aa mutants (using single aa mutants in sup fig 3-7, if there are any, or newly constructed mutants).

      We agree that the predictive performance of the DNN requires experimental validation. We evaluated the performance by withholding data from 20% of the library, including nearly 200 variants with single amino acid substitutions, and then compared the predicted effect of those substitutions to the measured effect. The results of this test are reported in Supplementary Fig. 14. Additionally, we have adjusted the main text to more clearly explain the evaluation process.

      “To evaluate the accuracy of the model predictions, we used the root-mean-square error (RMSE) for the model predictions compared with the measurement results. We calculated RMSE using only held-out data not used in the model training, and the split between held-out data and training data was chosen so that all variants with a specific amino acid sequence appear in only one of the two sets.” __ __

      • fig3/"Combining multiple substitutions in a single protein almost always has a log-additive effect on EC50." How additive are the other 2 parameters? this analysis should also be presented in fig 3. If they are not as additive is it simply because of lower accuracy of the measurements? If the mutational effects are largely additive, then a simple linear model (rather than the DNN) could be used to estimate the single mutant effects from the multiple mutant genotypes.

      We agree with the reviewer that exploring the log-additivity of the Hill equation parameters is informative, and have included Supplementary Figure 21, which displays this information. Furthermore, we expanded the discussion of log-additivity on all three parameters in the main text:

      “Combining multiple substitutions in a single protein almost always has a log-additive effect on EC50. That is, the proportional effects of two individual amino acid substitutions on the EC50 can be multiplied together. For example, if substitution A results in a 3-fold change, and substitution B results in a 2-fold change, the double substitution, AB, behaving log-additively, results in a 6-fold change. Only 0.57% (12 of 2101) of double amino acid substitutions in the measured data have EC50 values that differ from the log-additive effects of the single substitutions by more than 2.5-fold (Fig. 4). This result, combined with the wide distribution of residues that affect EC50, reinforces the view that allostery is a distributed biophysical phenomenon controlled by a free energy balance with additive contributions from many residues and interactions, a mechanism proposed previously1,39 and supported by other recent studies17, rather than a process driven by the propagation of local, contiguous structural rearrangements along a defined pathway.

      A similar analysis of log-additivity for G0 and G∞ is complicated by the more limited range of measured values for those parameters, the smaller number of substitutions that cause large shifts in G0 or G∞, and the higher relative measurement uncertainty at low G(L). However, the effects of multiple substitutions on G0 and G∞ are also consistent with log-additivity for almost every measured double substitution variant (Supplementary Fig. 21).”

      **Presentation/clarity of text and figures**

      • The main text implies that the DNN is trained to predict 3 parameters of the Hill equation but not the Hill coefficient (n). This should be clarified / justified in the main text.

      We agree that the decision to exclude the parameter ‘n’ requires explanation in the main text. To address this, we have added to the main text:

      “Measurements of the Hill coefficient, n, had high relative uncertainties for both barcode-sequencing and flow cytometry, and so the parameter n was not used in any quantitative analysis.”

      and

      “We trained the model to predict the Hill equation parameters G0, G∞, and EC50 (Supplementary Fig. 13), the three Hill equation parameters that were determined with relatively low uncertainty by the library-scale measurement.”

      • The DNN needs to be better explained and justified in the main text for a general audience. How do simpler additive models perform for phenotypic prediction / parameter inference?

      We agree with the reviewer that the DNN needs to be justified in the main text. As part of the revision plan, we propose to compare the predictive performance of the DNN to an additive model.

      • Ref 14. analyses a much smaller set of mutants in the same protein but using an explicit biophysical model. It would be helpful to have a more extensive comparison with the approach and conclusions to this previous study.

      Throughout the manuscript, we frame the results and discussion in terms of the referenced biophysical model. Using the model, we describe the biophysical effects that a substitution may have on LacI, based on observed changes to function associated with that substitution. We also comment briefly on the limitations of this model when applied to the extensive dataset presented here.

      “Most of the non-silent substitutions discussed above are more likely to affect the allosteric constant than either the ligand or operator affinities. Within the biophysical model, those affinities are specific to either the active or inactive state of LacI, i.e. they are defined conditionally, assuming that the protein is in the appropriate state. So, almost by definition, substitutions that affect the ligand-binding or operator-binding affinities (as defined in the models) must be at positions that are close to the ligand-binding site or within the DNA-binding domain. Substitutions that modify the ability of the LacI protein to access either the active state or inactive state, by definition, affect the allosteric constant. This includes, for example, substitutions that disrupt dimer formation (dissociated monomers are in the inactive state), substitutions that lock the dimer rigidly into either the active or inactive state, or substitutions that more subtly affect the balance between the active and inactive states. Thus, because there are many more positions far from the ligand- and DNA- binding regions than close to those regions, there are many more opportunities for substitutions to affect the allosteric constant than the other biophysical parameters. Note that this analysis assumes that substitutions don’t perturb the LacI structure too much, so that the active and inactive states remain somehow similar to the wild-type states. Our results suggest that this is not always the case: consider, for example, the substitutions at positions __K84 and M98 discussed above and the substitutions resulting in the inverted and band-stop phenotypes discussed below.”__

      • Enrichments need statistical tests to know how unexpected that results are e.g. p5 line 12 "67% of strongly inverted variants have substitutions near the ligand-binding pocket"

      We agree that this information is necessary to interpret the results. We have included p-values (previously reported only in the Methods section) throughout the main text of the manuscript.

      The publication by Poelwijk et al. was considered extensively when planning this work, and failing to cite that manuscript would have been tremendously unjust. We have included it, as well as a few additional references that have identified and discussed inverted LacI variants. We sincerely thank the reviewer for identifying this oversight.

      • What mechanisms do the authors envisage that could produce the band-stop dose response curves? There is likely previous theoretical work that could be cited here. In general there is little discussion of the biophysical mechanisms that could underlie the various mutational effects.

      We agree with the reviewer, that discussing the biophysical mechanisms that underlie many of the reported mutations is important to understand the results. We have expanded the subsection “Effects of amino acid substitutions on LacI phenotype” to include discussion on several of the key substitutions (or groups of substitutions) and their potential biophysical effects. Additionally, we consider mechanism that may underlie the band-stop sensor, and propose one model that could explain the band-stop phenotype:

      “In particular, the biphasic dose-response of the band-stop variants suggests negative cooperativity: that is, successive ligand binding steps have reduced ligand binding affinity. Negative cooperativity has been shown to be required for biphasic dose-response curves__42,43. The biphasic dose-response and apparent negative cooperativity are also reminiscent of systems where protein disorder and dynamics have been shown to play an important role in allosteric function1, including catabolite activator protein (CAP)44,45 and the Doc/Phd toxin-antitoxin system46. This suggests that entropic changes may also be important for the band-stop phenotype. A potential mechanism is that band-stop LacI variants have two distinct inactive states: an inactive monomeric state and an inactive dimeric state. In the absence of ligand, inactive monomers may dominate the population. Then, at intermediate ligand concentrations, ligand binding stabilizes dimerization of LacI into an active state which can bind to the DNA operator and repress transcription. When a second ligand binds to the dimer, it returns to an inactive dimeric state, similar to wildtype LacI. This mechanism, and other possible mechanisms, do not match the MWC model of allostery or its extensions2,13–15__ and require a more comprehensive study and understanding of the ensemble of states in which these band-stop LacI variants exist.”

      • "This result, combined with the wide distribution of residues that affect EC50, suggests that LacI allostery is controlled by a free energy balance with additive contributions from many residues and interactions." 'additive contributions and interactions' covers all possible models of vastly different complexity i.e. this sentence is rather meaningless.

      We have attempted to contextualize this statement by adding additional discussion and references. We hope these additions give more meaning to this section.

      “__This result, combined with the wide distribution of residues that affect EC50, reinforces the view that allostery is a distributed biophysical phenomenon controlled by a free energy balance with additive contributions from many residues and interactions, a mechanism proposed previously1,39 and supported by other recent studies17, rather than a process driven by the propagation of local, contiguous structural rearrangements along a defined pathway.”__

      • fig 4 c and d compress a lot of information into one figure and I found this figure confusing. It may be clearer to have multiple panels with each panel presenting one aspect. It is also not clear to me what the small circular nodes exactly represent, especially when you have one smaller node connected to two polygonal nodes, and why they don't have the same colour scale as the polygonal nodes.

      We agree with the reviewer that figure 4 (or Figure 5 in the revised manuscript) contains a lot of information. The purpose of this figure is to convey the structural and genetic diversity among the sets of inverted variants and band-stop variants. We designed this figure to convey this point at two levels: a brief overview, where the diversity is apparent by quickly considering the figure, and at a more informative level, with some quantitative data and structurally relevant points highlighted. We have modified the caption slightly, in an effort to improve clarity.

      • line 25 - 'causes a conformational change' -> 'energetic change' (allostery does not always involve conformational change

      We thank the reviewer for this comment and have adopted a more modern language describe allostery throughout the manuscript.

      • sup fig 5 legend misses '5'

      We thank the reviewer for pointing this out, we have attempted to number all figures and tables more carefully.

      • sup fig 7. pls add correlation coefficients to these plots (and move to main text figures).

      We agree that this information is of interest and have included this data as main text Figure 2. In addition, we have included coefficients of correlation in the caption of this figure.

      • Reference 21 is just a title and pubmed link

      We thank the reviewer for identifying this error, we have corrected this in the references.

      • "fitness per hour" -> growth rate

      To ensure that this connection is clearly established, when we introduce fitness for the first time, we clarify that it relates to growth rate:

      “Consequently, in the presence of tetracycline, the LacI dose-response modulates cellular fitness (i.e. growth rate) based on the concentration of the input ligand isopropyl-β-D-thiogalactoside (IPTG).”

      Also, we define ‘fitness’ in the Methods section:

      “The experimental approach for this work was designed to maintain bacterial cultures in exponential growth phase for the full duration of the measurements. So, in all analysis, the Malthusian definition of fitness was used, i.e. fitness is the exponential growth rate__58__.”

      • page 6 line 28 - "discoverable only via large-scale landscape measurements" - directed evolution approaches can also discover such genotypes (see e.g. Poelwijk /Tans paper). Please re-phrase.

      We agree with the reviewer and have adjusted the main text accordingly.

      “__Overall, our findings suggest that a surprising diversity of useful and potentially novel allosteric phenotypes exist with genotypes that are readily discoverable via large-scale landscape measurements.”__

      • pls define jargon the first time it is used e.g. band-stop and band-pass

      We agree that all unconventional terms should be explicitly defined when used, and we have attempted to define the band-pass and band-stop dose-response curves more clearly in the main text:

      “These include examples of LacI variants with band-stop dose-response curves (i.e. variants with high-low-high gene expression; e.g. Fig. 1e, Supplementary Fig. 7), and LacI variants with band-pass dose-response curves (i.e. variants with low-high-low gene expression; e.g. Supplementary Fig. 8).”

      **Methods/data availability/ experimental and analysis reproducibility:** The way that growth rate is calculated on page 17 equation 1- This section is confusing. Please be explicit about how you accounted for the lag phase, what the lag phase was, and total population growth during this time. In addition, please report the growth curves from the wells of the four plates, the final OD600 of the pooled samples, and exact timings of when the samples were removed from 37 degree incubation in a table. These are critical for calculating growth rate in individual clones downstream.

      We thank the reviewer for identifying the need to clarify this section of text. The ‘lag’ in this section referred to a delay before tetracycline began impacting the growth rate of cells. To address this, we have changed ‘lag’ in this context to ‘delay.’ Furthermore, we have attempted to clarify precisely the cause of this delay, and how we accounted for it in calculating growth rates:

      For samples grown with tetracycline, the tetracycline was only added to the culture media for Growth Plates 2‑4. Because of the mode of action of tetracycline (inhibition of translation), there was a delay in its effect on cell fitness: Immediately after diluting cells into Growth Plate 2 (the first plate with tetracycline), the cells still had a normal level of proteins needed for growth and proliferation and they continued to grow at nearly the same rate as without tetracycline. Over time, as the level of proteins required for cell growth decreased due to tetracycline, the growth rate of the cells decreased. Accordingly, the analysis accounts for the variation in cell fitness (growth rate) as a function of time after the cells were exposed to tetracycline. With the assumption that the fitness is approximately proportional to the number of proteins needed for growth, the fitness as a function of time is taken to approach the new value with an exponential decay:

      (3)

      where μitet is the steady-state fitness with tetracycline, and α is a transition rate. The transition rate was kept fixed at α = log(5), determined from a small-scale calibration measurement. Note that at the tetracycline concentration used during the library-scale measurement (20 µg/mL), μitet was greater than zero even at the lowest G(L) levels (Supplementary Fig. 10). From Eq. (3), the number of cells in each Growth Plate for samples grown with tetracycline is:

      • What were the upper and lower bounds of the measurements? (LacI deletion vs Tet deletion / autofluoresence phenotype - true 100% and true 0% activity). Knowing and reporting these bounds will also allow easier comparison between datasets in the future.

      We agree that knowing the limitations of the measurement are important for contextualizing the results. To address this point, we have included Supplementary Fig. 11, which shows the uncertainty of the measurement across gene expression levels.

      Please clarify whether there was only 1 biological replicate (because the plates were pooled before sequencing)? Or if there were replicates present an analysis of reproducibility.

      We thank the reviewer for pointing out the ambiguity in the original manuscript. The library-scale measurement reported here was completed once, the 24 growth conditions were spread across 96 wells, so each condition occupied 4 wells. The 4 wells were combined prior to DNA extraction. We have clarified this process in the methods by removing ‘duplicate’:

      “Growth Plate 2 contained the same IPTG gradient as Growth Plate 1 with the addition of tetracycline (20 µg/mL) to alternating rows in the plate, resulting in 24 chemical environments, with each environment spread across 4 wells.”

      Despite there being only a single library-scale measurement, the accuracy and reliability of the results are supported by many distinct biological replicates within the library (i.e. LacI variants with the same amino acid sequence but with different barcodes, see new Supplementary Fig. 9), as well as over 100 orthogonal dose-response curve measurements completed with flow cytometry (Figure 2). We believe these support the reproducibility of the work and we have included statistical analysis on the accuracy of the library-scale measurement results.

      “To test the accuracy of the new method for library-scale dose-response curve measurements, we independently verified the results for over 100 LacI variants from the library. For each verification measurement, we chemically synthesized the coding DNA sequence for a single variant and inserted it into a plasmid where LacI regulates the expression of a fluorescent protein. We transformed the plasmid into E. coli and measured the resulting dose-response curve with flow cytometry (e.g. Fig. 1e). We compared the Hill equation parameters from the library-scale measurement to those same parameters determined from flow cytometry measurements for each of the chemically synthesized LacI variants (Fig. 2). This served as a check of the new library-scale method’s overall ability to measure dose-response curves with quantitative accuracy. The accuracy for each Hill equation parameter in the library-scale measurement was: 4-fold for G0, 1.5-fold for G∞, 1.8-fold for EC50, and ± 0.28 for n. For G0, G∞, and EC50, we calculated the accuracy as: "exp" ["RMSE" ("ln" ("x" ))], where "RMSE" ("ln" ("x" )) is the root-mean-square difference between the logarithm of each parameter from the library-scale and cytometry measurements. For n, we calculated the accuracy simply as the root-mean-square difference between the library-scale and cytometry results (Supplementary Fig. 7).”

      • Please provide supplementary tables of the data (in addition to the raw sequencing files). Both a table summarising the growth rates, inferred parameter values and uncertainties for genotypes and a second table with the barcode sequence counts across timepoints and associated experimental data.

      We agree that access to this information is critical. Due to the size of the associated data, we have made this data available for download in a public repository. We direct readers to the repository information in the “Data Availability” statement:

      “The raw sequence data for long-read and short-read DNA sequencing have been deposited in the NCBI Sequence Read Archive and are available under the project accession number PRJNA643436. Plasmid sequences have been deposited in the NCBI Genbank under accession codes MT702633, and MT702634, for pTY1 and pVER, respectively.

      The processed data table containing comprehensive data and information for each LacI variant in the library is publicly available via the NIST Science Data Portal, with the identifier ark:/88434/mds2-2259 (https://data.nist.gov/od/id/mds2-2259 or https://doi.org/10.18434/M32259). The data table includes the DNA barcode sequences, the barcode read counts, the time points used for the libarary-scale measurement, fitness estimates for each barcoded variant across the 24 chemical environments, the results of both Bayesian inference models (including posterior medians, covariances, and 0.05, 0.25, 0.75, and 0.95 posterior quantiles), the LacI CDS and amino acid sequence for each barcoded variant (as determined by long-read sequencing), the number of LacI CDS reads in the long-read sequencing dataset for each barcoded variant, and the number of unintended mutations in other regions of the plasmid (from the long-read sequencing data).

      Code Availability

      All custom data analysis code is available at https://github.com/djross22/nist_lacI_landscape_analysis.”

      Reviewer #2 (Significance (Required)): The authors present an unprecedently systematic dataset of how mutations affect an allosteric protein. This illustrates the potential of mutational scanning for rapidly identifying diverse variants of allosteric proteins / regulators with desired or unexpected activities for synthetic biology/bioengineering. Previous studies have identified inverted dose-response curve for a lacI phenotypes https://www.cell.com/fulltext/S0092-8674(11)00710-0 but using directed evolution i.e. they were not comprehensive in nature. The audience of this study would be protein engineers, the allostery field, synthetic biologists and the mutation scanning community and evolutionary biologists interested in fitness landscapes. My relevant expertise is in deep mutational scanning and genotype-phenotype landscapes, including work on allosteric proteins and computational methods. Reviewer #3 (Evidence, reproducibility and clarity (Required)): In this interesting manuscript the authors developed in ingenious high throughput screening approach which utilizes DNA barcoding to select variants of LacI proteins with different allosteric profiles for IPTG control using E. coli fitness (growth rate) in a range of antibiotic concentrations as a readout thus providing a genotype-phenotype map for this enzyme. The authors used library of 10^5-10^ variants of LacI expressed from a plasmid and screened for distinct IPTG activation profiles under different conditions including several antibiotic stressors. As a result they identified various patterns of activation including normal (sigmoidal increase), inverted (decrease) and unusual stop-band where the dependence of growth on [IPTG] is non-monotonic. The study is well-conceived, well executed and provides statistically significant results. The key advance provided by this work is that it allows to identify specific mutations in LacI connected with one of three allosteric profiles. The paper is clearly written all protocols are explained and it can be reproduced in a lab that possesses proper expertise in genetics. Reviewer #3 (Significance (Required)): The significance of this work is that it discovered libraries of LacI variants which give rise to distinct profiles of allosteric control of activation of specific genes (in this case antibiotic resistance) by the Lac mechanism. The barcoding technology allowed to identify specific mutations which are (presumably) causal of changes in the way how allosteric activation of LacI by IPTG works. As such it provides a rich highly resolved dataset of LacI variants for further exploration and analysis. Alongside with these strengths several weaknesses should also be noted:

      1. First and foremost the paper does not provide any molecular-level biophysical insights into the impact of various types of mutations on molecular properties of LacI. Do the mutations change binding affinity to IPTG? Binding side? Communication dynamics? Stability? The diagrams of connectivity for the stop-band mutations (Fig.4) do not provide much help as they do not tell much which molecular properties of LacI are affected by mutations and why certain mutations have specific effect on allostery. A molecular level exploration would make this paper much stronger.

      We address this comment with comment (2), below.

      1. In the same vein a theoretical MD study would be quite illuminating in answering the key unanswered question of this work: Why do mutations have various and pronounced effects of allosteric regulation by LacI?. I think publication of this work should not be conditioned on such study but again adding would make the work much stronger.

      We appreciate the reviewer’s comments and agree that investigating the molecular mechanisms driving the phenotypic changes identified in this work is a compelling proposition. Throughout the manuscript, we identify positions and specific amino acid substitutions that affect the measurable function of LacI, and occasionally discuss the biophysical effects that may underly these changes. We have expanded the discussion to include possible molecular-level effects.

      The dataset reported here identifies many potential candidates for molecular-level study, either computationally or experimentally. However, this manuscript is scoped to report a large-scale method to measure the genotype-phenotype landscape of an allosteric protein, and a limited investigation into the emergence of novel phenotypes that are identified in the landscape.

      1. Lastly a recent study PNAS v.116 pp.11265-74 (2019) explored a library of variants of E. coli Adenylate Kinase and showed the relationship between allosteric effects due to substrate inhibition and stability of the protein. Perhaps a similar relationship can explored in this case of LacI.

      We thank the reviewer for highlighting this publication. We agree with the reviewer that similar effects may play a role in the activity of LacI. Establishing such a relationship would require additional experimentation, and, we think, is outside the scope of the submitted manuscript. Although, we hope follow-up studies using this dataset will investigate this phenomenon and other related mechanisms, that may underlie the band-stop phenotype and other observed effects.

    1. the n1te. d Sta es a t e lands owne d l d or possessed b y t hemall theirlands east c a1me the Mississippi. east o:f the Mississippi river, and hereby release all their claims upon the United States for spoliations of every kind

      The fact that they only wanted to acquire this land for 5 million is very demeaning

    2. the n1te. d Sta es a t e lands owne d l d or possessed b y t hemall theirlands east c a1me the Mississippi. east o:f the Mississippi river, and hereby release all their claims upon the United States for spoliations of every kind

      spoliations meaning destruction according to my google search, so basically the US gets to do whatever the hell it wants to with the land. Notice too how they see the land as expendable.

    1. SciScore for 10.1101/2020.12.10.20247205: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">Materials and Methods Ethics statement This study was approved by Yale Human Research Protection Program Institutional Review Boards (FWA00002571, protocol ID 2000027690).</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">Cytokines and FACS analyses were performed blinded.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Antibodies Anti-human antibodies used in this study, together with vendors and dilutions, are listed as follows: BB515 anti-hHLA-DR (G46-6) (1:400</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Anti-human</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-hHLA-DR ( G46-6 )</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Antimouse antibodies used in this study, together with vendors and dilutions, are listed as follows: FITC anti-mCD11c (N418) (1:400) (BioLegend), PerCP-Cy5.5 or FITC antimLy6C (HK1.4) (1:400) (BioLegend), PE or BV605 or BV711 anti-mNK1.1 (PK136) (1:400) (BioLegend), PE-Cy7 anti-mB220 (RA3-6B2) (1:200) (BioLegend), APC anti-mXCR1 (ZET) (1:200) (BioLegend), APC or AlexaFluor 700 or APC-Cy7 anti-mCD4 (RM4-5) (1:400) (BioLegend), APC-Cy7 anti-mLy6G (1A8) (1:400) (BioLegend), BV605 antimCD45 (30-F11) (1:400) (BioLegend), BV711 or PerCP-Cy5.5 anti-mCD8a (53-6.7) (1:400) (BioLegend), AlexaFluor 700 or BV785 anti-mCD11b (M1/70) (1:400) (BioLegend), PE anti-mCXCR3 (CXCR3-173) (1:200) (BioLegend), PE-Cy7 antimTCRgd</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Antimouse</div> <div>suggested: (C. Birchmeier, Max Delbruck Center for Molecular Medicine; Berlin; Germany Cat# Guinea pig anti-mouse Tlx3 polyclonal antibody, RRID:AB_2532145)</div> </div> <div style="margin-bottom:8px"> <div>anti-mCD11c</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>antimLy6C</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-mNK1.1</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-mB220 ( RA3-6B2 )</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-mXCR1</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-mCD4</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-mLy6G</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>antimCD45</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-mCD8a</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-mCD11b</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-mCXCR3</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>CXCR3-173</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>PE-Cy7</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For GPCR N-terminal extracellular domains, these yeast were pooled together with transfected yeast that were used to construct the previously described exoproteome library and a limited dilution of clones were sub-sampled, induced, and stained for FLAG using 1:100 anti-FLAG PE antibody (BioLegend).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-FLAG</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plates were washed three times with PBS-T (PBS with 0.1% Tween-20) and 50 μL of HRP anti-Human IgG Antibody at 1:5000 dilution (GenScript) or anti-Human IgM-Peroxidase Antibody at 1:5000 dilution (Sigma-Aldrich) diluted in dilution solution were added to each well.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-Human IgG</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-Human IgM-Peroxidase</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Percent max signal was calculated by subtracting background MFI and calculating values as a percentage of GM-CSF induced pSTAT5 MFI in the absence of IgG. Functional Validation of CXCL1 and CXCL7 Autoantibodies HTLA cells, a HEK293-derived cell line that stably expresses β-arrestin-TEV and tTALuciferase, were seeded in wells of a sterile tissue culture grade flat bottom 96-well plate (35,000 cells/well) in 100 μL DMEM (+ 10% FBS, 1% Penicillin/Streptomycin).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>CXCL1</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>CXCL7</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Following a wash, cells were blocked with anti-mouse CD16/32 antibodies (BioXCell) for 30 min at 4 °C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-mouse CD16/32</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Expi293 cells (Thermo Fisher Scientific) were transfected and maintained according to manufacturer protocols.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Expi293</div> <div>suggested: RRID:CVCL_D615)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">For protein production, Hi-5 cells were infected with P2 virus at a previously optimized titer and harvested 3–5 days after infection.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Hi-5</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Mice B6.Cg-Tg(K18-ACE2)2Prlmn/J (K18-hACE2) mice were purchased from the Jackson Laboratories and were subsequently bred and housed at Yale University.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>B6.Cg-Tg(K18-ACE2)2Prlmn/J ( K18-hACE2 )</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Materials and Methods Ethics statement This study was approved by Yale Human Research Protection Program Institutional Review Boards (FWA00002571, protocol ID 2000027690).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Yale Human Research Protection Program</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The clinical data were collected using EPIC EHR and REDCap 9.3.6 software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>REDCap</div> <div>suggested: (REDCap, RRID:SCR_003445)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The band corresponding to 257 base pairs was cut out and DNA (NGS library) was extracted using a QIAquick Gel Extraction Kit (Qiagen) according to standard manufacturer protocols.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>NGS</div> <div>suggested: (PM4NGS, RRID:SCR_019164)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data were analysed using FlowJo software version 10.6 software (Tree Star).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>FlowJo</div> <div>suggested: (FlowJo, RRID:SCR_008520)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Data analysis was performed using R, MATLAB, and GraphPad Prism. Reporting Summary Further information on research design will be made available in the Nature Research Reporting Summary linked to this article.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>MATLAB</div> <div>suggested: (MATLAB, RRID:SCR_001622)</div> </div> <div style="margin-bottom:8px"> <div>GraphPad</div> <div>suggested: (GraphPad Prism, RRID:SCR_002798)</div> </div> </td></tr></table>

      Results from OddPub: Thank you for sharing your data.


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.


      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

    1. Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., Bibi, S., Briner, C., Cicconi, P., Collins, A. M., Colin-Jones, R., Cutland, C. L., Darton, T. C., Dheda, K., Duncan, C. J. A., … Zuidewind, P. (2020). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet, 0(0). https://doi.org/10.1016/S0140-6736(20)32661-1

    1. SciScore for 10.1101/2020.12.06.413443: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Subsequently, Vero E6 cells were incubated with a 1:500 dilution of an antidsRNA J2 antibody (Jena Bioscience) in PBS supplemented with 1% FCS at 4°C overnight with shaking.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>antidsRNA J2</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Next, the plates were incubated with a 1:2,000 dilution of a goat anti-mouse IgG2aHRP antibody (Southern Biotech) in PBS supplemented with 1% FCS and incubated with gently shaking at RT for one hour.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-mouse IgG2aHRP</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Briefly, HepG2 or Vero E6 cells were plated in a 12-well plate at 5 x 10E5 cells/well in DMEM medium (Gibco) supplemented with 5% FCS, 1% P/S, 200 mmol/L L-glutamine, 1% MEM-non-essential amino acids, 1% sodium-pyruvate (all from Gibco) and incubated overnight at 37°C and 5% CO2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>HepG2</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">SARS-CoV-2 virus neutralization assay Viral neutralization assay followed by in-cell ELISA Vero E6 cells were plated in a 96-well plate at 1.6 x 10E04 cells/well in DMEM medium (Gibco) supplemented with 5% FCS, 1% penicillin-streptomycin, 200 mmol/L L-glumatine, 1% MEM-nonessential amino acids, 1% sodium-pyruvate (all from Gibco) and incubated overnight at 37°C and 5% CO2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Vero E6</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Protein expression Using the FreeStyle 293 Expression System (ThermoFisher), the different ACE2-Fc fusion proteins were transiently expressed in 3 x 240 mL culture media.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>ThermoFisher</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The main peak was pooled, the protein concentration determined by slope spectrometry [63] and adjusted to 1 mg/mL.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>slope</div> <div>suggested: (SLOPE, RRID:SCR_001185)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The chromatograms were evaluated with the Astra software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Astra</div> <div>suggested: (ASTRA, RRID:SCR_016255)</div> </div> </td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.


      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

    1. SciScore for 10.1101/2020.12.04.412098: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Chilled on ice, 100 μL of each sample was added to the VeroE6/TMPRSS2 cells that had been seeded into 96-well-plates at 5 x 104/100 μL/well a day before.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>VeroE6/TMPRSS2</div> <div>suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)</div> </div> </td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.


      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

    1. SciScore for 10.1101/2020.12.01.20241364: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      NIH rigor criteria are not applicable to paper type.

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The cells were then incubated with goat anti-human IgG (H+L) cross- adsorbed secondary antibody, alexa fluor 594 (ThermoFisher, Catalog # A-11014) at 1:400 dilution with FACS buffer.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human IgG</div> <div>suggested: (Innovative Research Cat# A11014, RRID:AB_1500628)</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Sample ID P1.1 TSS P2.1 A.HD1 A.HD2 A.HD3 A.COV1.1 A.COV1.2 A.COV2.1 A.COV2.2 A.COV3.1 A.COV3.2 A.COV4.1 A.COV4.2 A.COV5.2 A.COV6.2 A.HD4 A.HD5 A.HD6 A.HD7 A.HD8 A.HD9 A.HD10 A.HD11 A.HD12 A.HD13 P3.1 P4.1 P5.1 P6.1 P7.1 P3.2 P4.2 C.HD1 C.HD2 C.HD3 C.HD4 C.HD5 C.HD6 Condition MIS-C TSS MIS-C A.HD A.HD A.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>A.COV4.2 A.COV5.2 A.COV6.2 A.HD4 A.HD5 A.HD6 A.HD7 A.HD8 A.HD9 A.HD10 A.HD11 A.HD12</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>P4.2 C.HD1 C.HD2 C.HD3 C.HD4 C.HD5 C.HD6</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">HD Subject ID P1 TSS P2 A.HD1 A.HD2 A.HD3 A.COV1 A.COV1 A.COV2 A.COV2 A.COV3 A.COV3 A.COV4 A.COV4 A.COV5 A.COV6 A.HD4 A.HD5 A.HD6 A.HD7 A.HD8 A.HD9 A.HD10 A.HD11 A.HD12 A.HD13 P3 P4 P5 P6 P7 P3 P4 C.HD1 C.HD2 C.HD3 C.HD4 C.HD5 C.HD6 Time point A A A NA NA NA A B A B A B A B B B NA NA NA NA NA NA NA NA NA NA A A A A A B B NA NA NA NA NA NA # days between hosp.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>TSS P2 A.HD1 A.HD2 A.HD3 A.COV1 A.COV1 A.COV2 A.COV2 A.COV3 A.COV3 A.COV4 A.COV4 A.COV5 A.COV6 A.HD4 A.HD5 A.HD6 A.HD7 A.HD8 A.HD9 A.HD10 A.HD11 A.HD12 A.HD13</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>C.HD1 C.HD2 C.HD3 C.HD4 C.HD5 C.HD6</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Kaminski Kaminski Kaminski Kaminski Kaminski Kaminski Kaminski Kaminski Kaminski Kaminski Kaminski Kaminski Kaminski Kaminski Hafler Hafler Hafler Hafler Hafler Hafler Lucas2 Lucas2 Lucas2 Lucas2 Lucas2 Lucas2 Lucas2 Lucas2 Lucas2 Lucas2 Lucas2 Lucas2</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Lucas2 Lucas2 Lucas2 Lucas2 Lucas2 Lucas2 Lucas2 Lucas2 Lucas2 Lucas2 Lucas2</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The sequencing data was processed using CellRanger v3.1.0.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>CellRanger</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">PBMC single-cell RNA sequencing analysis Pediatric healthy donor, MIS-C, longitudinal recovered MIS-C, adult healthy donor, and adult COVID-19 PBMC CellRanger outputs were analyzed using the Seurat v3.2.1 package35.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Seurat</div> <div>suggested: (SEURAT, RRID:SCR_007322)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cluster specific markers were found that had an absolute logFC of at least 0.25, an adjusted p-value of less than 0.05, and were expressed in a minimum of 25% of cells in either cluster being compared.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Cluster</div> <div>suggested: (Cluster, RRID:SCR_013505)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">All scRNA-seq plots were done using ggplot2 v3.3.237.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>ggplot2</div> <div>suggested: (ggplot2, RRID:SCR_014601)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Connectivity mapping The Connectome v0.2.2 package was used to generate a network analysis of ligand- receptor interactions predicted to be up- or down-regulated in MIS-C compared to C.HD38.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Connectome</div> <div>suggested: (eConnectome, RRID:SCR_009618)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Heatmaps were visualized using the ComplexHeatmap v2.5.5 package.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>ComplexHeatmap</div> <div>suggested: (ComplexHeatmap, RRID:SCR_017270)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">These V(D)J contigs were re-annotated by aligning them to the IMGT reference database v3.1.3041 using IgBlast v1.13.0 in the Change-O V1.0.046 pipeline.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>IgBlast</div> <div>suggested: (IgBLAST, RRID:SCR_002873)</div> </div> </td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.


      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

    1. SciScore for 10.1101/2020.12.02.408823: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">Five-week old male hamsters were obtained from Charles River Laboratories and housed at Washington University.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Twenty-four hours after virus inoculation, the cells were fixed with formalin, and infected cells were detected by the addition of 100 µL of 1:1000 diluted anti-S protein monoclonal antibody (1C02, gift from Dr. Ellebedy at Washington University) in permeabilization buffer (1x PBS, 2% FBS, 0.2% saponin (Sigma, Cat #S7900)) for 1 h at 20°C or overnight at 4°C, followed by an anti-human-IgG-HRP antibody (Sigma, Cat. # A6029) in permeabilization buffer for 1 h at 20°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-S protein</div> <div>suggested: (Sigma-Aldrich Cat# A6029, RRID:AB_258272)</div> </div> <div style="margin-bottom:8px"> <div>anti-human-IgG-HRP</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Immunization with ChAd-SARS-CoV-2-S induced high levels of anti-S and anti-RBD IgG(H+L) and IgG2/IgG3 antibodies 21 days later, whereas low or undetectable levels of S- and RBD-specific antibodies were present in samples from ChAd-control immunized animals (Fig 2A-F and Fig S2).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-S</div> <div>suggested: (Novus Cat# H00000191-AP21, RRID:AB_10647247)</div> </div> <div style="margin-bottom:8px"> <div>anti-RBD IgG(H+L</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>IgG2/IgG3</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The antibody response was significantly higher after IN than IM immunization (5 to 7-fold, P < 0.0001 for anti-S and anti-RBD respectively, Fig 2G-H).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-RBD</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plaque assays were performed on Vero E6 cells in 24-well plates.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Vero E6</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The virus-serum mixtures were added to Vero-E6 cell monolayers in 96-well plates and incubated for 1 h at 37°C.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Vero-E6</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The data was analyzed with GraphPad Prism 9.0 and statistical significance was assigned when P values were < 0.05.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>GraphPad Prism</div> <div>suggested: (GraphPad Prism, RRID:SCR_002798)</div> </div> </td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.


      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: We did not find any issues relating to colormaps.


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

    1. SciScore for 10.1101/2020.12.02.408575: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Then 100 μL of each dilution were plated into quadruplicate wells of 96-well plates containing 80-90% confluent Vero 76 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Vero 76</div> <div>suggested: JCRB Cat# IFO50410, RRID:CVCL_0603)</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Results were compared with untreated controls by one-way ANOVA with Dunnett’s multiple comparison tests using GraphPad Prism (version 8) software.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>GraphPad Prism</div> <div>suggested: (GraphPad Prism, RRID:SCR_002798)</div> </div> </td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.


      Results from TrialIdentifier: We found the following clinical trial numbers in your paper:<br><table><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Identifier</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Status</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Title</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT00928135</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Completed</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Aerosolized Hypertonic Xylitol Versus Hypertonic Saline in C...</td></tr></table>


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

    1. This manuscript is in revision at eLife

      The decision letter after peer review, sent to the authors on December 1 2020, follows.

      Summary

      The study isolates bacteria from diverse Antarctic samples which utilise DMSP as the sole carbon source. It initially focuses on a Gammaproteobacterium, Psychrobacter sp.D2, which the authors establish lacks a known DMSP lyase enzyme despite having DMSP lyase activity (this needs to be quantified). Through RNA-seq and bioinformatics, they identify the gene cluster responsible for this activity and identify a novel DMSP lyase somewhat related to DddD in that it involves CoA, but critically also ATP, which distinguishes it from the pack of other known Ddd enzymes. This enzyme is a ATP-dependent DMSP CoA synthase required for growth on DMSP and its transcription is upregulated by DMSP availability. The novel mechanism of this enzyme is proposed from a strong structural component to the study. The authors propose the downstream pathway for DMSP catabolism, which we find to be oversold and requiring gene mutagenesis to confirm, and to be preliminary in comparison with the authors' other findings. Finally, the study attempts to show how widespread the enzyme is in sequenced bacteria, confidently showing it to be functional in other related Gammaproteobacteria and some Firmicutes.

      Essential Revisions

      1) Title: "a missing route", was it really missing? We would suggest a more precise title. Would be better to say "that releases DMS" or an alternative.

      2) This is a Ddd enzyme by definition and should be named as such.

      Line 27- We disagree with the use of a new gene prefix when there is a strong precedent for the use of Ddd for "DMSP-dependent DMS". If this enzyme is a DMSP lyase and is in bacteria then its naming should follow protocol and be called Ddd"X"-X-being a letter not currently utilised in known systems. Deviating from this convention causes confusion and is not appropriate. Furthermore, AcoD is already assigned in some bacteria to acetaldehyde dehydrogenase II.

      3) As presented, the bioinformatics-based evidence regarding the broad distribution of this enzyme (as claimed e.g. in the Abstract, line 33) does not stand up. Currently as presented in the manuscript, especially Fig 6, we are led to believe the enzyme is more widespread than can be demonstrated based on the authors' evidence (i.e., the authors allow a very low threshold of sequence identity and claim function outside of the groups they have tested). Either more work is needed to show that claims of such a wide distribution are merited, or the authors should limit their claims to what can be substantiated by their work. Specifically, the authors cannot comment on the "functional" enzyme being widespread outside of the Gamma's and Firmicutes that were tested, let alone the importance of the role in DMSP cycling. Only three "AcoD" enzymes were ratified in this study, which are relatively closely related to each (Psychrobacter sp. D2 Sporosarcina sp. P33 and Psychrobacter sp. P11G5 that are > 77% identical to each other). As can be seen in Fig 6, these three proteins cluster together and are far removed from all the other sequences on the figure, for which we have no evidence of their function (i.e., nothing can realistically be said on Deltas, Actinos or Alphas or the MAGS). Just to be clear, these other proteins shown in clades above and below the functional "AcoDs" in fig 6 are only ~30% identical to ratified "AcoD". Furthermore, only strain D2 was shown to make DMS; none of the other strains were tested. Far more testing of the diverse enzymes and strains are needed to make these statements as this study only tests one strain and three of the closely related enzymes (defined on Fig 6). Additional specific comments on this issue:

      Line 280. The sentence on MAGS and the environments containing them does not stand up for reasons summarised above. All MAGS shown on Fig 6 are not similar enough to "AcoD" to be termed as functional Ddd enzymes. More work has to be done on the strains and enzymes that are more divergent to true "AcoDs" before such a statement is supported. Please delete. Line 509-We agree with what the authors write about stringency. However, these parameters do not seem to have been utilised as stated here. Their stringency statement holds up for comparison between the D2 "AcoD" and two other tested "AcoD" enzymes and all those in the middle clade on Fig.6. But this is not the case for the proteins shown above and below this "AcoD" clade in Fig 6 which have at best around 30% identity to characterised enzymes. See below for examples. As the authors state in their methods, high-stringency methods are needed to exclude other acetyl-CoA synthetase family proteins. Thus, most of the genes shown on fig6 cannot be taken as having this Ddd activity.

      "To further validate that these AcoD homologs" the authors examined the activity of two closely related enzymes from a group of nine homologs with > 65 % sequence identity (starting line 283, Figure 6). It is not surprising that these enzymes have the same activity. Homologs outside this group of nine (Figure 6) are far less related to the characterized AcoD (< 32 % seq. identity). Conservation of the phosphate-transferring His (His292) and an active site Trp (Trp391) does not seem to be strong evidence for functional conservation. The manuscript does not provide any additional evidence that these less related enzymes also degrade DMSP. Either more experimentation is necessary, or the paragraph on the "Distribution of the ATP DMSP lysis pathway in bacteria" must be revised.

      For example: Psychrobacter AcoD (WP_068035783.1) is 31% identical to Bilophila sp. 4_1_30 (WP_009381183.1) in the below group of bacteria on Fig 6. Psychrobacter AcoD (WP_068035783.1) is 29% identical to Thermomicrobium roseum (WP_041435830.1) in the above group of bacteria on Fig 6. Line 283. This is not the case! The two sequences that were chosen to "validate" are far to close to the D2 "AcoD" than to MAGS and other potential "AcoDs" shown above and below the functional Ddd clade on Fig 6. This section design is weak and does not lend weight to the expansiveness of this family. More work on the more diverse enzymes and bacteria is needed to support the authors claims. Please delete or study the activity of the more diverse strains and their candidate "AcoDs". Fig. 6. This is a nicely presented figure that unfortunately slightly deceives the reader. The authors need to clearly show which strains they have shown to have Ddd activity (currently one as I understand it) and which enzymes they have shown to have the appropriate activity (currently three closely related enzymes as I understand it). If I am not wrong these are all confined to the middle clade of Gammas and Firmicutes. These stand clearly apart form the other strains (above and below) which have not been studied and which are only ~ 30% Identical to "AcoD" at the protein level. This is not clear on the figure and definitely misleads in the abstract and throughout the manuscript.

      4) We expect to see kinetics done on the new enzyme in line with what the authors have done in other related studies on Ddd and Dmd enzymes.

      This is important to place the work in context with previously identified Ddd and Dmd enzymes, many of which have been analysed by these authors in previous publications. The characterization of the AcoD activity remains entirely qualitative. The authors only provide relative activities measured at a single substrate concentration. This data does not support the following statement: "Mutations of these two residues significantly decreased the enzymatic activities of AcoD, suggesting that these residues play important roles in stabilizing the DMSP-CoA intermediate" (l.223-225).

      5) The manuscript does provide unambiguous evidence for the activity of AcoD and its function during growth on DMSP. On the other hand, the description of the "ATP DMSP lysis pathway" is less clear.

      Transcriptomics analysis (Figure 2C) suggest that growth on DMSP upregulate the genes 1696 (BCCT), 1697 (AcoD), 1698 and 1699. The function of the third and fourth protein remain unclear (line 253). Instead, a reductase (AcuI) encoded somewhere else on the same genome was shown to transform the acryloyl-CoA to propionate-CoA. What was the transcription profile of acuI acuH in the RNA-seq? were they induced by growth on DMSP? Is the 1696-1697-1698-1699 gene cluster conserved? What is the function of 1698 and 1699? These questions are only relevant if the authors plan to maintain the claim of having identified a new pathway. This pathway prediction component is very weak and could be supplemented by KO mutagenesis of the dddCB and acuI. Without such work this is speculation and needs to be written as such.

      6) Appropriate controls, units and quantification should be used:

      Line 102- Please give a normalised value for the level of DMS produced from DMSP per time and protein/cells.

      Figure 2. A. One would expect to see a growth curve of D2 on DMSP compared to acrylate, a conventional carbon source (e.g. pyruvate, glycerol or succinate) and a no carbon control. As "AcoD" is predicted to ligate CoA to DMSP it would be good to know if the strain grows on acrylate. It might be predicted to have different properties to e.g. Halomonas which does grow on acrylate. At least a no carbon and conventional carbon source should definitely be included.

      B. The units for this figure are not appropriate. It would be more appropriate to show the actual amount of DMS that is produced by the strain, ideally normalised to protein, cells or absorbance and time. Detail in the figure what the control is.

      C. Would like to see error bars on this figure. Also would have been sensible to colour code these to match panel D.

      Figure 3. B and C. as with Figure 2 we need to see levels of DMS normalised to cells/protein and time.

      Line 374 - No controls. Please include these as detailed above. No carbon, conventional carbon source, acrylate?

      Quantitative data supporting Supplementary Fig. 12 would be helpful. After all this route would have to explain that the bacteria can use acrylate CoA as sole carbon source (or at least alternatives would have to be discussed). Is the identified activity sufficient for this task?

      Line 388 - This method is/should be quantitative. It is standard practice to report DMS production normalised to time and cells/protein. Here we are only given peak area.

    1. t (a) the Ethnic-Maintenance I; (b) the Com-munity-Maintenance I; (c) the E-Pluribus-Unum I; (d) the Justice-Seek-ing l; (e) the Pedagogical-Meiiorist I; and (f) the Nonresearch Human 1.5

      Factors that should NOT be associated with the overall comparison being done between the two schools, but still had an impact on the author's own subjectivity of the two.

    Annotators

  6. Nov 2020
    1. Language Review Before we begin analyzing the rules let’s complete a short language review that will assist with pronunciation and spelling. In class, you will practice pronunciation with your Instructor. Short Vowels a, e, i, o, u, and sometimes y are indicated by lower case. Long Vowels A, E, I, O, U are indicated by upper case. Consonants Consonants are all of the other letters in the alphabet. b, c, d, f, g, h, j, k, l, m, n, p, q, r, s, t, v, w, x, and z.

      I like how this chapter starts off with a language review. Proper pronunciation and spelling is very important with medical terminology. I think it is important as a learner to know that going into the medical field. These are important skills and knowledge to take into the workplace and apply. I love how you have broken up the short vowels, long vowels and consonants into three paragraphs. Very clear and easy to read and understand.

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      Reviewer #1 (Evidence, reproducibility and clarity (Required)):

      In this study, the authors use focused-ion beam (FIB) milling coupled with cryo-electron tomography and subtomogram averaging to uncover the structure of the elusive proximal and distal centrioles, as well as different regions of the axoneme in the sperm of 3 mammalian species: pig, horse, and mouse. The in-situ tomograms of the sperm neck region beautifully illustrate the morphology of both the proximal centriole, confirming the partial degeneration of mouse sperm, and intriguingly, asymmetry in the microtubule wall of pig sperm. In distal centrioles, the authors show that in all mammalian species, microtubule doublets of the centriole wall are organized around a pair of singlet microtubules. The presented segmentation of the connecting piece is beautiful and nicely shows the connecting piece forming a nine-fold, asymmetric, chamber the centrioles. The authors further use subtomogram averaging to provide the first maps of the mammalian central pair and identify sperm-specific radial spoke-bridging barrel structures. Lastly, the authors perform further subtomogram averaging to show to the connecting site of the outer dense fibers to the microtubule doublet of the proximal principal piece and confirm the presence of the TAILS microtubule inner protein complex (Zabeo et al, 2018) in the singlet microtubules occupying the tip of sperm tails.

      The manuscript provides the clearest insight into flagellar base morphology to date, giving insight into the morphological difference between different mammalian cilia and centriole types. The manuscript is suitable for publication, once the following questions are addressed.

      We are ecstatic that the reviewer shares our enthusiasm for this work. We are particularly grateful that the reviewer appreciates the significance of the unique, and hitherto under-explored biology of the sperm centrioles and the flagellar base.

      **Major Points:**

      How many centrioles and axonemes were used in generating the averages presented in the paper? If too few samples were used, especially in centrioles undergoing dramatic remodeling or degeneration, the reality of MIPs and MAPs being present might be completely affected. For instance, In figure 1d, the authors present a cryoET map of the centriole microtubule triplet. However, centrioles are divided into several regions with different accessory elements. Here, the authors could show the presence of only part of the A-C linker. The A-C linker covers only 40% of the centriole, so does it mean that this centriole is made only of the accessories that characterize the proximal side of the centriole? In the same line, what were the boundaries governing subtomogram extraction? For example, in the distal centriole, were microtubules extracted from just before the start of the transition zone, to the end of the microtubule vaulting, more pronounced at the end of the proximal region? There are known heterogeneities in centriole, as well as flagella, ultrastructure along the proximal distal axis. If no pre-classification was performed for subtomogram longitudinal position along with the centriole and axoneme, structural features may be averaged out, and or present and not reflecting their real longitudinal localization. The classification should be applied here if it was not the case.

      These are all valid points. Because there is no easy way to target the PC/DC when cryo-FIB milling, and because there is only one of each structure in every cell, the chances of catching them in ~150-nm-thin lamellae are slim (not to mention the number of things that can and do go wrong when doing cryo-ET on lamellae). As such, the averages of the PC were generated from 3 tomograms (3 cells) and those of the DC from 2 tomograms (2 cells). We do have more tomograms with the PC/DC, but these were used for segmentation/visual inspection since we only used the best tomograms for averaging. These numbers are not entirely atypical for cryo-FIB datasets; the only other in situ centriole structures are from 5-6 centrioles (from Chlamydomonas, from Le Guennec et al 2020 doi: 10.1126/sciadv.aaz4137 and Klena et al 2020 doi: 10.15252/embj.2020106246).

      To allow readers to adjust their interpretations according to the small number of cells analysed, we explicitly stated the number of animals/cells/tomograms used to generate averages in Table S1. Furthermore, we amended the text to clarify which regions of the centrioles our averages represent. These changes are detailed below:

      (1) proximal centriole

      The lamellae used for averaging PC triplets caught mostly the proximal end of the centriole, and essentially all of the particles come from the most proximal ~ 400 nm. In a sense, this was a form of pre-classification. We now state explicitly that our structure represents only the proximal region and that proximal/distal differences may be identified in the future (see section on distal centriole below). Despite the limited particle number, we are confident in the presence of the MIPs as these are also visible in the raw data (the striations in Fig. 1a, now Fig. 1d, for instance). Page 7, Line 165 was edited accordingly as well as the legend to Fig. 1.

      (2) distal centriole

      The subtomograms used for the DC average were extracted from the region of the distal centriole closest to the base of the axoneme (i.e; the region marked “distal centriole” in Fig. 2h-i). Because the DC doublet average in Fig. 2j was generated from very few particles, we tried to be very conservative when interpreting it. Page 9, Line 216 was edited accordingly likewise the legend to Fig. 2.

      (3) axoneme

      We did attempt to average the axoneme from different regions of flagella (midpiece, proximal principal piece, distal principal piece). This is shown in Fig. 6d-l. The major difference we found was at the doublet-ODF connection. We did not find any striking differences in MIP densities, or in radial spoke densities along the proximodistal axis. As such, the averages in Fig. 5 are from the entire principal piece (but not the midpiece), which we state in the figure legend.

      Because mammalian sperm flagella are very long, it is possible that we missed more subtle differences. We now state this in the Discussion (page 20, line 491):

      **Minor Points:**

      • In line 3, motile cilia are not only used to swim, they can move liquid or mucus for instance.

      Done. Page 3, line 64

      • In line 175, the authors stated " a prominent MIP associated with protofilament A9, was also reported in centrioles isolated from CHO cells (Greenan et al. 2018) and in basal bodies from bovine respiratory epithelia (Greenan et al 2020). Actually, this MIP has been seen in many other centrioles from other species, such as Trichonympha (https://doi.org/10.1016/j.cub.2013.06.061 ), Chlamydomonas, and Paramecium ( DOI: 10.1126/sciadv.aaz4137 ). Citing these studies will reinforce the evolutionary conservation of this MIP and therefore its potential crucial role in the A microtubule.

      We thank the reviewer for pointing out these very important papers, we added them to the manuscript (page 7, lines 175-176).

      • In Line178, the authors stated: "Protofilaments A9 and A10 are proposed to be the location of the seam (Ichikawa et 2017)". High-resolution cryoEM maps confirmed it: https://doi.org/10.1016/j.cell.2019.09.030 . This publication should be cited. Moreover, authors should also refer to this paper when discussing MIPs in the microtubule doublet.

      Done (page 7, lines 178-179 and page 13, line 329).

      We also now cite Ma et al (along with Ichikawa et al 2019 doi: 10.1073/pnas.1911119116 and Khalifa et al 2020 doi: 10.7554/eLife.52760) in the Discussion when alluding to high-resolution structures as a possible means of identifying MIPs (page 19, lines 479).

      • In Line 187-189 the authors stated, "We resolved density of the A-C linker (gold) which is associated with protofilaments C9 and C10." The A-C linker interconnects the triplets of the proximal centriole (Guichard et. al. 2013, Li et. al. 2019, Klena et. al. 2020) with distinct regions binding the C-tubule, as shown by the authors in gold, as well as an A-link, making contact with the A-tubule through various protofilaments in a species-specific manner, but always on protofilament A9. The authors may have identified the A-link, labeled in green, on the outside of protofilament A8/A9 in Figure 1d.

      We thank the reviewer for pointing this out. The position of the olive green density associated with A8/A9 is indeed consistent with the A-link, and this is also now illustrated more clearly in the new version of Fig. 1e (now Fig. 1h, see below). We accordingly edited page 8, lines 187-188.

      • In figure 1e, the authors provide a 9-fold representation of the centriole based on their map. How relevant is this model ? the distance between triplet is inconsistent here, which has not been observed before. Do they use true 3D coordinates to generate this model? The A-C linker, which is only partially reconstructed, does not contact the A microtubule. Is it really the case? did the authors see that the A-link density of the A-C linker has disappeared? If these points are not clearly specified, this representation might be misleading.

      In order to avoid misleading readers, we replaced this panel with a model generated directly by plotting back the averages into their original positions and orientations in the tomogram (new Fig. 1h). This model now shows that the olive green density on A8/A9 is in the right position to form part of the A-C linker (as Reviewer 1 correctly pointed out in their previous point). We have amended the figure legend accordingly. We also described how the plotback was generated in the Materials and Methods section (page 26, line 648).

      As the reviewer points out, the distance between triplets does indeed seem inconsistent in the plotback. This is an interesting observation, but we feel it is a bit too preliminary to discuss in detail here. This can be explored in a follow-up study more focused on sperm centriole geometry.

      • The nomenclature regarding MIPs is sometimes confusing in this manuscript. For example, in lines 228-229 "We then determined the structure of DC doublets, revealing the presence of MIPs distinct from those in the PC." Does this include the gold and turquoise labeled structures in Figure 2j? These densities appear to correspond to the inner scaffold stem in the gold density presented in Figure 2j, and armA, presented in the turquoise density (Li et. al. 2011, Le Guennec et. al. 2020). The presence of this Stem here is important as it correlates with the presence of the molecular player making the inner scaffold (POC5, POC1B, CENTRIN): https://doi.org/10.1038/s41467-018-04678-8

      While we were initially very conservative with interpreting the DC doublet average (as stated above it comes from very few particles), we agree with the reviewer’s assessment that the gold and turquoise densities in Fig. 2j are consistent with the Stem and armA respectively of the inner scaffold. Because the inner scaffold contributes to centriole rigidity, it will be interesting to determine if and how it changes during remodelling of the atypical DC in mammalian sperm. Intriguingly, at least some inner scaffold components (including POC5, POC1B) reorganise into two rods in the mammalian sperm DC (Fishman et al 2018 doi: 10.1038/s41467-018-04678-8). We expanded the section on the DC average (page 9, lines 218-220):

      • The connecting piece is composed of column vaults emanating from the striated columns is compelling and beautiful segmentation data. However, it is important to note how many pig sperm proximal centrioles had immediate-short triplet side contact with the Y-shaped segmented column 9, as well as in how many mouse centrioles have the two electron-dense structures flanking the striated columns.

      Done. Material and Methods Page 25, lines 615-619.

      The resolution of the mammalian central pair is an important development brought by this work. The structural similarity between the central pair of pig and horse is convincing. However, with only 281 subtomograms being averaged for the murine central pair, corresponding to an estimated resolution of 49Å, the absence of the helical MIP of C1 with 8 nm periodicity suggests that there is simply not enough signal to capture it in the average. The same could be said for the smaller MIP displayed in Figure 4 c, panel ii. This point should be clearly stated.

      We agree with the reviewer that the quality of the mouse CPA structure is not on par with the pig and horse CPA structures. We now explicitly state this caveat in the text (pages 11, lines 276-277):

      Another piece of compelling data presented in this study is the attachment of the outer dense fibers to the axoneme of the midpiece and proximal and distal principal pieces. From the classification data presented along the flagellar length, it is clear that the only ODF contact made with the axoneme is at the proximal principle plate. However, this is far from obvious in the native top view images presented. Is it possible to include a zoomed inset of the connection between the A-tubule and ODF connection?

      We are very happy that the reviewer finds this data exciting. As Fig. 6 is quite cluttered as is, we instead tried to better annotate the cross-section views of the axoneme by tracing one doublet-ODF pair in each image (or only a doublet in the case of the distal principal piece). This shows that there is a gap between the doublet and the ODF in the midpiece, and that there is no such gap in the principal piece. We also hope that annotating one doublet-ODF pair helps the reader see that the same pattern holds true for the other doublets/ODFs. The legend to Fig. 6 was changed accordingly.

      Reviewer #1 (Significance (Required)):

      This work is of good quality and provides crucial information on the structure of centriole and axoneme in 3 different species. This work complements well the previous works.

      The audience for this type of study is large as it is of interest to researchers working on centrioles, cilium, and sperm cell architecture.

      We are pleased the reviewer appreciate the quality of our work and see the interest for broad audience.

      My expertise is cryo-tomography and centriole biology

      Reviewer #2 (Evidence, reproducibility and clarity (Required)):

      In this study, Leung et al. used state-of-the-art EM imaging techniques, including FIB cryo-milling, Volta Phase plate, cryo-electron tomography and subtomogram averaging, to study the structure of sperm flagella from three mammalian species, pig, horse and mouse. First, they described two unique centrioles in the sperm, the PC and the DC. They found the PCs are composed of a mixture of triplet and doublet MTs. In contrast, the DCs are composed mainly of doublet and singlet MTs. By using subtomogram averaging, they identified a number of accessory proteins, including many MIPs bound to the MT wall. Many are unique to the mammalian sperm. They further described the connecting piece region of the sperm enclosing the centrioles and found an asymmetric arrangement. Furthermore, the authors presented the structure of sperm axonemes from all three species. These include the DMT and the CPA. Finally, they described the tail region of the sperm and described how the DMTs transitioned to the singlet MTs.

      This is a beautiful piece of work! It is by far the most comprehensive structural study of mammalian sperm cells. These findings will serve as a valuable resource for structure and function analysis of the mammalian flagella in the future. Now the stage is set for identifying the molecular nature of the structures and densities described in this study.

      We thank the reviewer for their positive evaluation! We are very happy that they share our excitement for the work, and that they also see it as “setting the stage” for future studies at the molecular level.

      The manuscript is clearly written. The data analysis is thorough. The conclusions are solid and not overstated. I don't have any major issues for its publication. A number of minor suggestions are listed below. Most are related to the figures and figure legends.

      Figure 1d, the figure legend should mention this is the subtomogram average of PC triplet MTs from pig sperm, though this is mentioned in the text. Also, for convenience, the color codes for the MIPs should be mentioned in the figure legend.

      Done.

      Figure 2J, similarly, the figure legend should mention this is the subtomogram average of DC doublets. It also needs a description of the color codes of the identified MIPs. For the DMT, please indicate the A- and B-tubule, which are colored in light or dark blue.

      Done, except we would prefer not to enumerate the MIPs as we did not name them nor discuss them extensively in the main text as we do not want to over-interpret the MIPs at this point as the average is from relatively small number of particles. However, we did specify that the gold and turquoise densities on the luminal surface are consistent with the inner scaffold. The figure legend was edited accordingly.

      Line 228, "We then determined the structure of DC doublet by subtomogram averaging"

      Done.

      For both Fig 2 and Fig 3. the DC doublets are colored in dark and light blue, please specify which is the A- or B-tubule in the figure legends.

      Done.

      Line 273, need space between "goldenrod"

      We would prefer to keep “goldenrod” spelled as is since this is how the color is referred to in Chimera and ChimeraX.

      Figure 4. need to expand the figure legend. Panels I, ii, iii, iv, are cut-through view of the lumen of CPA microtubules C1 and C2.

      Done.

      Line 338, Interestingly, the RS1 barrel is radially distributed asymmetrically around the axoneme

      Done.

      Figure 5, need color codes for the arrowheads (light pink, pink, magenta) in panels i~n,

      Done.

      Figure 7, (a-c) please use arrowheads to indicate the location of caps in the singlet MT.

      Done.

      Reviewer #2 (Significance (Required)):

      This is a beautiful and significant work - by far the most comprehensive analysis of mammalian sperm structure

      We are thrilled the reviewer appreciate the novelty of our work.

      Reviewer #3 (Evidence, reproducibility and clarity (Required)):

      This is a very interesting study that explores the structural diversity of mammalian sperm flagella, in pig, mouse and horse, at high resolution using cryo-FIB milling and cryo-tomography. The study provides the first in situ cryo-EM structure of a mammalian centriole and describes a number of microtubule associated structures, such as MIPs and plugs at the plus-end of microtubules, that were not been reported so far. Additionally, the authors identify several asymmetries in the overall structure of the flagellum in the three species, which have implications for the understanding of the flagellar beat and waveform geometry in sperm, which are discussed by the authors. Although this study does not provide mechanistic novel information on the function of the described structures, it will undoubtedly serve as a reference for future theoretical and empirical work on the role of these structures in shaping the flagellar beat.

      With the exception of a couple of "eclectic word choices" in the Introduction (see detailed feedback in Minor Comments), the manuscript is also well written. Image acquisition and analysis are sound.

      We thank the reviewer for positively evaluating our work. We are glad that they feel our study will “serve as a reference” to inform future studies.

      However, I have some suggestions that should help the authors to strengthen their claims and present their results. The study is in principle suitable to be published, after the following points will be addressed:

      **Major comments:**

      • A major concern is that it is not clear how many animals, sperms and lamellae the authors used to acquire the data presented in the manuscript. This information needs to be provided, because it not uncommon to encounter aberrant flagella, even in a wildtype animal. The authors should state how many animals, and how many flagella per each animal were analyzed, in order to allow the reader to have an opinion on the reliability of their observations.

      • The figures are esthetically pleasing; however, the figures legends should be carefully revised to include necessary information about color codes, image annotations.

      We thank the reviewer for raising these points. We completely agree that the numbers of animals and cells are important pieces of information. As such, we now explicitly state the number of animals/cells/tomograms used for each average in Table S1. For more qualitative observations (such as the relationship between the asymmetry of the pig sperm PC and the Y-shaped segmented columns), we now state in the number of cells and animals in which we see each feature (see detailed response to Reviewer 1).

      **Minor comments:**

      • Line 26. I do not think that the word "menagerie" is properly used in this context.

      • Line 29. The same is true for the word "Bewildering" in this sentence.

      We apologise for our somewhat eclectic word choice. We see the reviewer’s point that unconventional word choice may distract readers, so we replaced these two words with ‘diverse’ and ‘an extensive’, respectively.

      • Line 286 "Our structures of the CPA are the first from any mammalian system, and our structures of the doublets are the first from any mammalian sperm, thus filling crucial gaps in the gallery of axoneme structures." Sentences like this one would fit much better in the Conclusions or at least in the Discussion.

      We thank the reviewer for this suggestion, but we would prefer to keep this sentence where it is, if possible. We think it is useful to tell the audience upfront why these structures are significant, especially since readers who aren’t deep in the field may be bogged down by all the details.

      • Line 377 "Large B-tubule MIPs have so far only been seen in human respiratory cilia (Fig. 5j) and in Trypanosoma (the ponticulus, Fig. 5n), but the morphometry of these MIPs differs from the helical MIPs in mammalian sperm." Please insert the citations for the studies about respiratory cilia and Trypanosoma flagella.

      Done.

      • In Figure 1. What do the stars shown in panel a and a' indicate?

      We indeed failed to specify what the asterisks/stars indicate. They are meant to emphasise that the electron-dense material in the lumen of the PC is continuous with the CP. We have now specified this in the text (page 10, lines 245).

      Given the complexity of the structures that compose the flagellar system of sperms, it would be helpful to add an illustration of the sperm with careful annotation of the centriole structures and the various segments of the flagellum.

      This is an excellent suggestion. To help orient readers, we added three panels to Fig. 1 (Fig. 1a-c) showing low-magnification images of whole sperm cells. We annotated different parts of the flagellum (neck, midpiece, principal piece, endpiece) so that readers can refer back to these panels in case they want to know which part of the cell the averages are from.

      • Figure 2. Explanation of the used color codes is missing. Additionally, the authors should include an explanation for the black and white arrows and for the 2 insets in i.

      Done. For the color code, please see response to Reviewer 2. For the black and white arrows, we edited the figure legend.

      • In "(j) In situ structure of the pig sperm DC with the tubulin backbone in grey and microtubule inner protein densities colored individually" ...it should be written "...sperm DC microtubule doublet..."

      Done.

      • In this figure, but also in every other figure that shows centriole, axoneme, or even microtubule averages it is important to indicate the microtubule polarity. Please add the symbol + and - to indicate microtubule polarity in the figures.

      Done. In order to avoid overcrowding, we only labelled the pig structures as the horse and the mouse structures are always shown in the same orientations as the pig.

      • Figure 3. Additional to the images in a,b, and c, the original tomographic slices (without segmentation) should be shown here, to allow the reader to visualize the structure.

      We now include three additional supplementary movies slicing through the respective tomograms.

      • Figure 7. Scale bars are missing in d-f.

      Done.

      • Scale bars are missing in most Supplementary figures.

      Done.

      • Table S1. The Information about horse and mouse centriole data is missing.

      The reviewer is correct, but this information is missing because we did not average from the horse and the mouse. For the mouse, the triplets were in various stages of degeneration, resulting in heterogeneity that precluded us from averaging. For the horse, we simply did not catch enough centrioles to generate a meaningful structure.

      Reviewer #3 (Significance (Required)):

      This study provides several novel structural insights in to the sperm flagellum structure that have implications for the understanding of the flagellar beat and waveform geometry in sperm. Although this study does not provide mechanistic novel information on the function of the described structures, it will undoubtedly serve as a reference for future theoretical and empirical work on the role of these structures in shaping the flagellar beat.

      Great to see the reviewer appreciate the novelty of our work.

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      Reviewer #1 (Evidence, reproducibility and clarity):

      **A. Summary:**

      In this modeling study, the authors devised a multicellular model to investigate how circadian clocks in different parts (organs) of plants coordinate their timing. The model uses a plausible mechanism to explain how having a different sensitivity to light leads to different phase and period of circadian clock, which is observed in different plant organs. The model allows for entrainment in Light-Dark (LD) cycles and then a release in always-light (LL) environments. The model disentangles numerous factors that have confounded previous experiments. In one instance, the authors assigned different light sensitivities to the different organs (e.g., root tip, hypocotyl, etc.) which unambiguously show that this one element alone - spatially differing sensitivity to light - is sufficient for recapitulating experimentally observed differences in periods and phases between plant organs. The model also recapitulates the spatial waves of gene expression within and between organs that experimentalists reported. At the sub-tissue level, the model-produced waves have similar patterns as the experimentally observed waves. This confirmation further validates the model. By having the cells share clock mRNA, from any clock component genes, showed the same, experimentally observed spatial dynamics. The main conclusion of the study is that regional differences (e.g., between different organs) in light senilities, when combined with cell-to-cell sharing of clock-gene mRNAs, enables a robust, yet flexible, circadian timing under noisy environmental cycles.

      Thank you for your assessment of our work. We plan to make the following revisions based on your feedback.

      **B. Specific points:**

      1.Lines 125-127: "To simulate the variability observed in single cell clock rhythms, we multiplied the level of each mRNA and protein by a time scaling parameter that was randomly selected from a normal distribution." - Why not add a white (Gaussian) noise term to these equations? How does multiplying by a random variable (for rescaling time) different from my proposal? Some explanation should be given in the text here.

      We opted for a time scaling approach as this generates between-cell period differences but avoids within-cell period differences. This is consistent with single cell experiments (S1 Fig; Gould et al., 2018, eLife). We will provide an explanation of this in the text.

      2.Does the spatial network model simplify calculations by assuming separations of timescales (e.g., for equilibration in concentrations of mRNAs that diffuse between cells)? If so, it would be good to spell these out in the beginning of the Results section (where the model is described).

      We agree that a more detailed discussion of the model assumptions would be beneficial and we will provide this in the text.

      3.Lines 161-162: "....in a phase only model by local...." should be "....in a phase model only by local...."

      Thank you for your correction.

      4.Lines 188-190: The authors observed that qualitatively similar/indistinguishable behaviors arose regardless of which elements are varied (e.g., global versus local cell-cell coupling, setting light input to be equal in all regions of the seedling, etc.). Then they claim here that "...these results show that the assumptions of local cell-to-cell coupling and differential light sensitivity between regions are the key aspects of our model that allow a match to experimental data." - I don't see how this follows from the observation almost any of the variations lead to the same behaviors in this section (spatial waves). Show the reasoning in the text here.

      We observed spatial waves with different local coupling regimes (4 v. 8 nearest neighbours). However, we did not observe spatial waves with global coupling (S10 Fig). This led us to conclude that local coupling is a key aspect. In addition, we do not observe waves when setting the light input to be equal in all regions of the seedling (S11 Fig). This confirms that local differences in light sensitivity are also required in our simulations to generate spatial waves. We will clarify these points with revisions to the text.

      5.Pgs. 9-10: Section on "Cell-to-cell coupling maintains global coordination under noisy light-dark cycles": The simulation results rigorously support the authors' main conclusion here, which is that local cell-to-cell coupling allows for global coordination under noisy LD cycles. But I'm missing an intuitive explanation (or just any explanation) for why this is. At the end of this section, the authors should provide some intuition or qualitative explanation for the observations that they produced using their model in this section.

      We will revise the text to provide an intuitive explanation of these results. The coupling decreases the within-region phase differences. Despite the between-regions phase differences persisting, this effect is sufficient to improve the overall global synchrony.

      6.Lines 261-262: Replace the present tenses with past tenses.

      Thank you for your correction.

      7.Is the main idea that cell-to-cell coupling allows for averaging of fluctuations, between organs or cells within the same organ, while allowing for coordination of the average quantities? Is this responsible for both the flexibility and robustness observed under noisy environmental cycles?

      The cell-to-cell-coupling allows for the averaging of fluctuations between cells and the regional flexibility arises from the different light sensitivities in each region. What was interesting to us was that under light-dark cycles the regional flexibility was not lost due to either the noise in the light or the averaging effect of the cell-to-cell coupling. We will revise the text to emphasize these points. Thank you for your prompts.

      8.Line 304: Is it really true that the mammalian circadian rhythm is centralized? Don't some parts of our bodies have different circadian clock (e.g., slight differences in phase) than some other parts of our bodies?

      There are indeed some small phase differences between parts of our bodies because the mammalian system, like the plant system, is imperfectly coupled. However, the mammalian system is considered more centralized because the suprachiasmatic nucleus in the brain receives the key entraining signal of light and then coordinates rhythms across the body (Bell-Pedersen et al., 2005, Nat Rev Gen; Brown & Azzi, 2013, Circadian Clocks). We will expand on these interesting points by adding a paragraph to the discussion.

      Reviewer #1 (Significance):

      **Overall assessment:**

      I enthusiastically recommend this work for publication after the authors address my comments below (please see "Specific points").

      The model's main strength is that the authors could vary each ingredient separately - light sensitivity of each cell/organ, which gene's mRNA diffuses between cells, cellular noise, local versus global cell-cell coupling, etc. Afterwards, the authors could determine which of these variations produces which experimentally observed behaviors. Another strength of the model is that it can reproduce not just one, but numerous, experimentally observed behaviors that are important for understanding circadian clocks in plants. Thus, the model is grounded in experimental truth and produces experimentally observed results. Crucially, since the authors could vary every single element in the model independently of the other elements, the authors are able to provide plausible explanations for why the experiments produced the results that they did (experimentally, a number of confounding factors prevented one from pinpointing to which element produced which observation).

      Another strength of the model is also extendable, by other researchers to investigate other plant physiologies in the future (e.g., circadian clock's influence on cell division). The authors highlight these future uses in the discussion section. Therefore, I believe that this work will be valuable to plant biologists, non-plant biologists who are interested in circadian clocks, and systems biologists in general.

      The manuscript is also well written and relatively easy to follow, even for non-plant biologists like myself.

      Thank you for the positive feedback - we are pleased that you find the manuscript of broad interest to a range of readers.

      Comment on Reviewer #2:

      I agree with his/her major criticism #3 (ELF4 long-distance movement). I find this to be a reasonable request. Fulfilling it would increase the paper's impact.

      Please see our response to reviewer #2.

      Comment on Reviewer #3:

      The reviewer's point (1) asks for a reasonable request.

      Regarding his/her point (2): This is also reasonable. I'd recommend his/her suggestion (a). In the end, I'd be interested to see how the authors respond to this (what function they choose to let adjacent cells be subjected to some correlated light-input intensity. I'd be happy with something simple such as + noise, where is a deterministic term that, for example, decreases exponentially as one moves away from some central cell. Basically, I'd let the authors decide how to implement this and accept their current implementation - no correlation in light-intensity between adjacent cells - as an extreme scenario, as this reviewer points out.

      Please see our response to reviewer #3.

      Reviewer #2 (Evidence, reproducibility and clarity):

      **Summary:**

      The manuscript presents an improved model of the circadian clock network that accounts for tissue-specific clock behavior, spatial differences in light sensitivity, and local coupling achieved through intercellular sharing of mRNA. In contrast to whole-plant or "phase-only" models, the authors' approach enables them to address the mechanism behind coupling and how the clock maintains regional synchrony in a noisy environment. Using 34 parameters to describe clock activity and applying the properties mentioned above, the authors demonstrate that their model can recapitulate the spatial waves in circadian gene expression observed and can simulate how the plant maintains local synchrony with regional differences in rhythms under noisy LD cycles. Spatial models that incorporate cell-type-specific sensitivities to environmental inputs and local coupling mechanisms will be most accurate for simulating clock activity under natural environments.

      Thank you for your assessment of our work. We plan to make the following revisions based on your feedback.

      *We have the following **major criticisms** as follows*

      1) When assigning light sensitivities in different regions of the plant, the authors assign a higher sensitivity value to the root tip (L=1.03) than they do to the other part of the root (L=0.90). We are curious why the root tip would have higher light sensitivity than the rest of the root. Is this based on experimental data (if so, please cite in this section or methods)? It seems that these L values were assigned simply to make sure they recapitulated the period differences observed in Fig. 2A. Are these values based on PhyB expression in those organs? Or perhaps based on cell density in those locations?

      We assign the light sensitivity to match observed experimental period differences across the plant (Fig 2A,B). This is based on previous experiments demonstrating that experimental period differences are dependent on light input through the light sensing gene PHYB (Greenwood et al., 2019, PLoS Bio; Nimmo et al., 2020, Physiologia Plantarum). For example, in WT seedlings, the root tip oscillates faster than the root, but this difference is lost in the phyb-9 mutant (Greenwood et al., 2019). Thus, we assume the root tip to be more sensitive to light than the roots.

      Further supporting this assumption, there is evidence that expression of phytochromes and cryptochromes are increased in the root tip relative to the root (e.g., Somers & Quail, 1995, Plant J; Bognar et al., 1999, PNAS; Toth et al., 2001, Plant Physiol), as the reviewer proposes. However, further experiments would be needed to verify that these differences in expression are what lead to the differences in clock timing. We will add a discussion of these experiments to the text.

      2) In the discussion of the test where they set the "light inputs to be equal" in all regions to simulate the phyb-9 mutant, could the authors please clarify whether that means they set the L light sensitivity value equal in all regions?

      This is indeed what we mean, we will rephrase the text for clarity.

      a. If they are referring to setting the L value equal to all regions, we suggest that this discussion be moved to the section about different light sensitivities instead of the local sharing of mRNA section.

      Thank you for your suggestion, we agree and will move this discussion.

      b. Additionally, is it possible to set the light sensitivity to zero for all parts of the plant? We think this would be more suitable to simulate the phyb-9 mutant phenotype.

      We thank the reviewer for this suggestion. We will include a simulation with light sensitivity set to zero in the revised manuscript, in addition to the existing simulations with light sensitivity set to 1.

      3) Based on the recent Chen et al. (2020) paper showing ELF4 long-distance movement, we think it would be of great interest for the authors to model ELF4 protein synthesis/translation as the coupling factor, in addition to the modeling using CCA1/LHY mRNA sharing. We understand you may be saving this analysis for a future modeling paper, but this addition to the paper could increase the impact of this paper.

      Thank you for the suggestion to improve our manuscript. We agree it will be of interest to model ELF4 protein as the local coupling factor. In the revision, we will simulate each clock protein (including ELF4) as the local coupling factor and compare.

      In addition, we will also modify the coupling mechanism to simulate the long-distance transport of ELF4 proposed by Chen et al., 2020. Our preliminary simulations show that we can couple shoot rhythms to those in the root tip, but that this long range coupling can not on its own generate the spatial structure observed in experiments. We agree with the reviewers that this analysis and an associated discussion will further increase the impact of the paper.

      4) This model is able to simulate circadian rhythms under 12:12 LD cycles, which represents two days of the year-the equinoxes. We are curious if the model can simulate rhythms under short days and long days as well. We understand this analysis may be outside the scope of this paper and may require changing the values of the 34 parameters used but think it could be a useful addition here or in future work.

      We agree it would be interesting to observe the behavior of the model under different day lengths. We will include simulations under short and long days in the revision.

      *And **minor criticisms** as follows*

      1) In the first paragraph of the results section, it would be helpful for the authors to reference Table S1 when they mention the 34 parameters used to model oscillator function

      We agree and we will implement this helpful suggestion.

      2) In the first paragraph of the section titled "Local flexibility persists under idealized and noisy LD cycles", it would be helpful for the authors to reference S12 Fig after the last sentence that starts "However, ELF4/LUX appeared more synchronized..."

      We agree and we will implement this helpful suggestion.

      3) In the first paragraph of the section titled "Cell-to-cell coupling maintains global communication under noisy light-dark cycles", the authors refer to a "Table 1" but I think they mean to refer to Table S1"

      Thank you, we will implement this helpful suggestion.

      4) In Fig. 1, panel C is described as demonstrating the cell-to-cell coupling through the "level of CCA1/LHY". This phrasing is vague and we think could be improved to the "mRNA level of CCA1/LHY".

      We agree and will implement this helpful suggestion.

      Reviewer #2 (Significance (Required)):

      This work would be broadly interesting to other researchers studying cell-to-cell signaling and coupling of circadian rhythms in plants and other species where spatial waves of gene expression have been observed (i.e., mice and humans). Additionally, the computational modeling aspect of this work was easily interpretable for someone outside this expertise. Our expertise lies in plant circadian biology.

      We thank the reviewer for recognising the broad appeal of our work.

      Reviewer #3 (Evidence, reproducibility and clarity):

      **Summary:**

      The authors start by taking a previously published model of the plant circadian clock and implement five changes: 1) updating the network topology to reflect some recent experimental findings, 2) make a spatial model loosely based on a seedling template 3) introduce coupling between cells based on shared levels of CCA1/LHY 4) randomly rescale time in each cell to induce inter-cell differences in period, 5) include a light sensitivity that depends on the region considered.

      For a certain configuration of light sensitivities/intensities, the different periods of oscillations in each seedling region roughly match that of experiments. With a sufficiently high coupling between cells, the system can also generate spatial waves, which are also observed in the experimental system.

      With pulsed light inputs the spatial pattern is still produced. The authors then investigate the robustness to environmental noise by generating stochastic light signals and show that the global synchrony, as measured with a synchronisation index, increases with cell-to-cell coupling strength. The paper is overall well-written, and the background and details of the analysis are well presented.

      Thank you for your assessment of our work. We plan to make the following revisions based on your feedback.

      **Major comments:**

      For the first part of paper, the output of the model is certainly the focus. There is virtually no discussion of the inferred parameters and how much confidence the authors have in their values.

      Thank you for this point. We will add discussion of the inferred parameters to the initial part of the results.

      My main issue with the paper is about the section with noisy light signals, which is included in the title and is ultimately one of the main themes of the article.

      Specifically, on line 224:

      "This decrease in cell-to-cell variation revealed an underlying spatial structure (Fig 4D, middle and right, and S13 Fig), comparable to that observed under idealized LD cycles (Fig 4B, middle and right, and S12 Fig)."

      Firstly, I don't feel these conclusions match with the data presented. Comparing figure 4D middle and right with figure 4B middle and right shows a clear and pronounced loss in spatial structure. In its current form, this statement has to change, but I believe there are at least two other major issues with this figure:

      We agree there are some differences in the spatial structure between idealized (Fig 4B) and noisy (Fig 4D) LD cycles. Preliminary simulations suggest that this is due to the way the noisy LD cycles are programmed.

      In the current implementation of noisy LD cycles, the maximum intensity of L, L**max, differs between each region, such that relative differences in light sensitivity between regions are maintained. This means that some phase differences between regions are maintained. However, as the reviewer correctly points out in point 1 below, due to the noise fluctuations, the average level of light is lower than under idealized LD cycles, and with considerable day-to-day variation. We believe this is why the spatial structure differs.

      Preliminary simulations suggest that if we normalize the mean light intensity such that the mean is equal between the two conditions (as the reviewer suggests in point 1 below), the spatial structure appears similar. We will present this analysis in the revision.

      1) The figure is clearly designed to invite a comparison between the noise-free light cycles on the left with the noisy cycles on the right. However, due to how the noisy light is simulated, the variance of light signal increases AND the average intensity of light decreases by 50%. When comparing the left and the right, we therefore don't know whether the changes are due to differences in the average signal or differences from the stochasticity. I think the authors should simulate a noisy light signal with the same mean intensity level as the deterministic signal.

      As discussed above, we agree that the average intensity of the light decreases due to the noise, and this complicates interpretation. We will simulate idealized and noisy light cycles with the same mean light level upon revision.

      2) The noise model for the light doesn't seem realistic. On line 484 is says:

      "We made the simplifying assumption that each cell is exposed to an independent noisy LD cycle due to their unique positions in the environment. LD cycles were input to the molecular model through the parameter L".

      In fact, this could be considered as an incredibly complex signal, because for 800 cells it means drawing 800 random light signals. The implication is that two adjacent cells receive statistically independent light signals. Depending on chance, one cell might receive tropical levels of light while its neighbour experiences a cloudy day. This affects the interpretation and conclusions from figures 4 and 5. I propose two different ways of improving the simulation of the noisy light signal:

      a) In one extreme case, all cells receive the same noisy light signal, and the other extreme, they all receive independent signals. You could consider a mixture model of light signals, where each cell receives \lambda L_global(t) + (1-\lambda) L_individual(t), where L_global(t) is a global light signal that is shared by all cells and L_individual(t) is a light signal unique to an individual cell. The mixing parameter \lambda controls how similar the light signal is between cells

      b) Clearly the light signal will differ depending on the region, but there will be some spatial correlation. You could also consider methods of simulating light such that neighbouring cells receive correlated signals, although this might be difficult.

      Thank you for your proposals. We agree that our current implementation of noisy LD cycles represents an extreme scenario. Given that there is no environmental data at sufficient resolution to reliably evaluate which implementation is most realistic, we will explore different approaches based on your suggestions and present them in our revision.

      Assuming that the problem with the mean signal is corrected, do you expect the average spatial pattern to be the same between figure 4 B and D with no coupling (J=0) (although an increase in the variance between cells)? Perhaps not (owing to nonlinearities in the system), but it would be interesting to comment.

      We agree that the decreased light intensity complicates interpretation of the spatial structure. Although in the current implementation relative light differences between regions are maintained, the spatial structure is altered because the mean intensities are lower. Preliminary simulations with the mean intensity fixed do result in spatial patterns more similar to that seen in Fig 4B, but with increased variance. Comprehensive simulations will be included in the revised manuscript.

      The different periods in the different regions of the seedling are caused by differences in light sensitivity, which the authors claim is justified from refs 12-15. An alternative hypothesis is the that biochemical parameters such as degradation rates are different between regions. This is briefly alluded to in the introduction, but I think it would be interesting to discuss further. What would be the pros and cons of the two different mechanisms?

      We agree that an alternative hypothesis is that biochemical parameters such as degradation rates may differ between regions. Experimental evidence, however, more supports the light sensitivity hypothesis. This is because, for example, mutations in light signalling remove the spatial differences between regions. We agree though that this is an important point, and will add a paragraph to the discussion discussing the pros and cons of the two different mechanisms.

      I understand that the authors used a pre-existing model, but I must say that I find the way that light is incorporated into the model a bit confusing.

      On line 345 it says:

      "L(t) represents the input light signal (L = 0, lights off; L > 0, lights on) and D(t) denotes a corresponding darkness input signal (D = 1, lights off; D = 0, lights on)."

      Surely the only thing that matters biophysically is the number of photons hitting the plant? Could you explain why the model needs to have a separate "darkness signal" compared to just a single light signal?

      A darkness signal has been introduced in many circadian clock models because degradation rates of the clock genes can depend upon the light or dark condition. We agree with the reviewer that we should explain this clearer in the text.

      In the model, the light intensity changes depending on the region. It might make more sense for interpretability if instead there is an additional light-sensitivity coefficient that depends on the region, because at the moment I'm not sure what units L(t) is supposed to take.

      Thank you for your suggestion. We will try to implement this approach.

      **Minor comments**

      Could you more explicitly describe a possible molecular mechanism through which the coupling acts?

      Thank you for your suggestion. We will more explicitly discuss likely transport mechanisms in the text.

      In Figure 1C it looks like different genes are coupling to different genes, so you may need to rearrange it.

      In our model, the level of CCA1/LHY is shared. Thus, CCA1/LHY from one cell can be considered to repress the expression of other interacting genes in the neighbour cell.

      Line 103: "We found that regional differences persist even under LD cycles, but cell to-cell minimized differences between neighbor cells." Missing word.

      Thank you for your correction.

      Line 124: "The coupling strength was set to 2 (Methods)." This is meaningless in isolation, so it would be better to briefly explain what the coupling parameter is before mentioning its value.

      Thank you for your suggestion, we will describe the coupling function in more detail.

      Through the text, I think De Caluwe should be corrected to De Caluwé

      Thank you for your correction.

      Typo line 493

      Thank you for your correction.

      Code and data are not made available.

      Model code will be made available from our project GitLab page: https://gitlab.com/slcu/teamJL/greenwood_tokuda_etal_2020

      Output of analysis of experimental data and simulations will also be made available on the GitLab page.

      Reviewer #3 (Significance (Required)):

      The authors motivate the paper by highlighting that their proposed model improves on phase-based models in that it describes underlying molecular mechanisms.

      From an experimental side, it's interesting that a model is developed and directly compared with measured spatio-temporal waves of gene expression. From a theoretical side, the authors address questions relating to oscillations, multi-scale modelling and noise robustness that also generalise to other systems. I therefore expect that both experimental and theoretical audiences will be interested in the results.

      There are many possible additions and modifications that could be made to the model, and so the model and analysis could provide a platform for future research. However, I can't comment on whether there are similar pre-existing models of the plant circadian clock that contain both a molecular description of the circadian clock as well as a spatial scale.

      We appreciate the reviewer’s view that the work is interesting to both experimental and theoretical audiences.

      Comments on Review #1:

      The time is rescaled in each cell, meaning that each cell has a unique period, but the dynamics remain deterministic and hence the peak-to-peak times will be exactly the same for each cell. I imagine this isn't completely consistent with single-cell data (if available), where peak-to-peak times are very likely to be variable due to noisy gene expression. In a future paper it would be interesting to analyse the system using stochastic differential equations.

      Please see our response to reviewer #1.

      Comments on Review #2:

      I agree on the following two points:

      1) It would add value to discuss whether the different ranking of light sensitivities by organ matches any available experimental data.

      Please see our response to reviewer #2.

      2) As the Reviewers point out, there are many possibilities for testing the robustness of the system to light clues, including varying the length of the day. Although outside of the scope of this paper, I wonder if it's possible to find data from a light sensor measuring light intensity across an entire year? Plugging such data into the model and measuring how the amplitude and period changes would be really interesting, in my opinion.

      Thank you for your suggestion. We also see this as an interesting future direction.

    2. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #3

      Evidence, reproducibility and clarity

      Summary:

      The authors start by taking a previously published model of the plant circadian clock and implement five changes: 1) updating the network topology to reflect some recent experimental findings, 2) make a spatial model loosely based on a seedling template 3) introduce coupling between cells based on shared levels of CCA1/LHY 4) randomly rescale time in each cell to induce inter-cell differences in period, 5) include a light sensitivity that depends on the region considered.

      For a certain configuration of light sensitivities/intensities, the different periods of oscillations in each seedling region roughly match that of experiments. With a sufficiently high coupling between cells, the system can also generate spatial waves, which are also observed in the experimental system.

      With pulsed light inputs the spatial pattern is still produced. The authors then investigate the robustness to environmental noise by generating stochastic light signals and show that the global synchrony, as measured with a synchronisation index, increases with cell-to-cell coupling strength. The paper is overall well-written, and the background and details of the analysis are well presented.

      Major comments:

      For the first part of paper, the output of the model is certainly the focus. There is virtually no discussion of the inferred parameters and how much confidence the authors have in their values.

      My main issue with the paper is about the section with noisy light signals, which is included in the title and is ultimately one of the main themes of the article.

      Specifically, on line 224:

      "This decrease in cell-to-cell variation revealed an underlying spatial structure (Fig 4D, middle and right, and S13 Fig), comparable to that observed under idealized LD cycles (Fig 4B, middle and right, and S12 Fig)."

      Firstly, I don't feel these conclusions match with the data presented. Comparing figure 4D middle and right with figure 4B middle and right shows a clear and pronounced loss in spatial structure. In its current form, this statement has to change, but I believe there are at least two other major issues with this figure:

      1) The figure is clearly designed to invite a comparison between the noise-free light cycles on the left with the noisy cycles on the right. However, due to how the noisy light is simulated, the variance of light signal increases AND the average intensity of light decreases by 50%. When comparing the left and the right, we therefore don't know whether the changes are due to differences in the average signal or differences from the stochasticity. I think the authors should simulate a noisy light signal with the same mean intensity level as the deterministic signal. . 2) The noise model for the light doesn't seem realistic. On line 484 is says:

      "We made the simplifying assumption that each cell is exposed to an independent noisy LD cycle due to their unique positions in the environment. LD cycles were input to the molecular model through the parameter L".

      In fact, this could be considered as an incredibly complex signal, because for 800 cells it means drawing 800 random light signals. The implication is that two adjacent cells receive statistically independent light signals. Depending on chance, one cell might receive tropical levels of light while its neighbour experiences a cloudy day. This affects the interpretation and conclusions from figures 4 and 5. I propose two different ways of improving the simulation of the noisy light signal:

      a) In one extreme case, all cells receive the same noisy light signal, and the other extreme, they all receive independent signals. You could consider a mixture model of light signals, where each cell receives \lambda L_global(t) + (1-\lambda) L_individual(t), where L_global(t) is a global light signal that is shared by all cells and L_individual(t) is a light signal unique to an individual cell. The mixing parameter \lambda controls how similar the light signal is between cells

      b) Clearly the light signal will differ depending on the region, but there will be some spatial correlation. You could also consider methods of simulating light such that neighbouring cells receive correlated signals, although this might be difficult.

      Assuming that the problem with the mean signal is corrected, do you expect the average spatial pattern to be the same between figure 4 B and D with no coupling (J=0) (although an increase in the variance between cells)? Perhaps not (owing to nonlinearities in the system), but it would be interesting to comment.

      The different periods in the different regions of the seedling are caused by differences in light sensitivity, which the authors claim is justified from refs 12-15. An alternative hypothesis is the that biochemical parameters such as degradation rates are different between regions. This is briefly alluded to in the introduction, but I think it would be interesting to discuss further. What would be the pros and cons of the two different mechanisms?

      I understand that the authors used a pre-existing model, but I must say that I find the way that light is incorporated into the model a bit confusing.

      On line 345 it says: "L(t) represents the input light signal (L = 0, lights off; L > 0, lights on) and D(t) denotes a corresponding darkness input signal (D = 1, lights off; D = 0, lights on)."

      Surely the only thing that matters biophysically is the number of photons hitting the plant? Could you explain why the model needs to have a separate "darkness signal" compared to just a single light signal?

      In the model, the light intensity changes depending on the region. It might make more sense for interpretability if instead there is an additional light-sensitivity coefficient that depends on the region, because at the moment I'm not sure what units L(t) is supposed to take.

      Minor comments

      Could you more explicitly describe a possible molecular mechanism through which the coupling acts?

      In Figure 1C it looks like different genes are coupling to different genes, so you may need to rearrange it.

      Line 103: "We found that regional differences persist even under LD cycles, but cell to-cell minimized differences between neighbor cells." Missing word.

      Line 124: "The coupling strength was set to 2 (Methods)." This is meaningless in isolation, so it would be better to briefly explain what the coupling parameter is before mentioning its value.

      Through the text, I think De Caluwe should be corrected to De Caluwé

      Typo line 493

      Code and data are not made available.

      Significance

      The authors motivate the paper by highlighting that their proposed model improves on phase-based models in that it describes underlying molecular mechanisms.

      From an experimental side, it's interesting that a model is developed and directly compared with measured spatio-temporal waves of gene expression. From a theoretical side, the authors address questions relating to oscillations, multi-scale modelling and noise robustness that also generalise to other systems. I therefore expect that both experimental and theoretical audiences will be interested in the results.

      There are many possible additions and modifications that could be made to the model, and so the model and analysis could provide a platform for future research. However, I can't comment on whether there are similar pre-existing models of the plant circadian clock that contain both a molecular description of the circadian clock as well as a spatial scale.

      REFEREE'S CROSS-COMMENTING

      Comments on Review #1:

      The time is rescaled in each cell, meaning that each cell has a unique period, but the dynamics remain deterministic and hence the peak-to-peak times will be exactly the same for each cell. I imagine this isn't completely consistent with single-cell data (if available), where peak-to-peak times are very likely to be variable due to noisy gene expression. In a future paper it would be interesting to analyse the system using stochastic differential equations.

      Comments on Review #2:

      I agree on the following two points:

      1) It would add value to discuss whether the different ranking of light sensitivities by organ matches any available experimental data.

      2) As the Reviewers point out, there are many possibilities for testing the robustness of the system to light clues, including varying the length of the day. Although outside of the scope of this paper, I wonder if it's possible to find data from a light sensor measuring light intensity across an entire year? Plugging such data into the model and measuring how the amplitude and period changes would be really interesting, in my opinion.

    3. Note: This preprint has been reviewed by subject experts for Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Referee #2

      Evidence, reproducibility and clarity

      Summary:

      The manuscript presents an improved model of the circadian clock network that accounts for tissue-specific clock behavior, spatial differences in light sensitivity, and local coupling achieved through intercellular sharing of mRNA. In contrast to whole-plant or "phase-only" models, the authors' approach enables them to address the mechanism behind coupling and how the clock maintains regional synchrony in a noisy environment. Using 34 parameters to describe clock activity and applying the properties mentioned above, the authors demonstrate that their model can recapitulate the spatial waves in circadian gene expression observed and can simulate how the plant maintains local synchrony with regional differences in rhythms under noisy LD cycles. Spatial models that incorporate cell-type-specific sensitivities to environmental inputs and local coupling mechanisms will be most accurate for simulating clock activity under natural environments.

      We have the following major criticisms as follows

      1) When assigning light sensitivities in different regions of the plant, the authors assign a higher sensitivity value to the root tip (L=1.03) than they do to the other part of the root (L=0.90). We are curious why the root tip would have higher light sensitivity than the rest of the root. Is this based on experimental data (if so, please cite in this section or methods)? It seems that these L values were assigned simply to make sure they recapitulated the period differences observed in Fig. 2A. Are these values based on PhyB expression in those organs? Or perhaps based on cell density in those locations?

      2) In the discussion of the test where they set the "light inputs to be equal" in all regions to simulate the phyb-9 mutant, could the authors please clarify whether that means they set the L light sensitivity value equal in all regions? a. If they are referring to setting the L value equal to all regions, we suggest that this discussion be moved to the section about different light sensitivities instead of the local sharing of mRNA section. b. Additionally, is it possible to set the light sensitivity to zero for all parts of the plant? We think this would be more suitable to simulate the phyb-9 mutant phenotype.

      3) Based on the recent Chen et al. (2020) paper showing ELF4 long-distance movement, we think it would be of great interest for the authors to model ELF4 protein synthesis/translation as the coupling factor, in addition to the modeling using CCA1/LHY mRNA sharing. We understand you may be saving this analysis for a future modeling paper, but this addition to the paper could increase the impact of this paper.

      4) This model is able to simulate circadian rhythms under 12:12 LD cycles, which represents two days of the year-the equinoxes. We are curious if the model can simulate rhythms under short days and long days as well. We understand this analysis may be outside the scope of this paper and may require changing the values of the 34 parameters used but think it could be a useful addition here or in future work.

      And minor criticisms as follows

      1) In the first paragraph of the results section, it would be helpful for the authors to reference Table S1 when they mention the 34 parameters used to model oscillator function

      2) In the first paragraph of the section titled "Local flexibility persists under idealized and noisy LD cycles", it would be helpful for the authors to reference S12 Fig after the last sentence that starts "However, ELF4/LUX appeared more synchronized..."

      3) In the first paragraph of the section titled "Cell-to-cell coupling maintains global communication under noisy light-dark cycles", the authors refer to a "Table 1" but I think they mean to refer to Table S1"

      4) In Fig. 1, panel C is described as demonstrating the cell-to-cell coupling through the "level of CCA1/LHY". This phrasing is vague and we think could be improved to the "mRNA level of CCA1/LHY".

      Significance

      This work would be broadly interesting to other researchers studying cell-to-cell signaling and coupling of circadian rhythms in plants and other species where spatial waves of gene expression have been observed (i.e., mice and humans). Additionally, the computational modeling aspect of this work was easily interpretable for someone outside this expertise. Our expertise lies in plant circadian biology.

    1. Note: This rebuttal was posted by the corresponding author to Review Commons. Content has not been altered except for formatting.

      Learn more at Review Commons


      Reply to the reviewers

      Reviewer #1 (Evidence, reproducibility and clarity (Required)):

      The authors generated and analyzed a great amount of single-cell RNA FISH data over time on circadian genes (Nr1d1, Cry1, Bmal1), and performed model selection/fitting to explain the observed mRNA distributions. They decomposed the mRNA variability into distinct sources, and showed that intrinsic noise (transcription burst) dominates the variance. Therefore, looking at transcript counts may not be feasible to estimate single-cell circadian phase. However, the study is quite descriptive and ends up being a bit dissatisfying, so if the authors could improve this aspect by perhaps analyzing a mechanism on cell-specific burst size (F5), gene-specific dependence on cell size (beta), or the positive/negative gene-pair correlations (rho), it would help quite a bit in this regard. The model selection/fitting itself was not really sufficient to compensate for this, as it stands .

      We thank the reviewer for appreciating the new smFISH data, the analyses performed, and the consequences regarding phase inference from single cell snapshots.

      The reviewer suggests “perhaps analyzing a mechanism on cell-specific burst size (F5), gene-specific dependence on cell size (beta), or the positive/negative gene-pair correlations (rho)”, and we have thus added a new Results paragraph (lines 281-316) and two new Supp Figures 13 and 14 to directly address this point.

      Specifically, we have added a dynamic, stochastic model of the circadian clock in order to add mechanistic insight into the parameters of the preferred model M4. Concerning \rho, in the initial manuscript we suggested that the correlations of cell-specific burst sizes (described by the parameter \rho) in the preferred model M4 could result from the underlying network topology. To substantiate this claim, we have now added an analysis of a stochastic model of the clock that includes gene-gene interaction amongst the core-clock genes. The core-clock network involves variables (such as protein levels), parameters (such as mRNA/ protein half-lives) and additional genes (such as Clock) that are not directly measurable in our experiments; and thus offering a detailed mechanistic mathematical model for our data is therefore not realistic. We therefore developed a simplified mathematical model for the three measured genes to explore the underlying mechanisms that could control the parameter \rho, as the referee suggests. As a starting point, we used the circadian clock gene network topology for Nr1d1, Cry1 and Bmal1 as modelled in Relógio et al. (Relógio et al., 2011) (see new Supplementary Material). To keep the model close to the inference framework, we used oscillatory functions for the burst frequency while the transcription rate (and hence the burst size) for each gene is affected by the protein levels of the other genes in the network. Using stochastic simulations we show that, for particular configurations of feedback where the negative repression of Nr1d1 by CRY1 is high, the network can generate positive mRNA correlation between Bmal1/Cry1 mRNA and negative correlation between Nr1d1/Cry1mRNA, as observed in our data (Figure 2C). Furthermore, using the same inference framework as for our data on the simulated mRNA distributions, the obtained \rho is positive for Bmal1/Cry1 and negative for Nr1d1/Cry1, which was also found for our data (Figure 3C). Even though the model is clearly a simplified representation of the clock, these simulations give credence to the scenario that the \rho parameter obtained from the data is a signature of the underlying network topology.

      While the emphasis of the paper is certainly on parameter inference of the single-cell RNA FISH data, we believe the addition of this dynamic model provides more mechanistic insight into the results of the model fitting and hence significantly more depth to the article.

      \*Specific comments:** *

      1.It is hard to distinguish the RNA FISH signals (Figure 1A, 2B). It is probably technically challenging as the mRNAs are of low abundance. I think it may help if they adjust the contrast for the cytoplasm stain or just delineate the cell boundaries.

      Thank you for pointing this out, and we agree that our rendering of the FISH images was not optimal and have now significantly improved it (see new Figure 1A and 2B). Considering the other reviewers’ comments related to the images, we have now 1) added the cell contours as requested; 2) use red/green for the smFISH signal in the pairs of genes; 3) we have improved the contrast to make it easier to distinguish the RNA FISH signals.

      2.In Figure 2C, the authors showed gene-pair correlations with cells of all sizes. Could the authors do a size-dependent extrinsic-noise filtering (Padovan-Merhar, Dev. Cell, 2015; Hansen et al., 2018, Cell Systems) to better dissect the correlations?

      We used negative binomial distributions to directly model the number of mRNA in the cells, which is a natural choice given that the raw smFISH are integer counts. The model incorporates cell size dependencies in a unified framework, which predicts the joint distribution of raw counts, which is why we showed raw counts in the main figure. That being said, as the referee suggests, it can be useful for exploratory purposes to see the relationship between the measured genes while regressing out the contribution of cell area, and we have now added this analysis as Supp Figure 9. On line 156-161 we write:

      “To also estimate the correlation between genes while accounting for cell area, we regressed out the area for each gene and recalculated the correlation coefficients [37,38]. Since all genes are positively correlated with area (Fig. 2A), this processing shifted the correlations for both pairs of genes. Specifically, the correlation coefficients for the area-filtered mRNA counts decreased but remained positive for Bmal1/Cry1 and became more negative for Nr1d1/Cry1(Supp Figure 9).”

      3.For fitting model M3, as the authors pointed out, there are many local minima. Is the fitting score truly sufficient to eliminate the possibility for partial synchrony especially considering that the authors didn't show how effective the Dex treatment was to synchronize the circadian phase?

      Thank you for this comment. In fact, we didn't mean to fully eliminate the possibility of imperfect synchronization, but have tried our best to address it both experimentally and with modeling.

      Experimentally, in addition to the Dex treatment, we also compared with a condition in which we entrained the cells using temperature cycles, which is a standard in the field to achieve the best synchronization. We obtained a fold change of 2.1, which was in the range of previous studies (Saini, et al, 2012) and was slightly higher than with Dex synchronisation (1.6). Given that the improvement was not high and that it was important for us to study the system under free-running conditions and not in an entrained state (i.e. phase locking, which distorts the free dynamics and noise characteristics of the oscillator), we used the Dex protocol.

      Model 3 was used as a computational approach to correct for the individual phases. In addition to the difficult optimisation landscape, the challenge with model M3 also resides in the difficulty of estimating an individual phase for each cell, as the two mRNA counts measured in each cell do not contain sufficient phase information. This could potentially be resolved by either measuring more genes simultaneously, but is, however, beyond the scope of the present manuscript. We have added discussion on this to the text on lines 244-248:

      “Thus, it was apparently difficult to use model M3 to correct the individual phase for each cell, likely due to the fact that the two mRNA counts measured in each cell do not contain sufficient phase information, and that the global optimisation problem contains many local minima. This could potentially be improved by measuring more genes simultaneously.”

      We have also added a new Results section (lines 305-316) and Supp Figure 14 to show that imperfect synchrony alone cannot explain the correlation structure observed in our data. Indeed, if two genes have a similarly phased oscillation, the expression of the two genes will be positively correlated (as shown in the new Supp Figure 14). Similarly, when the oscillations are in anti-phase, negative correlations will be found. Given that Nr1d1 and Cry1 are closer in phase than Bmal1 and Cry1, one would expect that the correlation between Nr1d1 and Cry1 (once accounting for area) would be more positive than for Bmal1 and Cry1, which was not found in the data (area-corrected correlations shown in Supp Figure 9). It therefore seems unlikely that the observed correlations could be caused by imperfect synchrony alone. Together with our simulations of the gene network (described above), we therefore argue that gene-gene interactions are a more plausible mechanistic explanation of the correlations observed in our measured bivariate mRNA distributions.

      4.Regarding model M4, the authors added a cell-specific noise term without specifying the contributing factors. Typically adding degrees of freedom should improve fitting and make it easier for a model to fit, why not in this case? Can the authors provide some explanations/mechanisms.

      We believe there has been a misunderstanding regarding model M4. By adding parameters, model M4 is indeed easier to fit. There is even a problem of overfitting whereby the burst frequency becomes unrealistically high and the model effectively fits a Poisson distribution to each individual cell. To avoid this, we lock the burst frequency values to the posterior mean values from model M2. After describing model M4, we write (lines 260-265):

      “When all parameters are free, we noticed that the burst frequency can become unrealistically high due to a tendency to overfit to individual cells, and we therefore locked the burst frequency to the posterior mean values from model M2. The PSIS-LOO scores overall favoured model M4 (Fig. 3B), and the predicted joint probability density shows good similarity to the observed data (Fig. 3D) (all time points shown in Supp figure 11).”

      Regarding the above comment in the reviewer’s summary on contributing factors of model M4 we added a simple dynamical model that attempts to explain at least one possible mechanism of generating correlations in cell-specific bursting parameters (see above).

      5.The authors should include the number (range) of cells analyzed in the figure legends.

      We have now added the number of cells used at each time point to the legend of Figure 1D. To respond to Reviewer #2 we have also added details on the number of smFISH replicates used at each time point. The number of cells for each replicate is shown in Supp Figures 2-5.

      Reviewer #1 (Significance (Required)):

      Overall, we felt conflicted about the manuscript. On one hand, the authors generated and analyzed a great amount of single-cell RNA FISH data over time on circadian genes. On the other hand, the manuscript was a bit dissatisfying/descriptive. If the authors could provide and analyze some sort of mechanisms on cell-specific burst size (F5), gene-specific dependence on cell size (beta), or the positive/negative gene-pair correlations (rho) it should help improve the manuscript.

      We thank the review for the suggestion to expand on the mechanistic interpretation, which we have followed. In addition, we would like to emphasise that a similar smFISH analysis of the core circadian oscillator has never been done, and we believe our data represents a significant contribution to the field. Moreover, our quite generic probabilistic inference framework for smFISH using mixture models to describe intrinsic (transcriptional bursting) and extrinsic fluctuations is also novel and the code provided (written using the Stan probabilistic programming language) might find a wide applicability.

      Concerning the mechanistic description, as described above, we added a stochastic, dynamic model of gene expression and propose that gene-gene interactions within the core-clock network topology represent a plausible mechanism for generating correlated burst parameters between genes, which are a feature of the preferred model M4 found during inference. We additionally added an explanatory figure to argue that, given the phase relationship between genes, imperfect synchronisation alone cannot explain the observed correlations that we observe between the pairs of genes. Together, this analysis provides more mechanistic insight into the underlying factors controlling the gene-gene relationships in our measured bivariate mRNA distributions.

      \*Referees cross-commenting** *

      I agree with Reviewer #3 regarding expanding the discussion to include the Shah & Tyagi and Raj et al citations on buffering. However caution should be exercised regarding ref 26 as it is quite controversial and subsequent analyses came to different conclusions (PMID: 30359620 and 30243562). The general consensus is that nuclear buffering of transcript noise (proposed in ref 26) is not a general phenomenon (ref 27 is specific to the calcium response pathway). In fact, the presence and evolution of specific pathways to buffer transcriptional noise, such as protein-protein mechanisms (Shah & Tyagi) or extended half-life proteins (Raj et al. and others), argues that transcript fluctuations are not probably buffered in general.

      Following the suggestion of Reviewer #3, we have expanded the Discussion to include the references cited (Shah & Tyagi, Raj and others).

      Previous work from our lab is also nuancing the conclusions from references 26 and 27. Specifically, buffering effects are expected to be highly gene-specific (3’UTR), and in fact we have not seen those with our unstable construct during live-cell imaging (Suter et al., 2011; Zoller et al., 2015). We have also added text in order to explicitly state that subsequent papers have nuanced the general claims in references 26 and 27. In the text we write (lines 335-342):

      “One explanation for the low intrinsic fluctuation in these studies is that transcriptional fluctuations are filtered by nuclear retention, though other reports suggest that Fano factors (variance/mean, a measure of overdispersion compared to the Poisson distribution) can be even larger in the cytoplasm than in the nucleus [38]. In the cells used here, the strong signature of transcriptional bursting and high intrinsic noise is consistent with live imaging of a Bmal1transcriptional reporter in the same cell line under similar growth conditions, where intrinsic noise was estimated to be 4-times larger than extrinsic noise [23].”.

      Reviewer #2 (Evidence, reproducibility and clarity (Required)):

      \*Summary:** *

      The authors study experimentally and computationally the dynamic transcription of circadian clock genes over time in individual cells with single molecule RNA-FISH with the aim to understand how different noise sources contribute to single cell transcription variability and basic functions of circadian clocks. The authors integrate experiments with computational modeling to understand biology.

      \*Major comments:** *

      This study has some major limitations that need to be addressed to test the model usefulness, to understand noise sources and to gain biological insights into circadian clocks.

      We thank this reviewer for the constructive feedback which enabled us to significantly strengthen the revised manuscript.

      The limitations are on the experiments, the computational implementation of the modeling and the integration of experiments with models.

      Although the experimental datasets contain several hundred cells per time point for multiple time points, only a single replica experiment is presented. From the presented data it is not clear how reproducible these temporal patterns are and if indeed differences between timepoints can be resolved if multiple biological replica experiments have been analyzed. To address this point at least three biological experiments needs to be presented and analyzed for each of the genes. Plotting the SEM on the means in figure 1B is misleading because several hundred cells have been measured which automatically makes the error small. The SEM just describes how well we can determine the mean from a distribution. Instead a mean and std from the biological replicas need to be plotted to show how experimental variability in experiments is resulting in the described expression pattern. This is similar to RNA-seq data or RT-PCR from multiple replica.

      We certainly agree that demonstrating reproducibility is important. Note that our smFISH data is from three independent cell culture dishes and microscopy slides, which included independent cell synchronization. This was described in the Methods but we agree that the data presentation was not showing the individual replicas, which we have now added. In Figure 1B, we now show the mean of each replicate for each time point. While the reviewer suggested displaying the mean and standard deviation across replicates, we show all data points at each time point to make it even more transparent. The mRNA distribution of each replicate is also shown in Supp Figures 2-5, together with individual quantification of mean, coefficient of variation and number of cells.

      In addition, to further demonstrate the reproducibility of the temporal patterns we have performed an additional independent experiment on four time points. This experiment shows that the oscillatory patterns for Nr1d1 and Cry1are clearly significant and reproducible (new Supp Figure 7). The combination of the replicates shown for the main experiment (Supp Figures 2-5) and the new replicate experiment (Supp Figure 7) shows that the oscillatory temporal patterns for the mean mRNA levels are robust and reproducible, and in fact similar as those found in bulk analyses (Ukai-Tadenuma et al., 2011; Hughes et al., 2009), which is expected.

      It is also not clear how good the cell segmentation works and how does cell segmentation influence the analysis. In figure 1A show the segmentation of the cell boundary together with the membrane stain.

      Thanks to this and other reviewers’ comments, we have now significantly improved the presentation of the FISH images. We have now 1) added the cell contours as requested; 2) used red/green for the smFISH signal in the pairs of genes; 3) we have improved the contrast to make it easier to distinguish the RNA FISH signals.

      We have also added Supp Figure 1 to show that the cell segmentation we used is reliable. In fact, as we had described, we used the sum Z-stack projections of the red channel (Wu et al., 2018), which we found provides the most accurate cell segmentation. We now show in Supp Figure 1 that the obtained segmentation shows convincing agreement with the cell autofluorescence .

      The authors use the RNA mean and RNA-FISH distributions and combine this data to build and compare different models. How do you know that the given data fulfils the central limit so that a model describing the mean is an adequate approach? To test this point, the authors should show through subsampling from the data and the model that indeed their data sets have enough cells to fulfil the central limit theorem.

      This comment reflects a misunderstanding of our approach, which we now try to better explain. In our inference framework we use a negative binomial (NB) distribution (and mixtures of NBs) to model the full distribution of mRNA counts, and our approach is therefore not based exclusively on the mean of the distribution. The estimation of model parameters and comparison of models is performed using the PSIS-LOO optimisation procedure (see below). The mixture model of NB binomials makes a few assumptions which we had clearly stated. In fact it captures both bursty transcription (in the limit of short bursts as is biologically plausible, which yields the NB distribution), and cell-to-cell variability (extrinsic noise) captured by the mixture. The suitability of the NB to model bursty transcription is established (Raj et al., 2006), and it is parameterized by a mean and a dispersion coefficient, such that the CV of the distribution is the inverse of the burst frequency (Zoller et al., 2015). Therefore the mean is indeed an important parameter of the model, but we do not see the relationship with the CLT. The used probabilistic inference (PSIS-LOO: Pareto-Smoothed Importance Sampling Leave-One-Out, Vehtari et al. 2017, see below) is established and state-of-the-art for selecting models of the appropriate complexity and we are not aware of a similar previous quantitative model for smFISH analysis.

      We have now added significantly more explanations both on the general approach as well as the methodological details in a fully-revised Methods section to avoid further misunderstanding.

      A strength of the manuscript is that several competing and biologically meaningful models have been generated. However, the manuscript lacks rigor in terms of how fitting and model selection is performed. It is not clear how good the models fit the data. To address this point, the authors should visually compare the model fits to the data and plot their fit errors as a function of model complexity.

      We fully agree that comparing different models using a model selection approach is a powerful methodology, in fact it is arguably the most systematic way to approach modeling problems in quantitative biology. Model selection is an active research area and there have been significant developments recently. Here, we used a state-of-the-art and established Bayesian approach (PSIS-LOO: Pareto-Smoothed Importance Sampling Leave-One-Out, Vehtari et al. 2017), which is certainly rigorous and more objective than visual comparison. The PSIS-LOO is conceptually similar to other approaches of model performance such as AIC or WAIC, and the entire field of model selection aims at establishing rigorous methods to assess the tradeoff between fit errors and model complexity. In PSIS-LOO, this is done by using pareto-smoothed importance sampling to estimate the expected log pointwise predictive density for a new dataset using leave-one-out cross-validation. The PSIS-LOO is the currently recommended metric for measuring model performance in Bayesian analysis (Vehtari et al., 2017) and is considered superior to other approaches such as computations of Bayes factors since it is less sensitive to model priors (Gelman et al. 2013). The performance of the models as measured with PSIS-LOO is shown in Figure 3B. As already mentioned, we have added further details as to how the fitting and model selection is performed in a revised Methods section. We agree that visual comparison is useful to gain intuition and this is why we showed the bivariate distributions in Figure 3D and in Supp Figure 11.

      Regarding the comment on “fit error”, note also that we probabilistically model the full mRNA distribution for each gene. In each cell, there is a likelihood score that measures the likelihood of observing the measured mRNA count given the modelled probability distribution. As our approach is based on this likelihood, the notion of “fitting error” needs to be replaced by the log likelihood (‘fitting error’ is mathematically equivalent to a log-likelihood when the noise model is Gaussian, which is not the case here).

      Another limitation is that the models have not been validated for example by using them to make predictions. One type of prediction could be to fit the model to one biological replica and then predict the other replica (cross validation). Another prediction would be to take the distribution fitted to the experimental data and then compare the model mean to the experimental mean.

      Thank you for this comment. As explained above, we used the state-of-the-art PSIS-LOO to measure the predictive performance of the models, which approximates the result of leave-one-out cross-validation using the full data set. To further assess the predictive capabilities of the model, we have now also added a “leave-replicate-out” cross-validation, as the reviewer suggests (new Supp Figure 12). The aim of our “leave-replicate-out” cross-validation was to test how well the predictions of each model generalise to independent cells that are not in the training set. To do this, we trained each model while omitting the data from one gene on a test slide. We then calculated the likelihood score of the test slide using the parameters from the training set, and repeated this for all slides. Similarly to the PSIS-LOO, the results of the leave-replicate-out cross-validation convincingly show that model M4 has the highest predictive performance. This is now described in the updated text on lines 265-271.

      The results from fitting and prediction should be plotted as a function of model complexity. This kind of analysis will illustrate how model complexity is supported by the data.

      As already mentioned, we used state-of-the-art algorithms to analyze prediction vs. complexity. With the above addition, we now have two methods of calculating the predictive performance of each model: the approximate leave-one-out score as measured with PSIS-LOO and the leave-replicate-out cross-validation. For each model, the PSIS-LOO score is plotted in Figure 3B and the leave-replicate-out cross-validation score is shown in Supp Figure 12.

      In the method section on models, a biological motivation must be presented to justify the different model assumption.

      Thank you for pointing out that the biological justification of the models needed to be expanded. In addition to the improved justifications already provided in the Results section, we have now updated the Methods section such that a biological motivation is included for each model.

      How do the models that fit the distributions describe the mean?

      As explained above, the inference is performed on the entire distributions, using a family of distributions (mixtures of NBs) which are parameterized in a biologically relevant manner (transcriptional bursting + extrinsic noise). The mean and variance of the distribution are now described on lines 585-586 in addition to Figure 3A.

      It is necessary to list model parameters for each of the models, their description, their parameter values, their parameter uncertainty and units of each parameter.

      Thank you, this has now been added as Supplementary Tables 2-5.

      It is not clear to me how the joint probability in figures 2,4, S2 and S4 have been used to fit the model.

      Again, the joint distributions are modeled using mixtures of NBs and the inference is performed on the entire dataset at once using a log-likelihood approach. This uses all the data at once, and it is embedded in a Bayesian model selection method. The way that the joint probability is used is now clarified in the revised Methods section and in the Results section (lines 208-214):

      “For both models M1 and M2, the likelihood of observing the data given the parameters of the model is evaluated using the model-specific NB distribution and the mRNA counts for both genes in each cell. This is performed for both Bmal1/Cry1 and Nr1d1/Cry1 pairs across all time points, and this likelihood is combined with model priors to define the posterior parameter distribution for each model (Methods). We applied Hamiltonian Monte Carlo sampling within the STAN probabilistic programming language to sample the posterior distribution and infer model parameters 40.”

      How do the models make sense in the context of the fact that human genes exist as a diploids?

      This is a good point, although note though that the 3T3 cells are from mice and not humans. 3T3 cells are tetraploid, and it turns out that under the justified assumption that the bursts are short (Zoller et al., 2015; Suter et al., 2011), the number of alleles rescales the burst frequency, i.e. the effective (observed) burst frequency equals the number of alleles times the burst frequency per allele, but it does not change the shape of the distributions. On line 580-582 we have now written: “Since 3T3 cells are tetraploid, and, again assuming that the bursts are short, the inferred burst frequency for tetraploid cells will be approximately four times that of a single allele.”

      The variance decomposition is shortly described but no results are presented to show how this is done. This should be better explained.

      The variance decomposition we used is not a new result; in fact, we used the analytical results of Bowsher, C. G. & Swain, P. S. “Identifying sources of variation and the flow of information in biochemical networks” (PNAS, 2012). The mathematical proofs of the formula we use are contained within that reference; however, we have re-written this section to make it clearer to the reader (lines 688-718).

      \*Minor comments:** *

      In figure 3A, it is not clear to me what these different plots relate to the models. It is also not clear what are equations that describe each model.

      The Methods section has now been improved to show the full data-generating mechanism for each model, and each model has its own section title to make it easier to find. We have also improved the legend for Figure 3 to make the relationship to each model clearer.

      The legends in figure 3 are not very informative. More details need to be presented to understand this figure.

      Thank you for pointing this out, and we have now re-written the figure legend for Figure 3 to make the figure clearer.

      Reviewer #2 (Significance (Required)):

      This is an interesting and important topic with the potential to have general implication of how to model periodic single cell gene expression data and eventually better understand circadian clocks. This study will expand on other modeling studies of circadian clocks and has the potential to advance the field (PMCID: PMC7229691). I personally have done similar analysis and experiments in another system and biological context which has demonstrated the power of this approach if implemented rigorously. I am not an expert in circadian clocks in human cells.

      We thank the reviewer for appreciating the implications for the circadian and single cell gene expression community. Note that to our knowledge, modeling smFISH counts using mixtures of negative binomials combined with Bayesian model selection has not been done. It is both highly relevant biologically (combines intrinsic and extrinsic fluctuations in a rigorous way), general and its applicability extends far beyond the circadian oscillator. Therefore, this approach for quantitative smFISH data analysis also fills an important methodological gap.

      \*Referees Cross commenting** *

      Reviewer #1:

      I agree with the assessment that model fitting and model selection was not sufficient. But I disagreed that the data is enough. Although many cells and time points are analyzed, there is no evidence of how reproducible each mRNA distribution can be measured at each time point. I think reproducibility is key and will also help with the model fitting and identification.

      Regarding the point on reproducibility, we have made the following four changes:

      1. We have added an independent 4 time-point experiment to show that the oscillatory patterns of the distributions are reproducible (Supp Figure 7).
      2. In Figure 1 we now also show the mean of each replicate for the main experiment (Figure 1B).
      3. We also show the mRNA distributions of each replicate in Supp Figures 2-5.
      4. We have added the “leave-replicate-out” cross-validation to show that that the model performance of the preferred model generalises to independent slides that were not included in training (Supp Figure 12). In responding to Reviewer #1 regarding the modeling, we have now also added a simplified dynamical model of circadian clock expression to add mechanistic insight into our proposed models. Overall, we have significantly expanded the description of the model selection approaches to help readers who are less familiar with Bayesian model selection methods.

      Reviewer #3:

      Regarding the red background, my understanding is that this comes from the probe hybridization. This is maybe because the probe concentration has not been optimized or the number of probes per gene is low and the signal to noise is not so good.Or it could be auto fluorescent background. In this case a different fluorophore needs to be used to avoid this problem.

      Thank you for those comments, and we agree with all reviewers that the presentation of the images needed to be improved. It turned out that in Figure 1, we had shown the cell mask in red so it is clearly not related to probe concentration or autofluorescence. We have now removed the cell mask channel from the main images which allows highlighting better the smFISH signals. All smFISH images for Figures 1 and 2 have been much improved, and we’ve added a new Supp Figure 1 to show the performance of our cell segmentation.

      Reviewer #3 (Evidence, reproducibility and clarity (Required)):

      In this paper Nicholas et al image mRNAs encoding the key controllers of circadian rhythms, Rev-erba, Cry and Bmal1 in single cells over time. It was shown earlier that single cells exhibit circadian rhythms using reporter genes. A large number of studies have shown that transcription is an inherently stochastic process, which raises a question as to how single cells are able to achieve their rhythms on the face of this noise. Their results show that the number of mRNAs for the three genes exhibit the expected periodicity, but this periodicity is associated with significant cell-to-cell variation. They also explore to what extent this variability derives from stochastic transcription vs other sources of variation that are extrinsic to the genes. The results are interesting and experimental and modeling results are important (however this reviewer is not able to judge the veracity of mathematics that underlay the models).

      We thank this reviewer for appreciating the importance of our work.

      \*Some of the concerns that arose are listed below:** *

      1.The images show an annoying red background. If the red is HCS cell mask, it should be removed, and RNA presented on grey scale. This will make a better presentation. The red hue also appears in fig 2 b but here it is one of the RNA. I suggest in Fig 2 one RNA can be presented in green and the other in red, while the nuclei in blue.

      Thank you for this comment. We had indeed shown the cell mask in the red channel and now removed it. Together with the other suggestions and comments from the reviewers, we implemented the following changes: 1) added the cell contours as requested; 2) use red/green for the smFISH signal in the pairs of genes; 3) we have improved the contrast to make it easier to distinguish the RNA FISH signals. The presentation of the images is now much improved.

      2.This paper and a few others talk about the cell size contributing to the cell-to-cell variability in mRNA numbers. Where does it come from physically? One can imagine based on the cell cycle stage there could be more than two copies of then gene in a cell, which will yield more RNAs, but they say that their cells don't have much cell cycle variability. Perhaps a clearer discussion is called for rather than just being polite to other investigators.

      The referee is right that several studies observed empirically that larger cells show more mRNA molecules in smFISH experiments (Padovan et al., 2015; Kempe et al., 2015). In Padovan et al. (2015), the authors found that transcriptional burst size changes with cell volume and burst frequency with cell cycle. The main theory for transcription scaling with cell volume is to maintain transcript concentration. Using cell fusion experiments, they showed that cellular size can directly and globally affect gene expression by modulating transcription. Furthermore, they proposed that the mechanism underlying the global regulation integrates both DNA content and cellular volume to produce the appropriate amount of RNA for a cell of a given size, which is consistent with a model whereby a factor limiting for transcription is sequestered to the DNA. We used these results to propose a model whereby burst size scales with area, and we found an increase in predictive performance (compare M2 with M1 in Figure 3B). While our model selection supported the inclusion of cell area, the variance decomposition showed that the fraction of variance due to cell area ranged from 4.2% for Nr1d1 to 17.6% for Bmal1. We have now expanded the introduction to discuss this in more depth (lines 73-80) as requested.

      3.References 26 and 27 are cited for 10-80% of variance due to gene extrinsic sources. These references actually deny that there is a significant transcriptional noise in most genes. Again, stronger discussion is called for.

      As mentioned in the reply to Reviewer 1, previous work from our lab is also nuancing the conclusions from references 26 and 27. Specifically, buffering effects are expected to be highly gene-specific (3’UTR), and in fact we have not seen those with our unstable construct during live-cell imaging (Suter et al., 2011; Zoller et al., 2015). We have also added text in order to explicitly state that subsequent papers have nuanced the general claims in references 26 and 27. In the text we write (lines 335-342):

      “One explanation for the low intrinsic fluctuation in these studies is that transcriptional fluctuations are filtered by nuclear retention, though other reports suggest that Fano factors (variance/mean, a measure of overdispersion compared to the Poisson distribution) can be even larger in the cytoplasm than in the nucleus [38]. In the cells used here, the strong signature of transcriptional bursting and high intrinsic noise is consistent with live imaging of a Bmal1transcriptional reporter in the same cell line under similar growth conditions, where intrinsic noise was estimated to be 4-times larger than extrinsic noise [23].”.

      4.The results raise a very important question, whether and to what extent the transcriptional noise propagates to the next step of gene regulation and are there buffering mechanisms in the cell. For example, Raj et al, Variability in gene expression underlies incomplete penetrance, Nature 2010, show that alternative pathways serve to buffer the impact of gene expression noise. Similarly, Shah and Tyagi, Barriers to transmission of transcriptional noise in a c-fos c-jun pathway, Mol Syst Biol, 2013, show that variability in mRNA is buffered at protein level and the level of protein-protein complexes. Furthermore, they show that to the extent those vary, the chromatin intrinsically buffers against the fluctuations in numbers of transcription factors. Mention of these and other studies will enrich the paper.

      We have modified the Discussion section and now discuss these papers (and a few more). We thank the reviewer for the suggestions, which will help the reader to have a broader overview of noise buffering in gene expression and indeed enrich the paper.

      Reviewer #3 (Significance (Required)):

      Significance is high. Quality is high.

      \*Referees Cross-Commenting** *

      I agree with the comments made by other reviewers particularly about references 26 and 27. The major conclusions of reference 26 were questioned by Hansen et al 2018. At the bottom of page 7 the authors are qualifying their results in the light of references 26 and 27. Perhaps now there is less of a need to do so.

      As mentioned above, we have added the following sentence citing the Hansen paper to make it clear to the reader that key conclusions of the references 26 and 27 are disputed (lines 335-342):

      “One explanation for the low intrinsic fluctuation in these studies is that transcriptional fluctuations are filtered by nuclear retention, though other reports suggest that Fano factors (variance/mean, a measure of overdispersion compared to the Poisson distribution) can be even larger in the cytoplasm than in the nucleus [38].

      References

      Gelman A, Carlin JB, Stern HS, Dunson DB, Vehtari A, Rubin DB. 2013. Bayesian Data Analysis, 3rd edn. CRC Press, London.

      Hughes ME, DiTacchio L, Hayes KR, Vollmers C, Pulivarthy S, Baggs JE, Panda S, Hogenesch JB. 2009. Harmonics of circadian gene transcription in mammals. PLoS Genet 5. doi:10.1371/journal.pgen.1000442

      Kempe H, Schwabe A, Cremazy F, Verschure PJ, Bruggeman FJ. 2015. The volumes and transcript counts of single cells reveal concentration homeostasis and capture biological noise. Mol Biol Cell 26:797–804. doi:10.1091/mbc.E14-08-1296

      Padovan-Merhar O, Nair GP, Biaesch AG, Mayer A, Scarfone S, Foley SW, Wu AR, Churchman LS, Singh A, Raj A. 2015. Single Mammalian Cells Compensate for Differences in Cellular Volume and DNA Copy Number through Independent Global Transcriptional Mechanisms. Mol Cell 58:339–352. doi:10.1016/j.molcel.2015.03.005

      Raj A, Peskin CS, Tranchina D, Vargas DY, Tyagi S. 2006. Stochastic mRNA synthesis in mammalian cells. PLoS Biol4:e309. doi:10.1371/journal.pbio.0040309

      Relógio A, Westermark PO, Wallach T, Schellenberg K, Kramer A, Herzel H. 2011. Tuning the mammalian circadian clock: Robust synergy of two loops. PLoS Comput Biol 7:1–18. doi:10.1371/journal.pcbi.1002309

      Saini C, Morf J, Stratmann M, Gos P, Schibler U. 2012. Simulated body temperature rhythms reveal the phase-shifting behavior and plasticity of mammalian circadian oscillators. Genes Dev 26:567–580. doi:10.1101/gad.183251.111

      Suter DM, Molina N, Gatfield D, Schneider K, Schibler U, Naef F. 2011. Mammalian Genes Are Transcribed with Widely Different Bursting Kinetics. Science (80- ) 332:472–474. doi:10.1126/science.1198817

      Ukai-Tadenuma M, Yamada RG, Xu H, Ripperger JA, Liu AC, Ueda HR. 2011. Delay in feedback repression by cryptochrome 1 Is required for circadian clock function. Cell 144:268–281. doi:10.1016/j.cell.2010.12.019

      Vehtari A, Gelman A, Gabry J. 2017. Practical Bayesian model evaluation using leave-one-out cross-validation and WAIC. Stat Comput 27:1413–1432. doi:10.1007/s11222-016-9696-4

      Wu C, Simonetti M, Rossell C, Mignardi M, Mirzazadeh R, Annaratone L, Marchiò C, Sapino A, Bienko M, Crosetto N, Nilsson M. 2018. RollFISH achieves robust quantification of single-molecule RNA biomarkers in paraffin-embedded tumor tissue samples. Commun Biol 1:1–8. doi:10.1038/s42003-018-0218-0

      Zoller B, Nicolas D, Molina N, Naef F. 2015. Structure of silent transcription intervals and noise characteristics of mammalian genes. Mol Syst Biol 11:823. doi:10.15252/msb.20156257

    1. I n r e c e n t y e a r s , t h e r e h a v e b e e n c a l l s f r o m d i f f e r e n t d i s c i p l i n e s — including AI, psychology, cognitive neuroscience, and philosophy—to gather under the new roof of cognitive science and to concentrate on integrative archi-tectures that are laid out specifi cally for the purpose of modeling and understanding the human mind. These cognitive architectures, including EPAM (Gobet, Richman, Staszewski, & Simon 1997); Newell, Laird, and Rosenbloom’s Soar (1987); and Anderson and Lebière’s ACT (Anderson, 1983, 1990), have become a fl ourishing new paradigm.

      Cognitive architectures

    1. Author Response

      We thank the reviewers for their thoughtful and constructive comments. We have updated the manuscript to take their suggestions and concerns into account and uploaded a new version to bioRxiv. Detailed replies to the comments can be found below.

      Summary: The work detailed here explores a model of recurrent cortical networks and shows that homeostatic synaptic plasticity must be present in connections between both excitatory (E) to inhibitory (I) neurons and vice versa to produce the known E/I assemblies found in the cortex. There are some interesting findings about the consequences of assemblies formed in this way: there are stronger synapses between neurons that respond to similar stimuli; excitatory neurons show feature-specific suppression after plasticity; and the inhibitory network does not just provide a general untuned inhibitory signal, but instead sculpts excitatory processing A major claim in the manuscript that argues for the broad impact of the work is that this is one of only a handful of papers to show how a local approximation rule can instantiate feedback (akin to the back-propagation of error used to train neural networks in machine learning) in a biologically plausible way.

      Reviewer #1:

      The manuscript investigates the situations in which stimulus-specific assemblies can emerge in a recurrent network of excitatory (E) and inhibitory (I, presumed parvalbumin-positive) neurons. The authors combine 1) Hebbian plasticity of I->E synapses that is proportional to the difference between the E neuron's firing rate and a homeostatic target and 2) plasticity of E->I synapses that is proportional to the difference between the total excitatory input to the I neuron and a homeostatic target. These are sufficient to produce E/I assemblies in a network in which only the excitatory recurrence exhibits tuning at the initial condition. While the full implementation of the plasticity rules, derived from gradient descent on an objective function, would rely on nonlocal weight information, local approximations of the rules still lead to the desired results.

      Overall the results make sense and represent a new unsupervised method for generating cell assemblies consisting of both excitatory and inhibitory neurons. Major concerns are that the proposed rule ends up predicting a rather nonstandard form of plasticity for certain synapses, and that the results could be fleshed out more. Also, the strong novelty claimed could be softened or contextualized better, given that other recent papers have shown how to achieve something like backprop in recurrent neural networks (e.g. Murray eLife 2019).

      Comments:

      1) The main text would benefit from greater exposition of the plasticity rule and the distinction between the full expression and the approximation. While the general idea of backpropagation may be familiar to a good number of readers, here it is being used in a nonstandard way (to implement homeostasis), and this should be described more fully, with a few key equations.

      Additionally, the point that, for a recurrent network, the proposed rules are only related to gradient descent under the assumption that the network adiabatically follows the stimulus, seems important enough to state in the main text.

      Thanks, that's a good point. We modified the relevant portion of the main text as follows (l. 88):

      “[…] To that end, we derive synaptic plasticity rules for excitatory input and inhibitory output connections of PV interneurons that are homeostatic for the excitatory population (see Materials & Methods). A stimulus-specific homeostatic control can be seen as a "trivial" supervised learning task, in which the objective is that all pyramidal neurons should learn to fire at a given target rate ρ 0 for all stimuli. Hence, a gradient-based optimisation would effectively require a backpropagation of error [Rumelhart et al., 1985] through time [BPTT; Werbos, 1990].

      Because backpropagation rules rely on non-local information that might not be available to the respective synapses, their biological plausibility is currently debated [Lillicrap et al., 2020, Sacramento et al., 2018, Guerguiev et al., 2017, Whittington and Bogacz, 2019, Bellec et al., 2020]. However, a local approximation of the full BPTT update can be obtained under the following assumptions: First, we assume that the sensory input to the network changes on a time scale that is slower than the intrinsic time scales in the network. This eliminates the necessity of backpropagating information through time, albeit still through the synapses in the network. This assumption results in what we call the ”gradient-based” rules (Eq. 15 in the Supplementary Materials), which are spatially non-local. Second, we assume that synaptic interactions in the network are sufficiently weak that higher-order synaptic interactions can be neglected. Third and finally, we assume that over the course of learning, the Pyr→PV connections and the PV→Pyr connections become positively correlated [Znamenskiy et al., 2018], such that we can replace PV->Pyr synapses by the reciprocal Pyr->PV synapse in the Pyr->PV learning rule, without rotating the update too far from the true gradient (see Supplementary Materials)."

      We also added the learning rules to the main text (l. 108).

      2) The paper has a clear and simple message, but not much exploration of that message or elaboration on the results. Figures 2 and 3 do not convey much information, other than the fact that blocking either form of plasticity fails to produce the desired effects. This seems somewhat obvious -- almost by definition one can't have E/I assemblies if E->I or I->E connections are forced to remain random. This point deserves at most one figure, or maybe even just a few panels.

      We appreciate that the result that both forms of plasticity are necessary may feel somewhat obvious. However, it may not be as obvious as it appears, because the incoming synapses onto INs follow a long-tailed distribution, like many other synapse types. Randomly sampling from such a distribution could in principle generate sufficient stimulus selectivity to render learning in the E->I connections superfluous (see Litwin-Kumar et al., 2017). That’s why we made sure to initialize the E->I weights such that they show a similar variability as in the data. We now comment on this aspect in the results section (l. 135):

      "Having shown that homeostatic plasticity acting on both input and output synapses of interneurons are sufficient to learn E/I assemblies, we now turn to the question of whether both are necessary . To this end, we perform "knock-out" experiments, in which we selectively block synaptic plasticity in either of the synapses. The motivation for these experiments is the observation that the incoming PV synapses follow a long-tailed distribution (Znamenskiy et al., 2018). This could provide a sufficient stimulus selectivity in the PV population for PV->Pyr plasticity alone to achieve a satisfactory E/I balance. A similar reasoning holds for static, but long-tailed outgoing PV synapses. This intuition is supported by result of Litwin-Kumar et al. (2017) that in a population of neurons analogous to our interneurons, the dimensionality of responses in that population can be high for static input synapses, when those are log-normally distributed."

      Secondly, we tried to write a manuscript for both fellow modelers (how to self-organize an E/I assembly?) and to our experimental colleagues (what conclusions can we draw from the Znamenskiy data?). In electrophysiological studies, the plasticity of incoming and outgoing synapses of INs both have been studied independently. The insight that those two forms of plasticity should act in synergy is something that we wanted to emphasize, because it could be studied in parallel in paired recordings. Hence the two figures. Looks as if we got only modelers as reviewers ;). Along these lines, we added a short paragraph to the discussion (l. 348):

      “Both Pyr->PV and PV->Pyr plasticity have been studied in slice (for reviews, see, Kullmann et al. 2007, Vogels et al. 2013), but mostly in isolation. The idea that the two forms of plasticity should act in synergy suggests that it may be interesting to study both forms in the same system, e.g., in reciprocally connected Pyr-PV pairs.“

      3) The derived plasticity rule for E->I synapses, which requires modulation of I synapses based on a difference from a target value for the excitatory subcomponent of the input current, does not take a typical form for biologically plausible learning rules (which usually operate on firing rates or voltages, for example). The authors should explore and discuss in more depth this assumption. Is there experimental evidence for it? It seems like it might be a difficult quantity to signal to the synapse in order to guide plasticity. The authors note in the discussion that BCM-type rules fail here -- are there other approaches that would work? What about a more local form of plasticity that involves only the excitatory current local to a dendrite, for example?

      We agree that the rule we propose for E->I synapses warrants a more extensive discussion regarding its potential biological implementation. We have added the following paragraph to the manuscript (l. 295):

      “A cellular implementation of such a plasticity rule would require the following ingredients: i) a signal that reflects the cell-wide excitatory current ii) a mechanism that changes Pyr->PV synapses in response to variations in this signal. On PV interneurons, NMDA receptors are enriched in excitatory feedback relative to feedforward connections [LeRoux et al., 2013]. Intracellular sodium and calcium could hence be a proxy of recurrent excitatory input. In addition, the activation of NMDA receptors has been shown to track intracellular sodium concentration [Yu and Salter, 1998] which at least partially reflects glutamatergic synaptic currents. Due to a lack of spines in PV dendrites, both postsynaptic sodium and calcium are expected to diffuse more broadly in the dendritic arbor [Hu et al., 2014, Kullmann and Lamsa, 2007], and thus might provide a signal for overall dendritic excitatory currents. Depending on how the excitatory inputs are distributed on PV interneuron dendrites [Larkum and Nevian, 2008, Jia et al., 2010, Grienberger et al., 2015], this integration does not need to be cell-wide, but could be local, e.g., to a dendrite, if the local excitatory input is a proxy for the global input.

      NMDA receptors at IN excitatory input synapses can mediate Hebbian long-term plasticity [Kullmann and Lamsa, 2007}, and blocking excitatory currents can abolish plasticity in those synapses [LeRoux et al., 2013]. Furthermore, NMDAR-dependent plasticity is expressed post-synaptically, and seems to require presynaptic activation [Kullmann and Lamsa, 2007]. Other molecular signals that reflect excitatory activity have been implicated in the homeostatic regulation of synapses onto INs, including Narp and BDNF [Chang et al., 2010, Rutherford et al., 1998, Lamsa et al., 2007]. In summary, we conjecture that PV interneurons and their excitatory inputs have the necessary prerequisites to implement the suggested local Pyr->PV plasticity rule.”

      Concerning other potential types of plasticity, we certainly do not expect that the suggested pair of rules is the only one that will work. We have added the following paragraph to the discussion (l. 322):

      “We expect that the rules we suggest here are only one set of many that can establish E/I assemblies. Given that the role of the input plasticity in the interneurons is the formation of a stimulus specificity, it is tempting to assume that this could equally well be achieved by classical forms of plasticity like the Bienenstock-Cooper-Munro (BCM) rule [Bienenstock, et al. 1982], which is commonly used in models of receptive field formation. However, in our hands, the combination of BCM plasticity in Pyr->PV synapses with homeostatic inhibitory plasticity in the \ItoE synapses showed complex dynamics, an analysis of which is beyond the scope of this article. In particular, this combination of rules often did not converge to a steady state, probably for the following reason. BCM rules tend to [...].

      We suspect that this instability can also arise for other Hebbian forms of plasticity in interneuron input synapses when they are combined with homeostatic inhibitory plasticity [Vogels et al. 2011] in their output synapses. The underlying reason is that for convergence, the two forms of plasticity need to work synergistically towards the same goal, i.e., the same steady state. For two arbitrary synaptic plasticity rules acting in different sets of synapses, it is likely that they aim for two different overall network configurations. Such competition can easily result in latching dynamics with a continuing turn-over of transiently stable states, in which the form of plasticity that acts more quickly gets to reach its goal transiently, only to be undermined by the other one later [Clopath et al. 2016].”

      4) Does the initial structure in excitatory recurrence play a role, or is it just there to match the data?

      For the results of Fig 4, the structure of excitatory recurrence is essential, because similarly tuned Pyr neurons should excite each other (absent the E-I assemblies). Without that structure in the Pyr->Pyr connections, the “paradoxical” inhibitory effect we report would not be paradoxical at all. For the results of Fig 1-3 the excitatory recurrence plays a role only insofar as it permits and reinforces stimulus selectivity in pyramidal neurons. If those synapses were unstructured (and strong), it could disrupt the Pyr selectivity, and there would be nothing to guide the formation of E/I assemblies. We have added the following sentence to the beginning of the results section (l. 77):

      “[...] Note that the Pyr->Pyr connections only play a decisive role for the results in Fig. 4, but are present in all simulations for consistency. [...]”

      Reviewer #2:

      In this work, the authors simulated a rate-based recurrent network with 512 excitatory and 64 inhibitory neurons. The authors use this model to investigate which forms of synaptic plasticity are needed to reproduce the stimulus-specific interactions observed between pyramidal neurons and parvalbumin-expressing (PV) interneurons in mouse V1. When there is homeostatic synaptic plasticity from both excitatory to inhibitory and reciprocally from inhibitory to excitatory neurons in the simulated networks, they showed that the emergent E/I assemblies are qualitatively similar to those observed in mouse V1, e.g. there are stronger synapses for neurons responding to similar stimuli. They also identified that synaptic plasticity must be present in both directions (from pyramidal neurons to PV neurons and vice versa) to produce such E/I assemblies. Furthermore, they identified that these E/I assemblies enable the excitatory population in their simulations to show feature-specific suppression. Therefore, the author claimed that they found evidence that these inhibitory circuits do not provide a "blanket of inhibition", but rather a specific, activity-dependent sculpting of the excitatory response. They also claim that the learning rule they developed in this model shows for the first time how a local approximation rule can instantiate feedback alignment in their network, which is a method for achieving an approximation to a backpropagation-like learning rule in realistic neural networks.

      We thank you for your thorough evaluation of the role of feedback alignment (FA) in our model. While we will attempt to address them point-by-point below, we feel that we may have misled this reviewer regarding the focus of the article. The core novelty of this work lies in elucidating potential mechanisms of experimentally observed E/I neuronal assemblies in mouse V1, and furthermore in proposing plasticity rules that can achieve such E/I assemblies. That they do so via a mechanism akin to feedback alignment is mentioned relatively briefly in the manuscript, and is merely offered as a mechanistic explanation for how inhibitory currents are ultimately balanced with excitation. We are fully aware of the fact that the suggested rules are by no means a local approximation of the full BPTT problem in RNNs, but feel that the reviewer read our paper primarily as a contribution to this very interesting literature (which it isn't in our claim).

      Major points:

      1) The authors claim that their synaptic plastic rule implements a recurrent variant of feedback alignment. Namely, "When we compare the weight updates the approximate rules perform to the updates that would occur using the gradient rule, the weight updates of the local approximations align to those of the gradient rules over learning". They also claim that this is the first time feedback alignment is demonstrated in a recurrent network. It seems that the weight replacement in this synaptic plastic rule is uniquely motivated by E/I balance, but the feedback alignment in [Lillicrap et al., 2016] is much more general. Thus, the precise connections between feedback alignment and this work remains a bit unclear.

      We had hoped that our claims in the manuscript were phrased sufficiently carefully, and regret that the reviewer was led to believe that our goal was to provide a general solution to biological backprop in recurrent networks. Of course, the problem we are tackling is not the full backprop problem, and we do not expect that the approximation holds for general tasks. It clearly won't, given that it effectively relies on a truncation after two time steps and makes a stationarity assumption. Still, we felt that it would have been a lost opportunity not to discuss the relation to feedback alignment, because any approximation warrants a justification, and for the replacement of I->E weights by E->I weights, feedback alignment readily provides one. We now discuss the assumptions underlying the local approximation more extensively in the main paper (see reply to Reviewer 1, comment 1).

      We also added a discussion to the section in the supplementary material, where the local approximations are derived (l. 760):

      “Overall, the local approximation of the learning rule relies on three assumptions: Slowly varying inputs, weak synaptic weights and alignment of input and output synapses of the interneurons. These assumptions clearly limit the applicability of the learning rules for other learning tasks. In particular, the learning rules will not allow the network to learn temporal sequences.”

      It would be good if the following things about this major claim of the manuscript could be expanded and/or clarified:

      i) In Fig S3 (upper, right vs. left), it is surprising that the Pyr->PV knock-out seems to produce a better alignment in PV->Pyr. Comparing the upper right of Fig S3 and the bottom figure of Fig 1g, it seems that the Pyr->PV knock-out performs equally well with a local approximation for the output connections of PV interneurons. Is this a special condition in this model that results in the emergence of the overall feedback alignment?

      The 0-th order approximation of I->E plasticity is, by itself, relatively good at following the full gradient for those synapses (because I->E synapses have virtually unmediated control over Pyr neuron activity). When E->I plasticity is also present, we believe that the higher variance in angle to the gradient (for I->E updates) may be due to perturbations introduced by the E->I updates. Each update to one weight matrix changes the gradient for the other, but this is ultimately what brings them into alignment with one another. Because this is a very technical point, we prefer not to discuss this at length in the manuscript. The more important point is summarized in the two bottom figures, which demonstrate that the gradients on the E->I synapses only align within 90 degrees when both synapse types are plastic.

      ii) In the feedback alignment paper [Lillicrap et al., 2016], those authors introduce a "Random Feedback Weights Support"; this uses a random matrix, B, to replace the transpose of the backpropagation weight matrix. Here, the alignment seems to be based on the intuition that "The excitatory input connections onto the interneurons serve as a proxy for the transpose of the output connections," and "the task of balancing excitation by feedback inhibition favours symmetric connection." It seems synaptic plasticity here is mechanistically different; it is only similar to the feedback alignment [Lillicrap et al., 2016] because both reach a final balanced state. Please clarify how the results here are to be interpreted as an instantiation of feedback alignment - whether it is simply that the end state is similar, or if the mechanism is thought to be more deeply connected.

      We believe that the mechanisms are indeed more deeply connected, as supported by the fact that the gradients align early on during learning. We added an extended discussion to the supplementary material (l. 744):

      “In feedback alignment, the matrix that backpropagates the errors is replaced by a random matrix B. Here, we instead use the feedforward weights in the layer below. Similar to the extension to feedback alignment of Akrout et al. [2019], those weights are themselves plastic. However, we believe that the underlying mechanism of feedback alignment still holds. The representation in the hidden layer (the interneurons) changes as if the weights to the output layer (the Pyr neurons) were equal to the weights they are replaced with (here, the input weights to the PV neurons). To exploit this representation, the weights to the output layer then align to the replacement weights, justifying the replacement post-hoc (Fig. 1G).”

      iii) The feedback alignment [Lillicrap et al., 2016] works when the weight matrix has its entries near zero (e^TWBe>0). Are there any analogous conditions for the synaptic plastic rule to succeed?

      Yes, the condition is very similar. We have added a corresponding discussion to the supplementary material (l. 753):

      “Note that the condition for feedback alignment to provide an update in the appropriate direction (e T B T W e>0, where e denotes the error, W the weights in the second layer, and B the random feedback matrix) reduces to the condition that W ei W ie is positive definite (assuming the errors are full rank). One way of assuring this is a sufficiently positive diagonal of this matrix product, i.e., a sufficiently high correlation between the incoming and outgoing synapses of the interneurons. A positive correlation of these weights is one of the observations of Znamenskiy et al. 2018 and also a result of learning in our model.

      While such a positive correlation is not necessarily present for all learning tasks or network models, we speculate that it will be for the task of learning an E/I balance in a Dalean network.”

      iv) In the supplementary material, the local approximation rule is developed using a 0th-order truncation of Eq's 15a and 15b. Is it noted that "If synapses are sufficiently weak ..., this approximation can be substituted into Eq. 15a and yields an equation that resembles a backpropagation rule in a feedforward network (E -> I -> E) with one hidden layer -- the interneurons." It would be helpful if the authors could discuss how this learning rule works in a general recurrent network, or if it will work for any network with sufficiently weak synapses.

      We now discuss the assumptions and their consequences more extensively, see reply to reviewer 1, comment 1.

      v) This synaptic plasticity rule seems to be closely related to another local approximation of backpropagation in recurrent neural network: e-prop in (Bellec et.al 2020, https://www.nature.com/articles/s41467-020-17236-y) and broadcast alignment (Nøkland 2016, Samadi et.al, 2017). These previous papers do not consider E/I balance in their approximations, but is E/I balance necessary for successful local approximation to these rules?

      We are not sure if we fully understand the comment. We do not expect that E/I balance is necessary for other biologically plausible approximations of BPTT. We merely suggest that for the task of learning E/I balance, the presented local approximation is valid.

      2) In the discussion, it reads as if the BCM rule cannot apply to this recurrent network because of the limited number of interneurons in the simulation ("parts of stimulus space are not represented by any interneurons"). Is this a limitation of the size of the model? Would scaling up the simulation change how applicable the BCM learning rule is? It would be helpful if the authors offer a more detailed discussion on why some forms of plasticity in interneurons fail to produce stimulus specificity.

      Increasing the size of the model would help only if it would increase the redundancy in the Pyr population response. Otherwise, the problem can only be solved by changing the E to I ratio.

      We feel that an exhaustive discussion of the dynamics of BCM in our network is beyond the scope of the paper, particularly because BCM comes in a broad variety (weight normalisation, weight limits, exact form of the sliding threshold?) and the exact behavior depends on various parameter choices. Similarly, we preferred to limit the discussion of other Hebbian rules, because it would be somewhat arbitrary which rules to discuss. Instead we added the following more abstract arguments to the discussion section (l. 322):

      “We expect that the rules we suggest here are only one set of many that can establish E/I assemblies. Given that the role of the input plasticity in the interneurons is the formation of a stimulus specificity, it is tempting to assume that this could equally well be achieved by classical forms of plasticity like the Bienenstock-Cooper-Munro (BCM) rule \citep{Bienenstock82}, which is commonly used in models of receptive field formation. However, in our hands, the combination of BCM plasticity in Pyr->PV synapses with homeostatic inhibitory plasticity in the PV->Pyr synapses showed complex dynamics, an analysis of which is beyond the scope of this article. In particular, this combination of rules often did not converge to a steady state, probably for the following reason. [...]

      We suspect that this instability can also arise for other Hebbian forms of plasticity in interneuron input synapses when they are combined with homeostatic inhibitory plasticity (Vogels et al., 2011) in their output synapses. The underlying reason is that for convergence, the two forms of plasticity need to work synergistically towards the same goal, i.e., the same steady state. For two arbitrary synaptic plasticity rules acting in different sets of synapses, it is likely that they aim for two different overall network configurations. Such competition can easily result in dynamics with a continuing turn-over of transiently stable states, in which the form of plasticity that acts more quickly gets to reach its goal transiently, only to be undermined by the other one later.”

      Minor comments:

      1) Section 1 of the Results is confusing. The authors jump back and forth between emphasizing the emergence of E/I assemblies and connecting the local approximation rule to general feedback alignment. It would be helpful if the authors reorganized this section: maybe discuss the E/I assemblies first (with Figure 1), then go on to discuss why it is important to compare this synaptic plastic rule with feedback alignment.

      We have extended the explanation of the plasticity rules [l. 108] and hope that this section is now more accessible.

      2) Although the authors claim that there exists a significant change after PV->Pyr knockout (Fig 2b), the current presentation of this result is confusing: how many neurons change their responses? (Reading directly from the distributional difference, it seems that the gray and blue distributions only differ by about 5-8 neurons).

      The change is admittedly modest, but significant.

      3) Effect sizes instead of p-values should be quoted and used throughout, because the large data size of the simulations seems to make even the smallest correlations significant.

      We used p-values to remain consistent with the article of Znamenskiy et al. Please note that we took care to sample a comparable number of synapses from the network as in Znamenskiy et al., to keep the p-values comparable. If we had sampled all synapses from the network, significance would indeed be trivial.

    1. Cyr, B. A., Berman, S. L., & Smith, M. L. (2015). The Role Of Communication Technology in Adolescent Relationships And Identity Development. Retrieved October 25, 2020, from https://eric.ed.gov/?q=source%3a%22Child+%26+Youth+Care+Forum%22&id=EJ1049705

      I believe this is in APA rather than in MLA format

    1. Reviewer #3: (Daniele Marinazzo)

      Dear authors,

      Thanks for the opportunity to read this nice paper. I appreciated the quality of the data analysis, and the quest towards associating electrophysiology and BOLD data through a data-driven transfer function, which can be interpreted as a proxy of the HRF. Also I completely agree with you that we need to move beyond a canonical response.

      There are a few issues I would like to discuss with you. I have done quite some work in this sense. On one hand this is good (and I think it's also the reason why I was invited to review this paper), on the other one there is always the risk that I have shaped my own goggles in these last years, and that I am projecting on your work some doubts and issues that I have with my own. In this case I apologize in advance, and I hope that we can have an enriching conversation.

      Please forgive me if I start by my own work; there is always the danger that reviewers try to make authors write the paper that they would write themselves, I will keep this in mind, but on the other hand I think that the best way to convey my thoughts to you is to let them flow as they come.

      So, here's our toolbox: https://www.nitrc.org/projects/rshrf. The idea behind it is that we can take peaks in the BOLD signal and take them as signatures of a pseudo neural event happening some time before at the neural level. This is in line with this work (which could also be relevant with respect to your power law figures):

      Tagliazucchi E, Balenzuela P, Fraiman D, Chialvo DR. Criticality in large-scale brain FMRI dynamics unveiled by a novel point process analysis. Front Physiol. 2012;3:15. Published 2012 Feb 8. doi:10.3389/fphys.2012.00015 and with the subsequent spatial clustering approach which has been called coactivation patterns (CAP)

      Liu X, Zhang N, Chang C, Duyn JH. Co-activation patterns in resting-state fMRI signals. Neuroimage. 2018;180(Pt B):485-494. doi:10.1016/j.neuroimage.2018.01.041 and innovation CAPs

      Karahanoğlu FI, Caballero-Gaudes C, Lazeyras F, Van de Ville D. Total activation: fMRI deconvolution through spatio-temporal regularization. Neuroimage. 2013;73:121-134. doi:10.1016/j.neuroimage.2013.01.067 Karahanoğlu FI, Van De Ville D. Transient brain activity disentangles fMRI resting-state dynamics in terms of spatially and temporally overlapping networks. Nat Commun. 2015;6:7751. Published 2015 Jul 16. doi:10.1038/ncomms8751

      Zoller DM, Bolton TAW, Karahanoglu FI, Eliez S, Schaer M, Van De Ville D. Robust Recovery of Temporal Overlap Between Network Activity Using Transient-Informed Spatio-Temporal Regression. IEEE Trans Med Imaging. 2019;38(1):291-302. doi:10.1109/TMI.2018.2863944

      We then fit these peaks with a GLM, with the time lag as a free parameter. We use several families of basis functions. In the original paper (Wu GR, Liao W, Stramaglia S, Ding JR, Chen H, Marinazzo D. A blind deconvolution approach to recover effective connectivity brain networks from resting state fMRI data. Med Image Anal. 2013;17(3):365-374. doi:10.1016/j.media.2013.01.003) we used canonical HRF and FIR (together with the rBETA, which is basically the portion of the BOLD peak exceeding a certain threshold, as in the Tagliazucchi paper above).

      We then included a mixture of gamma functions together with other families of basis functions in subsequent versions of the toolbox. Then we set up for validation of the approach with electrophysiological signatures, and that's where the doubts and pain kicked in. Some results on simultaneous EEG-fMRI, reported here (Wu G, Marinazzo D. 2015. Retrieving the Hemodynamic Response Function in resting state fMRI: methodology and applications. PeerJ PrePrints 3:e1317v1 https://doi.org/10.7287/peerj.preprints.1317v1 Wu GR, Deshpande G, Laureys S, Marinazzo D. Retrieving the Hemodynamic Response Function in resting state fMRI: Methodology and application. Conf Proc IEEE Eng Med Biol Soc. 2015;2015:6050-6053. doi:10.1109/EMBC.2015.7319771) were encouraging: for example we saw that the positive correlation between envelope of EEG and BOLD in the occipital cortex becomes more positive when we use instead the deconvolved BOLD and the EEG, while the negative correlation in the thalamus becomes more negative.

      Other things present in the PeerJ preprint were encouraging too (and I mention them since I think that they can be relevant to the validation of your approach): namely the retrieval of a simulated ground truth HRF within certain realistic limits of SNR and jitter, the correlation with cerebral blood flow (even though physiological regressors should always be taken into account, see: Wu GR, Marinazzo D. Sensitivity of the resting-state haemodynamic response function estimation to autonomic nervous system fluctuations. Philos Trans A Math Phys Eng Sci. 2016;374(2067):20150190. doi:10.1098/rsta.2015.0190 and this becomes even more relevant when considering aging and clinical datasets), and some similarity across resting state networks.

      So, the question is: can we really trust that peaks in M/EEG reflect the local pseudo-events that would originate the BOLD signal? Reading work by people who had thoroughly investigated this, e.g.

      Logothetis NK, Pauls J, Augath M, Trinath T, Oeltermann A. Neurophysiological investigation of the basis of the fMRI signal. Nature. 2001;412(6843):150-157. doi:10.1038/35084005

      Chen X, Sobczak F, Chen Y, et al. Mapping optogenetically-driven single-vessel fMRI with concurrent neuronal calcium recordings in the rat hippocampus. Nat Commun. 2019;10(1):5239. Published 2019 Nov 20. doi:10.1038/s41467-019-12850-x

      Yu X, He Y, Wang M, et al. Sensory and optogenetically driven single-vessel fMRI. Nat Methods. 2016;13(4):337-340. doi:10.1038/nmeth.3765

      and conversing with them, I got (almost) convinced that it's unlikely that spikes in coarsely recorded or reconstructed M/EEG signal can be one to one mapped to the HRF inducing events that we use in GLM (calcium or even better glutamate signal could be a better choice).

      Now, I like the way you associated HMM states with hemodynamic ones, thus adopting a more systemic/dynamical view, and taking fractional occupancy as a trigger. Do you think that these triggers can be better markers of BOLD-inducing neural events?

      Other issues:

      • What to make of events that are very close, and that would thus violate the assumption of linearity of the GLM?

      • Apart from hemodynamic changes, can aging be associated with different electrophysiological spectral features (both periodic and aperiodic), which in turn could influence the HMM analysis?

      • Detection of brain-behavior relationships with a non-huge dataset can be misleading, see for example this recent study:

      Towards Reproducible Brain-Wide Association Studies Scott Marek, Brenden Tervo-Clemmens, Finnegan J. Calabro, David F. Montez, Benjamin P. Kay, Alexander S. Hatoum, Meghan Rose Donohue, William Foran, Ryland L. Miller, Eric Feczko, Oscar Miranda-Dominguez, Alice M. Graham, Eric A. Earl, Anders J. Perrone, Michaela Cordova, Olivia Doyle, Lucille A. Moore, Greg Conan, Johnny Uriarte, Kathy Snider, Angela Tam, Jianzhong Chen, Dillan J. Newbold, Annie Zheng, Nicole A. Seider, Andrew N. Van, Timothy O. Laumann, Wesley K. Thompson, Deanna J. Greene, Steven E. Petersen, Thomas E. Nichols, B.T. Thomas Yeo, Deanna M. Barch, Hugh Garavan, Beatriz Luna, Damien A. Fair, Nico U.F. Dosenbach bioRxiv 2020.08.21.257758; doi: 10.1101/2020.08.21.257758

      • Why the parcellation in 38 regions? How are the results consistent/robust with finer parcellations?

      • You state that the DMN "is susceptible to aging and neurodegenerative disease". That's certainly probable, the thing is that DMN is possibly sensitive to everything and specific to a very few things.

      • Instead of a point-by-point statistical test, you could use the 3dMVM algorithm in AFNI (your reference 20) to test differences in the shape as a whole.

      • You analyse data from older subjects only. How confident can you be that you are observing effects specific to aging?

      Thanks for listening to this review version of "more of a comment than a question".

    1. SciScore for 10.1101/2020.11.06.20227215: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">The Penn Medicine BioBank is an established repository that routinely collects blood products from donors visiting the University of Pennsylvania Healthcare system upon written informed consent.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">In instances we did not find matched controls, we randomly selected patients with RT-PCR negative test results.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">RESULTS Identification of SARS-CoV-2-reactive Antibodies in Human Sera Collected Prior to the COVID-19 Pandemic We completed ELISAs to quantify levels of pre-pandemic SARS-CoV-2-reactive IgG antibodies in 204 human serum samples collected in 2017.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>SARS-CoV-2-reactive IgG</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Humans with Pre-pandemic SARS-CoV-2-reactive Antibodies Had Elevated Levels of Antibodies Against Previously Circulating Betacoronaviruses We completed ELISAs to quantify levels of pre-pandemic hCoV-reactive IgG antibodies in all 204 human serum samples collected in 2017.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>hCoV-reactive IgG</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">STAR METHODS KEY RESOURCES TABLE REAGENT or RESOURCE Antibodies Goat anti-human IgG-HRP mAb CR3022 mAb 1E9F9 Bacterial and Virus Strains SARS-CoV-2</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human IgG-HRP</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">After 2 hours of incubation, ELISA plates were washed 3 times with PBS-T and bound antibodies were detected using a 1:5000 dilution of goat anti-human IgG conjugated to horseradish peroxidase (Jackson ImmunoResearch Laboratories, West Grove PA: cat. 109-036-098).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human IgG</div> <div>suggested: (Jackson ImmunoResearch Labs Cat# 109-036-098, RRID:AB_2337596)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The next day, heat inactivated serum samples were serially diluted 2-fold and mixed with 50-200 focus forming units/well of VSVΔG-RFP SARS-CoV-2 pseudotype virus and 600ng/ml of 1E9F9, a mouse anti-VSV Indiana G (Absolute Antibody, Oxford, UK: cat# Ab01402-2.0).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-VSV</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">We also compared antibody titers in pre-pandemic serum samples among SARS-CoV-2 PCR-confirmed individuals in relationship to hospitalization or need for respiratory support due to COVID-19.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>COVID-19</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">F-H) ELISAs were completed to quantify levels of serum antibodies binding to the full length S proteins from 229E, NL63, and OC43 using pre-pandemic serum samples with (n=12) and without (n=51).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>NL63</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">* D7 NL63 D0 D7 D0 D7 OC43 SARS-CoV-2 O SA C R SC oV -2 D0 Spike Fold-Change OC43 titer (day 7/day 0) * N L6 D7 229E * D0 C **** 9E 8.192 4.096 2.048 1.024 5.12 2.56 1.28 6.4 3.2 1.6 B **** Fold-Change titer (day 7/day 0) IgG antibody titer (reciprocal dilution) A Survived Died Figure 3.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>IgG</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">CRL-3216, RRID:CVCL_0063 Thermo Fisher cat.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>CRL-3216</div> <div>detected: (CCLV Cat# CCLV-RIE 1018, RRID:CVCL_0063)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Cell lines 293F cells were from Thermo fisher (Thermo Fisher cat.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>293F</div> <div>suggested: RRID:CVCL_D615)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">. 293T cells were from ATCC (ATCC cat.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>293T</div> <div>suggested: KCB Cat# KCB 200744YJ, RRID:CVCL_0063)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">VeroE6/TMPRSS2 cells were a gift from Stefan Pohlman (German Primate Center, Leibniz Institute for Primate Research) as described previously17.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>VeroE6/TMPRSS2</div> <div>suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Vero E6 cells stably expressing TMPRSS2 were seeded in 100μl at 2.5x104 cells/well in a 96 well collagen coated plate.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Vero E6</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The serum-virus mixture was incubated for 1 hour at 37⁰C before being plated on VeroE6 TMPRSS2 cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>VeroE6 TMPRSS2</div> <div>suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">STAR METHODS KEY RESOURCES TABLE REAGENT or RESOURCE Antibodies Goat anti-human IgG-HRP mAb CR3022 mAb 1E9F9 Bacterial and Virus Strains SARS-CoV-2</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>STAR</div> <div>suggested: (STAR, RRID:SCR_015899)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The Penn Medicine BioBank is an established repository that routinely collects blood products from donors visiting the University of Pennsylvania Healthcare system upon written informed consent.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Pennsylvania Healthcare</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">ELISA plates (Thermo Fisher Scientific: cat. 14- 245-153) were coated overnight at 4oC with either 2 μg/mL SARS-CoV-2 antigen, 1.5 μg/mL hCOV antigen, or DPBS to control for background.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Thermo Fisher Scientific</div> <div>suggested: (Thermo Fisher Scientific, RRID:SCR_008452)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">QUANTIFICATION AND STATISTICAL ANALYSIS Statistical analyses were performed using Prism version 8 (GraphPad Software, San Diego CA)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Prism</div> <div>suggested: (PRISM, RRID:SCR_005375)</div> </div> <div style="margin-bottom:8px"> <div>GraphPad</div> <div>suggested: (GraphPad Prism, RRID:SCR_002798)</div> </div> </td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.


      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

    1. resuma y, y accessing different memory subpath th h th h' · ways roug e 1ppo-campus we can access and recount either abbreviated l b d • l. r . or e a orate vers10ns of our 11e expenences

      super interesting

    1. Author Response

      Summary: This study tackles a difficult problem of understanding the basis for hippocampal theta rhythms through reduction of a highly detailed model, seeking to validate a reduced model that would be more amenable to analysis. The reviewers appreciated the attention to this challenging problem and the substantial work that went into it, but had several fundamental concerns about the methodology, interpretation, and reporting.

      We appreciate the detailed feedback provided to us by the reviewers and editors and we are pleased that there was an appreciation for the attention we have given to this challenging problem and the substantial work that went into it. We would like to thank the reviewers for their efforts.

      This feedback helped us realize that there was possibly too much presented in this single paper and moving forward, we will split the work into two papers. While we agree with some of the feedback, we think that some aspects were misunderstood, which may be partially due to the extensiveness of the submitted paper. Below we provide general responses to the points raised, leaving specifics for elsewhere.

      Reviewer #1:

      This study takes two existing models of hippocampal theta rhythm generation, a reduced one with two populations of Izhikevich neurons, and a detailed one with numerous biophysically detailed neuronal models. The authors do some parameter variation on 3 parameters in the reduced model and ask which are sensitive control parameters. They then examine control of theta frequency through a phase response curve and propose an inhibition-based tuning mechanism. They then map between the reduced and detailed model, and find that connectivity but not synaptic weights are consistent. They take a subset of the detailed model and do a 2 parameter exploration of rhythm generation. They compare phenomenological outcomes of the model with results from an optogenetic experiment to support their interpretation of an inhibition-based tuning mechanism for intrinsic generation of theta rhythm in the hippocampus.

      This statement summarizes our work to a certain extent but it misses a key aspect – the ‘mapping’ between the minimal (that this reviewer refers to as ‘reduced’) and detailed model is what is used to rationalize and motivate the subsequent extensive 2-parametric exploration in a ‘piece’ of the detailed model (which we termed the segment model). We will aim to write this more clearly in an edited version.

      General comments:

      1) The paper shows the existence of potential rhythm mechanisms, but the approach is illustrative rather than definitive. For example, in a very lengthy section on parameter exploration in the reduced model, the authors find some domains which do and don't exhibit rhythms. Lacking further exploration or analytic results, it is hard to see if their interpretations are conclusive.

      We agree that these are interpretations (not meant to be conclusive), but the goal was to use the minimal model to develop further insight as we did with a hypothesis development presented in the middle of the paper.

      2) The authors present too much detail on too few dimensions of parameters. An exhaustive parameter search would normally go systematically through all parameters, and be digested in an automated manner. For reporting this, a condensed summary would be presented. Here the authors look at 3 parameters for the reduced model and 2 parameters in the detailed one - far fewer than the available parameter set. They discuss the properties of these parameter choices at length, but then pick out a couple of illustrative points in the parameter domain for further pursuit. This leaves the reader rather overwhelmed on the one hand, and is not a convincing thorough exploration of all parameters of the system on the other.

      See above.

      3) I wonder if the 'minimal' model is minimal enough. Clearly it is well- supplied with free parameters. Is there a simpler mapping to rate models or even dynamical systems that might provide more complete insights, albeit at the risk of further abstraction?

      We agree that models can be even more minimal, but the goal here was not to further analyse the minimal model through simpler mappings or otherwise. Rather, it was to exploit linkages between the minimal model and detailed models to help understand how theta rhythms could be generated in the biological system (Goutagny et al. 2009 intrinsic theta), using a piece of the detailed model as a ‘biological proxy’.

      4) Around line 560 and Fig 12 the authors conclude that only case a) is consistent with experiment. While it is important to match data to experiment, here the match is phenomenological. It misses the opportunity to do a quantitative match which could be done by taking advantage of the biological detail in the model.

      5) The paper is far too long and is a difficult read. Many items of discussion are interspersed in the results, for example around line 335 among many others.

      We will split the paper into two.

      Reviewer #2:

      In this work Chatzikalymniou et al. use models of hippocampus of different complexities to understand the emergence and robustness of intra-hippocampal theta rhythms. They use a segment of highly detailed model as a bridge to leverage insights from a minimal model of spiking point neurons to the level of a full hippocampus. This is an interesting approach as the minimal model is more amenable to analysis and probing the parameter space while the detailed model is potentially closer to experiment yet difficult and costly to explore.

      We completely agree.

      The study of network problems is very demanding, there are no good ways to address robustness of the realistic models and the parameter space makes brute force approaches impractical. The angle of attack proposed here is interesting. While this is surely not the only approach tenable, it is sensible, justified, and actually implemented. The amount of work which entered this project is clear. I essentially accept the proposed reasoning and the hypotheses put forward. The few remarks I have are rather minor, but I think they merit a response.

      1) l. 528-530 "This is particularly noticeable in Figure 9D where theta rhythms are present and can be seen to be due to the PYR cell population firing in bursts of theta frequency. Even more, we notice that the pattern of the input current to the PYR cells isn't theta-paced or periodic (see Figure 10Bi)."

      This is a loose statement. When you look at the raw LFP theta is also not apparent (e.g. Figure 9.Ei or Fi). What happens once you look at the spectrum of the activity shown in 10.Bi? Do you see theta or not?

      We agree – to be done.

      2) l. 562 "This implies that the different E-I balances in the segment model that allow LFP theta rhythms to emerge are not all consistent with the experimental data, and by extension, the biological system."

      This is speculative. We do not know how generic the results of Amilhon et al. are. They showed what you can find experimentally, not what you cannot find experimentally. I agree with the statement from l.581, though : "Thus, from the perspective of the experiments of Amilhon et al. (2015) theta rhythm generation via a case a type pathway seems more biologically realistic ..."

      We agree – to edit accordingly.

      3) There are several problems with access to code and data provided in the manuscript.

      l. 986, 1113 - osf.io does not give access l. 1027 - bitbucket of bezaire does not allow access l. 1030 - simtracker link is down l. 1129, 1141 - the github link does not exist (private repo?)

      Our apologies that all of these were not made public as intended.

      4) l. 1017 - Afferent inputs from CA3 and EC are also included in the form of Poisson-distributed spiking units from artificial CA3 and EC cells.

      Not obvious if Poisson is adequate here - did you check on the statistics of inputs? Any references? Different input statistics may induce specific correlations which might affect the size of fluctuations of the input current. I do not think this would be a significant effect here unless the departure from Poisson is highly significant. Any comments might be useful.

      We were simply using the same input protocol setup done by Bezaire et al. 2016.

      5) l. 909 - "Euler integration method is used to integrate the cell equations with a timestep of 0.1 msec."

      This seems dangerous. Is the computation so costly that more advanced integration is not viable?

      Our apologies as the timestep was erroneously reported. At initial stages of the project, larger stepsizes were attempted to speed up computation. The stepsize/integration used were as in minimal model of Ferguson et al. (2017). That is, Euler integration with a 0.04ms stepsize for the cell simulations and Runge-Kutta for network simulations.

      Reviewer #3:

      [...] I have a number of methodological issues with the paper. First, both models should be validated against experimental evidence given that the experimental results exist. The validation of a "minimal" model with data from another model is circumstantial and useful to link two models, but in no way is a scientific validation, in my opinion. Second, the model reduction arguments are simply taken as a piece of a large model. This is in now way a systematic reduction, which the authors should provide. In the absence of that, the two models are simply two different models. Third, it is not clear what aspects of the mechanisms cannot be investigated using the larger models that require the reduced models, given that the models do not necessarily match. Fourth, the concept of a minimal model should be clearly explained. They used caricature (toy) models of (2D quadratic models, aka Izhikevich models) combined with biophysically plausible descriptions of synapses. The model parameters in 2D quadratic models are not biophysical as the authors acknowledge, but they can be related to biophysical parameters through the specific equations provided in Rotstein (JCNS, 2015) and Turquist & Rotstein (Encyclopedia of Computational Neuroscience, 2018). In fact, they can represent either h-currents or M-currents. I suggest the authors determine this from these references. In this framework, the dynamics would result from a combination of these currents and persistent sodium or fast (transient) sodium activation. Fifth, from the original paper (Ferguson et al., 2017) their minimal model has 500 PV and 10000 PYR cells (I couldn't find the number of PV cells in this paper, but I assumed they were as in the original paper). This is not what I would call a minimal model. It is minimal only in comparison with the more detailed model. While this is a matter of semantics, it should be clarified since there are other minimal model approaches in the literature (e.g., Kopell group, Erdi group). Related to these models, it is typically assumed that the relationship between PYR to PV is 5/1. This is certainly not holy, but seems to have been validated. Here it is 20/1. Is there any reason for that? Sixth, the networks are so big that it is very difficult to gain some profound insight. What is it about the large networks and their contribution to the generation of theta activity that cannot be learned from "more minimal" networks?

      The published minimal model (Ferguson et al. 2017) used experimental data constraints on EPSC and IPSC ratios to come up with the prediction of connectivity. As this connectivity was found in the detailed model (with empirically determined connections), this can be considered a form of validation for the minimal model’s predictions if one considers the detailed as a ‘biological proxy’.

      We agree that the segment model is not a systematic reduction of the detailed model. The segment model reasonably represents a ‘piece’ of the CA1 microcircuit that was experimentally shown to be possible to be able to generate oscillations on its own (see Goutagny et al. 2009 Supplementary figure 11). This was the assumption in determining the network size of the previously published minimal model. A large network is needed in order to appropriate capture the very large EPSCs relative to IPSCs that are present in the experiment. This is the essence of why smaller network sizes cannot be justified.

      Because of these concerns and the development of the paper, I believe the paper is about the comparison between two existing models that the authors have constructed in the past and the parameter exploration of these models.

      We do not fully agree with this statement. The minimal model was constructed by us (Ferguson et al. 2017), but the detailed model was painstakingly constructed in a state-of-the-art fashion by Bezaire et al. 2016. We used a ‘piece’ of this detailed model (see above) so that we could make ‘links’ with the minimal model in understanding the generation of intrinsic theta rhythms. This ‘piece’ also allowed us to do the extensive exploration for the additional results presented. The paper is about taking advantage of the comparison and linkage of minimal and detailed models to show how theta rhythms are generated and their frequencies controlled.

      I find the paper extremely difficult to read. It is not about the narrative, but about the organization of the results and the lack (or scarcity) of clear statements. I can't seem to be able to easily extract the principles that emerge from the analysis. There are a big number of cases and data, but what do we get out of that?. Perhaps creating "telling titles" for each section/subsection would help, where the main result is the title of the section/subsection. I also find an issue with the acronyms. One has to keep track of numbers, cases, acronyms (N, B), etc. All that gets in the way of the understanding. I believe figures would help.

      Another confusing issue in the paper is the use of the concept of "building blocks". I am not opposed to the use of these words, on the contrary. But building blocks are typically associated with the model structure (e.g., currents in a neuron, neurons in a network). PIR, SFA and Rheo are a different type of building blocks, which I would call "functional building blocks". They are building blocks in a functional world of model behavior, but not in the world of modeling components. For example, PIR can be instantiated by different combinations of ionic currents receiving inhibitory inputs. Also, the definitions of the building blocks and how they are quantified should be clearly stated in a separate section or subsection.

      The concept of building blocks was directly taken from Gjorgjieva et al. 2016 as cited in Ferguson et al. 2017 when we first used it, but also cited in the present paper, but for a different point.

      I disagree with the authors' statement in lines 214-216, related to Fig. 4. They claim that "From them, we can say that the PYR cell firing does not speci1cally occur because of their IPSCs, as spiking can occur before or just after its IPSCs." Figure 4 (top, left panel) suggests the opposite, but instead of being a PIR mechanism, it is a "building-up" of the "adaptation" current in the PYR cell. (By "adaptation" current I mean the current corresponding to the second variable in the model. If this variable were the gating variable of the h-current, it would be the same type of mechanism suggested in Rotstein et al. (2005) and in the models presented in Stark et al. (2013).) The mechanism operates as follow: the first PV-spike (not shown in the figure) causes a rebound, which is not strong enough to produce a PYR spike before a new PV spike occurs (the first in the figure), this second PV-spike causes a stronger rebound (it is super clear in the figure), which is still not strong enough to produce a PYR-spike before the new PV-spike arrives, this third PV spike produces a still stronger rebound, which now causes a PYR spike. The fact that this PYR spike occurs before the PV spike is not indicative of the authors' conclusions, but quite the opposite.

      The authors should check whether the mechanistic hypothesis I just described, which is consistent with Fig. 4 (top, left panel), is also consist with the rest of the panels and, more generally, with their modeling results and the experimental data and whether it is general and, if not, what are the conditions under which it is. If my hypothesis ends up not being proven, then they should come up with an alternative hypothesis. The condition the authors' state about the parameter "b" and PIR is not necessarily general. PIR and other phenomena are typically controlled by the combined effect of more than one parameter. As it stands, their basic assumption behind the PRC is not necessarily valid.

      The subsequent hypothesis (about PYR bursting) is called to question in view of the previous comments. The experimental data should be able to provide an answer.

      See above.

      The authors should provide a more detailed explanation and justification for the presence of an inhibitory "bolus". What would the timescale be? Again, the data should provide evidence of that. In their discussion about the PRC, the authors essentially conclude what they hypothesis, but this conclusion is based on the "bolus" idea. The validity of this should be revised.

      The discussion about degeneracy of the theta rhythm generation is interesting. However, because of the size and complexity of the models, this degeneracy is expected. Their minimal modeling approach does not help in shedding any additional light. In addition, the authors' do not discuss the intrinsic sources of degeneracy and how they interact with the intrinsic ones.

      The last two sections were difficult to follow and I found them anecdotal. I was expecting a deeper mechanistic analysis. However, I have to acknowledge that because of my difficulty in following the paper, I might have missed important issues.

      These last sections are where the ‘piece’ of the detailed model (that we termed the segment model) - a ‘biological proxy’ - essentially shows that the theta rhythm is initiated from the pyramidal cells and that the frequency is controlled by the net input to the pyramidal cells.

      The discussion is extensive, exhaustive and interesting. But it is not clear how the paper results are integrated in this big picture, except for a number of generic statements.

      The proposal that the hippocampus has the circuitry to produce theta oscillations without the need of medial septum input has been proposed before by Gillies et. (2003) and the models in Rotstein et al. (2005) and Orban et al. (2005). But the idea from this work is not that the hippocampus (CA1) is a pacemaker, but rather what we now call a "resonator". To claim that the MS is simply an amplificatory of an existing oscillator is against the existing evidence.

      We agree that many models show theta generation without explicit mention of the medial septum. However, what our modelling work shows is how the intrinsic theta rhythm is generated – it is initiated by the pyramidal cells (large enough network size with some recurrent connections) and the control of the theta frequency (LFP) is due to the net input to the pyramidal cells – this is the main claim of the paper. This is explicitly in reference to an intrinsic theta rhythm experimental context. From there, we suggest that MS and other inputs could amplify an already existing intrinsic rhythm in the CA1 microcircuit.

      References:

      Bezaire, M. J., Raikov, I., Burk, K., Vyas, D., & Soltesz, I. (2016). Interneuronal mechanisms of hippocampal theta oscillation in a full-scale model of the rodent CA1 circuit. ELife, 5, e18566. https://doi.org/10.7554/eLife.18566

      Ferguson, K. A., Chatzikalymniou, A. P., & Skinner, F. K. (2017). Combining Theory, Model, and Experiment to Explain How Intrinsic Theta Rhythms Are Generated in an In Vitro Whole Hippocampus Preparation without Oscillatory Inputs. ENeuro, 4(4). https://doi.org/10.1523/ENEURO.0131-17.2017

      Gjorgjieva, J., Drion, G., & Marder, E. (2016). Computational implications of biophysical diversity and multiple timescales in neurons and synapses for circuit performance. Current Opinion in Neurobiology, 37, 44–52. https://doi.org/10.1016/j.conb.2015.12.008

      Goutagny, R., Jackson, J., & Williams, S. (2009). Self-generated theta oscillations in the hippocampus. Nature Neuroscience, 12(12), 1491–1493. https://doi.org/10.1038/nn.2440

    1. Augustus resigned his consulship, and to prove his good republican principles, filled its remaining term by L. Sestius, an open admirer of Brutus, who had fought on his side in the Civil Wars. To compensate for the abandonment of the consulate the Senate voted him TrlTv #pX)v TTIV cV0UTraTOV EcaEi KCa0aeCTraT EXEiV, COCYTE pTE ?V Tj Eiiyo&b T~ ElCYCk) TOU TrrCA)1Ipiou KaTaTiLEaOa-l a'VTT9V P1TT aviis a&VaVEoUv-eQl, Kal EV T7 UVTrTKOCk TO Tr?7EloV TCOV Kao-Taxo6l apX6vTcov iaXVEiv,. Dio is wrong if he meant that the Senate gave Augustus an imperiuin: he had already had it as proconsul of his province

      So the important parts to take out of this would be Augustus knew to resign from his consulship and show that he was really a man of the republic which after the civil war would give him the Imperium and therefore right to rule.

    1. Progress in understanding the chemical basis of behavior willmake it increasingly untenable to retain a belief in the concept offree will. To retain any degree of reality, the criminal justice systemwill need to adjust accordingly. However, to retain a degree oforderliness in society it will still be necessary to incarcerate indi-viduals found guilty of certain criminal acts. This is rationalized invarious ways including the following: To a), protect society; b),protect the offending individuals from society; c), provide suchindividuals with appropriate psychiatric help; d), act as a deterrent(the act of incarceration and the presence of a criminal codeforming part of the environment); and e), alleviate the pain of thevictim. The proposal is a pragmatic one, based on the belief thatthe welfare of society at l

      What is going to be different?

    Annotators

    1.  ClassroomJoin classCreate classCreate or join your first class!Join your first class!This account is managed by masoncityschools.org. Learn moreZachariah Ortonzorton23@masoncityschools.orgManage your Google AccountDefaultZachariah Ortonzorton23@masoncityschools.orgZach Ortonzorton@orton.freeAll Brand accountsManage accountsPrivacy Policy•Terms of Servicethis.gbar_=this.gbar_||{};(function(_){var window=this; try{ /* Copyright The Closure Library Authors. SPDX-License-Identifier: Apache-2.0 */ _.Fd=!_.x||_.dc(9);_.Gd=!_.x||_.dc(9);_.Hd=_.x&&!_.bc("9");_.Id=function(){if(!_.p.addEventListener||!Object.defineProperty)return!1;var a=!1,b=Object.defineProperty({},"passive",{get:function(){a=!0}});try{_.p.addEventListener("test",_.za,b),_.p.removeEventListener("test",_.za,b)}catch(c){}return a}(); _.Jd=_.Nb?"webkitTransitionEnd":_.Jb?"otransitionend":"transitionend"; }catch(e){_._DumpException(e)} try{ _.Kd=function(a,b,c){if(!a.o)if(c instanceof Array){c=_.la(c);for(var d=c.next();!d.done;d=c.next())_.Kd(a,b,d.value)}else{d=(0,_.q)(a.F,a,b);var e=a.D+c;a.D++;b.setAttribute("data-eqid",e);a.B[e]=d;b&&b.addEventListener?b.addEventListener(c,d,!1):b&&b.attachEvent?b.attachEvent("on"+c,d):a.C.log(Error("n`"+b))}}; }catch(e){_._DumpException(e)} try{ var Ld=document.querySelector(".gb_C .gb_D"),Md=document.querySelector("#gb.gb_Jc");Ld&&!Md&&_.Kd(_.vd,Ld,"click"); }catch(e){_._DumpException(e)} try{ var Gh=function(a){_.J.call(this);this.C=a;this.A=null;this.o={};this.D={};this.j={};this.B=null};_.n(Gh,_.J);_.Hh=function(a){if(a.A)return a.A;for(var b in a.j)if(a.j[b].af()&&a.j[b].Sb())return a.j[b];return null};_.h=Gh.prototype;_.h.zf=function(a){a&&_.Hh(this)&&a!=_.Hh(this)&&_.Hh(this).xe(!1);this.A=a};_.h.Ag=function(a){a=this.j[a]||a;return _.Hh(this)==a};_.h.Le=function(a,b){b=b.Xc();if(this.o[a]&&this.o[a][b])for(var c=0;c<this.o[a][b].length;c++)try{this.o[a][b][c]()}catch(d){this.C.log(d)}}; _.h.nh=function(a){return!this.D[a.Xc()]};_.h.Yg=function(a){this.j[a]&&(_.Hh(this)&&_.Hh(this).Xc()==a||this.j[a].xe(!0))};_.h.$a=function(a){this.B=a;for(var b in this.j)this.j[b].af()&&this.j[b].$a(a)};_.h.tf=function(a){this.j[a.Xc()]=a};var Ih=new Gh(_.M);_.Hc("dd",Ih); }catch(e){_._DumpException(e)} try{ var nj=document.querySelector(".gb_Sa .gb_D"),oj=document.querySelector("#gb.gb_Jc");nj&&!oj&&_.Kd(_.vd,nj,"click"); }catch(e){_._DumpException(e)} })(this.gbar_); // Google Inc. Stream was updatedShow  What Would You Do?Whitney Kading•8:02 AMDue Nov 12, 8:00 AMAdd class comment1. Watch the link provided below of an episode of ABC News' hit series, "What Would You Do?" 2. Complete the document titled, "What Would You Do" Graphic Organizer In-Person Learners: We will complete this activity in class on Monday and hand in a paper copy Online Learners AND Students absent from class on Monday: Complete and submit to turnitin.com by 8am ThursdayWhat Would You Do?: 'What Would You Do?': Diners react when mom denies son vaccinations Watch Full Episode | 2020-08-18https://abc.com/shows/what-would-you-do/episode-guide/2020-08/18-what-would-you-do-diners-react-when-mom-denies-son-vaccinationsYour workAssignedEstigfendZachariah Orton - "What Would You Do?" Graphic OrganizerGoogle DocsNo work attachedAdd or createGoogle DriveLinkFileCreate newDocsSlidesSheetsDrawingsTurn inNo private commentsPrivate commentsReplyAdd private comment…No class commentsClass commentsReplyAdd class comment…Your workAssignedEstigfendZachariah Orton - "What Would You Do?" Graphic OrganizerGoogle DocsNo work attachedAdd or createGoogle DriveLinkFileCreate newDocsSlidesSheetsDrawingsTurn inNo private commentsPrivate commentsReplyAdd private comment…English 10-3rd PeriodUpcomingDue Thursday8:00 AM – What Would You Do?View allShare something with your class…Assignment: "What Would You Do?"Whitney Kading posted a new assignment: What Would You Do?Created 8:02 AM8:02 AM – Deleted This assignment is visible to all teachers in this class. It will be permanently deleted in 30 days.Assignment: "Moral Behaviors Survey and Reflection"Whitney Kading posted a new assignment: Moral Behaviors Survey and ReflectionCreated Nov 5Nov 5 – Deleted This assignment is visible to all teachers in this class. It will be permanently deleted in 26 days.Assignment: "Unit 1 Discussion "Whitney Kading posted a new assignment: Unit 1 Discussion Created Nov 2Nov 2 – Deleted This assignment is visible to all teachers in this class. It will be permanently deleted in 23 days.Assignment: "Analyzing Mediums: Wonder"Whitney Kading posted a new assignment: Analyzing Mediums: WonderCreated Oct 29Oct 29 – Deleted This assignment is visible to all teachers in this class. It will be permanently deleted in 19 days.Assignment: "Wonder: Reading & Response 3"Whitney Kading posted a new assignment: Wonder: Reading & Response 3Created Oct 18Oct 18 – Deleted This assignment is visible to all teachers in this class. It will be permanently deleted in 8 days.Assignment: "Perspectives Analysis"Whitney Kading posted a new assignment: Perspectives AnalysisCreated Oct 12Oct 12 – Deleted This assignment is visible to all teachers in this class. It will be permanently deleted in 2 days.Assignment: "Analyzing Mediums: The Case Against Adnan Syed "Anne Petersen posted a new assignment: Analyzing Mediums: The Case Against Adnan Syed Created Oct 7Oct 7 – Deleted This assignment is visible to all teachers in this class. It will be permanently deleted today.Assignment: ""The Deal with Jay" Notes and Reflection"Whitney Kading posted a new assignment: "The Deal with Jay" Notes and ReflectionCreated Oct 4Oct 4 – Deleted This assignment is visible to all teachers in this class. It will be permanently deleted today.Assignment: ""Inconsistencies" Notes & Reflection (SERIAL PODCAST Ep. 4)"Whitney Kading posted a new assignment: "Inconsistencies" Notes & Reflection (SERIAL PODCAST Ep. 4)Created Sep 30Sep 30 (Edited Sep 30) – Deleted This assignment is visible to all teachers in this class. It will be permanently deleted today.Assignment: "Wonder Reading"Whitney Kading posted a new assignment: Wonder ReadingCreated Sep 27Sep 27 – Deleted This assignment is visible to all teachers in this class. It will be permanently deleted today.Assignment: ""The Breakup" Notes & Reflection (SERIAL PODCAST Ep.2)"Whitney Kading posted a new assignment: "The Breakup" Notes & Reflection (SERIAL PODCAST Ep.2)Created Sep 27Sep 27 – Deleted This assignment is visible to all teachers in this class. It will be permanently deleted today.Assignment: "The Alibi Notes & Reflection (SERIAL PODCAST)"Anne Petersen posted a new assignment: The Alibi Notes & Reflection (SERIAL PODCAST)Created Sep 23Sep 23 – Deleted This assignment is visible to all teachers in this class. It will be permanently deleted today.Assignment: "Wonder Reading"Anne Petersen posted a new assignment: Wonder ReadingCreated Sep 20Sep 20 (Edited Sep 21) – Deleted This assignment is visible to all teachers in this class. It will be permanently deleted today.Announcement: "Good morning, guys- Are you having…"Anne PetersenCreated Sep 15Sep 15 – Deleted This post is visible to all teachers in this class. It will be permanently deleted today.Good morning, guys- Are you having trouble reading through all of the information we send out? Did you know there is a simple way to get all text read aloud to you (even Google Classroom posts)? I wanted to let you know about a text-to-speech feature on your Chromebooks. You can click the Google Doc below for directions on how to get it all set up. Feel free to use it if you think it'd be helpful for you! Let me know if you have any questions.  Thanks! Mrs. PetersenNo class commentsReplyAdd class comment…Assignment: "Week 4 (Sept. 14-18) "Whitney Kading posted a new assignment: Week 4 (Sept. 14-18) Created Sep 13Sep 13 – Deleted This assignment is visible to all teachers in this class. It will be permanently deleted today.Announcement: "ONE more friendly announcement :) - If…"Whitney KadingCreated Sep 8Sep 8 – Deleted This post is visible to all teachers in this class. It will be permanently deleted today.ONE more friendly announcement :) - If you are turning in LATE work (missed the deadline for the week of Sunday at 8 pm) please share your late work with our emails, NOT through Google Classroom. We will not grade it from GC and it will remain a zero until we receive it via email. - If you are re-doing your work for a better score, same rule applies as above. Thanks, everyone!No class commentsReplyAdd class comment…Announcement: "Hi Everyone, You might notice that we…"Whitney KadingCreated Sep 8Sep 8 – Deleted This post is visible to all teachers in this class. It will be permanently deleted today.Hi Everyone, You might notice that we have submitted scores into Powerschool from last week's "Perspectives Activity" assignment. We gave each of you a score out of 8 on Step 4 of the writing analysis. Some of you might notice that you did not do so hot (lots of 4/8). Mainly most of you missed points due to only contributing minimal responses, when the prompt asked for a paragraph for each. Please see your score on Powerschool and revisit your responses. If you would like to add to your responses to gain a better score, please re share your newly finished product asap. Thanks! Kading and PetersenNo class commentsReplyAdd class comment…Assignment: "Week 3 (September 7th-11th)"Anne Petersen posted a new assignment: Week 3 (September 7th-11th)Created Sep 6Sep 6 – Deleted This assignment is visible to all teachers in this class. It will be permanently deleted today.Assignment: "Week 2: August 31-Sept. 4"Whitney Kading posted a new assignment: Week 2: August 31-Sept. 4Created Aug 30Aug 30 – Deleted This assignment is visible to all teachers in this class. It will be permanently deleted today. 1 class commentMaterial: "How To: Log into the HMH Website"Anne Petersen posted a new material: How To: Log into the HMH WebsiteCreated Aug 20Aug 20 – Deleted This material is visible to all teachers in this class. It will be permanently deleted today.To-doCalendarMason City High School Bowling Richard L. PatrasNo work due soonWoohoo, no work due soon!6th Hour - 9/10 PE6th Hour MoveUnenrollKerbee GratzNo work due soonWoohoo, no work due soon!Geometry - Per 7Foley MoveUnenrollKerri FoleyNo work due soonWoohoo, no work due soon!Skill Development5th MoveUnenrollJake PhillipsNo work due soonWoohoo, no work due soon!English 10-3rd Period MoveUnenrollWhitney KadingDue Thursday8:00 AM – What Would You Do?BiologyPeriod 1 MoveUnenrollPatrick KrugerDue tomorrow11:59 PM – Tuesday - Cell Overview NotesDue Wednesday11:59 PM – Wednesday - Edpuzzle - Cell Theory & OrganizationPsychology Fall 20204 MoveUnenrollAbby DonaldDue Wednesday10:00 PM – 9. AdolescencePd 2 Autos 1 Fall 2020 MoveUnenrollMarten Van AusdallNo work due soonWoohoo, no work due soon!if (window.parent !== window) document.querySelector('.dxu4Dd').style.display = 'none'; window['HqyC7b'] = window.performance && performance.timing.navigationStart + performance.now();this.gbar_=this.gbar_||{};(function(_){var window=this; try{ /* Copyright The Closure Library Authors. SPDX-License-Identifier: Apache-2.0 */ var Pd,Qd,Rd,Xd,Yd,Zd,$d,ae,be,ce,he;_.Nd=function(a){var b=a.length;if(0<b){for(var c=Array(b),d=0;d<b;d++)c[d]=a[d];return c}return[]};_.Od=function(a,b){var c=Array.prototype.slice.call(arguments,1);return function(){var d=c.slice();d.push.apply(d,arguments);return a.apply(this,d)}};Pd=null;Qd=/^[\w+/_-]+[=]{0,2}$/;Rd=function(a){return(a=a.querySelector&&a.querySelector("script[nonce]"))&&(a=a.nonce||a.getAttribute("nonce"))&&Qd.test(a)?a:""}; _.Sd=function(a){if(a&&a!=_.p)return Rd(a.document);null===Pd&&(Pd=Rd(_.p.document));return Pd};_.Td=function(a){var b=typeof a;return"object"!=b?b:a?Array.isArray(a)?"array":b:"null"};_.Ud=function(a){var b=_.Td(a);return"array"==b||"object"==b&&"number"==typeof a.length};_.Vd=function(){return Date.now()};_.Wd=function(a,b){return 0==a.lastIndexOf(b,0)};Xd=/&/g;Yd=/</g;Zd=/>/g;$d=/"/g;ae=/'/g;be=/\x00/g;ce=/[\x00&<>"']/; _.de=function(a,b){if(b)a=a.replace(Xd,"&amp;").replace(Yd,"&lt;").replace(Zd,"&gt;").replace($d,"&quot;").replace(ae,"&#39;").replace(be,"&#0;");else{if(!ce.test(a))return a;-1!=a.indexOf("&")&&(a=a.replace(Xd,"&amp;"));-1!=a.indexOf("<")&&(a=a.replace(Yd,"&lt;"));-1!=a.indexOf(">")&&(a=a.replace(Zd,"&gt;"));-1!=a.indexOf('"')&&(a=a.replace($d,"&quot;"));-1!=a.indexOf("'")&&(a=a.replace(ae,"&#39;"));-1!=a.indexOf("\x00")&&(a=a.replace(be,"&#0;"))}return a}; _.ee=function(a){var b=_.Sd(a.ownerDocument&&a.ownerDocument.defaultView);b&&a.setAttribute("nonce",b)};_.fe=function(a,b){a.src=_.Wa(b);_.ee(a)};_.ge=function(a){return a=_.de(a,void 0)};he=!_.x||_.dc(9);_.ie=!_.Mb&&!_.x||_.x&&_.dc(9)||_.Mb&&_.bc("1.9.1");_.je=_.x&&!_.bc("9");_.ke=_.x||_.Jb||_.Nb; _.le=function(a,b){this.width=a;this.height=b};_.h=_.le.prototype;_.h.aspectRatio=function(){return this.width/this.height};_.h.$b=function(){return!(this.width*this.height)};_.h.ceil=function(){this.width=Math.ceil(this.width);this.height=Math.ceil(this.height);return this};_.h.floor=function(){this.width=Math.floor(this.width);this.height=Math.floor(this.height);return this};_.h.round=function(){this.width=Math.round(this.width);this.height=Math.round(this.height);return this}; var oe;_.me=function(a,b){return(b||document).getElementsByTagName(String(a))};_.N=function(a,b){var c=b||document;if(c.getElementsByClassName)a=c.getElementsByClassName(a)[0];else{c=document;var d=b||c;a=d.querySelectorAll&&d.querySelector&&a?d.querySelector(a?"."+a:""):_.ne(c,"*",a,b)[0]||null}return a||null}; _.ne=function(a,b,c,d){a=d||a;b=b&&"*"!=b?String(b).toUpperCase():"";if(a.querySelectorAll&&a.querySelector&&(b||c))return a.querySelectorAll(b+(c?"."+c:""));if(c&&a.getElementsByClassName){a=a.getElementsByClassName(c);if(b){d={};for(var e=0,f=0,g;g=a[f];f++)b==g.nodeName&&(d[e++]=g);d.length=e;return d}return a}a=a.getElementsByTagName(b||"*");if(c){d={};for(f=e=0;g=a[f];f++)b=g.className,"function"==typeof b.split&&_.ca(b.split(/\s+/),c)&&(d[e++]=g);d.length=e;return d}return a}; _.pe=function(a,b){_.La(b,function(c,d){c&&"object"==typeof c&&c.Pb&&(c=c.Fb());"style"==d?a.style.cssText=c:"class"==d?a.className=c:"for"==d?a.htmlFor=c:oe.hasOwnProperty(d)?a.setAttribute(oe[d],c):_.Wd(d,"aria-")||_.Wd(d,"data-")?a.setAttribute(d,c):a[d]=c})};oe={cellpadding:"cellPadding",cellspacing:"cellSpacing",colspan:"colSpan",frameborder:"frameBorder",height:"height",maxlength:"maxLength",nonce:"nonce",role:"role",rowspan:"rowSpan",type:"type",usemap:"useMap",valign:"vAlign",width:"width"}; _.se=function(a,b){var c=String(b[0]),d=b[1];if(!he&&d&&(d.name||d.type)){c=["<",c];d.name&&c.push(' name="',_.ge(d.name),'"');if(d.type){c.push(' type="',_.ge(d.type),'"');var e={};_.Na(e,d);delete e.type;d=e}c.push(">");c=c.join("")}c=_.qe(a,c);d&&("string"===typeof d?c.className=d:Array.isArray(d)?c.className=d.join(" "):_.pe(c,d));2<b.length&&_.re(a,c,b,2);return c}; _.re=function(a,b,c,d){function e(k){k&&b.appendChild("string"===typeof k?a.createTextNode(k):k)}for(;d<c.length;d++){var f=c[d];if(!_.Ud(f)||_.Ba(f)&&0<f.nodeType)e(f);else{a:{if(f&&"number"==typeof f.length){if(_.Ba(f)){var g="function"==typeof f.item||"string"==typeof f.item;break a}if("function"===typeof f){g="function"==typeof f.item;break a}}g=!1}_.Ha(g?_.Nd(f):f,e)}}};_.te=function(a){return _.qe(document,a)}; _.qe=function(a,b){b=String(b);"application/xhtml+xml"===a.contentType&&(b=b.toLowerCase());return a.createElement(b)};_.ue=function(a){for(var b;b=a.firstChild;)a.removeChild(b)};_.ve=function(a){return a&&a.parentNode?a.parentNode.removeChild(a):null};_.we=function(a){return _.Ba(a)&&1==a.nodeType};_.xe=function(a){return 9==a.nodeType?a:a.ownerDocument||a.document};_.ye=function(a,b,c){for(var d=0;a&&(null==c||d<=c);){if(b(a))return a;a=a.parentNode;d++}return null}; }catch(e){_._DumpException(e)} try{ _.sj=function(a){_.z(this,a,0,-1,null,null)};_.v(_.sj,_.y);_.tj=function(a,b,c){a.rel=c;a.href=-1!=c.toLowerCase().indexOf("stylesheet")?_.Xa(b):b instanceof _.Va?_.Xa(b):b instanceof _.cb?_.db(b):_.db(_.jb(b))}; _.uj=function(a){return _.Ya(_.A(a,4)||"")}; }catch(e){_._DumpException(e)} try{ var vj=function(a,b,c){_.ud.log(46,{att:a,max:b,url:c})},xj=function(a,b,c){_.ud.log(47,{att:a,max:b,url:c});a<b?wj(a+1,b):_.M.log(Error("R`"+a+"`"+b),{url:c})},wj=function(a,b){if(yj){var c=_.te("SCRIPT");c.async=!0;c.type="text/javascript";c.charset="UTF-8";_.fe(c,yj);c.onload=_.Od(vj,a,b,c.src);c.onerror=_.Od(xj,a,b,c.src);_.ud.log(45,{att:a,max:b,url:c.src});_.me("HEAD")[0].appendChild(c)}},zj=function(a){_.z(this,a,0,-1,null,null)};_.v(zj,_.y); var Aj=_.G(_.qd,zj,17)||new zj,Bj,yj=(Bj=_.G(Aj,_.sj,1))?_.uj(Bj):null,Cj,Dj=(Cj=_.G(Aj,_.sj,2))?_.uj(Cj):null,Ej=function(){wj(1,2);if(Dj){var a=_.te("LINK");a.setAttribute("type","text/css");_.tj(a,Dj,"stylesheet");var b=_.Sd();b&&a.setAttribute("nonce",b);_.me("HEAD")[0].appendChild(a)}}; (function(){var a=_.rd();if(_.B(a,18))Ej();else{var b=_.A(a,19)||0;window.addEventListener("load",function(){window.setTimeout(Ej,b)})}})(); }catch(e){_._DumpException(e)} })(this.gbar_); // Google Inc. Google AccountZachariah Ortonzorton23@masoncityschools.orgGoogle appsClassesCalendarEnrolledTo-doMMason City High School Bowling66th Hour - 9/10 PE6th HourGGeometry - Per 7FoleySSkill Development5thEEnglish 10-3rd PeriodBBiologyPeriod 1PPsychology Fall 20204PPd 2 Autos 1 Fall 2020Archived classesSettings

      lol

    1. SciScore for 10.1101/2020.11.06.372037: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">The protocols were approved by the Institutional Animal Care and Use 503 Committee at the Washington University School of Medicine (Assurance number A3381-01).</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Cell Line Authentication</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">2020b), and a separate study using three different antibodies defined resistance 270 substitutions at R346, N440, E484, F490 and Q493 (Weisblum et al.,</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>E484, F490</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Cell Lines</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">MAbs in the left panel were purified from Expi293F cells transfected with antibody 437 expression vector (pABVec6W) expressing heavy chain V-D-J and light Chain V-J cloned from 438 single B cells.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Expi293F</div> <div>suggested: RRID:CVCL_D615)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">444 Plaque assays were performed to validate the VSV-SARS-CoV-2 mutant on Vero cells in the 445 presence and absence of the mAb in the overlay.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Vero</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Vero CCL81, Vero E6 and Vero E6-TMPRSS2 were maintained in DMEM 487 (Corning or VWR) supplemented with glucose, L-glutamine, sodium pyruvate, and 10% fetal 488 bovine serum (FBS).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Vero CCL81</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>Vero E6</div> <div>suggested: RRID:CVCL_XD71)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Vero E6-TMPRSS2 cells were generated using a lentivirus vector described as previously 490 (Case et al.,</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Vero E6-TMPRSS2</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Escape clones were plaque-purified on Vero-E6 TMPRSS2 cells in the 495 presence of mAb, and plaques in agarose plugs were amplified on MA104 cells with the mAb 496 present in the medium.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Vero-E6 TMPRSS2</div> <div>suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Experimental Models: Organisms/Strains</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">BALB/c mice were 523 immunized and boosted twice (two and four weeks later) with 5-10 µg of RBD and S protein (twice) sequentially, each adjuvanted with 50% AddaVax and give via an intramuscular route.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>BALB/c</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">s. mAb neutralization assays using VSV-SARS-CoV-2were 548 conducted similarly but using an MOI of 100. 549 QUANTIFICATION AND STATISTICAL ANALYSIS 551 All statistical tests were performed using GraphPad Prism 8.0 software as described in 552 the indicated figure legends.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>GraphPad Prism</div> <div>suggested: (GraphPad Prism, RRID:SCR_002798)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Non-linear regression (curve fit) was 554 performed for Fig 1A, S1A, S2A, and S7A using Prism 8.0.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Prism</div> <div>suggested: (PRISM, RRID:SCR_005375)</div> </div> </td></tr></table>

      Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


      Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:

      334 335 Limitations of this study 336 Use of chimeric VSV that depends on SARS-CoV-2 S protein for entry into cells greatly 337 facilitated the selection of 48 escape mutants. Although this chimeric VSV serves as an effective 338 mimic of SARS-CoV-2 spike mediated entry and viral neutralization, sequence analysis of 339 circulating human isolates reveals that 27 of those escape mutants are present in the context of 340 infectious SARS-CoV-2. The remaining 21 variants may represent S sequences with 341 compromised fitness in the background of SARS-CoV-2 highlighting one potential limitation of 342 our work. Additional limitations of our study are the relatively few polyclonal human sera that we 343 profiled against the panel of escape mutants that suggests substitutions at residue 484 are 344 associated with resistance. Additional human sera samples at lower dilution factors may help 345 determine the extent to which serum based neutralization of virus is affected by the escape 346 mutants. 347


      Results from TrialIdentifier: We found the following clinical trial numbers in your paper:<br><table><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Identifier</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Status</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Title</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04375046</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Not yet recruiting</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP...</td></tr><tr><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">NCT04287686</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Withdrawn</td><td style="min-width:95px; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) a...</td></tr></table>


      Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).


      Results from JetFighter: Please consider improving the rainbow (“jet”) colormap used on pages 36 and 38. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

    1. SciScore for 10.1101/2020.11.03.367391: (What is this?)

      Please note, not all rigor criteria are appropriate for all manuscripts.

      Table 1: Rigor

      <table><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Institutional Review Board Statement</td><td style="min-width:100px;border-bottom:1px solid lightgray">Informed consent was obtained from all participants.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Randomization</td><td style="min-width:100px;border-bottom:1px solid lightgray">The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Blinding</td><td style="min-width:100px;border-bottom:1px solid lightgray">The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Power Analysis</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr><tr"><td style="min-width:100px;margin-right:1em; border-right:1px solid lightgray; border-bottom:1px solid lightgray">Sex as a biological variable</td><td style="min-width:100px;border-bottom:1px solid lightgray">not detected.</td></tr></table>

      Table 2: Resources

      <table><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Antibodies</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">7,8,27-31 . 9,10,12,34-37, . a–d, Results of serological assays measuring plasma reactivity to RBD (a,b,c) and N protein (d) at the initial 1.3 and 6.2 month follow-up visit, respectively. a, Anti-RBD IgM. b, Anti-RBD IgG. c, Anti-RBD IgA d, Anti-N total antibodies.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Anti-RBD IgM.</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>Anti-RBD IgG</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>Anti-RBD IgA</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Positive and negative controls were included for validation 1. e, Relative change in plasma antibody levels between 1.3 and 6.2 months for anti-RBD IgM, IgG, IgA and anti-N total Ig, respectively. f-i, Relative change in antibody levels between 1.3 and 6.2 months plotted against the corresponding antibody levels at 1.3 months. i, Anti-N total antibodies.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-RBD IgM, IgG</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-N total Ig,</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>Anti-N total antibodies.</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The Elecsys anti‐SARS‐CoV-2 assay uses a recombinant protein representing the N antigen for the determination of antibodies against SARS‐CoV‐2.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>SARS‐CoV‐2</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plates were washed 6 times with washing buffer and then incubated with anti-human IgG, IgM or IgA secondary antibody conjugated to horseradish peroxidase (HRP) (Jackson Immuno Research</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human IgG</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>IgA</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The enriched B cells were incubated in FACS buffer (1× PBS, 2% FCS, 1 mM EDTA) with the following anti-human antibodies (all at 1:200 dilution): anti-CD20-PECy7 (BD Biosciences, 335793), anti-CD3-APC- eFluro 780 (Invitrogen, 47-0037-41)</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-human</div> <div>suggested: (GenWay Biotech Inc. Cat# 18-202-335793-0.1 mg, RRID:AB_1981874)</div> </div> <div style="margin-bottom:8px"> <div>anti-CD20-PECy7</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-CD3-APC- eFluro 780</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">2: Correlations of plasma antibody measurements. a, Normalized AUC for IgG anti-RBD plotted against Pylon IgG anti-RBD index values at 1.3 months. b, Normalized AUC for IgG anti-RBD plotted against Pylon IgG anti-RBD index values at 6.2 months. c, Normalized AUC for IgM anti-RBD plotted against Pylon IgM anti-RBD index values at 1.3 months. d, Normalized AUC for IgM anti-RBD plotted against Pylon IgM anti-RBD index values at 6.2 months. e, Normalized AUC for IgM anti-RBD at 6.2 months plotted against IgM anti-RBD at 1.3 months. f, Normalized AUC for IgG anti-RBD at 6.2 months plotted against IgG anti-RBD at 1.3 months. g, Normalized AUC for IgA anti-RBD at 6.2 months plotted against IgA anti-RBD at 1.3 months. h, COI values for anti-N total Ig titres at 6.2 months plotted against anti-N total Ig titres at 1.3 months. i, Anti-RBD IgG titres at 1.3 months plotted against anti-N total Ig titres at 1.3 months. j, Anti-RBD IgG titres at 6.2 months plotted against anti-N total Ig titres at 6.2 months. k, Anti-RBD IgM titres at 1.3 months plotted against anti-N total Ig titres at 1.3 months. l, Anti-RBD IgM titres at 6.2 months plotted against anti-N total Ig titres at 6.2 months. m, Anti-RBD IgA titres at 1.3 months plotted against anti-N total Ig titres at 1.3 months. l</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>IgM</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-RBD</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>anti-N</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Repertoire ** IGLV4−69 IGKV1−16 IGKV2−26 * IGLV1−36 IGKV1−6 IGLV7−43 **** IGKV2−40 IGLV4−3 IGKV1−43 IGLV2−18 ** Extended Data Fig. 4: Frequency distributions of human V genes. a, Two-sided binomial tests were used to compare the frequency distributions of human V genes of anti-SARS-CoV-2 antibodies from donors at 1.3 months to 6.2 months 1. b, Two-sided binomial tests were used to compared the frequency distributions of human V genes of anti-SARS-CoV-2 antibodies from this study to sequence from C. Soto et al. 49. b, For each patient, the number of IgG heavy chain sequences (black) analyzed from six individuals at month 1.3 (left panel) or month 6.2 post- infection (right panel).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>anti-SARS-CoV-2</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;text-align:center; padding-top:4px;" colspan="2">Software and Algorithms</td></tr><tr><td style="min-width:100px;text=align:center">Sentences</td><td style="min-width:100px;text-align:center">Resources</td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Plasma samples were assayed on the Pylon 3D analyzer (ET HealthCare, Palo Alto, CA) as previously described 4.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>ET HealthCare</div> <div>suggested: None</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">The average of its signal was used for normalization of all of the other values on the same plate with Excel software before calculating the area under the curve using Prism V8.4 (GraphPad).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>Excel</div> <div>suggested: None</div> </div> <div style="margin-bottom:8px"> <div>Prism</div> <div>suggested: (PRISM, RRID:SCR_005375)</div> </div> <div style="margin-bottom:8px"> <div>GraphPad</div> <div>suggested: (GraphPad Prism, RRID:SCR_002798)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Single CD3−CD8−CD14−CD16−CD20+Ova−RBD- PE+RBD-AF647+ B cells were sorted into individual wells of 96-well plates containing 4 μl of lysis buffer (0.5× PBS, 10 mM DTT, 3,000 units/ml RNasin Ribonuclease Inhibitors (Promega, N2615) per well using a FACS Aria III and FACSDiva software (Becton Dickinson) for acquisition and FlowJo for analysis.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>FACSDiva</div> <div>suggested: (BD FACSDiva Software, RRID:SCR_001456)</div> </div> <div style="margin-bottom:8px"> <div>FlowJo</div> <div>suggested: (FlowJo, RRID:SCR_008520)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Sequence analysis was performed using MacVector.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>MacVector</div> <div>suggested: (MacVector, RRID:SCR_015700)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">8k) was created with R pheatmap package (</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>pheatmap</div> <div>suggested: (pheatmap, RRID:SCR_016418)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Tomographic tilt series and large-area montages were acquired automatically using the SerialEM software package were collected at 1° intervals as samples were tilted +/- 62°.</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>SerialEM</div> <div>suggested: (SerialEM, RRID:SCR_017293)</div> </div> </td></tr><tr><td style="min-width:100px;vertical-align:top;border-bottom:1px solid lightgray">Tomograms were calculated, analyzed and modeled using the IMOD software package 56,57 on MacPro and iMac Pro computers (Apple, Inc).</td><td style="min-width:100px;border-bottom:1px solid lightgray"> <div style="margin-bottom:8px"> <div>IMOD</div> <div>suggested: (IMOD, RRID:SCR_003297)</div> </div> </td></tr></table>

      Results from OddPub: Thank you for sharing your data.


      Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.


      Results from TrialIdentifier: No clinical trial numbers were referenced.


      Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


      Results from JetFighter: We did not find any issues relating to colormaps.


      About SciScore

      SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

    1. 1¢ìÊbFì­¥Fì`5¤B ì +FÆ=5¼ÊFÆì²»­=FFAFBì 8Ûìnœ5^v¢t¢^ì 5ìdÛ±­Ë`FÊn=5Œì ¥5Íл5ìØ ̄»AìÍc5Êì-­Cì`5ÖFì=»F5ÊFB ì5ìØ­»AìÙ`­Üì5šF¢5:FìÍ­ì˜Fâ=`5¦o=5ìFÚ±5¢5Êt­£%ìÊbpÆìÙ5ÆìÊ`FìØ ̄»BìÊdFì¤5ÊÑ»5ì±`l­Æ­²aF½ìÙ5ÆìÊ­ìFÚ³5t¥ì1¢ìÊ`Fì­ÊdFÄì`5¢B ìÆÏ=aìÙ»lÍF»Æì5Æì2­8F»Êì*­ÝFì5¥Bì0­`£ì25ÝìØF»Fì=­¢=F»¢F@ìÊ ̄ìÍ»5=FìÊdFìFÖtBF¢=Fì­Kì.­AÆì±Ñ»±­ÆFì5¢BìBFãÆn^¥ì l¥ìÍdFì Ù­»@ìdFìD†ì=»F5ÊF

      a world god might have created (mechanical) vs. a world god did create (natural)

    2. S9ijĉ 3*öij dijNij(ij? ij ;ij+ij  F+ ijijĞ& ij qijØĥij ijNij°3ŠijĎ=Kij[éďijijĀijħO>ij = êě5>ij#āÁΜij ` ĖijzMijt8Wij6 ijij ij"ij,  DijžŸijij$ðij$ij1%ijijBij Â&<ijij ij ̄ ijÐ<ijUij# CH#ijij ij"2ijÙij 8ij2ijijPëB  {ij³Tij ij :+ij ìQ:ij ij ijNij(ij:ijX   lijÃC0ij ij+ ij /ij ij" Öijij½ Çijijo į :ij5Aijij%ȏ ÉÎ /ij,ijY1ijijĨ ij$o ,#ijijÑOijij? ij0ijY ¡ijb,ij ijIij \ ijij| İÅG-}ij(9VLij  -Gija€ijîijij!"' ¢ij

      Problem distinguishing between nature and religion

    1. Summary: There was general enthusiasm for exploring approaches to semantic relationships in language, and for the quantitative comparison of different modeling approaches. There were questions on the degree to which the current results tied in to past literature of semantic processing, which seemed like it could have been better integrated, to help make current advances in theory more clear. As one example, the overall framing to try to link computational models and neural processing seemed to be a stretch given the data.

      Reviewer #1:

      In this paper the authors examine neural representations of semantic information based on EEG recordings on 25 subjects on a two-word priming paradigm. The overall topic of how meaning is represented in the brain, and particularly the effort to understand this on a rapid timescale, is an important one. Although presented thoroughly, the analyses did not make a convincing step beyond prior investigations in linking semantic models to neuroscientific theories of meaning representation.

      Linking word embedding / high dimensional semantic spaces to brain data has been done before in both fMRI and M/EEG (some of these papers are cited here). That is, the potential to link these two types of data has been demonstrated. So, an important question is what key advance to the current data does this provide. This seems like it could be either a deep dive into the representational spaces of the language models, or using the models to advance our understanding of semantic representation in the brain. Unfortunately I was not convinced that either of these was realized.

      One important contribution seems to be the use of three word embedding models (i.e. three semantic spaces): CBOW, GloVe, and CWE. Although these are described briefly (L89 and following) the nature of the different predictions was not spelled out, and thus the different (contradictory or complementary) aspects of these models were not immediately clear. In other words, by the end of the paper it wasn't clear whether we learned anything about these models we didn't know before.

      The relationship of the reported ERP findings to contemporary views of semantic memory was lacking. There is a large literature on semantic memory that goes far beyond the N400. I don't mean to imply that the authors need to address ALL of it, but right now it is difficult to get even a sanity check on whether the topographic/neuroanatomical distributions for the models are reasonable. This difficulty also leads to some questions with the methods - for example, averaging model-brain correlations across all channels. Given that some channels are likely to be more informative than others, I'm not convinced the overall average is a good metric. All told a greater link between the language models and neural responses is needed (i.e. a clearer link to frameworks for semantic memory).

      Reviewer #2:

      Summary and General Assessment:

      25 participants performed a visual primed lexical decision task while EEG was recorded. The authors correlate the EEG-recorded neural activity with three different methods of deriving word embedding vectors. The goal was to investigate semantic processing in the brain, using metrics that have been derived using NLP tools. The main finding is that neural activity during the same time-window (~200-300 ms) that has been associated with semantic processing in classic EEG literature - the so-called N400 component - was significantly modulated by semantic similarity between the prime and target pairs as quantified by the word embeddings. The authors claim, therefore, that brains and machines have similar representations of semantics in their processing.

      My main concern, highlighted below, is that the claims exceed the findings of the paper. I believe that the current results nicely recapitulate the classic N400 literature using a continuous variable rather than a categorical design, but do not significantly contribute to our understanding of semantic processing in AI and humans.

      Major comments:

      1) Magnitude of claims

      My main concern is that the authors are claiming interpretations that are much broader than the experimental design and results can support. The experimental design adapts a classic lexical-decision priming paradigm, using the cosine-similarity in the word-embeddings as the index of semantic similarity between prime and target. They replicate an N400 result using this continuous measure rather than a categorical one. While this is interesting, it does not, in my view, contribute to the discussion of the similarity between brains and AI. Instead, it demonstrates that co-occurrence metrics can be used as proxies for semantic similarity between word pairs.

      2) Analytic rigor

      I also have my concerns regarding the analysis techniques selected. The authors primarily analyse activity as recorded from the single electrode, or average the data across all electrodes. The results across electrodes are just shown for visualisation purposes with no statistics. I would suggest instead applying a spatio-temporal permutation test to incorporate the spatial dimension.

      Relatedly, even though justification is given for primarily analysing data recorded from channel Cz based on previous N400 studies, it seems that a lot of the analyses are actually applied on Oz (e.g. line 288, and in Figure 4 caption). Is this a typo, or was the analysis indeed applied to Oz?

      The duration of the effects using the temporal cluster test are very short, in some cases less than 10 ms in duration. A priori, we would expect meaningful measures of semantic processing to be of a much longer duration.

      3) Completeness of description of analysis

      I found the reporting of the statistical results very much under-specified. Although behavioural analyses are sufficiently reported, EEG-analyses are not. I found no report of effect sizes, and specific p-values were missing in many cases.

      Reviewer #3:

      The study analyzed EEG responses to visually presented noun-noun pairs. Priming effects were estimated by subtracting the response to the same noun presented in prime position from the response in target position. These priming effects were then correlated with the cosine distance computed from 3 variations on a word embedding model.

      Semantic distances from word embedding models have been previously shown to predict brain responses (papers cited on line 74, but also work by Stefan Frank, e.g. Frank & Willems, 2017; Frank & Yang, 2018). The main text argues that previous studies, which used whole sentence stimuli, confound semantic composition with semantic representations, and that the innovation of the present study is that it uses a semantic priming paradigm to access "pure" (79) semantic representations.

      My main concern is that the conclusions are not supported by the data (point 1 below). I also have some concerns about the methods. In my view the data and analysis approach could potentially be interesting, but the framing would need to be quite different to emphasize conclusions that are appropriate for the evidence (and probably more modest).

      1) Interpretation of the results

      The main claim of the manuscript is that the correlations imply "Comparable semantic representation in neural and computer systems" (title), repeated as "common semantic representations between [the] two complex systems" (300 ff.) and "human-like computation in computational models" (13). This conclusion is not warranted by the results. The word embedding models are essentially (by design) statistical co-occurrence models. It has also long been known that humans, and N400s specifically are sensitive to language statistics (e.g., Kutas & Federmeier, 2011). The correlation is thus parsimoniously explained by the fact that both systems are sensitive to lexical co-occurrence statistics. The (implicit) null hypothesis that is rejected is merely that human responses are insensitive to these co-occurrence patterns at all. The alternative hypothesis does not by itself imply any deeper similarity in the representational format. Similarly, the comparison of correlations with different word embedding models can potentially tell us something about which specific co-occurrence patterns humans are sensitive to, but it does not by itself imply any deeper similarity of the representations.

      2) Methods

      The Methods section leaves open several crucial questions.

      2-A) Data was recorded from multiple subjects. However, the dependent variable was a correlation coefficient between single-trial ERP and trial-wise semantic dissimilarity. How did this model account for the multi-level structure of the data?

      2-B) It is not clear that the results are corrected for multiple comparison across the 600 time points. The threshold for significance in Figure 4 B varies for each time point, whereas a critical feature of classical permutation tests is to aggregate the maximum statistic across the time points to correct for multiple comparison. The legend also indicates that the test was performed "at each time point" (4) without mentioning correction.

      2-C) The statistical analysis is even less clear when different models are compared (309 ff.). For a significant result, a p-value should be provided and, if possible, some estimate of effect size.

      References

      Frank, S. L., & Willems, R. M. (2017). Word predictability and semantic similarity show distinct patterns of brain activity during language comprehension. Language, Cognition and Neuroscience, 32(9), 1192-1203. https://doi.org/10.1080/23273798.2017.1323109

      Frank, S. L., & Yang, J. (2018). Lexical representation explains cortical entrainment during speech comprehension. PLOS ONE, 13(5), e0197304. https://doi.org/10.1371/journal.pone.0197304